data_2pdd_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2pdd _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.9 t . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 120.645 0.26 . . . . 0.0 111.372 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 25.1 ttm180 -61.45 -43.41 98.91 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.534 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.472 ' HZ2' ' CB ' ' A' ' 9' ' ' LYS . 4.6 mtpm? -52.94 -39.61 63.01 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.936 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.911 ' HH ' ' NZ ' ' A' ' 14' ' ' LYS . 12.2 t80 -60.01 -50.5 73.48 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 118.7 -1.2 . . . . 0.0 109.196 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.91 -43.52 39.39 Favored 'General case' 0 C--N 1.29 -1.996 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.136 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.6 mtp180 -66.46 -45.46 79.66 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.308 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 39.1 mm-40 -46.73 -61.37 1.87 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.416 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.911 ' NZ ' ' HH ' ' A' ' 10' ' ' TYR . 11.4 ptpt -77.31 -22.99 51.11 Favored 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 118.599 -1.241 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.43 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 93.61 81.1 1.49 Allowed Glycine 0 N--CA 1.507 3.38 0 C-N-CA 119.731 -1.223 . . . . 0.0 111.477 179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.862 HG12 ' CD2' ' A' ' 38' ' ' PHE . 18.7 t -148.42 129.6 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.266 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -74.03 104.52 4.89 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.651 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.822 HG21 ' N ' ' A' ' 19' ' ' ARG . 11.5 tt -48.92 -44.2 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.928 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.822 ' N ' HG21 ' A' ' 18' ' ' ILE . 19.4 ttm180 -47.88 -54.48 12.47 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.508 -0.769 . . . . 0.0 112.467 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.456 ' HA ' HD21 ' A' ' 20' ' ' LEU . 61.4 mt -57.54 -35.85 70.85 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 112.088 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.635 HG22 ' HA ' ' A' ' 18' ' ' ILE . 13.2 t -52.03 140.96 6.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.673 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -142.56 66.45 1.33 Allowed 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.427 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.77 -101.26 0.27 Allowed Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.067 -1.539 . . . . 0.0 109.463 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -82.26 -42.31 19.04 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.151 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.416 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -160.91 119.0 0.86 Allowed Glycine 0 N--CA 1.477 1.424 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.7 pttp -75.07 46.29 0.3 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.966 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.529 ' C ' ' H ' ' A' ' 29' ' ' ARG . 14.9 p-10 -143.19 -152.34 0.41 Allowed 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.204 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.56 -8.46 0.54 Allowed Glycine 0 C--N 1.291 -1.959 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.388 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.529 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.8 mmt180 -102.95 34.91 2.68 Favored 'General case' 0 N--CA 1.503 2.184 0 C-N-CA 119.87 -0.732 . . . . 0.0 111.821 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.416 HG22 ' O ' ' A' ' 27' ' ' ASN . 6.3 t -85.27 127.38 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.493 ' N ' ' CD1' ' A' ' 31' ' ' LEU . 9.6 mp -96.31 172.36 8.0 Favored 'General case' 0 N--CA 1.505 2.314 0 C-N-CA 119.239 -0.984 . . . . 0.0 112.486 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -71.32 -33.98 70.16 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.877 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -80.21 -8.27 59.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.266 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -65.53 -53.04 47.81 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.456 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.509 HG22 HG13 ' A' ' 16' ' ' VAL . 3.8 mt -75.54 -34.4 29.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.789 179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -50.53 -41.96 54.51 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.934 -1.106 . . . . 0.0 109.848 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.59 67.5 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.979 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.862 ' CD2' HG12 ' A' ' 16' ' ' VAL . 77.9 t80 -42.9 -65.87 0.43 Allowed 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.581 -0.847 . . . . 0.0 112.232 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.1 tp . . . . . 0 C--N 1.302 -1.464 0 C-N-CA 119.367 -0.933 . . . . 0.0 112.548 -179.698 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.7 t . . . . . 0 N--CA 1.483 1.211 0 CA-C-O 120.813 0.339 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.429 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 12.0 ttt85 -64.36 -40.69 96.36 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.177 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 17.3 mttp -53.79 -37.96 64.01 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.083 -1.047 . . . . 0.0 110.539 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -60.71 -49.99 75.3 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.766 -1.173 . . . . 0.0 108.966 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.628 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -48.98 -43.63 40.2 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.573 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -59.45 -45.16 92.38 Favored 'General case' 0 C--N 1.294 -1.821 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.03 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -53.67 -40.05 65.61 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.308 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 15.4 mmmt -87.99 -3.24 58.93 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.612 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.75 3.08 48.55 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.359 -1.4 . . . . 0.0 110.331 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.576 HG12 ' CD2' ' A' ' 38' ' ' PHE . 54.2 t -74.4 133.05 32.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.778 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -84.3 108.9 17.42 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.655 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.552 ' HA ' HG22 ' A' ' 21' ' ' VAL . 15.7 tt -44.14 -41.2 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.383 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.517 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.4 tpm_? -48.73 -59.93 3.14 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 114.832 -1.076 . . . . 0.0 112.552 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.6 mt -55.49 -31.44 62.01 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.528 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.552 HG22 ' HA ' ' A' ' 18' ' ' ILE . 13.7 t -53.36 140.55 9.34 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.8 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -135.46 65.4 1.55 Allowed 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 114.997 -1.002 . . . . 0.0 109.801 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.68 -118.42 0.95 Allowed Glycine 0 N--CA 1.502 3.038 0 C-N-CA 119.633 -1.27 . . . . 0.0 111.805 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.16 -72.48 0.6 Allowed 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.086 -179.879 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.489 ' O ' ' N ' ' A' ' 27' ' ' ASN . . . -91.29 69.34 2.08 Favored Glycine 0 N--CA 1.496 2.67 0 C-N-CA 119.761 -1.209 . . . . 0.0 110.397 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -64.49 73.87 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.564 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.523 ' C ' ' H ' ' A' ' 29' ' ' ARG . 33.1 p-10 -174.37 -159.86 0.09 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.829 -0.748 . . . . 0.0 110.259 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.9 -7.62 1.1 Allowed Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.061 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.523 ' H ' ' C ' ' A' ' 27' ' ' ASN . 47.9 mmt-85 -116.5 46.26 1.64 Allowed 'General case' 0 N--CA 1.504 2.263 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.564 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.612 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.7 t -72.89 157.89 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.282 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.623 HD11 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -104.62 172.84 6.58 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.213 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -79.6 -34.34 40.83 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.582 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 51.8 mm-40 -76.04 -6.57 51.68 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 119.367 -0.933 . . . . 0.0 108.512 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -66.0 -55.47 16.53 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.408 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.628 HD11 ' HB3' ' A' ' 11' ' ' ALA . 3.5 mt -75.07 -32.59 27.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.701 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -51.24 -40.49 58.94 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.727 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.79 -37.24 70.45 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.533 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.576 ' CD2' HG12 ' A' ' 16' ' ' VAL . 65.7 t80 -40.78 -67.78 0.22 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.756 -0.778 . . . . 0.0 111.719 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.9 tp . . . . . 0 C--N 1.304 -1.382 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.751 -179.862 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 120.842 0.353 . . . . 0.0 110.559 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -65.92 -30.82 71.46 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.007 -1.077 . . . . 0.0 110.72 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.9 mmtt -62.23 -40.03 94.8 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.014 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.423 ' HE1' HG23 ' A' ' 35' ' ' ILE . 3.3 t80 -57.92 -46.92 84.27 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.245 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.463 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -49.2 -45.17 43.92 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 115.111 -0.95 . . . . 0.0 111.008 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -58.5 -44.59 89.48 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.389 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 mt-10 -54.72 -51.92 64.09 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 118.986 -1.085 . . . . 0.0 110.989 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.2 mmmt -81.39 6.12 15.44 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.886 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.455 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 56.45 75.5 0.25 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.657 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.91 HG12 ' CD2' ' A' ' 38' ' ' PHE . 46.9 t -144.82 126.45 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.159 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 65.5 t0 -74.51 107.88 6.92 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.269 -0.972 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.896 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.3 tt -42.88 -40.94 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.585 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.896 ' N ' HG21 ' A' ' 18' ' ' ILE . 32.7 mtm180 -54.89 -54.05 47.56 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.255 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -51.84 -36.52 48.47 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.52 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.499 HG13 ' OD1' ' A' ' 34' ' ' ASP . 13.8 t -56.56 142.72 11.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.843 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -142.05 62.26 1.44 Allowed 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 120.098 -0.641 . . . . 0.0 111.647 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.9 -107.23 0.83 Allowed Glycine 0 N--CA 1.5 2.916 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.82 -45.9 40.24 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.467 -0.893 . . . . 0.0 109.626 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.5 120.65 0.99 Allowed Glycine 0 N--CA 1.485 1.91 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -79.99 44.4 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.262 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.521 ' C ' ' H ' ' A' ' 29' ' ' ARG . 1.8 p30 -149.14 -152.05 0.42 Allowed 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.474 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.52 -11.44 0.48 Allowed Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.151 -1.499 . . . . 0.0 110.29 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.521 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.6 mmt180 -102.43 32.85 3.38 Favored 'General case' 0 N--CA 1.503 2.216 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.815 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.434 ' C ' HD11 ' A' ' 31' ' ' LEU . 3.6 t -85.57 135.86 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.376 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.62 HD11 ' N ' ' A' ' 31' ' ' LEU . 11.0 mp -103.45 173.76 6.16 Favored 'General case' 0 N--CA 1.509 2.515 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -72.75 -37.85 67.55 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.649 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -74.46 -9.19 58.34 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.997 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.499 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.9 t0 -66.79 -58.24 5.45 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 114.579 -1.191 . . . . 0.0 109.551 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.463 ' CD1' ' HB3' ' A' ' 11' ' ' ALA . 4.1 mt -72.51 -36.79 55.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -47.24 -41.12 17.9 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 119.102 -1.039 . . . . 0.0 110.245 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.74 -35.86 67.61 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.528 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.91 ' CD2' HG12 ' A' ' 16' ' ' VAL . 67.2 t80 -43.09 -70.73 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.377 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.509 ' HA ' HD11 ' A' ' 39' ' ' LEU . 30.9 tp . . . . . 0 C--N 1.3 -1.568 0 C-N-CA 119.612 -0.835 . . . . 0.0 110.79 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.6 t . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 120.937 0.399 . . . . 0.0 111.513 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 68.5 ttp85 -56.61 -43.79 80.52 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.319 -0.952 . . . . 0.0 111.594 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -48.39 -46.57 37.32 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.115 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -55.34 -49.55 71.93 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 118.866 -1.134 . . . . 0.0 109.385 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.99 -44.47 60.89 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.688 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -59.67 -43.48 93.98 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.825 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -57.7 -43.06 84.92 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.604 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.1 mmtt -82.3 -16.79 48.12 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.618 -0.833 . . . . 0.0 111.006 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.38 3.81 90.4 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.334 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 37.6 t -74.28 134.65 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.56 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -81.45 107.54 14.3 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.679 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.649 HG21 ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -44.84 -41.11 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 C-N-CA 119.965 -0.694 . . . . 0.0 111.142 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.649 ' N ' HG21 ' A' ' 18' ' ' ILE . 1.7 tmt_? -49.64 -59.0 4.19 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.491 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.2 mt -54.39 -25.8 26.65 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.77 -0.772 . . . . 0.0 112.401 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.65 HG13 ' OD1' ' A' ' 34' ' ' ASP . 8.2 t -62.58 139.9 20.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.691 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -136.49 54.63 1.87 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.5 -110.87 0.06 OUTLIER Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.065 -1.54 . . . . 0.0 109.536 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.458 ' HG1' HD11 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -78.05 -41.31 35.91 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.429 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.71 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -159.03 116.59 0.72 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.9 ptpp? -74.75 39.01 0.13 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.235 -0.986 . . . . 0.0 111.18 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.52 ' O ' ' N ' ' A' ' 29' ' ' ARG . 2.4 p30 -142.25 -152.74 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -47.44 -11.84 0.09 OUTLIER Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.205 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.52 ' N ' ' O ' ' A' ' 27' ' ' ASN . 17.4 mmt-85 -104.33 32.84 3.79 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.178 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.71 HG21 ' O ' ' A' ' 25' ' ' GLY . 3.4 t -82.33 128.34 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 119.391 -0.924 . . . . 0.0 108.62 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.566 HD13 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -97.83 175.68 6.07 Favored 'General case' 0 N--CA 1.507 2.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.79 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -74.06 -35.99 64.31 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 119.517 -0.873 . . . . 0.0 108.825 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -76.49 -8.01 56.3 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 119.362 -0.935 . . . . 0.0 108.627 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.65 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.8 t0 -66.4 -59.25 3.85 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 114.66 -1.154 . . . . 0.0 109.581 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.506 HG22 HD11 ' A' ' 35' ' ' ILE . 4.4 mt -70.48 -30.72 43.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.556 -0.857 . . . . 0.0 110.233 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -53.77 -41.36 67.1 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.486 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.64 -32.86 70.32 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.474 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -45.24 -70.07 0.11 Allowed 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.32 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.448 ' HA ' HD11 ' A' ' 39' ' ' LEU . 32.2 tp . . . . . 0 C--N 1.299 -1.588 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.713 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.5 t . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 120.751 0.31 . . . . 0.0 111.28 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 57.3 ttp180 -62.17 -39.75 93.71 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.984 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mttp -54.52 -40.22 68.38 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.748 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.1 t80 -58.95 -47.06 86.44 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 118.802 -1.159 . . . . 0.0 108.926 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.09 -44.8 42.41 Favored 'General case' 0 C--N 1.291 -1.958 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.662 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 72.1 mtt85 -59.73 -47.12 86.92 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.902 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -50.88 -41.63 58.39 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.332 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 22.7 mmtp -85.49 -19.43 31.23 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.789 -0.764 . . . . 0.0 110.797 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.38 31.58 27.47 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.467 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.738 HG12 ' CD2' ' A' ' 38' ' ' PHE . 40.6 t -105.37 145.3 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 C-N-CA 120.199 -0.601 . . . . 0.0 110.779 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.573 ' N ' HG11 ' A' ' 16' ' ' VAL . 29.2 t0 -91.11 105.56 17.9 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 120.029 -0.669 . . . . 0.0 110.299 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.898 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.7 tt -41.08 -41.71 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 CA-C-O 121.43 0.634 . . . . 0.0 111.797 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.898 ' N ' HG21 ' A' ' 18' ' ' ILE . 11.4 ttt85 -52.08 -57.43 9.56 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-N 115.281 -0.872 . . . . 0.0 111.975 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -52.5 -30.24 29.11 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.878 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.548 HG22 ' HA ' ' A' ' 18' ' ' ILE . 10.2 t -61.59 143.65 14.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.599 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -142.15 52.61 1.47 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.297 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.45 -106.58 0.04 OUTLIER Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.699 -1.715 . . . . 0.0 109.311 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.418 ' HG1' HD11 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -74.79 -44.03 51.67 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.464 179.865 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -160.51 121.97 1.08 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttm -76.79 40.14 0.24 Allowed 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.101 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.53 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.2 p-10 -142.72 -150.36 0.31 Allowed 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.797 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.4 -8.77 0.55 Allowed Glycine 0 C--N 1.284 -2.335 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.226 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.53 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.6 28.72 5.8 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.899 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 t -83.01 128.53 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.748 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.418 HD11 ' HG1' ' A' ' 24' ' ' THR . 10.7 mp -100.07 176.67 5.33 Favored 'General case' 0 N--CA 1.505 2.309 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.957 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.4 tttt -74.41 -36.01 63.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.802 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -76.37 -7.82 55.82 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.883 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -66.26 -51.97 52.26 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.187 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -74.66 -33.19 30.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.994 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -52.07 -40.89 61.85 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 118.716 -1.193 . . . . 0.0 109.566 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.81 -32.88 68.04 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.547 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.738 ' CD2' HG12 ' A' ' 16' ' ' VAL . 76.6 t80 -44.93 -70.54 0.1 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.433 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.426 HD11 ' HA ' ' A' ' 39' ' ' LEU . 37.4 tp . . . . . 0 C--N 1.302 -1.49 0 C-N-CA 119.478 -0.889 . . . . 0.0 111.306 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.0 t . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 120.868 0.366 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -61.42 -29.55 70.01 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.999 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 60.8 mmtt -59.5 -45.7 90.94 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.936 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -55.1 -46.67 75.52 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 119.341 -0.944 . . . . 0.0 109.04 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.93 -45.62 41.87 Favored 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.523 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 61.7 mtt-85 -64.11 -46.37 84.49 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.02 -0.991 . . . . 0.0 111.453 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 66.4 mt-10 -48.52 -48.74 38.11 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.366 -0.934 . . . . 0.0 111.344 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.819 ' HZ3' HD21 ' A' ' 39' ' ' LEU . 0.7 OUTLIER -83.34 -33.42 25.88 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.159 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.09 73.62 1.07 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.578 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.26 130.4 8.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 C-N-CA 120.019 -0.673 . . . . 0.0 110.193 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -76.26 103.04 6.09 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.08 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.539 HG21 ' H ' ' A' ' 19' ' ' ARG . 14.1 tt -42.23 -42.61 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.707 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.539 ' H ' HG21 ' A' ' 18' ' ' ILE . 34.7 ttp180 -45.46 -57.63 3.96 Favored 'General case' 0 C--N 1.289 -2.049 0 CA-C-N 115.264 -0.88 . . . . 0.0 112.415 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 53.1 mt -56.44 -35.97 68.47 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.647 -0.821 . . . . 0.0 112.3 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.53 HG22 ' HA ' ' A' ' 18' ' ' ILE . 16.8 t -50.18 141.44 3.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 C-N-CA 118.875 -1.13 . . . . 0.0 111.819 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.407 ' N ' HG11 ' A' ' 21' ' ' VAL . 0.7 OUTLIER -143.96 65.89 1.3 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.142 179.994 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.43 -105.55 0.6 Allowed Glycine 0 N--CA 1.499 2.84 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.07 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.94 -45.69 40.77 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.373 -0.931 . . . . 0.0 109.757 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.552 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -162.99 115.33 0.65 Allowed Glycine 0 N--CA 1.479 1.543 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -74.84 36.06 0.11 Allowed 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.091 -1.044 . . . . 0.0 110.769 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.552 ' H ' ' C ' ' A' ' 25' ' ' GLY . 26.3 t-20 -107.82 -179.82 4.01 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.98 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.535 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -50.01 -12.14 0.45 Allowed Glycine 0 N--CA 1.485 1.936 0 C-N-CA 119.112 -1.518 . . . . 0.0 110.016 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.516 ' H ' ' C ' ' A' ' 27' ' ' ASN . 14.7 mmt-85 -97.94 36.76 1.5 Allowed 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.624 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.694 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.4 t -71.11 153.0 8.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.001 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.694 ' N ' HG11 ' A' ' 30' ' ' VAL . 10.7 mp -105.56 173.21 6.41 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.332 -0.947 . . . . 0.0 111.312 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -77.18 -37.47 53.58 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.104 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -76.05 -5.58 47.1 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.396 -0.921 . . . . 0.0 109.066 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -65.12 -56.17 14.49 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.224 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.2 mt -69.59 -37.78 75.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.138 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -48.36 -40.46 25.58 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.985 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.21 -34.0 70.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.476 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -45.03 -71.9 0.07 Allowed 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.622 -0.831 . . . . 0.0 111.315 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.819 HD21 ' HZ3' ' A' ' 14' ' ' LYS . 10.5 tp . . . . . 0 C--N 1.305 -1.345 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.622 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.5 t . . . . . 0 N--CA 1.484 1.25 0 CA-C-O 120.932 0.396 . . . . 0.0 110.343 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -66.22 -44.28 84.26 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.551 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -52.65 -35.4 54.86 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.745 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -62.82 -49.83 73.38 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.863 -1.135 . . . . 0.0 108.894 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.49 -43.69 62.27 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.973 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 44.9 mtp180 -60.78 -47.09 87.87 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.721 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.96 -53.96 28.46 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.763 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.567 ' HZ2' ' HB2' ' A' ' 39' ' ' LEU . 13.7 ptmt -76.51 -24.61 53.71 Favored 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.915 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.411 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 92.66 70.69 1.16 Allowed Glycine 0 N--CA 1.503 3.154 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.623 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.7 HG12 ' CD2' ' A' ' 38' ' ' PHE . 19.2 t -148.2 145.55 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.929 -0.709 . . . . 0.0 110.287 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.584 ' N ' HG11 ' A' ' 16' ' ' VAL . 67.5 t0 -90.82 106.21 18.36 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.593 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.832 HG21 ' N ' ' A' ' 19' ' ' ARG . 16.6 tt -42.12 -41.72 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.512 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.832 ' N ' HG21 ' A' ' 18' ' ' ILE . 84.6 mtt-85 -50.08 -60.69 2.7 Favored 'General case' 0 C--N 1.285 -2.222 0 CA-C-N 115.021 -0.991 . . . . 0.0 112.421 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.448 ' HA ' HD21 ' A' ' 20' ' ' LEU . 75.6 mt -51.9 -18.1 1.21 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.467 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.609 HG22 ' HA ' ' A' ' 18' ' ' ILE . 6.2 t -72.34 139.8 19.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 C-N-CA 118.671 -1.212 . . . . 0.0 111.66 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 tt0 -138.68 55.39 1.73 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.858 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.54 -109.43 0.02 OUTLIER Glycine 0 N--CA 1.492 2.378 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.698 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.75 ' HG1' ' CD1' ' A' ' 31' ' ' LEU . 0.8 OUTLIER -70.06 -44.31 69.42 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.312 179.878 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.41 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -168.68 121.36 0.94 Allowed Glycine 0 N--CA 1.48 1.614 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.079 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.43 ' CE ' ' O ' ' A' ' 19' ' ' ARG . 0.7 OUTLIER -73.05 66.1 0.8 Allowed 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.304 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.506 ' C ' ' H ' ' A' ' 29' ' ' ARG . 12.3 p30 -152.07 -164.89 2.08 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.243 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.1 -9.52 0.9 Allowed Glycine 0 N--CA 1.483 1.783 0 C-N-CA 119.212 -1.471 . . . . 0.0 110.045 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.506 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.3 mmm-85 -100.76 30.99 3.71 Favored 'General case' 0 N--CA 1.501 2.08 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.531 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.543 HG11 ' N ' ' A' ' 31' ' ' LEU . 4.0 t -81.42 143.67 11.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 119.596 -0.841 . . . . 0.0 108.962 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.75 ' CD1' ' HG1' ' A' ' 24' ' ' THR . 5.4 mp -112.86 174.62 5.81 Favored 'General case' 0 N--CA 1.514 2.728 0 C-N-CA 119.49 -0.884 . . . . 0.0 112.302 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -73.29 -33.65 65.33 Favored 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.168 -1.013 . . . . 0.0 108.299 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -74.55 -12.88 60.58 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.124 -0.944 . . . . 0.0 108.912 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.413 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.2 t0 -63.87 -51.3 65.23 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.228 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.479 HD12 HG22 ' A' ' 35' ' ' ILE . 3.1 mt -75.79 -32.11 23.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.243 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -52.63 -40.45 62.79 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.598 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.92 -34.43 71.52 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.308 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.7 ' CD2' HG12 ' A' ' 16' ' ' VAL . 61.9 t80 -42.92 -70.83 0.09 Allowed 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.77 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.567 ' HB2' ' HZ2' ' A' ' 14' ' ' LYS . 53.5 tp . . . . . 0 C--N 1.301 -1.527 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.077 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 85.7 t . . . . . 0 N--CA 1.486 1.354 0 CA-C-O 121.006 0.432 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 61.3 ttt180 -63.29 -37.21 86.35 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.85 -1.14 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.8 mmtt -55.81 -40.35 72.64 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.491 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -56.62 -51.11 69.95 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.631 -1.228 . . . . 0.0 108.977 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.24 -45.38 54.01 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.246 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtp180 -62.89 -46.69 86.63 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.823 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -52.07 -55.8 18.42 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.782 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.6 mmtt -67.7 -66.03 0.61 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 133.66 64.73 0.07 OUTLIER Glycine 0 N--CA 1.499 2.867 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.721 HG12 ' CD2' ' A' ' 38' ' ' PHE . 41.9 t -142.24 138.99 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.479 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 38.2 t0 -83.96 109.23 17.45 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.639 -0.825 . . . . 0.0 110.553 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.75 HG21 ' N ' ' A' ' 19' ' ' ARG . 9.2 tt -44.05 -41.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.512 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.75 ' N ' HG21 ' A' ' 18' ' ' ILE . 58.6 ttp180 -50.33 -58.16 6.3 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.33 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.2 mt -54.93 -28.21 49.22 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.325 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.9 t -62.43 142.28 16.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 C-N-CA 118.754 -1.179 . . . . 0.0 111.308 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -142.23 66.24 1.34 Allowed 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.52 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.1 -103.22 0.66 Allowed Glycine 0 N--CA 1.5 2.93 0 C-N-CA 119.24 -1.457 . . . . 0.0 109.552 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.43 ' HG1' ' H ' ' A' ' 25' ' ' GLY . 0.7 OUTLIER -79.7 -51.81 8.75 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.486 179.912 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.43 ' H ' ' HG1' ' A' ' 24' ' ' THR . . . -151.25 114.19 0.63 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 pttm -76.0 55.95 0.95 Allowed 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.045 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.524 ' C ' ' H ' ' A' ' 29' ' ' ARG . 1.5 p30 -146.2 -162.34 1.5 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.259 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.46 -10.19 0.54 Allowed Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.303 -1.427 . . . . 0.0 110.153 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.524 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.2 mmt85 -104.39 35.25 2.78 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.751 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -78.07 145.24 10.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.296 -0.962 . . . . 0.0 108.625 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.534 HD11 ' N ' ' A' ' 31' ' ' LEU . 8.1 mp -102.86 173.04 6.49 Favored 'General case' 0 N--CA 1.511 2.596 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.708 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.6 tttm -74.18 -43.49 57.09 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.242 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -70.95 -5.18 28.96 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.45 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -68.37 -56.79 7.29 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.177 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.469 HD11 HG23 ' A' ' 35' ' ' ILE . 3.7 mt -71.45 -31.14 42.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.405 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -53.71 -42.33 67.92 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.602 -1.239 . . . . 0.0 109.531 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.8 -35.45 78.67 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.282 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.721 ' CD2' HG12 ' A' ' 16' ' ' VAL . 64.6 t80 -43.04 -70.47 0.11 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.266 -0.974 . . . . 0.0 111.342 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.1 tp . . . . . 0 C--N 1.302 -1.486 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.61 -179.831 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 84.9 t . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 120.865 0.364 . . . . 0.0 111.126 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 58.7 ttt-85 -58.09 -31.64 67.3 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.256 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -61.15 -39.97 92.1 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.206 -0.998 . . . . 0.0 110.511 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 6.1 t80 -59.08 -48.36 81.88 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 118.944 -1.102 . . . . 0.0 109.259 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.411 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -49.71 -42.38 45.74 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.791 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -61.96 -43.51 98.69 Favored 'General case' 0 C--N 1.292 -1.907 0 C-N-CA 119.484 -0.887 . . . . 0.0 111.082 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -55.04 -54.41 43.44 Favored 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.309 -0.956 . . . . 0.0 110.928 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.4 mmtp -79.82 -19.43 48.46 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.066 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 76.06 81.93 0.52 Allowed Glycine 0 N--CA 1.49 2.24 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.968 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.9 t -146.9 141.57 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.918 -0.713 . . . . 0.0 110.647 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -80.31 97.57 7.05 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.267 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.63 HG21 ' N ' ' A' ' 19' ' ' ARG . 11.4 tt -40.19 -37.79 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.534 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.63 ' N ' HG21 ' A' ' 18' ' ' ILE . 57.0 mtp180 -54.96 -62.72 1.48 Allowed 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.364 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.0 mt -51.17 -17.67 0.72 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.549 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.3 t -68.35 141.16 17.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 C-N-CA 118.502 -1.279 . . . . 0.0 111.447 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -139.83 67.77 1.37 Allowed 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.037 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.12 -114.01 1.34 Allowed Glycine 0 N--CA 1.498 2.814 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.025 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.34 -44.05 54.04 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.91 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.5 111.94 0.5 Allowed Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -75.85 53.07 0.73 Allowed 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.081 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.473 ' C ' ' N ' ' A' ' 29' ' ' ARG . 3.2 p30 -146.02 -164.09 1.88 Allowed 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 120.212 -0.595 . . . . 0.0 110.322 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -49.55 -13.57 0.5 Allowed Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.191 -1.48 . . . . 0.0 110.414 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.473 ' N ' ' C ' ' A' ' 27' ' ' ASN . 0.2 OUTLIER -101.11 33.95 2.69 Favored 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 119.917 -0.713 . . . . 0.0 112.152 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.459 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.7 t -76.66 150.18 6.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.047 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.629 HD11 ' N ' ' A' ' 31' ' ' LEU . 9.6 mp -107.98 174.88 5.69 Favored 'General case' 0 N--CA 1.511 2.619 0 C-N-CA 119.482 -0.887 . . . . 0.0 111.033 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.5 tttm -77.32 -38.14 51.13 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.292 -0.963 . . . . 0.0 108.786 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -73.9 -7.49 52.52 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.563 -0.855 . . . . 0.0 108.876 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -64.31 -57.65 8.79 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.706 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.465 HD12 HG13 ' A' ' 18' ' ' ILE . 4.7 mt -72.28 -29.01 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.6 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -53.13 -43.41 66.92 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.627 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.56 -35.02 75.02 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.543 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -43.78 -68.62 0.18 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.341 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.437 ' C ' HD21 ' A' ' 39' ' ' LEU . 4.5 tt . . . . . 0 C--N 1.304 -1.406 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.901 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.9 t . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 120.749 0.309 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.411 ' NH2' HH21 ' A' ' 12' ' ' ARG . 48.7 ttt-85 -60.95 -40.18 92.32 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.528 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -56.41 -41.34 76.16 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.586 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -56.28 -46.46 79.71 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.029 -1.068 . . . . 0.0 109.149 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.02 -44.9 61.1 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.67 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.411 HH21 ' NH2' ' A' ' 8' ' ' ARG . 6.5 mmp_? -59.47 -42.83 92.92 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.179 -179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.463 ' C ' ' H ' ' A' ' 15' ' ' GLY . 48.2 mt-10 -58.14 -64.52 0.88 Allowed 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.344 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.2 mmtm -69.29 8.71 0.55 Allowed 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.295 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.542 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 55.55 78.19 0.13 Allowed Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.787 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.542 HG21 ' O ' ' A' ' 15' ' ' GLY . 37.1 t -147.71 137.32 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.075 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 68.6 t0 -87.43 106.4 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.7 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.881 HG21 ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -43.85 -42.89 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.52 0.676 . . . . 0.0 111.862 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.881 ' N ' HG21 ' A' ' 18' ' ' ILE . 46.0 mtt-85 -49.33 -59.72 3.45 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 114.999 -1.001 . . . . 0.0 113.119 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 49.3 mt -55.76 -24.68 36.85 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.961 -0.695 . . . . 0.0 112.668 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.5 t -57.86 141.1 15.29 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 C-N-CA 118.641 -1.224 . . . . 0.0 112.033 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -136.4 59.18 1.71 Allowed 'General case' 0 N--CA 1.482 1.158 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.672 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.8 -110.41 0.09 OUTLIER Glycine 0 N--CA 1.494 2.551 0 C-N-CA 118.957 -1.592 . . . . 0.0 109.751 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.84 -43.59 29.93 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.322 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.491 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -159.84 114.82 0.63 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 ptmt -74.9 38.88 0.13 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.284 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.545 ' C ' ' H ' ' A' ' 29' ' ' ARG . 18.7 p-10 -124.43 -161.96 1.04 Allowed 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.207 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.06 -6.37 0.82 Allowed Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.156 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.545 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.44 34.93 2.59 Favored 'General case' 0 N--CA 1.502 2.126 0 C-N-CA 119.964 -0.695 . . . . 0.0 111.805 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -80.92 150.37 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 C-N-CA 119.341 -0.944 . . . . 0.0 108.934 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 5.4 mp -120.26 -179.91 4.09 Favored 'General case' 0 N--CA 1.515 2.801 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.011 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 tttp -78.86 -33.2 46.05 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.75 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.539 ' CD ' ' H ' ' A' ' 33' ' ' GLU . 2.3 pm0 -75.3 -7.67 54.57 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.6 -54.71 17.49 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 114.523 -1.217 . . . . 0.0 109.369 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.492 HG23 HD11 ' A' ' 35' ' ' ILE . 3.3 mt -72.98 -35.23 48.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.316 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -48.44 -40.71 27.09 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.208 -0.997 . . . . 0.0 110.177 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.14 -32.58 64.98 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.498 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.522 ' CD2' HG12 ' A' ' 16' ' ' VAL . 72.0 t80 -44.13 -69.08 0.15 Allowed 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.601 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.415 ' HA ' HD11 ' A' ' 39' ' ' LEU . 43.3 tp . . . . . 0 C--N 1.304 -1.412 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.12 -179.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t . . . . . 0 N--CA 1.496 1.87 0 CA-C-O 120.848 0.356 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.459 HH11 ' HG3' ' A' ' 8' ' ' ARG . 25.7 ttm-85 -60.73 -38.78 86.3 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.296 -0.961 . . . . 0.0 111.336 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -54.25 -42.31 69.79 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -57.19 -49.72 75.11 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 118.607 -1.237 . . . . 0.0 109.15 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.457 ' HB1' ' O ' ' A' ' 8' ' ' ARG . . . -48.36 -42.32 31.26 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.184 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -63.55 -45.79 88.91 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 119.398 -0.921 . . . . 0.0 111.225 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -50.85 -56.17 13.5 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.951 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 55.5 mmtt -79.88 -22.55 42.73 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.114 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 83.4 80.71 1.0 Allowed Glycine 0 N--CA 1.497 2.711 0 C-N-CA 119.573 -1.299 . . . . 0.0 110.496 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.586 HG12 ' CD2' ' A' ' 38' ' ' PHE . 28.2 t -147.61 135.28 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.409 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -78.35 102.96 7.99 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.266 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.924 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -44.85 -42.99 2.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.663 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.924 ' N ' HG21 ' A' ' 18' ' ' ILE . 17.5 tpp180 -52.62 -54.09 37.99 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.273 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.3 mt -55.7 -26.7 46.44 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.05 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.616 HG13 ' OD1' ' A' ' 34' ' ' ASP . 10.6 t -61.35 143.04 15.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.757 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -132.99 69.76 1.48 Allowed 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.613 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.81 -114.49 2.91 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.544 -1.313 . . . . 0.0 110.415 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.415 ' H ' ' HG1' ' A' ' 24' ' ' THR . 0.8 OUTLIER -76.07 -46.03 31.13 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.293 -179.992 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -153.4 109.82 0.42 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 11.8 pttm -77.28 61.07 2.08 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.81 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.531 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.5 OUTLIER -156.9 -161.59 1.11 Allowed 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.12 179.901 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -9.07 0.41 Allowed Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.59 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.531 ' H ' ' C ' ' A' ' 27' ' ' ASN . 14.9 mmt85 -111.9 40.95 2.04 Favored 'General case' 0 N--CA 1.507 2.385 0 C-N-CA 120.167 -0.613 . . . . 0.0 111.592 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.625 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.8 t -80.91 157.9 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.658 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.625 ' N ' HG11 ' A' ' 30' ' ' VAL . 7.9 mp -113.42 173.39 6.43 Favored 'General case' 0 N--CA 1.509 2.522 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.948 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -76.3 -43.06 43.19 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.053 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -66.79 -10.06 43.56 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.44 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.616 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.4 t0 -66.2 -57.52 7.41 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.568 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 mt -72.33 -33.27 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.649 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 39.5 t0 -49.71 -41.38 43.28 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.191 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.18 -35.04 68.86 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.467 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.586 ' CD2' HG12 ' A' ' 16' ' ' VAL . 70.5 t80 -43.72 -70.2 0.11 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.631 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.444 ' C ' HD21 ' A' ' 39' ' ' LEU . 4.1 tt . . . . . 0 C--N 1.305 -1.368 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.745 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 82.0 t . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 121.018 0.437 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -66.71 -45.39 78.86 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.959 -1.096 . . . . 0.0 110.697 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mttm -53.83 -35.85 61.88 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.638 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -63.27 -47.14 83.61 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.405 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.06 -42.64 63.31 Favored 'General case' 0 C--N 1.291 -1.95 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.595 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 69.2 mtp180 -60.98 -46.48 90.56 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.678 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -54.59 -44.01 72.64 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.879 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.0 mmtt -86.14 -69.78 0.64 Allowed 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.692 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.75 73.35 0.06 OUTLIER Glycine 0 N--CA 1.502 3.076 0 C-N-CA 119.88 -1.153 . . . . 0.0 110.773 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.75 HG12 ' CD2' ' A' ' 38' ' ' PHE . 39.9 t -144.67 137.44 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.493 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.1 t0 -79.85 112.28 16.98 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.804 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.834 HG21 ' N ' ' A' ' 19' ' ' ARG . 7.3 tp -43.11 -43.17 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.641 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.834 ' N ' HG21 ' A' ' 18' ' ' ILE . 14.7 tpt180 -59.91 -56.25 24.07 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.595 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 74.0 mt -47.16 -21.17 0.22 Allowed 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.558 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.67 HG13 ' OD1' ' A' ' 34' ' ' ASP . 15.5 t -76.5 143.18 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.976 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -132.48 65.33 1.58 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.983 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.2 -121.99 2.62 Favored Glycine 0 N--CA 1.502 3.058 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.242 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.849 ' HG1' HD22 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -73.26 -60.15 2.38 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.987 179.87 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.584 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -134.9 109.7 0.79 Allowed Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt -76.49 55.46 1.02 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.03 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.522 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.4 OUTLIER -156.89 -157.84 0.72 Allowed 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.585 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.36 -10.52 0.56 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.239 -1.458 . . . . 0.0 110.236 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.522 ' H ' ' C ' ' A' ' 27' ' ' ASN . 28.0 mmt180 -107.71 37.27 2.47 Favored 'General case' 0 N--CA 1.506 2.34 0 C-N-CA 120.074 -0.651 . . . . 0.0 111.709 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.642 ' C ' HD21 ' A' ' 31' ' ' LEU . 2.7 t -80.68 156.62 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 119.545 -0.862 . . . . 0.0 109.619 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.849 HD22 ' HG1' ' A' ' 24' ' ' THR . 3.9 mm? -105.78 172.49 6.77 Favored 'General case' 0 N--CA 1.508 2.459 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.365 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 48.4 tttm -77.1 -42.89 36.28 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 118.863 -1.135 . . . . 0.0 109.245 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -70.89 -3.38 18.87 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.47 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.67 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.4 t0 -67.33 -59.73 3.17 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.959 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.41 ' CG2' HG13 ' A' ' 16' ' ' VAL . 3.2 mt -72.1 -30.5 36.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.534 -0.867 . . . . 0.0 110.881 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -53.23 -41.58 65.52 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.895 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.18 -31.56 62.73 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.823 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.75 ' CD2' HG12 ' A' ' 16' ' ' VAL . 74.4 t80 -47.92 -69.89 0.11 Allowed 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 119.219 -0.993 . . . . 0.0 111.134 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.6 tt . . . . . 0 C--N 1.304 -1.4 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.931 -179.863 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 70.0 t . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 120.871 0.367 . . . . 0.0 110.714 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.412 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 34.0 ttm180 -60.62 -39.37 87.98 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.189 -1.005 . . . . 0.0 111.135 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.4 mttp -53.02 -42.84 66.06 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.4 ' HE2' HG23 ' A' ' 35' ' ' ILE . 9.9 t80 -57.61 -50.18 73.99 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.739 -1.184 . . . . 0.0 109.22 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.412 ' HB1' ' O ' ' A' ' 8' ' ' ARG . . . -49.8 -45.01 49.5 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.811 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -60.49 -45.82 92.37 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.075 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -52.36 -51.95 56.09 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 18.2 mtpp -81.29 -8.58 59.77 Favored 'General case' 0 N--CA 1.489 1.515 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.89 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.52 75.4 0.61 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.358 -1.401 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.637 HG12 ' CD2' ' A' ' 38' ' ' PHE . 42.8 t -144.25 126.53 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.946 -0.701 . . . . 0.0 110.413 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -72.79 100.77 2.95 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.526 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.599 HG21 ' H ' ' A' ' 19' ' ' ARG . 11.8 tt -41.25 -41.74 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.69 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.599 ' H ' HG21 ' A' ' 18' ' ' ILE . 17.9 tpp180 -52.12 -53.06 47.31 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.327 -0.852 . . . . 0.0 112.207 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.4 mt -57.84 -28.98 64.59 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.156 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 t -59.08 140.28 17.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.559 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -140.55 63.2 1.47 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.853 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.26 -101.85 0.35 Allowed Glycine 0 N--CA 1.496 2.656 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.44 ' H ' ' HG1' ' A' ' 24' ' ' THR . 0.8 OUTLIER -80.89 -42.7 21.02 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.631 -0.827 . . . . 0.0 110.098 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.93 114.77 0.62 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.1 pttt -75.87 57.33 1.03 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.963 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.521 ' C ' ' H ' ' A' ' 29' ' ' ARG . 41.3 p30 -149.89 -161.37 1.33 Allowed 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.633 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.09 -11.13 0.36 Allowed Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.597 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.521 ' H ' ' C ' ' A' ' 27' ' ' ASN . 18.9 mmt180 -104.58 35.52 2.72 Favored 'General case' 0 N--CA 1.504 2.258 0 C-N-CA 119.861 -0.735 . . . . 0.0 111.79 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -81.45 135.11 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 9.6 mp -101.52 174.01 6.17 Favored 'General case' 0 N--CA 1.511 2.616 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.795 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.422 ' HG2' ' HZ1' ' A' ' 32' ' ' LYS . 50.7 tttm -75.27 -34.18 61.32 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 119.137 -1.025 . . . . 0.0 108.304 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.1 tp10 -71.14 -16.21 62.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -63.22 -54.33 39.1 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 114.201 -1.363 . . . . 0.0 109.123 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.4 HG23 ' HE2' ' A' ' 10' ' ' TYR . 3.2 mt -73.34 -34.18 42.85 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.532 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -50.55 -41.31 53.92 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.502 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.46 -36.36 76.5 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.291 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.637 ' CD2' HG12 ' A' ' 16' ' ' VAL . 56.9 t80 -43.86 -69.96 0.12 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.374 -0.931 . . . . 0.0 111.489 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.78 ' C ' HD11 ' A' ' 39' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.305 -1.362 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.41 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.2 t . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 120.647 0.26 . . . . 0.0 111.483 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -62.94 -40.93 99.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 118.905 -1.118 . . . . 0.0 111.224 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -51.64 -40.34 59.78 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.411 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -61.04 -51.43 69.21 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 118.909 -1.116 . . . . 0.0 108.904 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.522 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -50.11 -43.14 51.54 Favored 'General case' 0 C--N 1.291 -1.945 0 CA-C-N 115.19 -0.913 . . . . 0.0 110.25 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -63.02 -47.32 83.56 Favored 'General case' 0 C--N 1.296 -1.749 0 CA-C-N 115.057 -0.974 . . . . 0.0 110.358 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -51.85 -31.4 27.68 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.153 -1.019 . . . . 0.0 110.108 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.3 mmtp -97.78 -10.1 25.4 Favored 'General case' 0 N--CA 1.495 1.796 0 C-N-CA 119.979 -0.689 . . . . 0.0 110.692 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.08 1.5 74.2 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.358 -1.401 . . . . 0.0 109.962 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.69 HG12 ' CD2' ' A' ' 38' ' ' PHE . 41.9 t -71.31 137.32 23.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.933 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -86.38 105.8 16.97 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.278 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.876 HG21 ' N ' ' A' ' 19' ' ' ARG . 16.4 tt -43.04 -43.04 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.994 -179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.876 ' N ' HG21 ' A' ' 18' ' ' ILE . 37.8 mtp180 -48.81 -57.72 5.94 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.865 -179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.2 mt -54.43 -29.63 49.93 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 119.723 -0.791 . . . . 0.0 112.56 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.457 HG22 ' HA ' ' A' ' 18' ' ' ILE . 13.7 t -55.6 140.35 13.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.623 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -132.46 62.27 1.65 Allowed 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.397 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -83.92 -121.43 0.86 Allowed Glycine 0 N--CA 1.496 2.699 0 C-N-CA 119.098 -1.525 . . . . 0.0 110.54 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.52 -66.22 0.92 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.708 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.67 -62.94 5.68 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.897 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 66.9 tttt 56.43 38.86 30.06 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.554 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.539 ' H ' HG21 ' A' ' 30' ' ' VAL . 38.2 p-10 -163.71 -160.77 0.6 Allowed 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.182 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.29 -5.41 0.71 Allowed Glycine 0 N--CA 1.484 1.885 0 C-N-CA 119.16 -1.495 . . . . 0.0 110.249 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.536 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -122.93 45.6 2.37 Favored 'General case' 0 N--CA 1.504 2.232 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.657 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.54 HG11 ' N ' ' A' ' 31' ' ' LEU . 3.1 t -70.4 160.4 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 C-N-CA 119.089 -1.044 . . . . 0.0 108.946 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.54 ' N ' HG11 ' A' ' 30' ' ' VAL . 9.3 mp -105.79 172.66 6.68 Favored 'General case' 0 N--CA 1.513 2.679 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.08 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -79.01 -37.51 39.01 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.393 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -72.45 -7.44 49.86 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -66.1 -59.0 4.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 114.563 -1.199 . . . . 0.0 109.621 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.522 HD11 ' HB3' ' A' ' 11' ' ' ALA . 3.7 mt -72.64 -28.54 27.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.548 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -53.41 -40.95 65.5 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.697 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.51 -35.54 68.14 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.583 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.69 ' CD2' HG12 ' A' ' 16' ' ' VAL . 67.0 t80 -42.19 -70.12 0.12 Allowed 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.666 -0.813 . . . . 0.0 112.284 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.459 ' HA ' HD11 ' A' ' 39' ' ' LEU . 32.2 tp . . . . . 0 C--N 1.303 -1.436 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.076 -179.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 60.7 t . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 120.854 0.359 . . . . 0.0 110.699 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.1 ttt85 -65.39 -43.97 88.99 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 118.782 -1.167 . . . . 0.0 110.254 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -56.09 -35.37 66.94 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.185 -1.006 . . . . 0.0 110.698 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -61.46 -45.5 93.99 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.837 -1.145 . . . . 0.0 109.111 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -48.32 -42.62 31.71 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.402 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -64.2 -44.82 90.8 Favored 'General case' 0 C--N 1.291 -1.935 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.061 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.8 mm-40 -51.29 -53.09 39.04 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.783 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -82.26 -22.62 35.71 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.646 -0.822 . . . . 0.0 111.012 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.5 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 83.36 78.85 1.06 Allowed Glycine 0 N--CA 1.497 2.702 0 C-N-CA 119.469 -1.348 . . . . 0.0 110.305 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.505 HG23 ' CD2' ' A' ' 38' ' ' PHE . 33.6 t -145.7 138.57 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 120.035 -0.666 . . . . 0.0 110.161 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.2 t0 -80.95 97.1 7.3 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.05 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.939 HG21 ' N ' ' A' ' 19' ' ' ARG . 11.8 tt -41.2 -41.73 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.562 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.939 ' N ' HG21 ' A' ' 18' ' ' ILE . 13.4 tpp180 -49.96 -57.92 6.52 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.713 -179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 51.2 mt -57.42 -36.62 71.58 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.547 -0.861 . . . . 0.0 112.163 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.636 HG13 ' OD1' ' A' ' 34' ' ' ASP . 14.8 t -47.08 140.92 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.69 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -133.78 65.37 1.58 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.294 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.49 -114.17 0.78 Allowed Glycine 0 N--CA 1.496 2.678 0 C-N-CA 119.14 -1.505 . . . . 0.0 109.951 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.938 ' HG1' HD13 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -82.08 -61.01 2.03 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.01 179.936 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.35 102.62 0.59 Allowed Glycine 0 N--CA 1.5 2.947 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.2 pttp -74.59 61.5 0.96 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.508 ' C ' ' H ' ' A' ' 29' ' ' ARG . 8.3 p30 -164.25 -154.97 0.27 Allowed 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.484 -0.887 . . . . 0.0 110.801 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.4 -9.99 0.5 Allowed Glycine 0 C--N 1.291 -1.964 0 C-N-CA 119.635 -1.269 . . . . 0.0 110.578 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.508 ' H ' ' C ' ' A' ' 27' ' ' ASN . 25.3 mmt180 -111.9 38.5 2.64 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.744 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.413 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.5 t -76.47 154.23 5.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 119.195 -1.002 . . . . 0.0 108.905 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.938 HD13 ' HG1' ' A' ' 24' ' ' THR . 29.3 mt -117.52 178.87 4.23 Favored 'General case' 0 N--CA 1.513 2.69 0 C-N-CA 119.587 -0.845 . . . . 0.0 112.24 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' A' ' 36' ' ' ASP . 27.3 tptp -78.39 -33.55 48.73 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -73.86 -11.58 60.41 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.636 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.1 t0 -66.98 -67.54 0.44 Allowed 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.104 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.4 mt -67.39 -35.49 73.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 C-N-CA 119.656 -0.817 . . . . 0.0 111.44 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 32' ' ' LYS . 5.7 m-20 -49.38 -42.53 42.49 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.721 -1.192 . . . . 0.0 110.081 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.62 -32.98 71.99 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.612 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.505 ' CD2' HG23 ' A' ' 16' ' ' VAL . 68.4 t80 -45.2 -69.9 0.12 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.873 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.2 tp . . . . . 0 C--N 1.303 -1.429 0 CA-C-N 115.275 -0.875 . . . . 0.0 112.112 -179.759 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t . . . . . 0 N--CA 1.501 2.12 0 CA-C-O 120.841 0.353 . . . . 0.0 110.827 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 32.7 ttm180 -60.04 -45.62 92.23 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.31 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.461 ' HG3' ' HZ1' ' A' ' 9' ' ' LYS . 9.9 mmmm -52.7 -41.78 64.23 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.632 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -57.85 -47.12 83.62 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 118.781 -1.167 . . . . 0.0 109.211 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.07 -45.47 61.42 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.793 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -56.56 -41.69 77.28 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.914 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -61.67 -33.54 74.16 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.911 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 50.6 mmtt -96.94 0.4 48.89 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.34 57.54 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.691 -1.242 . . . . 0.0 111.041 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.454 HG12 ' CD2' ' A' ' 38' ' ' PHE . 55.2 t -81.84 123.66 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.484 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -75.98 105.92 7.29 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.244 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.482 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 9.7 tt -41.62 -41.7 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.558 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.482 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.6 ttt85 -50.92 -53.87 29.06 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.987 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.407 ' HA ' HD21 ' A' ' 20' ' ' LEU . 74.6 mt -55.96 -28.17 55.84 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.818 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.583 HG13 ' OD1' ' A' ' 34' ' ' ASP . 10.6 t -65.31 142.6 16.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.687 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -140.52 66.28 1.39 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.051 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -78.51 -107.56 0.2 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.095 -1.526 . . . . 0.0 110.428 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.442 ' OG1' ' CD1' ' A' ' 31' ' ' LEU . 0.7 OUTLIER -87.27 -53.02 5.06 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.473 -179.938 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 108.93 0.63 Allowed Glycine 0 N--CA 1.5 2.915 0 C-N-CA 119.857 -1.163 . . . . 0.0 110.404 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -76.58 61.41 1.78 Allowed 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.013 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.535 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.7 p-10 -152.83 -161.26 1.26 Allowed 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.434 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.76 -6.67 1.27 Allowed Glycine 0 N--CA 1.484 1.836 0 C-N-CA 119.123 -1.513 . . . . 0.0 109.909 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.535 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.8 mmt180 -108.17 31.82 5.25 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 120.187 -0.605 . . . . 0.0 111.523 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -70.08 156.11 7.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.434 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.442 ' CD1' ' OG1' ' A' ' 24' ' ' THR . 28.3 mt -108.53 173.78 6.17 Favored 'General case' 0 N--CA 1.509 2.499 0 C-N-CA 119.279 -0.969 . . . . 0.0 112.448 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 43.3 tptt -76.93 -32.23 57.22 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.063 -0.971 . . . . 0.0 108.574 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -82.58 -5.09 58.59 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.358 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.583 ' OD1' HG13 ' A' ' 21' ' ' VAL . 1.6 t0 -64.39 -53.95 40.51 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.237 -0.892 . . . . 0.0 108.933 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -77.55 -37.89 25.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.678 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -47.17 -42.29 19.47 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.945 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.86 -37.08 73.08 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.6 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.454 ' CD2' HG12 ' A' ' 16' ' ' VAL . 66.1 t80 -42.67 -68.6 0.18 Allowed 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.463 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 11.2 tp . . . . . 0 C--N 1.303 -1.456 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.991 -179.87 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 79.9 t . . . . . 0 N--CA 1.507 2.416 0 CA-C-O 120.852 0.358 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.565 ' HE ' HD11 ' A' ' 18' ' ' ILE . 32.2 ttm180 -57.4 -38.09 73.74 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.239 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.7 mttp -52.43 -46.48 66.41 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.634 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -54.28 -47.74 72.02 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 118.9 -1.12 . . . . 0.0 109.092 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.415 ' HB1' ' CD1' ' A' ' 35' ' ' ILE . . . -49.48 -44.59 46.09 Favored 'General case' 0 C--N 1.288 -2.083 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.789 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 24.1 mmm180 -57.43 -43.86 84.2 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.745 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -57.57 -33.19 67.91 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.086 -1.045 . . . . 0.0 110.496 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.6 mmtt -93.51 -10.04 36.28 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.496 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 76.38 -0.9 62.61 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.458 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.841 HG12 ' CD2' ' A' ' 38' ' ' PHE . 54.7 t -70.77 124.4 26.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.772 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.42 ' HB3' HD13 ' A' ' 20' ' ' LEU . 51.3 t0 -77.08 105.88 8.44 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.048 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.583 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.1 tt -37.82 -42.63 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.266 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.583 ' N ' HG21 ' A' ' 18' ' ' ILE . 51.7 ttp85 -49.36 -55.06 14.2 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.472 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.42 HD13 ' HB3' ' A' ' 17' ' ' ASP . 52.7 mt -53.07 -41.83 65.25 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.556 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.589 HG13 ' OD1' ' A' ' 34' ' ' ASP . 13.5 t -48.52 144.56 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 C-N-CA 119.267 -0.973 . . . . 0.0 111.863 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -137.95 60.85 1.61 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.476 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.32 -114.82 0.24 Allowed Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.927 -1.606 . . . . 0.0 109.943 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.1 -50.03 12.8 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.879 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.447 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -150.02 109.4 0.43 Allowed Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 pttt -75.97 43.51 0.28 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.177 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.511 ' C ' ' H ' ' A' ' 29' ' ' ARG . 27.7 p-10 -119.05 -164.92 1.08 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.028 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.03 -4.2 2.21 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.196 -1.478 . . . . 0.0 110.332 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.511 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.1 mmt180 -110.71 41.42 1.79 Allowed 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.469 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.714 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.5 t -73.46 156.4 6.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.435 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.714 ' N ' HG11 ' A' ' 30' ' ' VAL . 10.1 mp -105.74 173.0 6.5 Favored 'General case' 0 N--CA 1.511 2.577 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.142 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -76.94 -38.69 52.87 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 119.259 -0.977 . . . . 0.0 109.676 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -76.8 -2.91 35.61 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.222 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.589 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.3 t0 -67.18 -55.13 15.43 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.778 -1.101 . . . . 0.0 109.632 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.443 HG22 HG13 ' A' ' 16' ' ' VAL . 3.7 mt -75.17 -36.96 38.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.806 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.67 -40.54 53.89 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.421 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.35 -33.87 69.99 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.609 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.841 ' CD2' HG12 ' A' ' 16' ' ' VAL . 83.2 t80 -44.74 -69.65 0.13 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.067 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.702 ' C ' HD11 ' A' ' 39' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.609 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.441 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 121.079 0.466 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 71.2 ttt180 -71.02 -39.42 72.37 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.01 -1.076 . . . . 0.0 110.504 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttp -58.92 -26.61 64.51 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 118.988 -1.085 . . . . 0.0 110.467 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.408 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 7.6 t80 -69.62 -49.73 51.08 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 118.843 -1.143 . . . . 0.0 108.579 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.83 -41.47 23.91 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.43 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.37 -46.6 86.02 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.776 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -54.9 -35.35 64.02 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.976 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.8 mmtt -92.06 -16.79 25.94 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.849 -0.741 . . . . 0.0 110.72 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 80.46 4.75 90.07 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.523 -1.322 . . . . 0.0 110.623 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.547 HG12 ' CD2' ' A' ' 38' ' ' PHE . 41.1 t -76.46 138.55 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.651 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 36.8 t0 -81.37 104.4 11.79 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.761 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.848 HG21 ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -40.87 -41.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.654 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.848 ' N ' HG21 ' A' ' 18' ' ' ILE . 11.9 tpp180 -50.96 -59.56 4.02 Favored 'General case' 0 C--N 1.29 -2.007 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.308 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 84.8 mt -52.98 -28.44 23.84 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.013 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.457 HG13 ' OD1' ' A' ' 34' ' ' ASP . 7.6 t -61.65 141.19 17.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 C-N-CA 118.915 -1.114 . . . . 0.0 112.181 -179.842 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -139.4 44.02 1.99 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.075 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.27 -104.25 0.01 OUTLIER Glycine 0 N--CA 1.492 2.37 0 C-N-CA 119.244 -1.455 . . . . 0.0 110.157 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.488 ' OG1' ' CD2' ' A' ' 31' ' ' LEU . 2.5 p -73.41 -37.84 65.8 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.08 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -179.65 121.13 0.72 Allowed Glycine 0 N--CA 1.479 1.517 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.423 ' O ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pttm -58.57 -157.31 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.507 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.52 ' CG ' ' H ' ' A' ' 28' ' ' GLY . 25.4 t-20 59.31 176.29 0.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.013 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.52 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -46.12 -17.16 0.19 Allowed Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.733 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.482 ' N ' ' O ' ' A' ' 27' ' ' ASN . 14.5 mmt85 -80.13 35.41 0.32 Allowed 'General case' 0 N--CA 1.493 1.723 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.19 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.77 HG11 ' N ' ' A' ' 31' ' ' LEU . 11.7 t -101.6 156.48 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.442 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.77 ' N ' HG11 ' A' ' 30' ' ' VAL . 1.9 pt? -129.64 -170.71 2.35 Favored 'General case' 0 N--CA 1.512 2.634 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.633 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.43 ' C ' ' H ' ' A' ' 34' ' ' ASP . 77.8 tttt -71.02 -55.37 8.43 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.54 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 60.9 tt0 -61.03 -5.68 1.53 Allowed 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.9 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.457 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.2 t0 -67.85 -59.76 3.04 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.386 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.402 HD13 ' H ' ' A' ' 35' ' ' ILE . 3.3 mp -66.55 -37.47 79.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.653 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -46.6 -42.78 16.6 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.348 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.17 -35.91 76.8 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.394 -0.923 . . . . 0.0 110.666 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.547 ' CD2' HG12 ' A' ' 16' ' ' VAL . 60.6 t80 -43.46 -67.54 0.27 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.467 -0.893 . . . . 0.0 112.171 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.4 tp . . . . . 0 C--N 1.302 -1.497 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.246 -179.719 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.5 t . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.024 0.44 . . . . 0.0 110.239 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 59.0 ttp85 -60.98 -51.5 68.98 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.093 -1.043 . . . . 0.0 110.749 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.1 mttt -51.26 -39.75 57.39 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.753 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -59.7 -45.95 90.56 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.206 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -53.12 -46.15 68.62 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.696 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -55.91 -40.96 73.83 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -63.08 -45.95 89.72 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.4 mmtt -78.31 -10.07 59.51 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.449 -0.901 . . . . 0.0 111.183 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.96 1.5 90.64 Favored Glycine 0 N--CA 1.496 2.642 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.899 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.653 HG12 ' CD2' ' A' ' 38' ' ' PHE . 57.8 t -74.5 130.54 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.507 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -83.22 110.01 17.71 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.155 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.598 HG21 ' H ' ' A' ' 19' ' ' ARG . 5.7 tp -42.26 -41.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.466 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.598 ' H ' HG21 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -48.07 -59.1 3.64 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.822 -179.83 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 46.8 mt -60.45 -18.41 51.01 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.475 HG22 ' HA ' ' A' ' 18' ' ' ILE . 10.2 t -70.64 139.73 19.56 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 118.552 -1.259 . . . . 0.0 111.649 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.401 ' O ' ' CD ' ' A' ' 22' ' ' GLN . 0.6 OUTLIER -145.7 79.44 1.56 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.706 179.901 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.18 -99.12 1.97 Allowed Glycine 0 N--CA 1.504 3.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -79.07 -38.97 35.05 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.428 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.524 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -170.61 116.16 0.63 Allowed Glycine 0 N--CA 1.485 1.932 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 pttp -74.1 38.64 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.001 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.524 ' H ' ' C ' ' A' ' 25' ' ' GLY . 25.0 t-20 -117.07 -179.59 3.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.712 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.523 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -47.57 -14.95 0.24 Allowed Glycine 0 N--CA 1.492 2.432 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.197 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.513 ' N ' ' O ' ' A' ' 27' ' ' ASN . 32.2 mmm-85 -95.47 37.22 1.2 Allowed 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.119 -0.632 . . . . 0.0 111.556 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.518 ' C ' HD21 ' A' ' 31' ' ' LEU . 2.6 t -70.99 154.64 7.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.105 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.778 HD21 ' N ' ' A' ' 31' ' ' LEU . 2.9 mm? -106.5 173.3 6.38 Favored 'General case' 0 N--CA 1.509 2.492 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.951 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.6 tmtt? -77.13 -41.43 41.96 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.386 -0.925 . . . . 0.0 108.926 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -71.78 -3.63 23.17 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.399 -0.818 . . . . 0.0 109.35 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -68.52 -56.04 9.68 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.079 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.419 HD13 ' CD1' ' A' ' 18' ' ' ILE . 1.8 mt -73.09 -37.54 53.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.643 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -51.22 -39.37 56.42 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.341 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.5 -33.62 71.42 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.347 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.653 ' CD2' HG12 ' A' ' 16' ' ' VAL . 65.9 t80 -45.07 -68.04 0.23 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.016 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 56.1 tp . . . . . 0 C--N 1.302 -1.481 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.995 -179.918 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.1 t . . . . . 0 N--CA 1.494 1.727 0 CA-C-O 120.938 0.399 . . . . 0.0 111.161 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.484 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 55.5 ttt180 -57.06 -36.05 70.07 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.384 -0.926 . . . . 0.0 111.199 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mmtm -54.85 -47.61 73.94 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 119.136 -1.026 . . . . 0.0 110.217 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -53.73 -46.94 71.02 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.073 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 8' ' ' ARG . . . -52.12 -46.32 65.29 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.651 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.2 mtp180 -59.48 -44.29 93.08 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.679 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -56.69 -42.74 79.6 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.575 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -86.8 -13.92 43.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.834 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 75.91 67.84 1.64 Allowed Glycine 0 N--CA 1.488 2.134 0 C-N-CA 119.327 -1.416 . . . . 0.0 110.089 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.888 HG12 ' CD2' ' A' ' 38' ' ' PHE . 53.1 t -137.18 130.51 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.339 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -77.3 109.53 11.26 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.07 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.667 HG21 ' N ' ' A' ' 19' ' ' ARG . 6.9 tp -44.69 -41.96 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.503 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.667 ' N ' HG21 ' A' ' 18' ' ' ILE . 63.7 ttt-85 -56.15 -52.69 63.46 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.738 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.7 mt -57.18 -31.04 65.01 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.746 -0.781 . . . . 0.0 112.725 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.565 HG13 ' OD1' ' A' ' 34' ' ' ASP . 7.8 t -57.46 141.87 13.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 118.437 -1.305 . . . . 0.0 111.868 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -136.77 77.71 1.66 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.933 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.26 -108.93 3.34 Favored Glycine 0 N--CA 1.51 3.596 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.621 ' HG1' HD12 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -77.02 -47.91 19.36 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.297 -179.926 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.74 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -151.07 109.28 0.42 Allowed Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.9 pttp -76.07 55.36 0.92 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.601 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.511 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.4 OUTLIER -157.16 -154.95 0.49 Allowed 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 119.746 -0.782 . . . . 0.0 110.546 179.886 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.0 -8.2 0.59 Allowed Glycine 0 C--N 1.289 -2.04 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.246 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.511 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.6 mmt85 -109.09 37.34 2.59 Favored 'General case' 0 N--CA 1.504 2.24 0 C-N-CA 120.217 -0.593 . . . . 0.0 112.076 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.74 HG21 ' O ' ' A' ' 25' ' ' GLY . 3.2 t -80.92 147.4 6.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.076 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.621 HD12 ' HG1' ' A' ' 24' ' ' THR . 6.7 mp -109.37 177.34 4.77 Favored 'General case' 0 N--CA 1.511 2.604 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.51 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.429 ' C ' ' H ' ' A' ' 34' ' ' ASP . 3.6 tmtt? -75.47 -48.74 21.3 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.879 179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -65.47 -5.45 7.84 Favored 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.207 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.565 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.6 t0 -69.5 -53.62 18.2 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.605 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.611 HD12 HD13 ' A' ' 18' ' ' ILE . 2.5 mt -72.46 -30.05 33.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 C-N-CA 119.676 -0.81 . . . . 0.0 110.757 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 36' ' ' ASP . 5.8 m-20 -55.5 -40.69 72.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.279 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.68 -34.81 76.31 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.284 179.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.888 ' CD2' HG12 ' A' ' 16' ' ' VAL . 70.1 t80 -44.55 -69.27 0.14 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.346 -0.942 . . . . 0.0 111.232 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.401 HD11 ' HA ' ' A' ' 39' ' ' LEU . 69.5 tp . . . . . 0 C--N 1.299 -1.604 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.916 -179.882 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.0 t . . . . . 0 N--CA 1.481 1.083 0 CA-C-O 120.978 0.418 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -61.94 -48.03 82.22 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 118.872 -1.131 . . . . 0.0 110.884 -179.906 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -53.76 -38.83 64.81 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.91 179.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -59.11 -44.73 92.0 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 118.883 -1.127 . . . . 0.0 109.36 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -52.05 -43.8 63.96 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.805 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -57.04 -43.49 81.98 Favored 'General case' 0 C--N 1.292 -1.893 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.886 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 59.9 mt-10 -59.06 -53.69 55.47 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.382 -0.927 . . . . 0.0 111.185 179.936 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -78.28 -14.48 59.41 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.115 -179.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 74.15 76.1 0.73 Allowed Glycine 0 N--CA 1.495 2.575 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.883 179.913 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.689 HG12 ' CD2' ' A' ' 38' ' ' PHE . 53.5 t -145.74 126.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 120.161 -0.616 . . . . 0.0 109.965 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -74.5 106.99 6.36 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.739 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.777 HG21 ' N ' ' A' ' 19' ' ' ARG . 10.2 tt -44.64 -40.04 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.036 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.777 ' N ' HG21 ' A' ' 18' ' ' ILE . 11.0 tpt85 -49.68 -54.3 19.44 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.411 -179.912 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 70.8 mt -63.21 -29.17 70.56 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.87 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.649 HG13 ' OD1' ' A' ' 34' ' ' ASP . 11.5 t -55.93 139.19 15.52 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 C-N-CA 118.812 -1.155 . . . . 0.0 111.987 -179.717 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.1 mm100 -137.44 44.43 2.25 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.255 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.24 -107.48 0.01 OUTLIER Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.138 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.551 ' HG1' HD11 ' A' ' 31' ' ' LEU . 0.9 OUTLIER -78.75 -42.45 28.09 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.81 179.969 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -166.17 124.05 1.2 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.995 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 27' ' ' ASN . 14.9 ptmt -61.64 -156.87 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.009 -1.077 . . . . 0.0 110.678 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.553 ' ND2' ' N ' ' A' ' 28' ' ' GLY . 1.8 p-10 43.4 -154.18 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.567 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.553 ' N ' ' ND2' ' A' ' 27' ' ' ASN . . . -53.14 -20.91 10.0 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 120.074 -1.06 . . . . 0.0 111.63 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.436 ' O ' ' O ' ' A' ' 25' ' ' GLY . 22.2 mmt180 -78.25 27.03 0.2 Allowed 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 118.909 -1.116 . . . . 0.0 111.35 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.479 ' H ' ' C ' ' A' ' 28' ' ' GLY . 3.3 t -92.44 129.22 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 C-N-CA 120.028 -0.669 . . . . 0.0 110.914 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.551 HD11 ' HG1' ' A' ' 24' ' ' THR . 10.6 mp -103.44 -177.58 3.41 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.432 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -75.8 -36.12 59.83 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.047 -1.061 . . . . 0.0 109.268 179.82 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -78.87 -2.68 40.96 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.375 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.649 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.3 t0 -68.78 -55.89 9.8 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.751 179.926 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.514 HG22 HD11 ' A' ' 35' ' ' ILE . 3.7 mt -72.52 -39.21 61.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.481 179.937 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -47.8 -39.95 19.67 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 118.966 -1.093 . . . . 0.0 109.806 179.875 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.52 -34.19 67.42 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.586 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.689 ' CD2' HG12 ' A' ' 16' ' ' VAL . 76.7 t80 -40.88 -66.42 0.33 Allowed 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.086 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 10.1 tp . . . . . 0 C--N 1.302 -1.477 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.752 -179.949 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.5 t . . . . . 0 N--CA 1.498 1.95 0 CA-C-O 120.875 0.369 . . . . 0.0 111.242 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 56.1 ttp180 -60.92 -35.85 77.78 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.46 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.7 mmtp -55.65 -42.9 75.69 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.395 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.5 t80 -58.26 -48.65 79.75 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.799 -1.16 . . . . 0.0 109.329 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.27 -43.25 42.88 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.018 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 79.1 mtt180 -58.27 -43.81 88.11 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.977 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -55.68 -53.15 60.11 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.826 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.3 mmmt -80.4 0.38 33.47 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.148 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 58.51 70.89 0.86 Allowed Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.25 -1.452 . . . . 0.0 110.403 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.844 HG12 ' CD2' ' A' ' 38' ' ' PHE . 19.9 t -141.64 139.2 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.113 -179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.495 ' N ' HG11 ' A' ' 16' ' ' VAL . 63.0 t0 -85.99 107.95 18.0 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.507 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.708 HG21 ' N ' ' A' ' 19' ' ' ARG . 15.3 tt -46.49 -40.97 4.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 119.769 -0.772 . . . . 0.0 110.92 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.708 ' N ' HG21 ' A' ' 18' ' ' ILE . 5.1 tpm_? -48.16 -57.59 5.67 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.71 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.417 ' HA ' HD21 ' A' ' 20' ' ' LEU . 89.1 mt -54.0 -35.47 61.9 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.704 -0.799 . . . . 0.0 111.783 -179.87 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.493 HG13 ' OD1' ' A' ' 34' ' ' ASP . 11.6 t -56.38 139.5 15.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.432 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -138.94 53.91 1.75 Allowed 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.694 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.82 -114.79 0.06 OUTLIER Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.603 -1.284 . . . . 0.0 111.378 -179.851 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.461 ' HG1' HD12 ' A' ' 31' ' ' LEU . 1.5 p -92.96 -71.06 0.67 Allowed 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.884 -179.851 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.428 ' O ' ' OD1' ' A' ' 27' ' ' ASN . . . -58.93 -50.05 71.79 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.356 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.401 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 21.6 pttp 41.6 36.56 0.59 Allowed 'General case' 0 C--N 1.294 -1.806 0 CA-C-O 121.507 0.67 . . . . 0.0 110.79 -179.894 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.528 ' C ' ' H ' ' A' ' 29' ' ' ARG . 13.6 p-10 -159.41 -160.21 0.81 Allowed 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.224 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.94 -7.79 1.18 Allowed Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.021 179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.528 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -121.48 48.66 1.64 Allowed 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.39 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -69.69 158.18 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.344 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.479 HD11 ' N ' ' A' ' 31' ' ' LEU . 8.8 mp -104.46 171.14 7.5 Favored 'General case' 0 N--CA 1.51 2.538 0 C-N-CA 119.408 -0.917 . . . . 0.0 111.154 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 36.0 tttp -76.77 -39.42 51.68 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.205 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -73.01 -6.37 45.01 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 119.337 -0.945 . . . . 0.0 108.879 179.819 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.493 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.7 t0 -65.32 -62.93 1.25 Allowed 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.026 -179.97 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.437 HG21 HG13 ' A' ' 16' ' ' VAL . 5.2 mt -67.52 -31.29 52.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.801 179.91 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -51.27 -41.13 60.21 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.128 -1.029 . . . . 0.0 110.1 179.895 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -75.2 -32.71 61.28 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.844 ' CD2' HG12 ' A' ' 16' ' ' VAL . 77.4 t80 -43.82 -69.87 0.12 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.571 -0.852 . . . . 0.0 111.696 -179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 24.1 tp . . . . . 0 C--N 1.298 -1.631 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.654 -179.824 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 N--CA 1.493 1.714 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 47.5 ttp85 -51.91 -51.56 56.04 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.702 -0.799 . . . . 0.0 112.947 -179.751 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.649 ' CB ' ' HZ1' ' A' ' 9' ' ' LYS . 0.2 OUTLIER -49.07 -49.47 41.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.688 -179.846 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.458 ' N ' ' CG ' ' A' ' 9' ' ' LYS . 2.3 t80 -51.93 -44.57 63.94 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.079 179.921 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.85 -43.9 63.4 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.58 -0.848 . . . . 0.0 110.928 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -59.64 -43.25 93.95 Favored 'General case' 0 C--N 1.293 -1.849 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.371 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -54.7 -60.01 3.94 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.55 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -75.17 11.07 1.26 Allowed 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.374 -179.896 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.541 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 53.59 75.84 0.21 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.596 -1.288 . . . . 0.0 111.611 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.756 HG12 ' CD2' ' A' ' 38' ' ' PHE . 22.4 t -147.84 135.38 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.843 179.914 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.407 ' N ' HG11 ' A' ' 16' ' ' VAL . 60.6 t0 -82.99 111.32 18.74 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.563 -0.855 . . . . 0.0 111.015 179.923 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.676 HG21 ' H ' ' A' ' 19' ' ' ARG . 15.7 tt -46.11 -40.48 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.943 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.676 ' H ' HG21 ' A' ' 18' ' ' ILE . 52.4 ttt85 -51.86 -58.81 5.39 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 114.867 -1.06 . . . . 0.0 112.301 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.0 mt -50.45 -31.42 15.12 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.524 -179.83 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -62.03 140.74 18.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.781 -1.167 . . . . 0.0 111.159 -179.852 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -134.9 57.15 1.82 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.644 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.4 -112.24 0.08 OUTLIER Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.132 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.525 ' H ' ' HG1' ' A' ' 24' ' ' THR . 0.7 OUTLIER -73.79 -47.85 35.84 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.164 -1.014 . . . . 0.0 109.91 179.971 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.533 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -157.33 114.43 0.61 Allowed Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.53 ' HZ3' HH21 ' A' ' 19' ' ' ARG . 12.0 ptmm? -74.83 36.9 0.11 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.728 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.547 ' CG ' ' H ' ' A' ' 28' ' ' GLY . 25.9 t-20 -109.5 -179.02 3.71 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.547 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -50.93 -11.07 0.5 Allowed Glycine 0 N--CA 1.488 2.124 0 C-N-CA 118.828 -1.653 . . . . 0.0 109.963 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.524 ' H ' ' C ' ' A' ' 27' ' ' ASN . 44.2 mmt-85 -101.01 43.58 1.05 Allowed 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.751 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.488 HG11 ' N ' ' A' ' 31' ' ' LEU . 3.0 t -76.52 163.17 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.397 179.852 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.488 ' N ' HG11 ' A' ' 30' ' ' VAL . 8.6 mp -112.37 174.36 5.92 Favored 'General case' 0 N--CA 1.512 2.655 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.329 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.9 tttp -78.02 -41.38 35.96 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.402 -0.919 . . . . 0.0 108.823 179.867 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -71.53 -5.5 33.7 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.213 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.0 -56.87 8.26 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.36 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.634 HG22 HG13 ' A' ' 16' ' ' VAL . 3.3 mp -72.06 -36.01 55.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.385 -0.926 . . . . 0.0 110.95 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -48.37 -42.12 30.74 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.177 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.48 -34.72 72.71 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.389 179.858 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.756 ' CD2' HG12 ' A' ' 16' ' ' VAL . 69.5 t80 -43.21 -70.63 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.602 179.916 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.6 tp . . . . . 0 C--N 1.299 -1.588 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.019 -179.782 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.894 0.378 . . . . 0.0 110.699 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 12' ' ' ARG . 53.2 ttp180 -65.04 -42.66 94.08 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.763 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.0 mttm -53.48 -36.55 61.79 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.603 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.6 t80 -61.38 -49.6 76.27 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 118.73 -1.188 . . . . 0.0 108.857 179.773 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.06 -43.32 51.12 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.995 179.771 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 8' ' ' ARG . 95.3 mtt180 -65.52 -47.05 77.25 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.025 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mm-40 -48.15 -50.72 27.77 Favored 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.504 -0.879 . . . . 0.0 111.274 -179.92 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.547 ' HB2' ' HZ3' ' A' ' 14' ' ' LYS . 0.5 OUTLIER -82.88 -36.66 25.17 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 119.403 -0.919 . . . . 0.0 111.5 -179.917 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.23 75.47 1.04 Allowed Glycine 0 N--CA 1.505 3.252 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.663 HG12 ' CD2' ' A' ' 38' ' ' PHE . 11.0 t -147.75 131.45 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 C-N-CA 120.012 -0.675 . . . . 0.0 110.049 179.908 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -75.13 103.02 5.13 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.925 179.975 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.858 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.4 tt -42.34 -37.88 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 CA-C-O 121.688 0.756 . . . . 0.0 110.836 179.949 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.858 ' N ' HG21 ' A' ' 18' ' ' ILE . 44.3 ttt85 -50.15 -58.5 5.43 Favored 'General case' 0 C--N 1.287 -2.132 0 CA-C-N 114.413 -1.267 . . . . 0.0 112.502 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 66.7 mt -59.99 -13.84 13.28 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.774 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.531 HG22 ' HA ' ' A' ' 18' ' ' ILE . 6.6 t -75.38 140.11 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 118.582 -1.247 . . . . 0.0 111.38 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.7 mt-30 -144.08 54.83 1.29 Allowed 'General case' 0 N--CA 1.49 1.527 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.017 -179.898 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -73.87 -96.74 0.1 OUTLIER Glycine 0 N--CA 1.495 2.57 0 C-N-CA 118.827 -1.654 . . . . 0.0 109.676 179.928 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.14 -43.11 29.74 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.419 -0.912 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -171.34 119.07 0.77 Allowed Glycine 0 N--CA 1.482 1.709 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.877 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.462 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttm -56.63 -163.23 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.868 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.656 ' O ' HG22 ' A' ' 30' ' ' VAL . 8.8 p30 49.99 -157.71 0.09 Allowed 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.585 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.512 ' C ' ' H ' ' A' ' 30' ' ' VAL . . . -49.16 -30.74 10.87 Favored Glycine 0 N--CA 1.498 2.791 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.172 -179.825 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.444 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.0 mmt85 -74.34 34.44 0.09 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.963 -1.095 . . . . 0.0 111.711 -179.877 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.656 HG22 ' O ' ' A' ' 27' ' ' ASN . 4.9 t -98.6 139.29 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.394 179.908 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.402 ' N ' HG11 ' A' ' 30' ' ' VAL . 10.8 mp -108.22 177.99 4.64 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.298 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.416 ' HG2' ' HZ1' ' A' ' 32' ' ' LYS . 22.6 tttm -75.55 -35.59 60.64 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.735 179.837 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -76.89 -9.35 58.63 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.102 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.453 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.7 t0 -65.33 -57.92 7.18 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.704 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.542 HG21 HG13 ' A' ' 16' ' ' VAL . 5.1 mt -70.2 -29.27 38.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.878 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -53.75 -41.22 66.9 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.873 -1.131 . . . . 0.0 109.58 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.29 -33.78 67.68 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.384 -0.826 . . . . 0.0 110.561 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.663 ' CD2' HG12 ' A' ' 16' ' ' VAL . 74.2 t80 -43.67 -68.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.471 -0.892 . . . . 0.0 111.251 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.806 ' C ' HD11 ' A' ' 39' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.301 -1.536 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.595 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 120.94 0.4 . . . . 0.0 110.802 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -66.23 -41.2 90.37 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.034 -1.066 . . . . 0.0 111.071 -179.922 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.0 mttp -53.09 -35.74 59.94 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.515 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -63.08 -51.54 66.22 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.049 179.83 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -42.15 53.17 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.186 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.9 mtp180 -62.17 -46.86 87.06 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.874 179.911 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -50.49 -50.82 51.74 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.051 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.926 ' HZ2' HD21 ' A' ' 39' ' ' LEU . 0.6 OUTLIER -78.78 -25.47 44.36 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.024 -179.963 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.46 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 96.73 68.75 0.98 Allowed Glycine 0 N--CA 1.505 3.278 0 C-N-CA 119.985 -1.102 . . . . 0.0 111.307 179.944 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.493 HG23 ' CD2' ' A' ' 38' ' ' PHE . 42.2 t -147.98 147.83 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.183 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -94.83 108.54 20.56 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.864 -0.734 . . . . 0.0 110.591 179.921 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.905 HG21 ' N ' ' A' ' 19' ' ' ARG . 10.4 tt -42.68 -41.93 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 120.019 -0.673 . . . . 0.0 111.51 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.905 ' N ' HG21 ' A' ' 18' ' ' ILE . 34.2 mtm-85 -52.42 -57.61 9.32 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.258 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.2 mt -52.88 -25.99 13.4 Favored 'General case' 0 N--CA 1.49 1.527 0 C-N-CA 119.611 -0.835 . . . . 0.0 111.918 -179.826 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.662 HG13 ' OD1' ' A' ' 34' ' ' ASP . 6.5 t -64.13 143.27 15.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.054 -1.058 . . . . 0.0 112.003 -179.817 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -136.63 63.0 1.59 Allowed 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.1 -113.18 0.61 Allowed Glycine 0 N--CA 1.497 2.707 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.775 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.438 ' HG1' HD12 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -74.26 -46.27 42.55 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.385 -179.941 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.17 110.46 0.44 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -75.21 61.05 1.12 Allowed 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.47 -0.892 . . . . 0.0 110.797 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.462 ' C ' ' H ' ' A' ' 29' ' ' ARG . 7.4 p30 -150.35 -164.85 2.12 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.284 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.06 -13.3 0.61 Allowed Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.38 -1.391 . . . . 0.0 110.581 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.462 ' H ' ' C ' ' A' ' 27' ' ' ASN . 1.0 OUTLIER -102.87 34.23 2.93 Favored 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 119.863 -0.735 . . . . 0.0 112.278 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.497 ' C ' HD11 ' A' ' 31' ' ' LEU . 2.7 t -75.34 149.86 6.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 C-N-CA 119.057 -1.057 . . . . 0.0 108.818 179.804 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.689 HD11 ' N ' ' A' ' 31' ' ' LEU . 11.0 mp -107.11 173.6 6.25 Favored 'General case' 0 N--CA 1.511 2.601 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.424 -179.878 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.4 tttm -77.16 -35.06 56.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.712 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.5 mm-40 -75.71 -9.12 58.32 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 114.961 -1.018 . . . . 0.0 108.582 179.794 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.662 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.6 t0 -63.77 -57.01 11.25 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.005 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 mp -65.16 -37.03 79.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.464 -0.894 . . . . 0.0 109.694 179.792 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -45.75 -44.65 13.95 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.353 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.05 76.21 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.471 -0.891 . . . . 0.0 110.493 179.92 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.493 ' CD2' HG23 ' A' ' 16' ' ' VAL . 57.2 t80 -46.29 -71.04 0.08 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.647 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.926 HD21 ' HZ2' ' A' ' 14' ' ' LYS . 12.6 tp . . . . . 0 C--N 1.305 -1.366 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.416 -179.781 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t . . . . . 0 N--CA 1.485 1.305 0 CA-C-O 120.839 0.352 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 41.3 ttp180 -63.57 -34.37 77.66 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 118.737 -1.185 . . . . 0.0 110.767 -179.937 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt -60.12 -41.66 93.12 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.757 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -57.28 -46.34 83.22 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.069 -1.052 . . . . 0.0 109.062 179.909 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.71 -45.99 63.76 Favored 'General case' 0 C--N 1.291 -1.948 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.485 179.867 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.2 mtp85 -59.11 -46.12 89.15 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.806 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -54.58 -39.33 67.69 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.457 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -89.38 -3.75 58.32 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.67 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.27 6.99 66.55 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.568 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.467 HG12 ' CD2' ' A' ' 38' ' ' PHE . 63.6 t -78.13 125.38 37.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.978 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -78.56 110.32 13.56 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.322 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.49 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -43.23 -40.02 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.117 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.49 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 55.0 mtt-85 -52.64 -59.46 4.44 Favored 'General case' 0 C--N 1.286 -2.153 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.228 -179.896 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.1 mt -52.15 -24.84 7.67 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.215 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.753 HG13 ' OD1' ' A' ' 34' ' ' ASP . 8.6 t -63.61 139.54 21.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 118.936 -1.106 . . . . 0.0 112.18 -179.813 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -131.88 64.54 1.59 Allowed 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 114.906 -1.043 . . . . 0.0 109.876 -179.929 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.11 -114.96 0.88 Allowed Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.437 -1.363 . . . . 0.0 110.499 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.452 ' HG1' HD12 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -82.32 -44.87 15.67 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.824 -0.75 . . . . 0.0 110.136 -179.935 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -147.45 103.8 0.28 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.995 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -76.33 60.38 1.53 Allowed 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.677 -179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.522 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.6 p-10 -157.05 -159.4 0.85 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.256 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.73 -9.09 0.67 Allowed Glycine 0 N--CA 1.484 1.876 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.522 ' H ' ' C ' ' A' ' 27' ' ' ASN . 10.9 mmt-85 -107.76 34.38 3.58 Favored 'General case' 0 N--CA 1.507 2.381 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.574 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -74.42 146.71 9.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.186 -1.006 . . . . 0.0 109.019 179.84 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.648 HD11 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -105.44 177.56 4.82 Favored 'General case' 0 N--CA 1.511 2.589 0 C-N-CA 119.597 -0.841 . . . . 0.0 112.131 -179.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 12.9 tmtt? -76.5 -41.02 48.43 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.09 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.28 -4.21 34.75 Favored 'General case' 0 C--N 1.311 -1.07 0 C-N-CA 119.37 -0.932 . . . . 0.0 109.183 179.823 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.753 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.7 t0 -67.37 -61.55 1.86 Allowed 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.748 179.94 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.7 mt -69.63 -30.57 45.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.486 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -52.25 -40.55 61.83 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.668 179.899 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.96 -35.64 72.24 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.258 179.875 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.467 ' CD2' HG12 ' A' ' 16' ' ' VAL . 57.6 t80 -44.73 -70.05 0.12 Allowed 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.373 179.921 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.4 tp . . . . . 0 C--N 1.304 -1.385 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.896 -179.964 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 81.1 t . . . . . 0 N--CA 1.479 0.99 0 CA-C-O 120.936 0.398 . . . . 0.0 111.277 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.5 ttp180 -63.8 -43.44 96.3 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.194 -1.002 . . . . 0.0 111.364 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.2 mttm -52.98 -37.63 61.51 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.646 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -63.45 -48.84 76.04 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.035 -1.066 . . . . 0.0 109.012 179.766 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.442 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -49.38 -42.65 42.85 Favored 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.573 179.898 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.6 mmm180 -58.66 -45.27 89.73 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.973 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -54.0 -45.03 71.36 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 118.99 -1.084 . . . . 0.0 110.147 179.978 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -82.21 -16.64 48.92 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.54 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 81.56 1.77 90.26 Favored Glycine 0 N--CA 1.494 2.522 0 C-N-CA 119.51 -1.329 . . . . 0.0 110.582 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.817 HG12 ' CD2' ' A' ' 38' ' ' PHE . 42.1 t -70.56 127.39 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.49 -0.884 . . . . 0.0 110.678 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 48.9 t0 -75.0 107.24 6.93 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.67 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.546 HG21 ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -42.55 -41.35 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.391 -179.88 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.546 ' N ' HG21 ' A' ' 18' ' ' ILE . 21.3 ttm105 -49.24 -53.08 23.27 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.185 -179.877 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -57.42 -41.3 80.15 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.193 -179.78 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.5 t -48.51 141.51 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.261 -179.827 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -141.58 55.13 1.51 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.719 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.45 -112.03 0.06 OUTLIER Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.974 -1.584 . . . . 0.0 109.96 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.477 ' HG1' HD11 ' A' ' 31' ' ' LEU . 1.1 p -78.29 -43.78 27.12 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.329 -0.948 . . . . 0.0 109.629 179.904 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.677 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -156.39 116.36 0.71 Allowed Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.934 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.6 pttm -76.58 45.83 0.42 Allowed 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.745 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.525 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.2 p-10 -142.58 -153.74 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.047 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.34 -9.07 0.9 Allowed Glycine 0 C--N 1.287 -2.171 0 C-N-CA 119.024 -1.56 . . . . 0.0 109.906 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.525 ' H ' ' C ' ' A' ' 27' ' ' ASN . 23.0 mmt180 -100.26 27.59 5.56 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 119.896 -0.722 . . . . 0.0 111.686 -179.972 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.677 HG21 ' O ' ' A' ' 25' ' ' GLY . 3.3 t -79.95 128.31 38.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 119.475 -0.89 . . . . 0.0 108.669 179.886 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.477 HD11 ' HG1' ' A' ' 24' ' ' THR . 10.8 mp -95.11 173.13 7.72 Favored 'General case' 0 N--CA 1.502 2.127 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.691 -179.811 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -73.94 -34.12 64.2 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 119.069 -1.053 . . . . 0.0 108.649 179.897 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -78.03 -6.62 55.11 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.699 -0.8 . . . . 0.0 108.924 179.878 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.34 -58.13 5.36 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.066 179.916 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.53 HG21 HG13 ' A' ' 16' ' ' VAL . 4.2 mt -74.07 -35.73 42.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.082 -179.894 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -50.24 -41.61 50.39 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.857 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.32 -35.0 71.09 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.731 -0.787 . . . . 0.0 110.66 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.817 ' CD2' HG12 ' A' ' 16' ' ' VAL . 69.0 t80 -42.6 -69.05 0.15 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.255 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.6 tp . . . . . 0 C--N 1.301 -1.509 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.949 -179.976 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 120.9 0.381 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 39.6 ttm-85 -61.08 -38.62 86.9 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.536 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.6 mmtt -56.99 -42.88 81.07 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.558 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -55.6 -47.3 76.74 Favored 'General case' 0 C--N 1.302 -1.499 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.464 179.912 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -53.43 -48.38 68.82 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.117 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mmm-85 -60.96 -43.83 98.2 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.217 179.908 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 56.3 mm-40 -58.23 -28.66 65.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.679 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 11.5 mmmt -101.42 -11.28 19.49 Favored 'General case' 0 N--CA 1.5 2.027 0 C-N-CA 119.874 -0.73 . . . . 0.0 110.655 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.42 63.53 1.7 Allowed Glycine 0 N--CA 1.496 2.635 0 C-N-CA 119.592 -1.289 . . . . 0.0 110.675 179.948 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.423 HG12 ' CD2' ' A' ' 38' ' ' PHE . 62.7 t -145.21 130.36 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.127 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -87.14 121.49 29.67 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.606 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.624 HG21 ' H ' ' A' ' 19' ' ' ARG . 3.8 tp -45.29 -44.1 3.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.78 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.624 ' H ' HG21 ' A' ' 18' ' ' ILE . 53.9 ttp180 -49.21 -58.71 4.55 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.434 -0.803 . . . . 0.0 112.331 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 57.7 mt -52.69 -29.54 27.18 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.784 -0.766 . . . . 0.0 112.033 -179.849 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 t -69.11 139.34 20.61 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 C-N-CA 118.783 -1.167 . . . . 0.0 111.362 -179.818 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 -145.82 54.03 1.16 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.153 -179.978 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.56 -106.46 0.03 OUTLIER Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.309 -1.424 . . . . 0.0 111.174 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.81 -65.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.574 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -138.72 107.02 0.54 Allowed Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.547 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttp -55.9 -163.34 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.379 -0.929 . . . . 0.0 110.545 179.971 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.547 ' ND2' ' O ' ' A' ' 26' ' ' LYS . 3.0 p30 57.66 -163.06 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 CA-C-O 121.362 0.601 . . . . 0.0 112.273 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.535 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -51.1 -21.22 5.31 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.55 -179.808 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.4 mmt85 -90.09 38.76 0.94 Allowed 'General case' 0 N--CA 1.505 2.289 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.256 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.5 HG11 ' N ' ' A' ' 31' ' ' LEU . 4.0 t -90.46 149.34 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.956 179.85 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.5 ' N ' HG11 ' A' ' 30' ' ' VAL . 7.6 mp -106.89 175.19 5.58 Favored 'General case' 0 N--CA 1.509 2.484 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.738 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.8 tttm -76.53 -38.21 55.49 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.43 -0.908 . . . . 0.0 109.425 179.849 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 57.9 mm-40 -73.69 -6.57 47.62 Favored 'General case' 0 C--N 1.307 -1.239 0 C-N-CA 119.441 -0.903 . . . . 0.0 108.966 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -67.57 -55.79 12.03 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.443 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.49 HG22 HD11 ' A' ' 35' ' ' ILE . 2.5 mt -73.18 -34.18 43.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.371 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -52.22 -40.03 61.06 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.448 179.926 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.24 -34.87 68.6 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.423 ' CD2' HG12 ' A' ' 16' ' ' VAL . 72.4 t80 -45.5 -70.3 0.11 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.454 -0.898 . . . . 0.0 111.184 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.771 ' C ' HD21 ' A' ' 39' ' ' LEU . 3.0 tt . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.606 -179.903 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 92.5 t . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 121.024 0.44 . . . . 0.0 110.587 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.9 ttp180 -63.65 -31.19 72.28 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.67 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.9 mmtp -55.31 -44.81 76.13 Favored 'General case' 0 C--N 1.306 -1.298 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.021 179.939 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.524 ' OH ' ' NZ ' ' A' ' 14' ' ' LYS . 9.6 t80 -57.98 -51.16 70.8 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.927 -1.109 . . . . 0.0 108.56 179.782 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -45.28 55.44 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.129 179.829 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -62.32 -47.12 85.65 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.447 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -52.12 -41.0 62.13 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.239 179.8 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.524 ' NZ ' ' OH ' ' A' ' 10' ' ' TYR . 3.2 mmmm -81.31 -69.17 0.63 Allowed 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.53 179.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 138.8 33.68 0.18 Allowed Glycine 0 N--CA 1.501 2.986 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.607 179.97 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.71 HG12 ' CD2' ' A' ' 38' ' ' PHE . 64.5 t -109.44 138.81 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.729 -180.0 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.438 ' N ' HG11 ' A' ' 16' ' ' VAL . 8.6 t70 -84.39 121.7 27.91 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.474 179.969 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.835 HG21 ' N ' ' A' ' 19' ' ' ARG . 3.0 tp -48.57 -44.13 13.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 119.934 -0.707 . . . . 0.0 111.541 -179.911 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.835 ' N ' HG21 ' A' ' 18' ' ' ILE . 32.9 ttm180 -54.07 -49.27 69.43 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.655 -179.908 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.4 mt -57.16 -34.72 68.73 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.52 -0.872 . . . . 0.0 112.102 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.474 HG13 ' OD1' ' A' ' 34' ' ' ASP . 9.8 t -66.7 139.62 20.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.394 -179.879 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -142.93 58.58 1.42 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.27 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.26 -104.36 0.23 Allowed Glycine 0 N--CA 1.496 2.666 0 C-N-CA 119.471 -1.347 . . . . 0.0 111.951 -179.838 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.34 -69.45 0.85 Allowed 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . -40.85 -52.79 3.88 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.03 -1.081 . . . . 0.0 110.559 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.521 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 5.2 mtmp? 48.36 -177.78 0.01 OUTLIER 'General case' 0 C--N 1.29 -2.012 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.925 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 25' ' ' GLY . 7.0 p30 43.13 -171.45 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.563 -179.94 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.92 -7.13 0.41 Allowed Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.178 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.514 ' H ' ' C ' ' A' ' 27' ' ' ASN . 42.2 mmt-85 -111.24 45.9 1.14 Allowed 'General case' 0 N--CA 1.503 2.201 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.794 -179.922 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.806 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.9 t -67.83 158.38 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.11 179.853 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.806 ' N ' HG11 ' A' ' 30' ' ' VAL . 8.8 mt -104.27 173.14 6.43 Favored 'General case' 0 N--CA 1.51 2.564 0 C-N-CA 119.516 -0.873 . . . . 0.0 111.395 -179.916 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.469 ' C ' ' H ' ' A' ' 34' ' ' ASP . 18.7 tptm -73.33 -52.77 12.67 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.381 -0.928 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -63.01 -5.5 3.02 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.224 -0.99 . . . . 0.0 109.849 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.474 ' OD1' HG13 ' A' ' 21' ' ' VAL . 4.5 t0 -66.11 -59.07 4.13 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.414 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.58 HD12 HD11 ' A' ' 18' ' ' ILE . 3.7 mt -73.24 -33.47 41.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.765 -0.774 . . . . 0.0 111.328 179.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -51.22 -41.53 60.36 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.917 179.916 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.96 -33.81 66.11 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.544 -0.863 . . . . 0.0 110.607 179.89 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.71 ' CD2' HG12 ' A' ' 16' ' ' VAL . 70.0 t80 -46.06 -70.93 0.08 Allowed 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.232 179.973 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt . . . . . 0 C--N 1.306 -1.309 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.956 -179.97 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 54.4 t . . . . . 0 N--CA 1.5 2.044 0 CA-C-O 120.796 0.332 . . . . 0.0 110.806 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -62.27 -29.02 70.12 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.185 -1.006 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mmtm -59.59 -42.99 93.8 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.145 -179.943 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.432 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 8.3 t80 -60.02 -49.51 77.39 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 118.743 -1.183 . . . . 0.0 108.664 179.863 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.17 -44.1 52.64 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.858 -179.981 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 57.7 mtp85 -62.25 -46.44 88.81 Favored 'General case' 0 C--N 1.295 -1.765 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.276 -179.869 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -52.96 -32.38 45.7 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.07 -1.052 . . . . 0.0 109.896 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 48.5 mmtt -94.47 -18.34 21.59 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 78.55 13.26 83.39 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.826 HG12 ' CD2' ' A' ' 38' ' ' PHE . 26.9 t -84.12 145.12 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.794 -179.83 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.5 ' N ' HG11 ' A' ' 16' ' ' VAL . 54.0 t0 -85.62 99.23 11.14 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.297 -179.961 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.595 ' HA ' HG22 ' A' ' 21' ' ' VAL . 17.3 tt -40.75 -42.65 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.842 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.525 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 43.9 ttt85 -50.24 -61.38 2.2 Favored 'General case' 0 C--N 1.287 -2.122 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.923 -179.938 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -52.18 -28.55 18.64 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.847 -0.741 . . . . 0.0 112.754 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.595 HG22 ' HA ' ' A' ' 18' ' ' ILE . 11.1 t -55.99 141.31 12.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.72 -1.192 . . . . 0.0 112.382 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -136.69 72.55 1.43 Allowed 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.719 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.6 -105.15 1.59 Allowed Glycine 0 N--CA 1.503 3.127 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.265 -179.86 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.811 ' HG1' HD13 ' A' ' 31' ' ' LEU . 1.3 p -93.7 -68.6 0.79 Allowed 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.115 -179.956 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.516 ' C ' HD21 ' A' ' 27' ' ' ASN . . . -105.42 83.41 0.37 Allowed Glycine 0 N--CA 1.501 3.023 0 C-N-CA 120.022 -1.085 . . . . 0.0 110.472 -179.888 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -69.56 74.48 0.39 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.262 -0.975 . . . . 0.0 110.154 179.992 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.546 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.0 OUTLIER -167.76 -161.52 0.39 Allowed 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.587 179.929 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.55 -4.08 1.25 Allowed Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.03 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.546 ' H ' ' C ' ' A' ' 27' ' ' ASN . 25.9 mmt180 -117.33 42.43 2.56 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.295 -0.562 . . . . 0.0 111.374 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -70.37 157.53 6.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 C-N-CA 119.28 -0.968 . . . . 0.0 108.74 179.841 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.811 HD13 ' HG1' ' A' ' 24' ' ' THR . 60.0 mt -107.01 175.06 5.62 Favored 'General case' 0 N--CA 1.513 2.676 0 C-N-CA 119.031 -1.068 . . . . 0.0 112.037 179.973 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -77.22 -32.95 56.21 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.524 179.932 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -79.13 -8.97 59.41 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 119.39 -0.924 . . . . 0.0 108.929 -179.967 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.584 ' OD1' HG13 ' A' ' 21' ' ' VAL . 1.9 t0 -64.4 -54.54 31.16 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.257 -179.931 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.4 mt -71.17 -34.22 53.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-N 114.588 -1.187 . . . . 0.0 110.867 179.874 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -49.7 -41.39 43.17 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.945 179.831 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.1 -34.83 71.48 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.646 179.79 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.826 ' CD2' HG12 ' A' ' 16' ' ' VAL . 69.3 t80 -42.43 -68.91 0.16 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.689 -0.804 . . . . 0.0 111.483 -179.961 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.8 tp . . . . . 0 C--N 1.302 -1.489 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.901 -179.98 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 69.3 t . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 120.881 0.372 . . . . 0.0 110.223 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.558 HH21 ' HE ' ' A' ' 12' ' ' ARG . 36.0 ttt85 -59.22 -27.74 66.02 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.802 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.1 mmmt -60.99 -44.82 96.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.753 -179.926 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -56.29 -48.33 76.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.266 179.816 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.94 -45.93 67.89 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.558 ' HE ' HH21 ' A' ' 8' ' ' ARG . 13.7 mmt85 -60.42 -43.47 96.72 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.681 -179.93 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -57.37 -54.98 40.72 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.114 179.993 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -71.34 -70.17 0.33 Allowed 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.759 -179.912 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.47 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 137.67 69.59 0.05 OUTLIER Glycine 0 N--CA 1.499 2.849 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.996 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.822 HG12 ' CD2' ' A' ' 38' ' ' PHE . 25.0 t -144.41 129.03 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 C-N-CA 120.015 -0.674 . . . . 0.0 110.341 -179.973 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -73.55 106.61 5.4 Favored 'General case' 0 C--N 1.301 -1.508 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.387 179.849 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.8 tt -45.11 -42.27 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 119.938 -0.705 . . . . 0.0 111.468 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.526 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 71.8 mtm180 -46.29 -58.83 3.35 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.227 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.6 mt -55.46 -35.78 65.85 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.725 -0.79 . . . . 0.0 112.209 -179.798 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 t -53.88 140.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.881 -1.128 . . . . 0.0 111.513 -179.805 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -145.2 67.18 1.23 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.424 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . -81.15 -100.63 0.35 Allowed Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.32 -1.419 . . . . 0.0 109.946 179.962 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -78.15 -47.47 18.06 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.148 179.866 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.673 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -157.68 116.23 0.7 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.979 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 9.0 ptmm? -75.18 51.45 0.53 Allowed 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.991 179.953 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.534 ' C ' ' H ' ' A' ' 29' ' ' ARG . 2.9 p30 -147.6 -161.33 1.31 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.711 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.39 -10.89 0.12 Allowed Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.615 -1.279 . . . . 0.0 110.982 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.534 ' H ' ' C ' ' A' ' 27' ' ' ASN . 27.8 mmm-85 -106.0 38.73 1.94 Allowed 'General case' 0 N--CA 1.504 2.241 0 C-N-CA 120.044 -0.662 . . . . 0.0 112.259 -179.943 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.673 HG21 ' O ' ' A' ' 25' ' ' GLY . 4.1 t -82.3 145.62 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.725 179.79 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.424 HD11 ' N ' ' A' ' 31' ' ' LEU . 10.9 mp -106.78 174.49 5.86 Favored 'General case' 0 N--CA 1.51 2.572 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.185 -179.857 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -76.62 -34.31 58.34 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.368 -0.933 . . . . 0.0 108.926 179.743 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -77.0 -9.23 58.56 Favored 'General case' 0 C--N 1.312 -1.056 0 C-N-CA 119.521 -0.872 . . . . 0.0 108.912 179.84 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.424 ' OD1' ' N ' ' A' ' 23' ' ' GLY . 2.7 t0 -62.77 -49.58 74.43 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.232 179.933 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.569 HG21 HG13 ' A' ' 16' ' ' VAL . 4.8 mt -78.43 -33.53 17.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.259 179.889 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -52.29 -41.81 63.22 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.32 179.935 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.66 -35.88 75.56 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.704 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.822 ' CD2' HG12 ' A' ' 16' ' ' VAL . 64.7 t80 -43.08 -69.05 0.15 Allowed 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.335 -179.974 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.437 ' HA ' HD11 ' A' ' 39' ' ' LEU . 37.6 tp . . . . . 0 C--N 1.3 -1.558 0 CA-C-N 115.366 -0.833 . . . . 0.0 112.643 -179.751 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t . . . . . 0 N--CA 1.488 1.452 0 CA-C-O 120.936 0.398 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 28.5 ttp180 -60.83 -33.52 73.15 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.643 -179.939 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.0 mmtp -59.72 -41.13 90.19 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.334 179.895 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -58.49 -47.6 83.54 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.006 -1.078 . . . . 0.0 109.023 179.924 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.489 ' HB1' ' CD1' ' A' ' 35' ' ' ILE . . . -48.86 -46.07 41.84 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.966 179.746 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 59.2 mtp85 -57.53 -45.5 84.96 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.863 -179.875 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -53.36 -43.88 68.1 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.184 -1.007 . . . . 0.0 110.872 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 14.3 mmmt -81.43 -22.69 38.01 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.929 179.691 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.92 13.95 70.84 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.94 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.488 HG23 ' CD2' ' A' ' 38' ' ' PHE . 38.3 t -83.92 139.53 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.042 179.834 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 46.1 t0 -84.64 100.96 11.79 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.294 179.944 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.595 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -39.28 -39.58 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 CA-C-O 121.437 0.636 . . . . 0.0 111.613 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.595 ' N ' HG21 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -50.33 -62.61 1.48 Allowed 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.092 179.911 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -50.61 -28.38 8.65 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.944 -0.703 . . . . 0.0 112.222 -179.704 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.0 t -60.4 141.34 17.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 118.888 -1.125 . . . . 0.0 112.071 -179.788 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.6 mt-30 -134.31 64.51 1.6 Allowed 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.602 -179.993 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.59 -115.61 0.71 Allowed Glycine 0 N--CA 1.498 2.828 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.435 -179.911 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -81.54 -68.12 0.72 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.009 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.64 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -115.46 100.19 0.94 Allowed Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.887 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 7.4 ptmm? -76.09 50.67 0.62 Allowed 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.514 -0.874 . . . . 0.0 110.775 179.941 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.525 ' C ' ' H ' ' A' ' 29' ' ' ARG . 2.7 p30 -151.01 -155.65 0.64 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.902 -0.719 . . . . 0.0 110.583 -179.941 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.6 -7.73 0.71 Allowed Glycine 0 C--N 1.29 -1.982 0 C-N-CA 119.357 -1.401 . . . . 0.0 110.258 -179.859 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.525 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.5 mmt85 -111.56 39.25 2.38 Favored 'General case' 0 N--CA 1.506 2.353 0 C-N-CA 120.149 -0.621 . . . . 0.0 111.81 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.64 HG21 ' O ' ' A' ' 25' ' ' GLY . 2.9 t -76.64 155.45 5.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 C-N-CA 119.364 -0.934 . . . . 0.0 108.986 179.797 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.488 ' HA ' HD21 ' A' ' 31' ' ' LEU . 38.0 mt -109.44 175.43 5.45 Favored 'General case' 0 N--CA 1.514 2.732 0 C-N-CA 119.276 -0.97 . . . . 0.0 111.832 -179.902 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -78.21 -33.4 49.96 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.004 179.723 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 35.1 mm-40 -79.25 -4.99 53.33 Favored 'General case' 0 C--N 1.314 -0.955 0 C-N-CA 119.468 -0.893 . . . . 0.0 109.08 179.862 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -67.31 -58.4 4.87 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 114.687 -1.142 . . . . 0.0 109.249 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.49 HG22 HD11 ' A' ' 35' ' ' ILE . 6.0 mt -70.78 -31.33 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.738 179.703 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -51.97 -41.06 61.83 Favored 'General case' 0 C--N 1.309 -1.172 0 C-N-CA 118.906 -1.118 . . . . 0.0 110.101 -179.888 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.3 -33.37 65.16 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.619 179.906 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.488 ' CD2' HG23 ' A' ' 16' ' ' VAL . 68.3 t80 -44.68 -71.23 0.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.354 -0.939 . . . . 0.0 111.801 179.937 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.497 ' HA ' HD11 ' A' ' 39' ' ' LEU . 32.3 tp . . . . . 0 C--N 1.3 -1.55 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.489 -179.797 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 N--CA 1.485 1.3 0 CA-C-O 120.813 0.339 . . . . 0.0 111.166 . . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 24.9 ttt-85 -62.29 -48.9 77.85 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.208 -179.747 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 54.5 mttt -52.43 -38.03 58.2 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.799 179.875 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -61.48 -46.15 91.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 118.669 -1.213 . . . . 0.0 108.91 179.836 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.0 -43.18 63.53 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.648 179.9 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -56.29 -45.14 80.32 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.759 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -54.33 -42.64 70.42 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.077 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.0 mmtt -90.04 0.5 57.08 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.274 179.878 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 61.63 16.49 51.0 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.684 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.892 HG12 ' CD2' ' A' ' 38' ' ' PHE . 52.5 t -79.03 137.22 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.773 179.99 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.422 ' N ' HG11 ' A' ' 16' ' ' VAL . 56.8 t0 -85.45 102.45 13.48 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.721 179.889 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.921 HG21 ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -42.76 -42.62 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.906 -0.718 . . . . 0.0 111.712 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.921 ' N ' HG21 ' A' ' 18' ' ' ILE . 56.4 ttt-85 -46.54 -60.06 2.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.689 179.901 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 50.6 mt -55.4 -37.54 67.73 Favored 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.683 -0.807 . . . . 0.0 112.255 -179.683 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.587 HG22 ' HA ' ' A' ' 18' ' ' ILE . 11.0 t -49.51 141.28 2.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.19 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -140.96 62.14 1.48 Allowed 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.485 179.95 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . -80.84 -103.74 0.31 Allowed Glycine 0 N--CA 1.499 2.85 0 C-N-CA 119.101 -1.524 . . . . 0.0 109.494 179.946 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.505 ' HG1' HD22 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -78.02 -36.01 49.2 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.291 -0.964 . . . . 0.0 108.718 179.791 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.07 -156.91 6.96 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 179.895 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.418 ' HZ3' ' HB3' ' A' ' 26' ' ' LYS . 14.7 ttpp -163.78 36.06 0.09 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.648 -0.821 . . . . 0.0 109.349 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -154.08 -158.46 0.87 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.818 -179.999 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.28 -21.63 1.99 Allowed Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.195 -1.478 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -93.09 34.44 1.12 Allowed 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.89 179.945 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.657 ' C ' HD21 ' A' ' 31' ' ' LEU . 3.4 t -82.68 155.08 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.525 -0.87 . . . . 0.0 109.57 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.855 HD21 ' N ' ' A' ' 31' ' ' LEU . 3.6 mm? -104.15 173.26 6.38 Favored 'General case' 0 N--CA 1.509 2.485 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -75.31 -43.75 49.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.419 -0.912 . . . . 0.0 108.916 179.798 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -71.27 -6.79 42.49 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.48 -0.888 . . . . 0.0 109.765 -179.948 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.575 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.7 t0 -62.92 -58.2 8.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.646 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.516 HG22 HD11 ' A' ' 35' ' ' ILE . 2.6 mt -69.99 -36.76 70.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.666 -0.814 . . . . 0.0 110.87 -179.92 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -48.56 -43.26 35.54 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.577 -1.249 . . . . 0.0 110.084 179.95 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.24 -35.48 78.0 Favored 'General case' 0 C--N 1.306 -1.316 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.567 -179.968 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.892 ' CD2' HG12 ' A' ' 16' ' ' VAL . 60.3 t80 -44.93 -68.04 0.23 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.385 179.984 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.2 tp . . . . . 0 C--N 1.302 -1.472 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.137 -179.893 . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.1 t . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.7 0.286 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 56.7 ttt180 -60.1 -36.07 76.61 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.076 -1.049 . . . . 0.0 111.268 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 51.4 mmtt -55.3 -45.63 76.27 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.212 -0.995 . . . . 0.0 110.336 179.87 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.71 ' CB ' ' HZ2' ' A' ' 32' ' ' LYS . 2.5 t80 -54.64 -46.64 73.98 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.101 179.906 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.53 -45.62 47.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.933 -179.863 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 -58.65 -43.39 89.8 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.18 -179.944 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 75.5 mt-10 -57.3 -31.43 65.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.301 -0.959 . . . . 0.0 110.935 -179.943 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.9 mmtt -96.71 -6.72 35.77 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.101 179.944 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 74.62 53.72 6.4 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.409 HG12 ' CD2' ' A' ' 38' ' ' PHE . 43.0 t -136.39 128.5 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.78 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.786 ' O ' HD13 ' A' ' 20' ' ' LEU . 39.1 t0 -88.28 94.42 9.83 Favored 'General case' 0 N--CA 1.494 1.768 0 C-N-CA 119.556 -0.858 . . . . 0.0 111.036 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.919 HG21 ' N ' ' A' ' 19' ' ' ARG . 15.0 tt -23.25 -41.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.437 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -179.95 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.919 ' N ' HG21 ' A' ' 18' ' ' ILE . 45.1 mtm-85 -45.59 -50.23 13.36 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -179.834 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.786 HD13 ' O ' ' A' ' 17' ' ' ASP . 0.3 OUTLIER -76.66 -2.25 31.85 Favored 'General case' 0 N--CA 1.5 2.061 0 C-N-CA 119.114 -1.035 . . . . 0.0 113.28 -179.665 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.535 HG13 ' OD1' ' A' ' 34' ' ' ASP . 85.2 t -74.75 146.25 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 C-N-CA 118.219 -1.392 . . . . 0.0 110.477 179.94 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.502 ' N ' HG11 ' A' ' 21' ' ' VAL . 53.5 mt-30 -135.3 62.92 1.62 Allowed 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.502 179.962 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.15 -118.88 0.44 Allowed Glycine 0 N--CA 1.498 2.825 0 C-N-CA 119.215 -1.469 . . . . 0.0 110.432 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -75.62 -45.83 35.16 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.432 179.968 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.99 106.49 0.3 Allowed Glycine 0 N--CA 1.486 2.009 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -74.39 64.69 1.16 Allowed 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.79 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.514 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.8 p-10 -152.48 -164.96 2.08 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.538 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.42 -8.63 0.83 Allowed Glycine 0 N--CA 1.485 1.953 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.228 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.514 ' H ' ' C ' ' A' ' 27' ' ' ASN . 12.3 mmt85 -108.57 37.86 2.4 Favored 'General case' 0 N--CA 1.503 2.214 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.537 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.588 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.9 t -77.63 158.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 119.504 -0.879 . . . . 0.0 108.949 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.588 ' N ' HG11 ' A' ' 30' ' ' VAL . 9.9 mp -113.64 177.51 4.61 Favored 'General case' 0 N--CA 1.513 2.707 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.591 -179.954 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.71 ' HZ2' ' CB ' ' A' ' 10' ' ' TYR . 15.9 tptp -77.3 -40.3 44.91 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.871 179.692 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -74.64 -4.22 35.9 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.469 179.843 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.535 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.0 t70 -64.93 -54.01 37.49 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.529 179.965 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.461 HD12 HG22 ' A' ' 35' ' ' ILE . 4.3 mt -75.5 -36.97 36.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.698 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 55.6 t0 -48.93 -40.46 30.21 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 118.688 -1.205 . . . . 0.0 109.91 179.895 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.89 -35.73 69.83 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.357 -179.998 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.409 ' CD2' HG12 ' A' ' 16' ' ' VAL . 72.2 t80 -45.7 -71.48 0.07 Allowed 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.24 179.862 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.449 ' HA ' HD11 ' A' ' 39' ' ' LEU . 18.1 tp . . . . . 0 C--N 1.302 -1.486 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.713 -179.841 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.0 t . . . . . 0 N--CA 1.492 1.665 0 CA-C-O 120.969 0.414 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 27.8 ttm180 -58.36 -37.98 76.31 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 118.973 -1.091 . . . . 0.0 110.48 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -53.83 -44.81 70.58 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.289 -179.845 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.43 ' HE1' HG23 ' A' ' 35' ' ' ILE . 4.9 t80 -57.67 -48.44 79.5 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 118.991 -1.083 . . . . 0.0 109.299 179.785 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.533 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -50.82 -45.26 59.43 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.323 179.972 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -60.46 -45.83 92.28 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.433 -179.885 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -55.76 -29.42 59.56 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.796 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.1 mmtt -108.58 -5.31 16.55 Favored 'General case' 0 N--CA 1.502 2.158 0 C-N-CA 120.123 -0.631 . . . . 0.0 110.768 179.97 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 62.0 81.13 0.09 OUTLIER Glycine 0 N--CA 1.491 2.305 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.588 179.923 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.929 HG12 ' CD2' ' A' ' 38' ' ' PHE . 24.5 t -147.76 129.44 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.139 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -70.7 96.92 1.28 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.577 -179.975 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.776 HG21 ' H ' ' A' ' 19' ' ' ARG . 16.0 tt -40.52 -41.69 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.969 179.891 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.776 ' H ' HG21 ' A' ' 18' ' ' ILE . 10.0 tpt180 -55.14 -60.42 3.41 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.278 179.996 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.0 mt -49.42 -20.39 0.69 Allowed 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.964 -179.912 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.452 HG22 ' HA ' ' A' ' 18' ' ' ILE . 5.9 t -68.32 139.5 20.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.997 -179.846 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -142.61 52.56 1.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.012 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.4 -95.99 0.06 OUTLIER Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.651 -1.261 . . . . 0.0 111.036 -179.95 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.46 -46.3 16.14 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.38 -0.928 . . . . 0.0 110.291 -179.863 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -161.74 111.97 0.5 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.93 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.447 ' O ' ' OD1' ' A' ' 27' ' ' ASN . 17.5 ptmt -55.7 -163.5 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.77 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.64 ' ND2' ' N ' ' A' ' 28' ' ' GLY . 0.4 OUTLIER 50.82 -160.51 0.08 Allowed 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.416 -179.922 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.64 ' N ' ' ND2' ' A' ' 27' ' ' ASN . . . -50.2 -26.5 9.32 Favored Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.898 -1.144 . . . . 0.0 111.438 -179.823 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.435 ' O ' ' O ' ' A' ' 25' ' ' GLY . 22.0 mmt180 -75.19 29.59 0.1 Allowed 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.592 -179.883 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.52 ' H ' ' C ' ' A' ' 28' ' ' GLY . 2.9 t -90.74 133.72 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.375 179.901 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.469 HD11 ' N ' ' A' ' 31' ' ' LEU . 9.8 mp -104.18 178.82 4.45 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.786 179.943 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -74.43 -36.86 63.42 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.132 179.731 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -75.11 -8.55 56.87 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.189 179.872 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -66.07 -57.34 7.95 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.634 179.829 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.47 HG22 HD11 ' A' ' 35' ' ' ILE . 3.8 mt -66.58 -31.34 53.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.276 -179.951 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -51.57 -40.94 60.7 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.065 -1.054 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.84 -33.19 68.24 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.687 179.924 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.929 ' CD2' HG12 ' A' ' 16' ' ' VAL . 64.9 t80 -45.47 -69.39 0.14 Allowed 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.129 -179.967 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.459 HD11 ' HA ' ' A' ' 39' ' ' LEU . 18.8 tp . . . . . 0 C--N 1.303 -1.45 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.821 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.435 ' H3 ' HG21 ' A' ' 1' ' ' VAL . 2.7 t . . . . . 0 N--CA 1.482 1.172 0 CA-C-O 120.828 0.347 . . . . 0.0 110.277 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.428 HG21 ' N ' ' A' ' 3' ' ' ALA . 18.4 mm -55.37 159.98 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.912 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.428 ' N ' HG21 ' A' ' 2' ' ' ILE . . . -56.88 164.7 1.46 Allowed 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.491 -0.884 . . . . 0.0 110.833 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 55.6 mtt -66.79 150.62 97.54 Favored Pre-proline 0 C--N 1.303 -1.443 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.465 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -61.11 -42.68 34.38 Favored 'Trans proline' 0 C--O 1.217 -0.562 0 C-N-CA 120.769 0.98 . . . . 0.0 110.76 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.6 m -47.17 -29.97 2.63 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.647 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.9 t -87.88 -42.38 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 C-N-CA 119.442 -0.903 . . . . 0.0 111.372 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 25.1 ttm180 -61.45 -43.41 98.91 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.534 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.472 ' CB ' ' HZ2' ' A' ' 9' ' ' LYS . 4.6 mtpm? -52.94 -39.61 63.01 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.936 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.911 ' HH ' ' NZ ' ' A' ' 14' ' ' LYS . 12.2 t80 -60.01 -50.5 73.48 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 118.7 -1.2 . . . . 0.0 109.196 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.91 -43.52 39.39 Favored 'General case' 0 C--N 1.29 -1.996 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.136 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.6 mtp180 -66.46 -45.46 79.66 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.308 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 39.1 mm-40 -46.73 -61.37 1.87 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.416 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.911 ' NZ ' ' HH ' ' A' ' 10' ' ' TYR . 11.4 ptpt -77.31 -22.99 51.11 Favored 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 118.599 -1.241 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.43 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 93.61 81.1 1.49 Allowed Glycine 0 N--CA 1.507 3.38 0 C-N-CA 119.731 -1.223 . . . . 0.0 111.477 179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.862 HG12 ' CD2' ' A' ' 38' ' ' PHE . 18.7 t -148.42 129.6 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.266 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -74.03 104.52 4.89 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.651 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.822 HG21 ' N ' ' A' ' 19' ' ' ARG . 11.5 tt -48.92 -44.2 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.928 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.822 ' N ' HG21 ' A' ' 18' ' ' ILE . 19.4 ttm180 -47.88 -54.48 12.47 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.508 -0.769 . . . . 0.0 112.467 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.456 ' HA ' HD21 ' A' ' 20' ' ' LEU . 61.4 mt -57.54 -35.85 70.85 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 112.088 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.635 HG22 ' HA ' ' A' ' 18' ' ' ILE . 13.2 t -52.03 140.96 6.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.673 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -142.56 66.45 1.33 Allowed 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.427 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.77 -101.26 0.27 Allowed Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.067 -1.539 . . . . 0.0 109.463 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -82.26 -42.31 19.04 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.151 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.416 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -160.91 119.0 0.86 Allowed Glycine 0 N--CA 1.477 1.424 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.7 pttp -75.07 46.29 0.3 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.966 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.529 ' C ' ' H ' ' A' ' 29' ' ' ARG . 14.9 p-10 -143.19 -152.34 0.41 Allowed 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.204 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.56 -8.46 0.54 Allowed Glycine 0 C--N 1.291 -1.959 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.388 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.529 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.8 mmt180 -102.95 34.91 2.68 Favored 'General case' 0 N--CA 1.503 2.184 0 C-N-CA 119.87 -0.732 . . . . 0.0 111.821 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.416 HG22 ' O ' ' A' ' 27' ' ' ASN . 6.3 t -85.27 127.38 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.493 ' N ' ' CD1' ' A' ' 31' ' ' LEU . 9.6 mp -96.31 172.36 8.0 Favored 'General case' 0 N--CA 1.505 2.314 0 C-N-CA 119.239 -0.984 . . . . 0.0 112.486 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -71.32 -33.98 70.16 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.877 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -80.21 -8.27 59.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.266 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -65.53 -53.04 47.81 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.456 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.509 HG22 HG13 ' A' ' 16' ' ' VAL . 3.8 mt -75.54 -34.4 29.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.789 179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -50.53 -41.96 54.51 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.934 -1.106 . . . . 0.0 109.848 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.59 67.5 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.979 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.862 ' CD2' HG12 ' A' ' 16' ' ' VAL . 77.9 t80 -42.9 -65.87 0.43 Allowed 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.581 -0.847 . . . . 0.0 112.232 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.1 tp -72.12 -42.99 65.42 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.367 -0.933 . . . . 0.0 112.548 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -42.2 -46.56 4.47 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 119.351 -0.939 . . . . 0.0 111.454 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -47.04 -38.44 10.81 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.464 -1.351 . . . . 0.0 110.443 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.2 -92.14 1.69 Allowed Glycine 0 N--CA 1.494 2.54 0 C-N-CA 119.612 -1.28 . . . . 0.0 110.564 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.503 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.648 -179.941 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' A' ' 2' ' ' ILE . 16.5 m . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 120.904 0.383 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.512 ' HA ' HD11 ' A' ' 2' ' ' ILE . 13.6 mm 55.29 162.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.955 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.49 ' N ' HG21 ' A' ' 2' ' ' ILE . . . -60.88 140.75 57.61 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.249 -0.981 . . . . 0.0 110.469 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.415 ' HB2' ' HE1' ' A' ' 4' ' ' MET . 56.5 mtm -58.66 153.62 40.09 Favored Pre-proline 0 C--N 1.306 -1.308 0 C-N-CA 119.421 -0.912 . . . . 0.0 110.439 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -66.56 68.71 0.49 Allowed 'Trans proline' 0 CA--C 1.549 1.244 0 C-N-CA 120.884 1.056 . . . . 0.0 110.822 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.2 p -174.7 -39.31 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.572 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.7 t -75.02 -44.41 44.33 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.97 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.429 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 12.0 ttt85 -64.36 -40.69 96.36 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.177 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 17.3 mttp -53.79 -37.96 64.01 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.083 -1.047 . . . . 0.0 110.539 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -60.71 -49.99 75.3 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.766 -1.173 . . . . 0.0 108.966 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.628 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -48.98 -43.63 40.2 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.573 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -59.45 -45.16 92.38 Favored 'General case' 0 C--N 1.294 -1.821 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.03 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -53.67 -40.05 65.61 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.308 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 15.4 mmmt -87.99 -3.24 58.93 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.612 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.75 3.08 48.55 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.359 -1.4 . . . . 0.0 110.331 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.576 HG12 ' CD2' ' A' ' 38' ' ' PHE . 54.2 t -74.4 133.05 32.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.778 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -84.3 108.9 17.42 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.655 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.552 ' HA ' HG22 ' A' ' 21' ' ' VAL . 15.7 tt -44.14 -41.2 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.383 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.517 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.4 tpm_? -48.73 -59.93 3.14 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 114.832 -1.076 . . . . 0.0 112.552 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.6 mt -55.49 -31.44 62.01 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.528 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.552 HG22 ' HA ' ' A' ' 18' ' ' ILE . 13.7 t -53.36 140.55 9.34 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.8 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -135.46 65.4 1.55 Allowed 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 114.997 -1.002 . . . . 0.0 109.801 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.68 -118.42 0.95 Allowed Glycine 0 N--CA 1.502 3.038 0 C-N-CA 119.633 -1.27 . . . . 0.0 111.805 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.16 -72.48 0.6 Allowed 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.086 -179.879 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.489 ' O ' ' N ' ' A' ' 27' ' ' ASN . . . -91.29 69.34 2.08 Favored Glycine 0 N--CA 1.496 2.67 0 C-N-CA 119.761 -1.209 . . . . 0.0 110.397 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -64.49 73.87 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.564 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.523 ' C ' ' H ' ' A' ' 29' ' ' ARG . 33.1 p-10 -174.37 -159.86 0.09 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.829 -0.748 . . . . 0.0 110.259 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.9 -7.62 1.1 Allowed Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.061 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.523 ' H ' ' C ' ' A' ' 27' ' ' ASN . 47.9 mmt-85 -116.5 46.26 1.64 Allowed 'General case' 0 N--CA 1.504 2.263 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.564 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.612 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.7 t -72.89 157.89 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.282 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.623 HD11 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -104.62 172.84 6.58 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.213 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -79.6 -34.34 40.83 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.582 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 51.8 mm-40 -76.04 -6.57 51.68 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 119.367 -0.933 . . . . 0.0 108.512 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -66.0 -55.47 16.53 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.408 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.628 HD11 ' HB3' ' A' ' 11' ' ' ALA . 3.5 mt -75.07 -32.59 27.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.701 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -51.24 -40.49 58.94 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.727 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.432 ' O ' ' N ' ' A' ' 41' ' ' GLY . . . -71.79 -37.24 70.45 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.533 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.576 ' CD2' HG12 ' A' ' 16' ' ' VAL . 65.7 t80 -40.78 -67.78 0.22 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.756 -0.778 . . . . 0.0 111.719 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.9 tp -73.99 -25.83 60.13 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.751 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -139.33 75.54 1.52 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.212 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 37' ' ' ALA . . . -93.76 29.66 8.3 Favored Glycine 0 N--CA 1.5 2.904 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.92 -176.84 46.55 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.533 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.345 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.857 -179.841 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 N--CA 1.48 1.047 0 CA-C-O 120.857 0.361 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.7 HG21 ' N ' ' A' ' 3' ' ' ALA . 25.0 mm -52.83 166.84 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 C-N-CA 119.532 -0.867 . . . . 0.0 110.835 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.7 ' N ' HG21 ' A' ' 2' ' ' ILE . . . 45.17 58.38 4.13 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.739 -0.784 . . . . 0.0 111.173 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.632 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 20.6 ptt? -125.45 -15.41 0.05 OUTLIER Pre-proline 0 N--CA 1.5 2.067 0 N-CA-C 114.855 1.428 . . . . 0.0 114.855 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.632 ' CD ' ' N ' ' A' ' 4' ' ' MET . 1.3 Cg_endo -66.23 -47.93 2.96 Favored 'Trans proline' 0 C--N 1.357 0.986 0 CA-C-N 120.18 1.1 . . . . 0.0 110.94 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.417 ' O ' ' OG ' ' A' ' 6' ' ' SER . 29.7 t -164.93 30.44 0.06 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.493 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.496 HG13 ' HB3' ' A' ' 3' ' ' ALA . 53.3 t -100.39 -76.63 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 C-N-CA 120.141 -0.624 . . . . 0.0 110.559 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -65.92 -30.82 71.46 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.007 -1.077 . . . . 0.0 110.72 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.9 mmtt -62.23 -40.03 94.8 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.014 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.423 ' HE1' HG23 ' A' ' 35' ' ' ILE . 3.3 t80 -57.92 -46.92 84.27 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.245 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.463 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -49.2 -45.17 43.92 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 115.111 -0.95 . . . . 0.0 111.008 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -58.5 -44.59 89.48 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.389 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 mt-10 -54.72 -51.92 64.09 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 118.986 -1.085 . . . . 0.0 110.989 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.2 mmmt -81.39 6.12 15.44 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.886 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.455 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 56.45 75.5 0.25 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.657 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.91 HG12 ' CD2' ' A' ' 38' ' ' PHE . 46.9 t -144.82 126.45 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.159 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 65.5 t0 -74.51 107.88 6.92 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.269 -0.972 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.896 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.3 tt -42.88 -40.94 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.585 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.896 ' N ' HG21 ' A' ' 18' ' ' ILE . 32.7 mtm180 -54.89 -54.05 47.56 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.255 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -51.84 -36.52 48.47 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.52 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.499 HG13 ' OD1' ' A' ' 34' ' ' ASP . 13.8 t -56.56 142.72 11.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.843 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -142.05 62.26 1.44 Allowed 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 120.098 -0.641 . . . . 0.0 111.647 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.9 -107.23 0.83 Allowed Glycine 0 N--CA 1.5 2.916 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.82 -45.9 40.24 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.467 -0.893 . . . . 0.0 109.626 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.5 120.65 0.99 Allowed Glycine 0 N--CA 1.485 1.91 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -79.99 44.4 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.262 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.521 ' C ' ' H ' ' A' ' 29' ' ' ARG . 1.8 p30 -149.14 -152.05 0.42 Allowed 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.474 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.52 -11.44 0.48 Allowed Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.151 -1.499 . . . . 0.0 110.29 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.521 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.6 mmt180 -102.43 32.85 3.38 Favored 'General case' 0 N--CA 1.503 2.216 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.815 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.434 ' C ' HD11 ' A' ' 31' ' ' LEU . 3.6 t -85.57 135.86 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.376 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.62 HD11 ' N ' ' A' ' 31' ' ' LEU . 11.0 mp -103.45 173.76 6.16 Favored 'General case' 0 N--CA 1.509 2.515 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -72.75 -37.85 67.55 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.649 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -74.46 -9.19 58.34 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.997 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.499 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.9 t0 -66.79 -58.24 5.45 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 114.579 -1.191 . . . . 0.0 109.551 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.463 ' CD1' ' HB3' ' A' ' 11' ' ' ALA . 4.1 mt -72.51 -36.79 55.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.519 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 25.0 t70 -47.24 -41.12 17.9 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 119.102 -1.039 . . . . 0.0 110.245 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' A' ' 41' ' ' GLY . . . -72.74 -35.86 67.61 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.528 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.91 ' CD2' HG12 ' A' ' 16' ' ' VAL . 67.2 t80 -43.09 -70.73 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.377 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.509 HD11 ' HA ' ' A' ' 39' ' ' LEU . 30.9 tp -69.74 -60.91 2.02 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.612 -0.835 . . . . 0.0 110.79 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.519 ' HB1' ' O ' ' A' ' 36' ' ' ASP . . . -47.27 -65.58 0.54 Allowed 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.344 -0.943 . . . . 0.0 111.107 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 37' ' ' ALA . . . -51.74 -39.5 47.0 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.445 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.31 162.55 33.09 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 119.449 -1.357 . . . . 0.0 110.531 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.371 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.762 -180.0 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.0 p . . . . . 0 N--CA 1.479 1.014 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 15.6 mm -69.2 156.14 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.069 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -91.38 -171.35 2.91 Favored 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 119.953 -0.699 . . . . 0.0 110.85 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 28.0 mtt -76.05 154.01 84.65 Favored Pre-proline 0 N--CA 1.488 1.431 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.341 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.568 ' HA ' ' HZ2' ' A' ' 9' ' ' LYS . 10.0 Cg_endo -66.14 73.38 0.36 Allowed 'Trans proline' 0 CA--C 1.546 1.103 0 C-N-CA 120.875 1.05 . . . . 0.0 111.21 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 11.5 t -178.78 -26.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 119.297 -0.961 . . . . 0.0 111.246 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.6 t -84.17 -61.49 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.513 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 68.5 ttp85 -56.61 -43.79 80.52 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.319 -0.952 . . . . 0.0 111.594 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.568 ' HZ2' ' HA ' ' A' ' 5' ' ' PRO . 27.2 mttp -48.39 -46.57 37.32 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.115 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -55.34 -49.55 71.93 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 118.866 -1.134 . . . . 0.0 109.385 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.99 -44.47 60.89 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.688 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -59.67 -43.48 93.98 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.825 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -57.7 -43.06 84.92 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.604 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.1 mmtt -82.3 -16.79 48.12 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.618 -0.833 . . . . 0.0 111.006 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.38 3.81 90.4 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.334 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 37.6 t -74.28 134.65 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.56 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -81.45 107.54 14.3 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.679 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.649 HG21 ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -44.84 -41.11 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 C-N-CA 119.965 -0.694 . . . . 0.0 111.142 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.649 ' N ' HG21 ' A' ' 18' ' ' ILE . 1.7 tmt_? -49.64 -59.0 4.19 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.491 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.2 mt -54.39 -25.8 26.65 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.77 -0.772 . . . . 0.0 112.401 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.65 HG13 ' OD1' ' A' ' 34' ' ' ASP . 8.2 t -62.58 139.9 20.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.691 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -136.49 54.63 1.87 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.5 -110.87 0.06 OUTLIER Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.065 -1.54 . . . . 0.0 109.536 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.458 ' HG1' HD11 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -78.05 -41.31 35.91 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.429 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.71 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -159.03 116.59 0.72 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.9 ptpp? -74.75 39.01 0.13 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.235 -0.986 . . . . 0.0 111.18 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.52 ' O ' ' N ' ' A' ' 29' ' ' ARG . 2.4 p30 -142.25 -152.74 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -47.44 -11.84 0.09 OUTLIER Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.205 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.52 ' N ' ' O ' ' A' ' 27' ' ' ASN . 17.4 mmt-85 -104.33 32.84 3.79 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.178 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.71 HG21 ' O ' ' A' ' 25' ' ' GLY . 3.4 t -82.33 128.34 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 119.391 -0.924 . . . . 0.0 108.62 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.566 HD13 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -97.83 175.68 6.07 Favored 'General case' 0 N--CA 1.507 2.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.79 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -74.06 -35.99 64.31 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 119.517 -0.873 . . . . 0.0 108.825 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -76.49 -8.01 56.3 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 119.362 -0.935 . . . . 0.0 108.627 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.65 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.8 t0 -66.4 -59.25 3.85 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 114.66 -1.154 . . . . 0.0 109.581 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.506 HG22 HD11 ' A' ' 35' ' ' ILE . 4.4 mt -70.48 -30.72 43.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.556 -0.857 . . . . 0.0 110.233 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -53.77 -41.36 67.1 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.486 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.64 -32.86 70.32 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.474 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -45.24 -70.07 0.11 Allowed 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.32 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.448 ' HA ' HD11 ' A' ' 39' ' ' LEU . 32.2 tp -70.92 -57.36 4.66 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.713 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.416 ' O ' ' O ' ' A' ' 39' ' ' LEU . . . -59.76 -151.3 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.298 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.913 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.55 -46.83 2.62 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.589 -1.291 . . . . 0.0 110.516 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.77 14.68 38.01 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 119.293 -1.432 . . . . 0.0 110.243 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.396 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.894 179.95 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.487 HG21 ' N ' ' A' ' 2' ' ' ILE . 6.4 p . . . . . 0 N--CA 1.48 1.051 0 CA-C-O 120.936 0.398 . . . . 0.0 110.009 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.487 ' N ' HG21 ' A' ' 1' ' ' VAL . 11.7 mm -51.85 157.46 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.875 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.528 ' HB2' HG13 ' A' ' 7' ' ' VAL . . . -88.34 61.53 6.23 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.956 -0.698 . . . . 0.0 110.669 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.63 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 23.4 ptt? -115.6 -16.01 0.1 Allowed Pre-proline 0 N--CA 1.508 2.473 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.63 ' CD ' ' N ' ' A' ' 4' ' ' MET . 5.9 Cg_endo -70.18 -70.07 0.02 OUTLIER 'Trans proline' 0 C--N 1.356 0.942 0 CA-C-N 120.177 1.099 . . . . 0.0 110.716 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.1 t -146.55 28.9 1.05 Allowed 'General case' 0 N--CA 1.49 1.537 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.832 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.528 HG13 ' HB2' ' A' ' 3' ' ' ALA . 93.5 t -97.12 -60.49 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.28 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 57.3 ttp180 -62.17 -39.75 93.71 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.984 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mttp -54.52 -40.22 68.38 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.748 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.1 t80 -58.95 -47.06 86.44 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 118.802 -1.159 . . . . 0.0 108.926 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.09 -44.8 42.41 Favored 'General case' 0 C--N 1.291 -1.958 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.662 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 72.1 mtt85 -59.73 -47.12 86.92 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.902 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -50.88 -41.63 58.39 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.332 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 22.7 mmtp -85.49 -19.43 31.23 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.789 -0.764 . . . . 0.0 110.797 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.38 31.58 27.47 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.467 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.738 HG12 ' CD2' ' A' ' 38' ' ' PHE . 40.6 t -105.37 145.3 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 C-N-CA 120.199 -0.601 . . . . 0.0 110.779 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.573 ' N ' HG11 ' A' ' 16' ' ' VAL . 29.2 t0 -91.11 105.56 17.9 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 120.029 -0.669 . . . . 0.0 110.299 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.898 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.7 tt -41.08 -41.71 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 CA-C-O 121.43 0.634 . . . . 0.0 111.797 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.898 ' N ' HG21 ' A' ' 18' ' ' ILE . 11.4 ttt85 -52.08 -57.43 9.56 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-N 115.281 -0.872 . . . . 0.0 111.975 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -52.5 -30.24 29.11 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.878 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.548 HG22 ' HA ' ' A' ' 18' ' ' ILE . 10.2 t -61.59 143.65 14.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.599 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -142.15 52.61 1.47 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.297 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.45 -106.58 0.04 OUTLIER Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.699 -1.715 . . . . 0.0 109.311 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.418 ' HG1' HD11 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -74.79 -44.03 51.67 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.464 179.865 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -160.51 121.97 1.08 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttm -76.79 40.14 0.24 Allowed 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.101 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.53 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.2 p-10 -142.72 -150.36 0.31 Allowed 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.797 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.4 -8.77 0.55 Allowed Glycine 0 C--N 1.284 -2.335 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.226 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.53 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.6 28.72 5.8 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.899 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 t -83.01 128.53 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.748 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.418 HD11 ' HG1' ' A' ' 24' ' ' THR . 10.7 mp -100.07 176.67 5.33 Favored 'General case' 0 N--CA 1.505 2.309 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.957 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.4 tttt -74.41 -36.01 63.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.802 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -76.37 -7.82 55.82 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.883 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -66.26 -51.97 52.26 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.187 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -74.66 -33.19 30.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.994 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -52.07 -40.89 61.85 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 118.716 -1.193 . . . . 0.0 109.566 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.81 -32.88 68.04 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.547 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.738 ' CD2' HG12 ' A' ' 16' ' ' VAL . 76.6 t80 -44.93 -70.54 0.1 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.433 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.533 ' O ' ' N ' ' A' ' 41' ' ' GLY . 37.4 tp -68.05 -25.21 65.25 Favored 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.478 -0.889 . . . . 0.0 111.306 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.479 ' C ' ' H ' ' A' ' 42' ' ' GLY . . . 43.47 17.86 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.191 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -67.67 4.1 4.39 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 119.346 -1.407 . . . . 0.0 110.331 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.479 ' H ' ' C ' ' A' ' 40' ' ' ALA . . . -166.59 -6.18 0.03 OUTLIER Glycine 0 N--CA 1.484 1.871 0 C-N-CA 119.405 -1.379 . . . . 0.0 110.59 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.435 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.774 179.972 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 34.7 m . . . . . 0 N--CA 1.483 1.197 0 CA-C-O 120.961 0.41 . . . . 0.0 110.111 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -70.61 -175.11 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.732 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -54.0 117.21 3.03 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.437 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.649 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 0.0 OUTLIER -116.87 -13.27 0.09 OUTLIER Pre-proline 0 N--CA 1.5 2.061 0 N-CA-C 114.925 1.454 . . . . 0.0 114.925 179.919 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.649 ' CD ' ' N ' ' A' ' 4' ' ' MET . 7.6 Cg_endo -70.63 79.11 1.24 Allowed 'Trans proline' 0 C--N 1.359 1.087 0 CA-C-N 120.1 1.071 . . . . 0.0 110.832 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.2 t 54.91 12.02 0.55 Allowed 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.369 -0.932 . . . . 0.0 111.311 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.0 t -82.32 -64.63 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.628 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -61.42 -29.55 70.01 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.999 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 60.8 mmtt -59.5 -45.7 90.94 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.936 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -55.1 -46.67 75.52 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 119.341 -0.944 . . . . 0.0 109.04 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.93 -45.62 41.87 Favored 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.523 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 61.7 mtt-85 -64.11 -46.37 84.49 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.02 -0.991 . . . . 0.0 111.453 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 66.4 mt-10 -48.52 -48.74 38.11 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.366 -0.934 . . . . 0.0 111.344 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.819 ' HZ3' HD21 ' A' ' 39' ' ' LEU . 0.7 OUTLIER -83.34 -33.42 25.88 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.159 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.09 73.62 1.07 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.578 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.26 130.4 8.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 C-N-CA 120.019 -0.673 . . . . 0.0 110.193 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -76.26 103.04 6.09 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.08 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.539 HG21 ' H ' ' A' ' 19' ' ' ARG . 14.1 tt -42.23 -42.61 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.707 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.539 ' H ' HG21 ' A' ' 18' ' ' ILE . 34.7 ttp180 -45.46 -57.63 3.96 Favored 'General case' 0 C--N 1.289 -2.049 0 CA-C-N 115.264 -0.88 . . . . 0.0 112.415 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 53.1 mt -56.44 -35.97 68.47 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.647 -0.821 . . . . 0.0 112.3 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.53 HG22 ' HA ' ' A' ' 18' ' ' ILE . 16.8 t -50.18 141.44 3.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 C-N-CA 118.875 -1.13 . . . . 0.0 111.819 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.407 ' N ' HG11 ' A' ' 21' ' ' VAL . 0.7 OUTLIER -143.96 65.89 1.3 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.142 179.994 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.43 -105.55 0.6 Allowed Glycine 0 N--CA 1.499 2.84 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.07 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.94 -45.69 40.77 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.373 -0.931 . . . . 0.0 109.757 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.552 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -162.99 115.33 0.65 Allowed Glycine 0 N--CA 1.479 1.543 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -74.84 36.06 0.11 Allowed 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.091 -1.044 . . . . 0.0 110.769 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.552 ' H ' ' C ' ' A' ' 25' ' ' GLY . 26.3 t-20 -107.82 -179.82 4.01 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.98 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.535 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -50.01 -12.14 0.45 Allowed Glycine 0 N--CA 1.485 1.936 0 C-N-CA 119.112 -1.518 . . . . 0.0 110.016 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.516 ' H ' ' C ' ' A' ' 27' ' ' ASN . 14.7 mmt-85 -97.94 36.76 1.5 Allowed 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.624 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.694 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.4 t -71.11 153.0 8.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.001 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.694 ' N ' HG11 ' A' ' 30' ' ' VAL . 10.7 mp -105.56 173.21 6.41 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.332 -0.947 . . . . 0.0 111.312 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -77.18 -37.47 53.58 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.104 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -76.05 -5.58 47.1 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.396 -0.921 . . . . 0.0 109.066 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -65.12 -56.17 14.49 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.224 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.2 mt -69.59 -37.78 75.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.138 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -48.36 -40.46 25.58 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.985 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.21 -34.0 70.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.476 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -45.03 -71.9 0.07 Allowed 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.622 -0.831 . . . . 0.0 111.315 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.819 HD21 ' HZ3' ' A' ' 14' ' ' LYS . 10.5 tp -74.95 -53.76 8.42 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.622 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 45.21 16.87 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.16 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -62.4 -68.67 1.57 Allowed Glycine 0 N--CA 1.487 2.072 0 C-N-CA 119.361 -1.4 . . . . 0.0 110.27 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.63 -112.27 0.01 OUTLIER Glycine 0 N--CA 1.488 2.16 0 C-N-CA 119.366 -1.397 . . . . 0.0 110.364 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.311 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.724 179.951 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.743 HG11 ' N ' ' A' ' 2' ' ' ILE . 96.2 t . . . . . 0 N--CA 1.483 1.204 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.743 ' N ' HG11 ' A' ' 1' ' ' VAL . 9.9 mm -49.98 166.78 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.592 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.599 ' H ' HG21 ' A' ' 2' ' ' ILE . . . -78.98 44.72 0.57 Allowed 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.723 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.642 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 42.8 mtt -91.21 -29.92 0.33 Allowed Pre-proline 0 N--CA 1.491 1.607 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.642 ' CD ' ' N ' ' A' ' 4' ' ' MET . 6.2 Cg_exo -65.67 -153.28 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 120.367 0.711 . . . . 0.0 110.939 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.0 m -71.96 32.08 0.05 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.031 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.56 ' H ' ' C ' ' A' ' 5' ' ' PRO . 73.5 t -79.0 -62.69 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 119.505 -0.878 . . . . 0.0 110.343 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -66.22 -44.28 84.26 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.551 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -52.65 -35.4 54.86 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.745 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -62.82 -49.83 73.38 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.863 -1.135 . . . . 0.0 108.894 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.49 -43.69 62.27 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.973 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 44.9 mtp180 -60.78 -47.09 87.87 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.721 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.96 -53.96 28.46 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.763 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.567 ' HZ2' ' HB2' ' A' ' 39' ' ' LEU . 13.7 ptmt -76.51 -24.61 53.71 Favored 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.915 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.411 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 92.66 70.69 1.16 Allowed Glycine 0 N--CA 1.503 3.154 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.623 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.7 HG12 ' CD2' ' A' ' 38' ' ' PHE . 19.2 t -148.2 145.55 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.929 -0.709 . . . . 0.0 110.287 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.584 ' N ' HG11 ' A' ' 16' ' ' VAL . 67.5 t0 -90.82 106.21 18.36 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.593 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.832 HG21 ' N ' ' A' ' 19' ' ' ARG . 16.6 tt -42.12 -41.72 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.512 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.832 ' N ' HG21 ' A' ' 18' ' ' ILE . 84.6 mtt-85 -50.08 -60.69 2.7 Favored 'General case' 0 C--N 1.285 -2.222 0 CA-C-N 115.021 -0.991 . . . . 0.0 112.421 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.448 ' HA ' HD21 ' A' ' 20' ' ' LEU . 75.6 mt -51.9 -18.1 1.21 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.467 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.609 HG22 ' HA ' ' A' ' 18' ' ' ILE . 6.2 t -72.34 139.8 19.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 C-N-CA 118.671 -1.212 . . . . 0.0 111.66 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 tt0 -138.68 55.39 1.73 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.858 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.54 -109.43 0.02 OUTLIER Glycine 0 N--CA 1.492 2.378 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.698 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.75 ' HG1' ' CD1' ' A' ' 31' ' ' LEU . 0.8 OUTLIER -70.06 -44.31 69.42 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.312 179.878 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.41 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -168.68 121.36 0.94 Allowed Glycine 0 N--CA 1.48 1.614 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.079 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.43 ' CE ' ' O ' ' A' ' 19' ' ' ARG . 0.7 OUTLIER -73.05 66.1 0.8 Allowed 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.304 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.506 ' C ' ' H ' ' A' ' 29' ' ' ARG . 12.3 p30 -152.07 -164.89 2.08 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.243 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.1 -9.52 0.9 Allowed Glycine 0 N--CA 1.483 1.783 0 C-N-CA 119.212 -1.471 . . . . 0.0 110.045 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.506 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.3 mmm-85 -100.76 30.99 3.71 Favored 'General case' 0 N--CA 1.501 2.08 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.531 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.543 HG11 ' N ' ' A' ' 31' ' ' LEU . 4.0 t -81.42 143.67 11.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 119.596 -0.841 . . . . 0.0 108.962 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.75 ' CD1' ' HG1' ' A' ' 24' ' ' THR . 5.4 mp -112.86 174.62 5.81 Favored 'General case' 0 N--CA 1.514 2.728 0 C-N-CA 119.49 -0.884 . . . . 0.0 112.302 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -73.29 -33.65 65.33 Favored 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.168 -1.013 . . . . 0.0 108.299 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -74.55 -12.88 60.58 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.124 -0.944 . . . . 0.0 108.912 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.413 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.2 t0 -63.87 -51.3 65.23 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.228 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.479 HD12 HG22 ' A' ' 35' ' ' ILE . 3.1 mt -75.79 -32.11 23.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.243 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.566 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 54.1 t0 -52.63 -40.45 62.79 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.598 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.92 -34.43 71.52 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.308 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.7 ' CD2' HG12 ' A' ' 16' ' ' VAL . 61.9 t80 -42.92 -70.83 0.09 Allowed 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.77 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.567 ' HB2' ' HZ2' ' A' ' 14' ' ' LYS . 53.5 tp -69.92 -53.85 16.03 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.077 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.566 ' HB1' ' O ' ' A' ' 36' ' ' ASP . . . -48.86 -11.67 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.05 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.514 ' H ' ' C ' ' A' ' 39' ' ' LEU . . . 50.79 46.55 48.34 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.259 -1.448 . . . . 0.0 110.447 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 70.4 90.9 0.08 OUTLIER Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.424 -1.37 . . . . 0.0 110.304 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 C-N-CA 119.505 -0.878 . . . . 0.0 111.122 -179.921 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.43 ' H3 ' HG21 ' A' ' 1' ' ' VAL . 4.1 t . . . . . 0 N--CA 1.483 1.208 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 12.7 mm -60.79 172.38 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.448 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -158.57 -154.48 0.43 Allowed 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.964 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.522 ' C ' ' H ' ' A' ' 6' ' ' SER . 67.4 mtt -75.32 150.48 85.11 Favored Pre-proline 0 N--CA 1.484 1.24 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.629 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -68.3 31.1 0.15 Allowed 'Trans proline' 0 CA--C 1.548 1.214 0 C-N-CA 121.014 1.143 . . . . 0.0 111.674 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.522 ' H ' ' C ' ' A' ' 4' ' ' MET . 31.4 t -151.68 -25.63 0.19 Allowed 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 118.94 -1.104 . . . . 0.0 111.817 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.441 HG22 ' HB2' ' A' ' 4' ' ' MET . 85.7 t -76.14 -60.38 2.39 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 C-N-CA 119.258 -0.977 . . . . 0.0 111.183 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 61.3 ttt180 -63.29 -37.21 86.35 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.85 -1.14 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.8 mmtt -55.81 -40.35 72.64 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.491 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -56.62 -51.11 69.95 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.631 -1.228 . . . . 0.0 108.977 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.24 -45.38 54.01 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.246 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtp180 -62.89 -46.69 86.63 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.823 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -52.07 -55.8 18.42 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.782 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.6 mmtt -67.7 -66.03 0.61 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 133.66 64.73 0.07 OUTLIER Glycine 0 N--CA 1.499 2.867 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.721 HG12 ' CD2' ' A' ' 38' ' ' PHE . 41.9 t -142.24 138.99 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.479 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 38.2 t0 -83.96 109.23 17.45 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.639 -0.825 . . . . 0.0 110.553 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.75 HG21 ' N ' ' A' ' 19' ' ' ARG . 9.2 tt -44.05 -41.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.512 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.75 ' N ' HG21 ' A' ' 18' ' ' ILE . 58.6 ttp180 -50.33 -58.16 6.3 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.33 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.2 mt -54.93 -28.21 49.22 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.325 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.9 t -62.43 142.28 16.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 C-N-CA 118.754 -1.179 . . . . 0.0 111.308 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -142.23 66.24 1.34 Allowed 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.52 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.1 -103.22 0.66 Allowed Glycine 0 N--CA 1.5 2.93 0 C-N-CA 119.24 -1.457 . . . . 0.0 109.552 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.43 ' HG1' ' H ' ' A' ' 25' ' ' GLY . 0.7 OUTLIER -79.7 -51.81 8.75 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.486 179.912 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.43 ' H ' ' HG1' ' A' ' 24' ' ' THR . . . -151.25 114.19 0.63 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 pttm -76.0 55.95 0.95 Allowed 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.045 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.524 ' C ' ' H ' ' A' ' 29' ' ' ARG . 1.5 p30 -146.2 -162.34 1.5 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.259 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.46 -10.19 0.54 Allowed Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.303 -1.427 . . . . 0.0 110.153 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.524 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.2 mmt85 -104.39 35.25 2.78 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.751 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -78.07 145.24 10.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.296 -0.962 . . . . 0.0 108.625 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.534 HD11 ' N ' ' A' ' 31' ' ' LEU . 8.1 mp -102.86 173.04 6.49 Favored 'General case' 0 N--CA 1.511 2.596 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.708 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.6 tttm -74.18 -43.49 57.09 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.242 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -70.95 -5.18 28.96 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.45 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -68.37 -56.79 7.29 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.177 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.469 HD11 HG23 ' A' ' 35' ' ' ILE . 3.7 mt -71.45 -31.14 42.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.405 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.652 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 17.7 m-20 -53.71 -42.33 67.92 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.602 -1.239 . . . . 0.0 109.531 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.8 -35.45 78.67 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.282 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.721 ' CD2' HG12 ' A' ' 16' ' ' VAL . 64.6 t80 -43.04 -70.47 0.11 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.266 -0.974 . . . . 0.0 111.342 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.425 ' O ' ' O ' ' A' ' 40' ' ' ALA . 55.1 tp -71.05 -65.29 0.76 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.61 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.652 ' HB1' ' O ' ' A' ' 36' ' ' ASP . . . -50.4 179.53 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.271 -0.971 . . . . 0.0 110.586 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 47.74 32.58 8.43 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.295 -1.431 . . . . 0.0 110.288 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 163.21 -176.08 39.45 Favored Glycine 0 N--CA 1.485 1.916 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.076 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.322 0 C-N-CA 119.258 -0.977 . . . . 0.0 110.907 -179.97 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.5 m . . . . . 0 N--CA 1.483 1.203 0 CA-C-O 120.938 0.399 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.9 OUTLIER -103.6 -176.17 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.235 0 CA-C-O 121.376 0.608 . . . . 0.0 111.283 179.934 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.429 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 45.33 -174.9 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.279 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.536 ' C ' ' H ' ' A' ' 6' ' ' SER . 92.1 mtp -84.76 154.79 61.74 Favored Pre-proline 0 N--CA 1.487 1.384 0 C-N-CA 119.934 -0.706 . . . . 0.0 110.242 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -66.43 30.98 0.11 Allowed 'Trans proline' 0 CA--C 1.55 1.302 0 C-N-CA 120.924 1.082 . . . . 0.0 111.998 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.536 ' H ' ' C ' ' A' ' 4' ' ' MET . 21.0 t -142.52 -20.81 0.68 Allowed 'General case' 0 N--CA 1.5 2.07 0 C-N-CA 119.484 -0.886 . . . . 0.0 111.237 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 84.9 t -82.23 -52.78 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 C-N-CA 119.427 -0.909 . . . . 0.0 111.126 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 58.7 ttt-85 -58.09 -31.64 67.3 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.256 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -61.15 -39.97 92.1 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.206 -0.998 . . . . 0.0 110.511 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 6.1 t80 -59.08 -48.36 81.88 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 118.944 -1.102 . . . . 0.0 109.259 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.411 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -49.71 -42.38 45.74 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.791 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -61.96 -43.51 98.69 Favored 'General case' 0 C--N 1.292 -1.907 0 C-N-CA 119.484 -0.887 . . . . 0.0 111.082 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -55.04 -54.41 43.44 Favored 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.309 -0.956 . . . . 0.0 110.928 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.4 mmtp -79.82 -19.43 48.46 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.066 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 76.06 81.93 0.52 Allowed Glycine 0 N--CA 1.49 2.24 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.968 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.9 t -146.9 141.57 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.918 -0.713 . . . . 0.0 110.647 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -80.31 97.57 7.05 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.267 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.63 HG21 ' N ' ' A' ' 19' ' ' ARG . 11.4 tt -40.19 -37.79 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.534 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.63 ' N ' HG21 ' A' ' 18' ' ' ILE . 57.0 mtp180 -54.96 -62.72 1.48 Allowed 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.364 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.0 mt -51.17 -17.67 0.72 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.549 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.3 t -68.35 141.16 17.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 C-N-CA 118.502 -1.279 . . . . 0.0 111.447 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -139.83 67.77 1.37 Allowed 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.037 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.12 -114.01 1.34 Allowed Glycine 0 N--CA 1.498 2.814 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.025 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.34 -44.05 54.04 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.91 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.5 111.94 0.5 Allowed Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -75.85 53.07 0.73 Allowed 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.081 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.473 ' C ' ' N ' ' A' ' 29' ' ' ARG . 3.2 p30 -146.02 -164.09 1.88 Allowed 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 120.212 -0.595 . . . . 0.0 110.322 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -49.55 -13.57 0.5 Allowed Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.191 -1.48 . . . . 0.0 110.414 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.473 ' N ' ' C ' ' A' ' 27' ' ' ASN . 0.2 OUTLIER -101.11 33.95 2.69 Favored 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 119.917 -0.713 . . . . 0.0 112.152 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.459 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.7 t -76.66 150.18 6.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.047 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.629 HD11 ' N ' ' A' ' 31' ' ' LEU . 9.6 mp -107.98 174.88 5.69 Favored 'General case' 0 N--CA 1.511 2.619 0 C-N-CA 119.482 -0.887 . . . . 0.0 111.033 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.5 tttm -77.32 -38.14 51.13 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.292 -0.963 . . . . 0.0 108.786 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -73.9 -7.49 52.52 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.563 -0.855 . . . . 0.0 108.876 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -64.31 -57.65 8.79 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.706 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.465 HD12 HG13 ' A' ' 18' ' ' ILE . 4.7 mt -72.28 -29.01 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.6 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -53.13 -43.41 66.92 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.627 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.418 ' O ' ' O ' ' A' ' 40' ' ' ALA . . . -69.56 -35.02 75.02 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.543 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -43.78 -68.62 0.18 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.341 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.437 ' C ' HD21 ' A' ' 39' ' ' LEU . 4.5 tt -73.78 -68.65 0.49 Allowed 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.901 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.418 ' O ' ' O ' ' A' ' 37' ' ' ALA . . . -66.62 -173.85 0.26 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.334 -0.946 . . . . 0.0 111.025 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -161.51 46.63 0.37 Allowed Glycine 0 N--CA 1.485 1.9 0 C-N-CA 119.711 -1.233 . . . . 0.0 110.208 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -71.57 75.06 0.71 Allowed Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.551 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.324 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.905 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.497 HG21 ' N ' ' A' ' 2' ' ' ILE . 9.7 p . . . . . 0 N--CA 1.482 1.142 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.526 HG21 ' H ' ' A' ' 3' ' ' ALA . 18.0 mm -66.25 165.54 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.444 -0.902 . . . . 0.0 110.404 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.526 ' H ' HG21 ' A' ' 2' ' ' ILE . . . -64.83 92.42 0.1 Allowed 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.576 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.496 ' O ' ' N ' ' A' ' 6' ' ' SER . 34.1 mtm -67.38 151.01 97.57 Favored Pre-proline 0 C--N 1.306 -1.294 0 C-N-CA 119.242 -0.983 . . . . 0.0 109.947 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -62.51 72.86 0.11 Allowed 'Trans proline' 0 CA--C 1.545 1.032 0 C-N-CA 120.683 0.922 . . . . 0.0 110.616 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.496 ' N ' ' O ' ' A' ' 4' ' ' MET . 8.8 t -175.63 -16.95 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.217 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.9 t -88.64 -48.92 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.079 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.411 ' NH2' HH21 ' A' ' 12' ' ' ARG . 48.7 ttt-85 -60.95 -40.18 92.32 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.528 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -56.41 -41.34 76.16 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.586 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -56.28 -46.46 79.71 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.029 -1.068 . . . . 0.0 109.149 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.02 -44.9 61.1 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.67 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.411 HH21 ' NH2' ' A' ' 8' ' ' ARG . 6.5 mmp_? -59.47 -42.83 92.92 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.179 -179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.463 ' C ' ' H ' ' A' ' 15' ' ' GLY . 48.2 mt-10 -58.14 -64.52 0.88 Allowed 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.344 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.2 mmtm -69.29 8.71 0.55 Allowed 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.295 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.542 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 55.55 78.19 0.13 Allowed Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.787 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.542 HG21 ' O ' ' A' ' 15' ' ' GLY . 37.1 t -147.71 137.32 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.075 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 68.6 t0 -87.43 106.4 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.7 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.881 HG21 ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -43.85 -42.89 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.52 0.676 . . . . 0.0 111.862 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.881 ' N ' HG21 ' A' ' 18' ' ' ILE . 46.0 mtt-85 -49.33 -59.72 3.45 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 114.999 -1.001 . . . . 0.0 113.119 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 49.3 mt -55.76 -24.68 36.85 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.961 -0.695 . . . . 0.0 112.668 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.5 t -57.86 141.1 15.29 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 C-N-CA 118.641 -1.224 . . . . 0.0 112.033 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -136.4 59.18 1.71 Allowed 'General case' 0 N--CA 1.482 1.158 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.672 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.8 -110.41 0.09 OUTLIER Glycine 0 N--CA 1.494 2.551 0 C-N-CA 118.957 -1.592 . . . . 0.0 109.751 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.84 -43.59 29.93 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.322 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.491 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -159.84 114.82 0.63 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 ptmt -74.9 38.88 0.13 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.284 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.545 ' C ' ' H ' ' A' ' 29' ' ' ARG . 18.7 p-10 -124.43 -161.96 1.04 Allowed 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.207 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.06 -6.37 0.82 Allowed Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.156 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.545 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.44 34.93 2.59 Favored 'General case' 0 N--CA 1.502 2.126 0 C-N-CA 119.964 -0.695 . . . . 0.0 111.805 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -80.92 150.37 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 C-N-CA 119.341 -0.944 . . . . 0.0 108.934 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 5.4 mp -120.26 -179.91 4.09 Favored 'General case' 0 N--CA 1.515 2.801 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.011 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 tttp -78.86 -33.2 46.05 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.75 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.539 ' H ' ' CD ' ' A' ' 33' ' ' GLU . 2.3 pm0 -75.3 -7.67 54.57 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.6 -54.71 17.49 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 114.523 -1.217 . . . . 0.0 109.369 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.492 HG23 HD11 ' A' ' 35' ' ' ILE . 3.3 mt -72.98 -35.23 48.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.316 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -48.44 -40.71 27.09 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.208 -0.997 . . . . 0.0 110.177 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.14 -32.58 64.98 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.498 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.522 ' CD2' HG12 ' A' ' 16' ' ' VAL . 72.0 t80 -44.13 -69.08 0.15 Allowed 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.601 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.415 ' HA ' HD11 ' A' ' 39' ' ' LEU . 43.3 tp -73.04 -50.23 24.21 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.12 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 45.5 54.09 7.81 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.65 -0.82 . . . . 0.0 111.125 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -158.29 16.42 0.29 Allowed Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.371 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.76 -29.81 11.37 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.301 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.327 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.865 -179.962 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 N--CA 1.481 1.097 0 CA-C-O 121.005 0.431 . . . . 0.0 109.912 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -143.7 176.02 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 C-N-CA 119.795 -0.762 . . . . 0.0 110.321 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -56.19 120.19 7.15 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.219 -0.992 . . . . 0.0 110.345 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.401 ' O ' ' N ' ' A' ' 6' ' ' SER . 61.7 mtt -64.2 150.68 92.05 Favored Pre-proline 0 C--N 1.306 -1.289 0 C-N-CA 119.08 -1.048 . . . . 0.0 110.839 -179.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -61.78 80.88 0.09 OUTLIER 'Trans proline' 0 CA--C 1.543 0.972 0 C-N-CA 120.874 1.049 . . . . 0.0 110.932 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.401 ' N ' ' O ' ' A' ' 4' ' ' MET . 3.9 t 175.9 -8.48 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 C-N-CA 119.569 -0.852 . . . . 0.0 110.611 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t -103.51 -66.56 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 C-N-CA 120.14 -0.624 . . . . 0.0 111.263 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.459 HH11 ' HG3' ' A' ' 8' ' ' ARG . 25.7 ttm-85 -60.73 -38.78 86.3 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.296 -0.961 . . . . 0.0 111.336 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -54.25 -42.31 69.79 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -57.19 -49.72 75.11 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 118.607 -1.237 . . . . 0.0 109.15 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.457 ' HB1' ' O ' ' A' ' 8' ' ' ARG . . . -48.36 -42.32 31.26 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.184 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -63.55 -45.79 88.91 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 119.398 -0.921 . . . . 0.0 111.225 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -50.85 -56.17 13.5 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.951 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 55.5 mmtt -79.88 -22.55 42.73 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.114 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 83.4 80.71 1.0 Allowed Glycine 0 N--CA 1.497 2.711 0 C-N-CA 119.573 -1.299 . . . . 0.0 110.496 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.586 HG12 ' CD2' ' A' ' 38' ' ' PHE . 28.2 t -147.61 135.28 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.409 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -78.35 102.96 7.99 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.266 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.924 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -44.85 -42.99 2.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.663 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.924 ' N ' HG21 ' A' ' 18' ' ' ILE . 17.5 tpp180 -52.62 -54.09 37.99 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.273 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.3 mt -55.7 -26.7 46.44 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.05 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.616 HG13 ' OD1' ' A' ' 34' ' ' ASP . 10.6 t -61.35 143.04 15.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.757 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -132.99 69.76 1.48 Allowed 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.613 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.81 -114.49 2.91 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.544 -1.313 . . . . 0.0 110.415 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.415 ' H ' ' HG1' ' A' ' 24' ' ' THR . 0.8 OUTLIER -76.07 -46.03 31.13 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.293 -179.992 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -153.4 109.82 0.42 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 11.8 pttm -77.28 61.07 2.08 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.81 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.531 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.5 OUTLIER -156.9 -161.59 1.11 Allowed 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.12 179.901 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -9.07 0.41 Allowed Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.59 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.531 ' H ' ' C ' ' A' ' 27' ' ' ASN . 14.9 mmt85 -111.9 40.95 2.04 Favored 'General case' 0 N--CA 1.507 2.385 0 C-N-CA 120.167 -0.613 . . . . 0.0 111.592 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.625 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.8 t -80.91 157.9 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.658 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.625 ' N ' HG11 ' A' ' 30' ' ' VAL . 7.9 mp -113.42 173.39 6.43 Favored 'General case' 0 N--CA 1.509 2.522 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.948 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -76.3 -43.06 43.19 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.053 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -66.79 -10.06 43.56 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.44 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.616 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.4 t0 -66.2 -57.52 7.41 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.568 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 mt -72.33 -33.27 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.649 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.776 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 39.5 t0 -49.71 -41.38 43.28 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.191 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.18 -35.04 68.86 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.467 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.586 ' CD2' HG12 ' A' ' 16' ' ' VAL . 70.5 t80 -43.72 -70.2 0.11 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.631 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' A' ' 41' ' ' GLY . 4.1 tt -69.4 -57.05 5.77 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.745 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.776 ' HB1' ' O ' ' A' ' 36' ' ' ASP . . . -49.44 90.04 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.491 -0.884 . . . . 0.0 110.461 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . 137.42 -36.2 1.98 Allowed Glycine 0 N--CA 1.5 2.916 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 51.5 -105.12 0.19 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.329 -1.415 . . . . 0.0 110.505 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.363 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.661 -179.978 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.489 ' O ' ' SD ' ' A' ' 4' ' ' MET . 13.4 t . . . . . 0 N--CA 1.482 1.142 0 CA-C-O 120.938 0.399 . . . . 0.0 109.942 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.459 ' HA ' HD11 ' A' ' 2' ' ' ILE . 19.9 mm -75.38 156.28 6.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.996 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.435 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 52.42 104.6 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.637 -0.825 . . . . 0.0 111.136 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.613 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 60.9 mmm -114.34 -32.73 0.1 Allowed Pre-proline 0 N--CA 1.508 2.44 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.613 ' CD ' ' H ' ' A' ' 4' ' ' MET . 2.6 Cg_endo -72.61 -161.6 0.11 Allowed 'Trans proline' 0 C--O 1.216 -0.598 0 N-CA-C 110.325 -0.683 . . . . 0.0 110.325 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 73.0 m -77.69 53.23 1.08 Allowed 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.303 -0.959 . . . . 0.0 109.902 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 82.0 t -102.93 -83.23 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.642 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -66.71 -45.39 78.86 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.959 -1.096 . . . . 0.0 110.697 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mttm -53.83 -35.85 61.88 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.638 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -63.27 -47.14 83.61 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.405 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.06 -42.64 63.31 Favored 'General case' 0 C--N 1.291 -1.95 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.595 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 69.2 mtp180 -60.98 -46.48 90.56 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.678 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -54.59 -44.01 72.64 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.879 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.0 mmtt -86.14 -69.78 0.64 Allowed 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.692 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.75 73.35 0.06 OUTLIER Glycine 0 N--CA 1.502 3.076 0 C-N-CA 119.88 -1.153 . . . . 0.0 110.773 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.75 HG12 ' CD2' ' A' ' 38' ' ' PHE . 39.9 t -144.67 137.44 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.493 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.1 t0 -79.85 112.28 16.98 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.804 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.834 HG21 ' N ' ' A' ' 19' ' ' ARG . 7.3 tp -43.11 -43.17 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.641 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.834 ' N ' HG21 ' A' ' 18' ' ' ILE . 14.7 tpt180 -59.91 -56.25 24.07 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.595 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 74.0 mt -47.16 -21.17 0.22 Allowed 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.558 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.67 HG13 ' OD1' ' A' ' 34' ' ' ASP . 15.5 t -76.5 143.18 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.976 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -132.48 65.33 1.58 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.983 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.2 -121.99 2.62 Favored Glycine 0 N--CA 1.502 3.058 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.242 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.849 ' HG1' HD22 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -73.26 -60.15 2.38 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.987 179.87 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.584 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -134.9 109.7 0.79 Allowed Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt -76.49 55.46 1.02 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.03 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.522 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.4 OUTLIER -156.89 -157.84 0.72 Allowed 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.585 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.36 -10.52 0.56 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.239 -1.458 . . . . 0.0 110.236 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.522 ' H ' ' C ' ' A' ' 27' ' ' ASN . 28.0 mmt180 -107.71 37.27 2.47 Favored 'General case' 0 N--CA 1.506 2.34 0 C-N-CA 120.074 -0.651 . . . . 0.0 111.709 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.642 ' C ' HD21 ' A' ' 31' ' ' LEU . 2.7 t -80.68 156.62 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 119.545 -0.862 . . . . 0.0 109.619 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.849 HD22 ' HG1' ' A' ' 24' ' ' THR . 3.9 mm? -105.78 172.49 6.77 Favored 'General case' 0 N--CA 1.508 2.459 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.365 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 48.4 tttm -77.1 -42.89 36.28 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 118.863 -1.135 . . . . 0.0 109.245 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -70.89 -3.38 18.87 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.47 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.67 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.4 t0 -67.33 -59.73 3.17 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.959 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.41 ' CG2' HG13 ' A' ' 16' ' ' VAL . 3.2 mt -72.1 -30.5 36.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.534 -0.867 . . . . 0.0 110.881 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -53.23 -41.58 65.52 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.895 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.18 -31.56 62.73 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.823 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.75 ' CD2' HG12 ' A' ' 16' ' ' VAL . 74.4 t80 -47.92 -69.89 0.11 Allowed 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 119.219 -0.993 . . . . 0.0 111.134 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.6 tt -71.63 -54.49 10.22 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.931 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 46.28 63.6 1.81 Allowed 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 119.629 -0.828 . . . . 0.0 111.039 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -62.92 -81.37 0.1 OUTLIER Glycine 0 N--CA 1.49 2.253 0 C-N-CA 119.33 -1.414 . . . . 0.0 110.366 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 57.11 -103.35 0.28 Allowed Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.285 -1.436 . . . . 0.0 110.276 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.785 179.972 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.636 ' CG2' ' H ' ' A' ' 3' ' ' ALA . 13.1 mt . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.695 0.283 . . . . 0.0 110.429 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.636 ' H ' ' CG2' ' A' ' 2' ' ' ILE . . . 55.11 162.21 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.935 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 36.7 mtm -61.76 152.96 73.93 Favored Pre-proline 0 C--N 1.306 -1.312 0 C-N-CA 119.007 -1.077 . . . . 0.0 110.333 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.532 ' C ' ' H ' ' A' ' 7' ' ' VAL . 3.6 Cg_endo -62.62 172.01 5.04 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 120.942 1.094 . . . . 0.0 111.452 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m 64.37 -10.06 0.15 Allowed 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.102 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.532 ' H ' ' C ' ' A' ' 5' ' ' PRO . 70.0 t -82.27 -65.08 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.714 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.412 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 34.0 ttm180 -60.62 -39.37 87.98 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.189 -1.005 . . . . 0.0 111.135 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.4 mttp -53.02 -42.84 66.06 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.4 ' HE2' HG23 ' A' ' 35' ' ' ILE . 9.9 t80 -57.61 -50.18 73.99 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.739 -1.184 . . . . 0.0 109.22 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.412 ' HB1' ' O ' ' A' ' 8' ' ' ARG . . . -49.8 -45.01 49.5 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.811 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -60.49 -45.82 92.37 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.075 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -52.36 -51.95 56.09 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 18.2 mtpp -81.29 -8.58 59.77 Favored 'General case' 0 N--CA 1.489 1.515 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.89 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.52 75.4 0.61 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.358 -1.401 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.637 HG12 ' CD2' ' A' ' 38' ' ' PHE . 42.8 t -144.25 126.53 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.946 -0.701 . . . . 0.0 110.413 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -72.79 100.77 2.95 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.526 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.599 HG21 ' H ' ' A' ' 19' ' ' ARG . 11.8 tt -41.25 -41.74 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.69 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.599 ' H ' HG21 ' A' ' 18' ' ' ILE . 17.9 tpp180 -52.12 -53.06 47.31 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.327 -0.852 . . . . 0.0 112.207 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.4 mt -57.84 -28.98 64.59 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.156 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 t -59.08 140.28 17.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.559 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -140.55 63.2 1.47 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.853 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.26 -101.85 0.35 Allowed Glycine 0 N--CA 1.496 2.656 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.44 ' H ' ' HG1' ' A' ' 24' ' ' THR . 0.8 OUTLIER -80.89 -42.7 21.02 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.631 -0.827 . . . . 0.0 110.098 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.93 114.77 0.62 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.1 pttt -75.87 57.33 1.03 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.963 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.521 ' C ' ' H ' ' A' ' 29' ' ' ARG . 41.3 p30 -149.89 -161.37 1.33 Allowed 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.633 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.09 -11.13 0.36 Allowed Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.597 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.521 ' H ' ' C ' ' A' ' 27' ' ' ASN . 18.9 mmt180 -104.58 35.52 2.72 Favored 'General case' 0 N--CA 1.504 2.258 0 C-N-CA 119.861 -0.735 . . . . 0.0 111.79 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -81.45 135.11 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 9.6 mp -101.52 174.01 6.17 Favored 'General case' 0 N--CA 1.511 2.616 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.795 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.422 ' HG2' ' HZ1' ' A' ' 32' ' ' LYS . 50.7 tttm -75.27 -34.18 61.32 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 119.137 -1.025 . . . . 0.0 108.304 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.1 tp10 -71.14 -16.21 62.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -63.22 -54.33 39.1 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 114.201 -1.363 . . . . 0.0 109.123 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.4 HG23 ' HE2' ' A' ' 10' ' ' TYR . 3.2 mt -73.34 -34.18 42.85 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.532 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -50.55 -41.31 53.92 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.502 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.46 -36.36 76.5 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.291 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.637 ' CD2' HG12 ' A' ' 16' ' ' VAL . 56.9 t80 -43.86 -69.96 0.12 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.374 -0.931 . . . . 0.0 111.489 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.78 ' C ' HD11 ' A' ' 39' ' ' LEU . 0.2 OUTLIER -76.08 -50.15 15.5 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.41 -179.905 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 51.02 47.88 24.08 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.715 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -81.61 3.52 78.28 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.363 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -68.72 74.84 0.31 Allowed Glycine 0 N--CA 1.491 2.319 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.383 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.387 0 C-N-CA 119.299 -0.961 . . . . 0.0 110.726 179.987 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.45 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 121.249 0.547 . . . . 0.0 110.914 . . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 53.75 164.35 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.078 -0.965 . . . . 0.0 111.243 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 79.1 mtp -75.48 150.66 84.84 Favored Pre-proline 0 C--N 1.305 -1.327 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.03 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -63.85 83.38 0.14 Allowed 'Trans proline' 0 CA--C 1.54 0.804 0 C-N-CA 120.665 0.91 . . . . 0.0 110.808 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 172.42 -31.21 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.469 -0.893 . . . . 0.0 110.821 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.2 t -88.25 -41.47 14.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.483 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -62.94 -40.93 99.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 118.905 -1.118 . . . . 0.0 111.224 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -51.64 -40.34 59.78 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.411 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -61.04 -51.43 69.21 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 118.909 -1.116 . . . . 0.0 108.904 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.522 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -50.11 -43.14 51.54 Favored 'General case' 0 C--N 1.291 -1.945 0 CA-C-N 115.19 -0.913 . . . . 0.0 110.25 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -63.02 -47.32 83.56 Favored 'General case' 0 C--N 1.296 -1.749 0 CA-C-N 115.057 -0.974 . . . . 0.0 110.358 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -51.85 -31.4 27.68 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.153 -1.019 . . . . 0.0 110.108 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.3 mmtp -97.78 -10.1 25.4 Favored 'General case' 0 N--CA 1.495 1.796 0 C-N-CA 119.979 -0.689 . . . . 0.0 110.692 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.08 1.5 74.2 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.358 -1.401 . . . . 0.0 109.962 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.69 HG12 ' CD2' ' A' ' 38' ' ' PHE . 41.9 t -71.31 137.32 23.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.933 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -86.38 105.8 16.97 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.278 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.876 HG21 ' N ' ' A' ' 19' ' ' ARG . 16.4 tt -43.04 -43.04 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.994 -179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.876 ' N ' HG21 ' A' ' 18' ' ' ILE . 37.8 mtp180 -48.81 -57.72 5.94 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.865 -179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.2 mt -54.43 -29.63 49.93 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 119.723 -0.791 . . . . 0.0 112.56 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.457 HG22 ' HA ' ' A' ' 18' ' ' ILE . 13.7 t -55.6 140.35 13.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.623 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -132.46 62.27 1.65 Allowed 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.397 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -83.92 -121.43 0.86 Allowed Glycine 0 N--CA 1.496 2.699 0 C-N-CA 119.098 -1.525 . . . . 0.0 110.54 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.52 -66.22 0.92 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.708 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.67 -62.94 5.68 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.897 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 66.9 tttt 56.43 38.86 30.06 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.554 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.539 ' H ' HG21 ' A' ' 30' ' ' VAL . 38.2 p-10 -163.71 -160.77 0.6 Allowed 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.182 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.29 -5.41 0.71 Allowed Glycine 0 N--CA 1.484 1.885 0 C-N-CA 119.16 -1.495 . . . . 0.0 110.249 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.536 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -122.93 45.6 2.37 Favored 'General case' 0 N--CA 1.504 2.232 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.657 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.54 HG11 ' N ' ' A' ' 31' ' ' LEU . 3.1 t -70.4 160.4 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 C-N-CA 119.089 -1.044 . . . . 0.0 108.946 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.54 ' N ' HG11 ' A' ' 30' ' ' VAL . 9.3 mp -105.79 172.66 6.68 Favored 'General case' 0 N--CA 1.513 2.679 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.08 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -79.01 -37.51 39.01 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.393 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -72.45 -7.44 49.86 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -66.1 -59.0 4.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 114.563 -1.199 . . . . 0.0 109.621 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.522 HD11 ' HB3' ' A' ' 11' ' ' ALA . 3.7 mt -72.64 -28.54 27.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.548 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.524 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 21.0 t70 -53.41 -40.95 65.5 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.697 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.51 -35.54 68.14 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.583 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.69 ' CD2' HG12 ' A' ' 16' ' ' VAL . 67.0 t80 -42.19 -70.12 0.12 Allowed 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.666 -0.813 . . . . 0.0 112.284 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.459 ' HA ' HD11 ' A' ' 39' ' ' LEU . 32.2 tp -67.35 -46.0 74.71 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.076 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.524 ' HB1' ' O ' ' A' ' 36' ' ' ASP . . . -48.42 177.6 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.016 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 57.46 15.06 15.26 Favored Glycine 0 N--CA 1.489 2.224 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.211 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 77.99 -52.93 3.71 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.151 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.26 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.888 180.0 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.413 0 CA-C-O 121.082 0.467 . . . . 0.0 110.517 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -58.44 135.56 57.27 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.681 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.491 ' O ' HG22 ' A' ' 7' ' ' VAL . 13.8 mmt -50.45 153.19 2.77 Favored Pre-proline 0 C--N 1.305 -1.352 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.261 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.442 ' O ' ' OG ' ' A' ' 6' ' ' SER . 2.5 Cg_endo -56.94 169.9 1.7 Allowed 'Trans proline' 0 C--O 1.212 -0.799 0 C-N-CA 120.634 0.89 . . . . 0.0 110.961 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.442 ' OG ' ' O ' ' A' ' 5' ' ' PRO . 1.4 p 72.45 -11.73 0.79 Allowed 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.982 -0.687 . . . . 0.0 111.894 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 4' ' ' MET . 60.7 t -89.08 -71.41 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.699 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.1 ttt85 -65.39 -43.97 88.99 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 118.782 -1.167 . . . . 0.0 110.254 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -56.09 -35.37 66.94 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.185 -1.006 . . . . 0.0 110.698 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -61.46 -45.5 93.99 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.837 -1.145 . . . . 0.0 109.111 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -48.32 -42.62 31.71 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.402 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -64.2 -44.82 90.8 Favored 'General case' 0 C--N 1.291 -1.935 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.061 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.8 mm-40 -51.29 -53.09 39.04 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.783 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -82.26 -22.62 35.71 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.646 -0.822 . . . . 0.0 111.012 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.5 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 83.36 78.85 1.06 Allowed Glycine 0 N--CA 1.497 2.702 0 C-N-CA 119.469 -1.348 . . . . 0.0 110.305 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.505 HG23 ' CD2' ' A' ' 38' ' ' PHE . 33.6 t -145.7 138.57 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 120.035 -0.666 . . . . 0.0 110.161 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.2 t0 -80.95 97.1 7.3 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.05 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.939 HG21 ' N ' ' A' ' 19' ' ' ARG . 11.8 tt -41.2 -41.73 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.562 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.939 ' N ' HG21 ' A' ' 18' ' ' ILE . 13.4 tpp180 -49.96 -57.92 6.52 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.713 -179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 51.2 mt -57.42 -36.62 71.58 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.547 -0.861 . . . . 0.0 112.163 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.636 HG13 ' OD1' ' A' ' 34' ' ' ASP . 14.8 t -47.08 140.92 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.69 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -133.78 65.37 1.58 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.294 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.49 -114.17 0.78 Allowed Glycine 0 N--CA 1.496 2.678 0 C-N-CA 119.14 -1.505 . . . . 0.0 109.951 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.938 ' HG1' HD13 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -82.08 -61.01 2.03 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.01 179.936 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.35 102.62 0.59 Allowed Glycine 0 N--CA 1.5 2.947 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.2 pttp -74.59 61.5 0.96 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.508 ' C ' ' H ' ' A' ' 29' ' ' ARG . 8.3 p30 -164.25 -154.97 0.27 Allowed 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.484 -0.887 . . . . 0.0 110.801 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.4 -9.99 0.5 Allowed Glycine 0 C--N 1.291 -1.964 0 C-N-CA 119.635 -1.269 . . . . 0.0 110.578 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.508 ' H ' ' C ' ' A' ' 27' ' ' ASN . 25.3 mmt180 -111.9 38.5 2.64 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.744 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.413 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.5 t -76.47 154.23 5.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 119.195 -1.002 . . . . 0.0 108.905 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.938 HD13 ' HG1' ' A' ' 24' ' ' THR . 29.3 mt -117.52 178.87 4.23 Favored 'General case' 0 N--CA 1.513 2.69 0 C-N-CA 119.587 -0.845 . . . . 0.0 112.24 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' A' ' 36' ' ' ASP . 27.3 tptp -78.39 -33.55 48.73 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -73.86 -11.58 60.41 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.636 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.1 t0 -66.98 -67.54 0.44 Allowed 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.104 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.4 mt -67.39 -35.49 73.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 C-N-CA 119.656 -0.817 . . . . 0.0 111.44 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 32' ' ' LYS . 5.7 m-20 -49.38 -42.53 42.49 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.721 -1.192 . . . . 0.0 110.081 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.434 ' HA ' ' HB1' ' A' ' 40' ' ' ALA . . . -69.62 -32.98 71.99 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.612 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.505 ' CD2' HG23 ' A' ' 16' ' ' VAL . 68.4 t80 -45.2 -69.9 0.12 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.873 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.2 tp -68.36 -27.91 66.66 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.275 -0.875 . . . . 0.0 112.112 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.434 ' HB1' ' HA ' ' A' ' 37' ' ' ALA . . . -46.24 -39.7 10.3 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.092 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.92 -0.88 4.56 Favored Glycine 0 N--CA 1.503 3.128 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.28 132.11 50.14 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.326 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.345 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.837 179.965 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 121.209 0.528 . . . . 0.0 110.596 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.11 157.3 23.12 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.566 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 69.1 mtm -52.07 148.0 11.9 Favored Pre-proline 0 N--CA 1.484 1.269 0 C-N-CA 119.161 -1.015 . . . . 0.0 110.727 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.503 ' C ' ' HG ' ' A' ' 6' ' ' SER . 6.3 Cg_endo -64.67 156.06 63.42 Favored 'Trans proline' 0 CA--C 1.54 0.815 0 C-N-CA 120.975 1.117 . . . . 0.0 111.699 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.503 ' HG ' ' C ' ' A' ' 5' ' ' PRO . 0.8 OUTLIER 66.44 30.97 8.44 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.87 -0.732 . . . . 0.0 111.745 179.885 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t -130.3 -69.26 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.827 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 32.7 ttm180 -60.04 -45.62 92.23 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.31 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.461 ' HG3' ' HZ1' ' A' ' 9' ' ' LYS . 9.9 mmmm -52.7 -41.78 64.23 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.632 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -57.85 -47.12 83.62 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 118.781 -1.167 . . . . 0.0 109.211 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.07 -45.47 61.42 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.793 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -56.56 -41.69 77.28 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.914 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -61.67 -33.54 74.16 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.911 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 50.6 mmtt -96.94 0.4 48.89 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.34 57.54 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.691 -1.242 . . . . 0.0 111.041 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.454 HG12 ' CD2' ' A' ' 38' ' ' PHE . 55.2 t -81.84 123.66 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.484 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -75.98 105.92 7.29 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.244 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.482 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 9.7 tt -41.62 -41.7 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.558 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.482 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.6 ttt85 -50.92 -53.87 29.06 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.987 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.407 ' HA ' HD21 ' A' ' 20' ' ' LEU . 74.6 mt -55.96 -28.17 55.84 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.818 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.583 HG13 ' OD1' ' A' ' 34' ' ' ASP . 10.6 t -65.31 142.6 16.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.687 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -140.52 66.28 1.39 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.051 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -78.51 -107.56 0.2 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.095 -1.526 . . . . 0.0 110.428 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.442 ' OG1' ' CD1' ' A' ' 31' ' ' LEU . 0.7 OUTLIER -87.27 -53.02 5.06 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.473 -179.938 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 108.93 0.63 Allowed Glycine 0 N--CA 1.5 2.915 0 C-N-CA 119.857 -1.163 . . . . 0.0 110.404 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -76.58 61.41 1.78 Allowed 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.013 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.535 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.7 p-10 -152.83 -161.26 1.26 Allowed 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.434 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.76 -6.67 1.27 Allowed Glycine 0 N--CA 1.484 1.836 0 C-N-CA 119.123 -1.513 . . . . 0.0 109.909 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.535 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.8 mmt180 -108.17 31.82 5.25 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 120.187 -0.605 . . . . 0.0 111.523 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -70.08 156.11 7.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.434 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.442 ' CD1' ' OG1' ' A' ' 24' ' ' THR . 28.3 mt -108.53 173.78 6.17 Favored 'General case' 0 N--CA 1.509 2.499 0 C-N-CA 119.279 -0.969 . . . . 0.0 112.448 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 43.3 tptt -76.93 -32.23 57.22 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.063 -0.971 . . . . 0.0 108.574 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -82.58 -5.09 58.59 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.358 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.583 ' OD1' HG13 ' A' ' 21' ' ' VAL . 1.6 t0 -64.39 -53.95 40.51 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.237 -0.892 . . . . 0.0 108.933 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -77.55 -37.89 25.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.678 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -47.17 -42.29 19.47 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.945 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.86 -37.08 73.08 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.6 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.454 ' CD2' HG12 ' A' ' 16' ' ' VAL . 66.1 t80 -42.67 -68.6 0.18 Allowed 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.463 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 11.2 tp -72.0 -66.97 0.57 Allowed 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.991 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -54.9 118.02 3.92 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.9 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' A' ' 43' ' ' ALA . . . -56.08 -58.44 14.15 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.391 -1.385 . . . . 0.0 110.442 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 56.29 -85.6 0.01 OUTLIER Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.261 -1.447 . . . . 0.0 110.341 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 41' ' ' GLY . . . . . . . . 0 C--N 1.306 -1.294 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.919 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.44 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.413 0.625 . . . . 0.0 111.466 . . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 43.24 101.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.839 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.439 ' O ' ' N ' ' A' ' 6' ' ' SER . 14.2 mmt -47.99 152.8 1.31 Allowed Pre-proline 0 C--N 1.307 -1.242 0 C-N-CA 119.251 -0.98 . . . . 0.0 110.074 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -63.32 73.24 0.14 Allowed 'Trans proline' 0 CA--C 1.55 1.277 0 C-N-CA 120.844 1.03 . . . . 0.0 111.021 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.439 ' N ' ' O ' ' A' ' 4' ' ' MET . 2.1 p 175.55 3.36 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.291 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 79.9 t -113.44 -70.49 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.507 2.416 0 C-N-CA 120.091 -0.644 . . . . 0.0 111.127 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.565 ' HE ' HD11 ' A' ' 18' ' ' ILE . 32.2 ttm180 -57.4 -38.09 73.74 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.239 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.7 mttp -52.43 -46.48 66.41 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.634 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -54.28 -47.74 72.02 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 118.9 -1.12 . . . . 0.0 109.092 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.415 ' HB1' ' CD1' ' A' ' 35' ' ' ILE . . . -49.48 -44.59 46.09 Favored 'General case' 0 C--N 1.288 -2.083 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.789 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 24.1 mmm180 -57.43 -43.86 84.2 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.745 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -57.57 -33.19 67.91 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.086 -1.045 . . . . 0.0 110.496 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.6 mmtt -93.51 -10.04 36.28 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.496 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 76.38 -0.9 62.61 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.458 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.841 HG12 ' CD2' ' A' ' 38' ' ' PHE . 54.7 t -70.77 124.4 26.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.772 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.42 ' HB3' HD13 ' A' ' 20' ' ' LEU . 51.3 t0 -77.08 105.88 8.44 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.048 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.583 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.1 tt -37.82 -42.63 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.266 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.583 ' N ' HG21 ' A' ' 18' ' ' ILE . 51.7 ttp85 -49.36 -55.06 14.2 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.472 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.42 HD13 ' HB3' ' A' ' 17' ' ' ASP . 52.7 mt -53.07 -41.83 65.25 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.556 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.589 HG13 ' OD1' ' A' ' 34' ' ' ASP . 13.5 t -48.52 144.56 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 C-N-CA 119.267 -0.973 . . . . 0.0 111.863 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -137.95 60.85 1.61 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.476 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.32 -114.82 0.24 Allowed Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.927 -1.606 . . . . 0.0 109.943 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.1 -50.03 12.8 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.879 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.447 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -150.02 109.4 0.43 Allowed Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 pttt -75.97 43.51 0.28 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.177 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.511 ' C ' ' H ' ' A' ' 29' ' ' ARG . 27.7 p-10 -119.05 -164.92 1.08 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.028 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.03 -4.2 2.21 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.196 -1.478 . . . . 0.0 110.332 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.511 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.1 mmt180 -110.71 41.42 1.79 Allowed 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.469 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.714 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.5 t -73.46 156.4 6.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.435 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.714 ' N ' HG11 ' A' ' 30' ' ' VAL . 10.1 mp -105.74 173.0 6.5 Favored 'General case' 0 N--CA 1.511 2.577 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.142 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -76.94 -38.69 52.87 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 119.259 -0.977 . . . . 0.0 109.676 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -76.8 -2.91 35.61 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.222 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.589 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.3 t0 -67.18 -55.13 15.43 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.778 -1.101 . . . . 0.0 109.632 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.443 HG22 HG13 ' A' ' 16' ' ' VAL . 3.7 mt -75.17 -36.96 38.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.806 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.67 -40.54 53.89 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.421 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' A' ' 40' ' ' ALA . . . -71.35 -33.87 69.99 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.609 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.841 ' CD2' HG12 ' A' ' 16' ' ' VAL . 83.2 t80 -44.74 -69.65 0.13 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.067 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.702 ' C ' HD11 ' A' ' 39' ' ' LEU . 0.3 OUTLIER -66.5 -65.9 0.62 Allowed 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.441 -179.851 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' A' ' 37' ' ' ALA . . . -71.03 126.53 29.81 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.911 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 55.17 82.91 0.05 OUTLIER Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.305 -1.426 . . . . 0.0 110.324 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -154.98 98.83 0.18 Allowed Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.691 -1.242 . . . . 0.0 110.366 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.302 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.021 179.928 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.568 HG21 ' N ' ' A' ' 3' ' ' ALA . 17.8 mm . . . . . 0 N--CA 1.485 1.304 0 CA-C-O 120.947 0.403 . . . . 0.0 111.231 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.568 ' N ' HG21 ' A' ' 2' ' ' ILE . . . 46.24 103.03 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.669 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.489 ' O ' HG22 ' A' ' 7' ' ' VAL . 15.9 mmt -46.29 149.1 1.39 Allowed Pre-proline 0 N--CA 1.485 1.317 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.23 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.457 ' C ' ' H ' ' A' ' 7' ' ' VAL . 2.3 Cg_endo -56.99 174.62 0.4 Allowed 'Trans proline' 0 C--O 1.214 -0.691 0 C-N-CA 120.707 0.938 . . . . 0.0 111.235 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 5' ' ' PRO . 1.3 t 72.3 -15.69 0.47 Allowed 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 120.046 -0.661 . . . . 0.0 111.457 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 4' ' ' MET . 47.8 t -88.99 -68.6 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.889 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 71.2 ttt180 -71.02 -39.42 72.37 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.01 -1.076 . . . . 0.0 110.504 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttp -58.92 -26.61 64.51 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 118.988 -1.085 . . . . 0.0 110.467 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.408 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 7.6 t80 -69.62 -49.73 51.08 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 118.843 -1.143 . . . . 0.0 108.579 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.83 -41.47 23.91 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.43 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.37 -46.6 86.02 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.776 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -54.9 -35.35 64.02 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.976 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.8 mmtt -92.06 -16.79 25.94 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.849 -0.741 . . . . 0.0 110.72 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 80.46 4.75 90.07 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.523 -1.322 . . . . 0.0 110.623 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.547 HG12 ' CD2' ' A' ' 38' ' ' PHE . 41.1 t -76.46 138.55 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.651 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 36.8 t0 -81.37 104.4 11.79 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.761 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.848 HG21 ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -40.87 -41.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.654 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.848 ' N ' HG21 ' A' ' 18' ' ' ILE . 11.9 tpp180 -50.96 -59.56 4.02 Favored 'General case' 0 C--N 1.29 -2.007 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.308 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 84.8 mt -52.98 -28.44 23.84 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.013 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.457 HG13 ' OD1' ' A' ' 34' ' ' ASP . 7.6 t -61.65 141.19 17.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 C-N-CA 118.915 -1.114 . . . . 0.0 112.181 -179.842 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -139.4 44.02 1.99 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.075 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.27 -104.25 0.01 OUTLIER Glycine 0 N--CA 1.492 2.37 0 C-N-CA 119.244 -1.455 . . . . 0.0 110.157 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.488 ' OG1' ' CD2' ' A' ' 31' ' ' LEU . 2.5 p -73.41 -37.84 65.8 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.08 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -179.65 121.13 0.72 Allowed Glycine 0 N--CA 1.479 1.517 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.423 ' O ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pttm -58.57 -157.31 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.507 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.52 ' CG ' ' H ' ' A' ' 28' ' ' GLY . 25.4 t-20 59.31 176.29 0.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.013 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.52 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -46.12 -17.16 0.19 Allowed Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.733 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.482 ' N ' ' O ' ' A' ' 27' ' ' ASN . 14.5 mmt85 -80.13 35.41 0.32 Allowed 'General case' 0 N--CA 1.493 1.723 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.19 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.77 HG11 ' N ' ' A' ' 31' ' ' LEU . 11.7 t -101.6 156.48 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.442 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.77 ' N ' HG11 ' A' ' 30' ' ' VAL . 1.9 pt? -129.64 -170.71 2.35 Favored 'General case' 0 N--CA 1.512 2.634 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.633 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.43 ' C ' ' H ' ' A' ' 34' ' ' ASP . 77.8 tttt -71.02 -55.37 8.43 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.54 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 60.9 tt0 -61.03 -5.68 1.53 Allowed 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.9 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.457 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.2 t0 -67.85 -59.76 3.04 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.386 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.402 HD13 ' H ' ' A' ' 35' ' ' ILE . 3.3 mp -66.55 -37.47 79.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.653 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -46.6 -42.78 16.6 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.348 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.17 -35.91 76.8 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.394 -0.923 . . . . 0.0 110.666 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.547 ' CD2' HG12 ' A' ' 16' ' ' VAL . 60.6 t80 -43.46 -67.54 0.27 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.467 -0.893 . . . . 0.0 112.171 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.4 tp -72.48 -25.82 61.56 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.246 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -44.9 -25.29 0.29 Allowed 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.085 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -60.18 -84.31 0.05 OUTLIER Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.405 -1.378 . . . . 0.0 110.483 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -71.11 102.85 1.13 Allowed Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.367 -1.396 . . . . 0.0 110.452 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.355 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.731 -179.959 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.873 HG21 ' H ' ' A' ' 3' ' ' ALA . 11.7 mm . . . . . 0 N--CA 1.485 1.292 0 CA-C-O 120.944 0.402 . . . . 0.0 111.128 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.873 ' H ' HG21 ' A' ' 2' ' ' ILE . . . 56.0 79.41 0.17 Allowed 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.489 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.637 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 71.0 mtp -121.84 -30.32 0.05 OUTLIER Pre-proline 0 N--CA 1.508 2.461 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.637 ' CD ' ' H ' ' A' ' 4' ' ' MET . 2.3 Cg_endo -66.36 76.3 0.36 Allowed 'Trans proline' 0 CA--C 1.543 0.974 0 CA-C-N 119.073 0.705 . . . . 0.0 111.493 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 93.9 p 40.65 52.2 3.07 Favored 'General case' 0 N--CA 1.493 1.684 0 C-N-CA 119.965 -0.694 . . . . 0.0 111.661 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.5 t -96.73 -77.41 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 C-N-CA 119.831 -0.748 . . . . 0.0 110.239 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 59.0 ttp85 -60.98 -51.5 68.98 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.093 -1.043 . . . . 0.0 110.749 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.1 mttt -51.26 -39.75 57.39 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.753 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -59.7 -45.95 90.56 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.206 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -53.12 -46.15 68.62 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.696 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -55.91 -40.96 73.83 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -63.08 -45.95 89.72 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.4 mmtt -78.31 -10.07 59.51 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.449 -0.901 . . . . 0.0 111.183 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.96 1.5 90.64 Favored Glycine 0 N--CA 1.496 2.642 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.899 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.653 HG12 ' CD2' ' A' ' 38' ' ' PHE . 57.8 t -74.5 130.54 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.507 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -83.22 110.01 17.71 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.155 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.598 HG21 ' H ' ' A' ' 19' ' ' ARG . 5.7 tp -42.26 -41.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.466 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.598 ' H ' HG21 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -48.07 -59.1 3.64 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.822 -179.83 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 46.8 mt -60.45 -18.41 51.01 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.475 HG22 ' HA ' ' A' ' 18' ' ' ILE . 10.2 t -70.64 139.73 19.56 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 118.552 -1.259 . . . . 0.0 111.649 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.401 ' O ' ' CD ' ' A' ' 22' ' ' GLN . 0.6 OUTLIER -145.7 79.44 1.56 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.706 179.901 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.18 -99.12 1.97 Allowed Glycine 0 N--CA 1.504 3.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -79.07 -38.97 35.05 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.428 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.524 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -170.61 116.16 0.63 Allowed Glycine 0 N--CA 1.485 1.932 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 pttp -74.1 38.64 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.001 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.524 ' H ' ' C ' ' A' ' 25' ' ' GLY . 25.0 t-20 -117.07 -179.59 3.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.712 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.523 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -47.57 -14.95 0.24 Allowed Glycine 0 N--CA 1.492 2.432 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.197 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.513 ' N ' ' O ' ' A' ' 27' ' ' ASN . 32.2 mmm-85 -95.47 37.22 1.2 Allowed 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.119 -0.632 . . . . 0.0 111.556 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.518 ' C ' HD21 ' A' ' 31' ' ' LEU . 2.6 t -70.99 154.64 7.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.105 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.778 ' N ' HD21 ' A' ' 31' ' ' LEU . 2.9 mm? -106.5 173.3 6.38 Favored 'General case' 0 N--CA 1.509 2.492 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.951 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.6 tmtt? -77.13 -41.43 41.96 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.386 -0.925 . . . . 0.0 108.926 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -71.78 -3.63 23.17 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.399 -0.818 . . . . 0.0 109.35 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -68.52 -56.04 9.68 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.079 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.419 HD13 ' CD1' ' A' ' 18' ' ' ILE . 1.8 mt -73.09 -37.54 53.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.643 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -51.22 -39.37 56.42 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.341 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.5 -33.62 71.42 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.347 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.653 ' CD2' HG12 ' A' ' 16' ' ' VAL . 65.9 t80 -45.07 -68.04 0.23 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.016 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 56.1 tp -74.0 -67.19 0.63 Allowed 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.995 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 41.44 55.78 3.35 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.897 -0.721 . . . . 0.0 111.575 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 76.6 -44.33 1.98 Allowed Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.491 -1.337 . . . . 0.0 110.677 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 70.05 157.03 1.73 Allowed Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.318 -1.42 . . . . 0.0 110.158 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.394 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.944 -179.966 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.4 m . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.818 0.342 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.581 HG21 ' N ' ' A' ' 3' ' ' ALA . 18.4 mm -73.24 162.77 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 C-N-CA 119.232 -0.987 . . . . 0.0 111.006 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.581 ' N ' HG21 ' A' ' 2' ' ' ILE . . . -55.9 148.59 16.75 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.798 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 4.2 mmt -67.91 153.96 94.41 Favored Pre-proline 0 C--N 1.304 -1.402 0 C-N-CA 119.364 -0.934 . . . . 0.0 109.93 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.416 ' O ' ' OG ' ' A' ' 6' ' ' SER . 9.2 Cg_endo -70.19 52.96 1.19 Allowed 'Trans proline' 0 CA--C 1.558 1.687 0 C-N-CA 120.79 0.993 . . . . 0.0 111.56 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.416 ' OG ' ' O ' ' A' ' 5' ' ' PRO . 27.2 m -166.24 -1.89 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.142 -1.023 . . . . 0.0 110.869 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.1 t -88.25 -66.46 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 C-N-CA 119.683 -0.807 . . . . 0.0 111.161 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.484 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 55.5 ttt180 -57.06 -36.05 70.07 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.384 -0.926 . . . . 0.0 111.199 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mmtm -54.85 -47.61 73.94 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 119.136 -1.026 . . . . 0.0 110.217 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -53.73 -46.94 71.02 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.073 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 8' ' ' ARG . . . -52.12 -46.32 65.29 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.651 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.2 mtp180 -59.48 -44.29 93.08 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.679 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -56.69 -42.74 79.6 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.575 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -86.8 -13.92 43.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.834 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 75.91 67.84 1.64 Allowed Glycine 0 N--CA 1.488 2.134 0 C-N-CA 119.327 -1.416 . . . . 0.0 110.089 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.888 HG12 ' CD2' ' A' ' 38' ' ' PHE . 53.1 t -137.18 130.51 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.339 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -77.3 109.53 11.26 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.07 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.667 HG21 ' N ' ' A' ' 19' ' ' ARG . 6.9 tp -44.69 -41.96 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.503 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.667 ' N ' HG21 ' A' ' 18' ' ' ILE . 63.7 ttt-85 -56.15 -52.69 63.46 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.738 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.7 mt -57.18 -31.04 65.01 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.746 -0.781 . . . . 0.0 112.725 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.565 HG13 ' OD1' ' A' ' 34' ' ' ASP . 7.8 t -57.46 141.87 13.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 118.437 -1.305 . . . . 0.0 111.868 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -136.77 77.71 1.66 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.933 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.26 -108.93 3.34 Favored Glycine 0 N--CA 1.51 3.596 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.621 ' HG1' HD12 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -77.02 -47.91 19.36 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.297 -179.926 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.74 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -151.07 109.28 0.42 Allowed Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.9 pttp -76.07 55.36 0.92 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.601 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.511 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.4 OUTLIER -157.16 -154.95 0.49 Allowed 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 119.746 -0.782 . . . . 0.0 110.546 179.886 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.0 -8.2 0.59 Allowed Glycine 0 C--N 1.289 -2.04 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.246 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.511 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.6 mmt85 -109.09 37.34 2.59 Favored 'General case' 0 N--CA 1.504 2.24 0 C-N-CA 120.217 -0.593 . . . . 0.0 112.076 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.74 HG21 ' O ' ' A' ' 25' ' ' GLY . 3.2 t -80.92 147.4 6.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.076 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.621 HD12 ' HG1' ' A' ' 24' ' ' THR . 6.7 mp -109.37 177.34 4.77 Favored 'General case' 0 N--CA 1.511 2.604 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.51 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.429 ' C ' ' H ' ' A' ' 34' ' ' ASP . 3.6 tmtt? -75.47 -48.74 21.3 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.879 179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -65.47 -5.45 7.84 Favored 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.207 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.565 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.6 t0 -69.5 -53.62 18.2 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.605 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.611 HD12 HD13 ' A' ' 18' ' ' ILE . 2.5 mt -72.46 -30.05 33.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 C-N-CA 119.676 -0.81 . . . . 0.0 110.757 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 36' ' ' ASP . 5.8 m-20 -55.5 -40.69 72.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.279 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.68 -34.81 76.31 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.284 179.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.888 ' CD2' HG12 ' A' ' 16' ' ' VAL . 70.1 t80 -44.55 -69.27 0.14 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.346 -0.942 . . . . 0.0 111.232 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.448 ' O ' ' O ' ' A' ' 40' ' ' ALA . 69.5 tp -66.49 -53.95 29.42 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.916 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.448 ' O ' ' O ' ' A' ' 39' ' ' LEU . . . -57.54 -113.7 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.87 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 154.63 33.6 0.03 OUTLIER Glycine 0 N--CA 1.493 2.448 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.372 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.72 -66.75 1.73 Allowed Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.551 -1.309 . . . . 0.0 110.303 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.406 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.815 179.946 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.479 HG21 ' N ' ' A' ' 3' ' ' ALA . 18.2 mm . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 121.044 0.45 . . . . 0.0 111.272 . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.479 ' N ' HG21 ' A' ' 2' ' ' ILE . . . -45.94 142.17 2.77 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.604 179.851 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.668 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 14.3 mtt -124.82 -31.97 0.04 OUTLIER Pre-proline 0 N--CA 1.509 2.483 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.668 ' CD ' ' H ' ' A' ' 4' ' ' MET . 5.7 Cg_exo -65.07 -159.47 0.04 OUTLIER 'Trans proline' 0 C--O 1.217 -0.574 0 C-N-CA 120.476 0.784 . . . . 0.0 111.439 -179.911 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.4 t -77.35 45.18 0.45 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.026 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.44 ' H ' ' C ' ' A' ' 5' ' ' PRO . 32.0 t -86.46 -71.79 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.689 179.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -61.94 -48.03 82.22 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 118.872 -1.131 . . . . 0.0 110.884 -179.906 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -53.76 -38.83 64.81 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.91 179.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -59.11 -44.73 92.0 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 118.883 -1.127 . . . . 0.0 109.36 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -52.05 -43.8 63.96 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.805 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -57.04 -43.49 81.98 Favored 'General case' 0 C--N 1.292 -1.893 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.886 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 59.9 mt-10 -59.06 -53.69 55.47 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.382 -0.927 . . . . 0.0 111.185 179.936 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -78.28 -14.48 59.41 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.115 -179.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 74.15 76.1 0.73 Allowed Glycine 0 N--CA 1.495 2.575 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.883 179.913 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.689 HG12 ' CD2' ' A' ' 38' ' ' PHE . 53.5 t -145.74 126.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 120.161 -0.616 . . . . 0.0 109.965 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -74.5 106.99 6.36 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.739 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.777 HG21 ' N ' ' A' ' 19' ' ' ARG . 10.2 tt -44.64 -40.04 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.036 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.777 ' N ' HG21 ' A' ' 18' ' ' ILE . 11.0 tpt85 -49.68 -54.3 19.44 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.411 -179.912 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 70.8 mt -63.21 -29.17 70.56 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.87 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.649 HG13 ' OD1' ' A' ' 34' ' ' ASP . 11.5 t -55.93 139.19 15.52 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 C-N-CA 118.812 -1.155 . . . . 0.0 111.987 -179.717 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.1 mm100 -137.44 44.43 2.25 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.255 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.24 -107.48 0.01 OUTLIER Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.138 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.551 ' HG1' HD11 ' A' ' 31' ' ' LEU . 0.9 OUTLIER -78.75 -42.45 28.09 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.81 179.969 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -166.17 124.05 1.2 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.995 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 27' ' ' ASN . 14.9 ptmt -61.64 -156.87 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.009 -1.077 . . . . 0.0 110.678 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.553 ' ND2' ' N ' ' A' ' 28' ' ' GLY . 1.8 p-10 43.4 -154.18 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.567 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.553 ' N ' ' ND2' ' A' ' 27' ' ' ASN . . . -53.14 -20.91 10.0 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 120.074 -1.06 . . . . 0.0 111.63 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.436 ' O ' ' O ' ' A' ' 25' ' ' GLY . 22.2 mmt180 -78.25 27.03 0.2 Allowed 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 118.909 -1.116 . . . . 0.0 111.35 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.479 ' H ' ' C ' ' A' ' 28' ' ' GLY . 3.3 t -92.44 129.22 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 C-N-CA 120.028 -0.669 . . . . 0.0 110.914 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.551 HD11 ' HG1' ' A' ' 24' ' ' THR . 10.6 mp -103.44 -177.58 3.41 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.432 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -75.8 -36.12 59.83 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.047 -1.061 . . . . 0.0 109.268 179.82 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -78.87 -2.68 40.96 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.375 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.649 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.3 t0 -68.78 -55.89 9.8 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.751 179.926 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.514 HG22 HD11 ' A' ' 35' ' ' ILE . 3.7 mt -72.52 -39.21 61.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.481 179.937 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -47.8 -39.95 19.67 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 118.966 -1.093 . . . . 0.0 109.806 179.875 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.52 -34.19 67.42 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.586 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.689 ' CD2' HG12 ' A' ' 16' ' ' VAL . 76.7 t80 -40.88 -66.42 0.33 Allowed 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.086 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 10.1 tp -75.08 -61.09 2.01 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.752 -179.949 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.46 -160.04 0.02 OUTLIER 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 119.624 -0.831 . . . . 0.0 110.721 179.965 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.67 -0.69 2.25 Favored Glycine 0 N--CA 1.502 3.041 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.741 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -96.24 -152.44 29.0 Favored Glycine 0 N--CA 1.504 3.198 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.487 179.951 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.25 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.753 -179.998 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 26.7 mm . . . . . 0 N--CA 1.484 1.249 0 CA-C-O 121.126 0.489 . . . . 0.0 110.965 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.82 177.58 6.96 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.134 179.936 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 4.3 ptp -63.98 152.29 87.71 Favored Pre-proline 0 C--N 1.303 -1.442 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.352 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.499 ' C ' ' H ' ' A' ' 7' ' ' VAL . 1.1 Cg_endo -59.11 -179.5 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 120.956 1.104 . . . . 0.0 111.219 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' A' ' 5' ' ' PRO . 1.6 p 71.91 -20.69 0.24 Allowed 'General case' 0 N--CA 1.49 1.564 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.599 179.896 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.499 ' H ' ' C ' ' A' ' 5' ' ' PRO . 94.5 t -95.2 -56.64 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 C-N-CA 119.581 -0.848 . . . . 0.0 111.242 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 56.1 ttp180 -60.92 -35.85 77.78 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.46 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.7 mmtp -55.65 -42.9 75.69 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.395 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.5 t80 -58.26 -48.65 79.75 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.799 -1.16 . . . . 0.0 109.329 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.27 -43.25 42.88 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.018 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 79.1 mtt180 -58.27 -43.81 88.11 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.977 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -55.68 -53.15 60.11 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.826 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.3 mmmt -80.4 0.38 33.47 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.148 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 58.51 70.89 0.86 Allowed Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.25 -1.452 . . . . 0.0 110.403 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.844 HG12 ' CD2' ' A' ' 38' ' ' PHE . 19.9 t -141.64 139.2 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.113 -179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.495 ' N ' HG11 ' A' ' 16' ' ' VAL . 63.0 t0 -85.99 107.95 18.0 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.507 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.708 HG21 ' N ' ' A' ' 19' ' ' ARG . 15.3 tt -46.49 -40.97 4.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 119.769 -0.772 . . . . 0.0 110.92 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.708 ' N ' HG21 ' A' ' 18' ' ' ILE . 5.1 tpm_? -48.16 -57.59 5.67 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.71 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.417 ' HA ' HD21 ' A' ' 20' ' ' LEU . 89.1 mt -54.0 -35.47 61.9 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.704 -0.799 . . . . 0.0 111.783 -179.87 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.493 HG13 ' OD1' ' A' ' 34' ' ' ASP . 11.6 t -56.38 139.5 15.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.432 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -138.94 53.91 1.75 Allowed 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.694 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.82 -114.79 0.06 OUTLIER Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.603 -1.284 . . . . 0.0 111.378 -179.851 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.461 ' HG1' HD12 ' A' ' 31' ' ' LEU . 1.5 p -92.96 -71.06 0.67 Allowed 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.884 -179.851 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.428 ' O ' ' OD1' ' A' ' 27' ' ' ASN . . . -58.93 -50.05 71.79 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.356 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.401 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 21.6 pttp 41.6 36.56 0.59 Allowed 'General case' 0 C--N 1.294 -1.806 0 CA-C-O 121.507 0.67 . . . . 0.0 110.79 -179.894 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.528 ' C ' ' H ' ' A' ' 29' ' ' ARG . 13.6 p-10 -159.41 -160.21 0.81 Allowed 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.224 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.94 -7.79 1.18 Allowed Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.021 179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.528 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -121.48 48.66 1.64 Allowed 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.39 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -69.69 158.18 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.344 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.479 HD11 ' N ' ' A' ' 31' ' ' LEU . 8.8 mp -104.46 171.14 7.5 Favored 'General case' 0 N--CA 1.51 2.538 0 C-N-CA 119.408 -0.917 . . . . 0.0 111.154 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 36.0 tttp -76.77 -39.42 51.68 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.205 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -73.01 -6.37 45.01 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 119.337 -0.945 . . . . 0.0 108.879 179.819 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.493 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.7 t0 -65.32 -62.93 1.25 Allowed 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.026 -179.97 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.437 HG21 HG13 ' A' ' 16' ' ' VAL . 5.2 mt -67.52 -31.29 52.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.801 179.91 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.497 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 33.8 t70 -51.27 -41.13 60.21 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.128 -1.029 . . . . 0.0 110.1 179.895 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -75.2 -32.71 61.28 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.844 ' CD2' HG12 ' A' ' 16' ' ' VAL . 77.4 t80 -43.82 -69.87 0.12 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.571 -0.852 . . . . 0.0 111.696 -179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.508 ' C ' ' H ' ' A' ' 41' ' ' GLY . 24.1 tp -65.43 -49.86 67.6 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.654 -179.824 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.497 ' HB1' ' O ' ' A' ' 36' ' ' ASP . . . -50.61 -10.15 0.06 Allowed 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.26 -0.976 . . . . 0.0 110.996 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.508 ' H ' ' C ' ' A' ' 39' ' ' LEU . . . -45.19 -57.07 5.77 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.642 -1.266 . . . . 0.0 110.758 179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -71.5 -87.3 0.14 Allowed Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.275 -1.441 . . . . 0.0 110.535 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.256 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.756 179.968 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 120.946 0.403 . . . . 0.0 110.146 . . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.426 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 48.74 -179.01 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.879 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.483 ' C ' ' H ' ' A' ' 6' ' ' SER . 16.1 mmt -87.91 151.13 49.21 Favored Pre-proline 0 N--CA 1.49 1.557 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.314 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -69.43 36.62 0.22 Allowed 'Trans proline' 0 CA--C 1.55 1.29 0 C-N-CA 120.82 1.013 . . . . 0.0 111.448 179.91 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.593 ' C ' HG21 ' A' ' 7' ' ' VAL . 13.8 t -154.87 33.7 0.4 Allowed 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 119.364 -0.934 . . . . 0.0 111.312 179.909 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.593 HG21 ' C ' ' A' ' 6' ' ' SER . 48.5 t -142.63 -79.03 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 119.455 -0.898 . . . . 0.0 112.32 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 47.5 ttp85 -51.91 -51.56 56.04 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.702 -0.799 . . . . 0.0 112.947 -179.751 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.649 ' CB ' ' HZ1' ' A' ' 9' ' ' LYS . 0.2 OUTLIER -49.07 -49.47 41.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.688 -179.846 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.458 ' N ' ' CG ' ' A' ' 9' ' ' LYS . 2.3 t80 -51.93 -44.57 63.94 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.079 179.921 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.85 -43.9 63.4 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.58 -0.848 . . . . 0.0 110.928 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -59.64 -43.25 93.95 Favored 'General case' 0 C--N 1.293 -1.849 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.371 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -54.7 -60.01 3.94 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.55 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -75.17 11.07 1.26 Allowed 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.374 -179.896 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.541 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 53.59 75.84 0.21 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.596 -1.288 . . . . 0.0 111.611 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.756 HG12 ' CD2' ' A' ' 38' ' ' PHE . 22.4 t -147.84 135.38 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.843 179.914 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.407 ' N ' HG11 ' A' ' 16' ' ' VAL . 60.6 t0 -82.99 111.32 18.74 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.563 -0.855 . . . . 0.0 111.015 179.923 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.676 HG21 ' H ' ' A' ' 19' ' ' ARG . 15.7 tt -46.11 -40.48 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.943 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.676 ' H ' HG21 ' A' ' 18' ' ' ILE . 52.4 ttt85 -51.86 -58.81 5.39 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 114.867 -1.06 . . . . 0.0 112.301 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.0 mt -50.45 -31.42 15.12 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.524 -179.83 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -62.03 140.74 18.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.781 -1.167 . . . . 0.0 111.159 -179.852 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -134.9 57.15 1.82 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.644 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.4 -112.24 0.08 OUTLIER Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.132 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.525 ' H ' ' HG1' ' A' ' 24' ' ' THR . 0.7 OUTLIER -73.79 -47.85 35.84 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.164 -1.014 . . . . 0.0 109.91 179.971 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.533 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -157.33 114.43 0.61 Allowed Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.53 ' HZ3' HH21 ' A' ' 19' ' ' ARG . 12.0 ptmm? -74.83 36.9 0.11 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.728 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.547 ' CG ' ' H ' ' A' ' 28' ' ' GLY . 25.9 t-20 -109.5 -179.02 3.71 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.547 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -50.93 -11.07 0.5 Allowed Glycine 0 N--CA 1.488 2.124 0 C-N-CA 118.828 -1.653 . . . . 0.0 109.963 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.524 ' H ' ' C ' ' A' ' 27' ' ' ASN . 44.2 mmt-85 -101.01 43.58 1.05 Allowed 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.751 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.488 HG11 ' N ' ' A' ' 31' ' ' LEU . 3.0 t -76.52 163.17 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.397 179.852 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.488 ' N ' HG11 ' A' ' 30' ' ' VAL . 8.6 mp -112.37 174.36 5.92 Favored 'General case' 0 N--CA 1.512 2.655 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.329 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.9 tttp -78.02 -41.38 35.96 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.402 -0.919 . . . . 0.0 108.823 179.867 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -71.53 -5.5 33.7 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.213 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.0 -56.87 8.26 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.36 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.634 HG22 HG13 ' A' ' 16' ' ' VAL . 3.3 mp -72.06 -36.01 55.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.385 -0.926 . . . . 0.0 110.95 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -48.37 -42.12 30.74 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.177 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.48 -34.72 72.71 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.389 179.858 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.756 ' CD2' HG12 ' A' ' 16' ' ' VAL . 69.5 t80 -43.21 -70.63 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.602 179.916 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.6 tp -69.01 -60.85 2.08 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.019 -179.782 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -49.23 168.95 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.4 -0.92 . . . . 0.0 110.836 179.928 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -161.81 19.04 0.18 Allowed Glycine 0 N--CA 1.487 2.037 0 C-N-CA 119.488 -1.339 . . . . 0.0 110.55 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.89 34.79 52.05 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.394 -1.384 . . . . 0.0 110.534 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.387 -0.925 . . . . 0.0 110.77 -179.963 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.651 HG21 ' H ' ' A' ' 3' ' ' ALA . 17.0 mm . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 120.877 0.37 . . . . 0.0 110.813 . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.651 ' H ' HG21 ' A' ' 2' ' ' ILE . . . -78.56 174.52 11.27 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.668 179.979 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.465 ' O ' ' N ' ' A' ' 6' ' ' SER . 64.9 mtm -68.81 149.02 98.02 Favored Pre-proline 0 C--N 1.307 -1.26 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.615 -179.941 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -62.37 77.23 0.1 Allowed 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 120.547 0.831 . . . . 0.0 110.394 179.82 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.465 ' N ' ' O ' ' A' ' 4' ' ' MET . 7.6 p -176.76 -15.87 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 119.666 -0.813 . . . . 0.0 110.094 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.6 t -95.87 -47.85 12.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.699 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 12' ' ' ARG . 53.2 ttp180 -65.04 -42.66 94.08 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.763 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.0 mttm -53.48 -36.55 61.79 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.603 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.6 t80 -61.38 -49.6 76.27 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 118.73 -1.188 . . . . 0.0 108.857 179.773 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.06 -43.32 51.12 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.995 179.771 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 8' ' ' ARG . 95.3 mtt180 -65.52 -47.05 77.25 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.025 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mm-40 -48.15 -50.72 27.77 Favored 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.504 -0.879 . . . . 0.0 111.274 -179.92 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.547 ' HB2' ' HZ3' ' A' ' 14' ' ' LYS . 0.5 OUTLIER -82.88 -36.66 25.17 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 119.403 -0.919 . . . . 0.0 111.5 -179.917 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.23 75.47 1.04 Allowed Glycine 0 N--CA 1.505 3.252 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.663 HG12 ' CD2' ' A' ' 38' ' ' PHE . 11.0 t -147.75 131.45 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 C-N-CA 120.012 -0.675 . . . . 0.0 110.049 179.908 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -75.13 103.02 5.13 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.925 179.975 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.858 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.4 tt -42.34 -37.88 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 CA-C-O 121.688 0.756 . . . . 0.0 110.836 179.949 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.858 ' N ' HG21 ' A' ' 18' ' ' ILE . 44.3 ttt85 -50.15 -58.5 5.43 Favored 'General case' 0 C--N 1.287 -2.132 0 CA-C-N 114.413 -1.267 . . . . 0.0 112.502 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 66.7 mt -59.99 -13.84 13.28 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.774 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.531 HG22 ' HA ' ' A' ' 18' ' ' ILE . 6.6 t -75.38 140.11 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 118.582 -1.247 . . . . 0.0 111.38 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.7 mt-30 -144.08 54.83 1.29 Allowed 'General case' 0 N--CA 1.49 1.527 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.017 -179.898 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -73.87 -96.74 0.1 OUTLIER Glycine 0 N--CA 1.495 2.57 0 C-N-CA 118.827 -1.654 . . . . 0.0 109.676 179.928 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.14 -43.11 29.74 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.419 -0.912 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -171.34 119.07 0.77 Allowed Glycine 0 N--CA 1.482 1.709 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.877 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.462 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttm -56.63 -163.23 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.868 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.656 ' O ' HG22 ' A' ' 30' ' ' VAL . 8.8 p30 49.99 -157.71 0.09 Allowed 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.585 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.512 ' C ' ' H ' ' A' ' 30' ' ' VAL . . . -49.16 -30.74 10.87 Favored Glycine 0 N--CA 1.498 2.791 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.172 -179.825 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.444 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.0 mmt85 -74.34 34.44 0.09 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.963 -1.095 . . . . 0.0 111.711 -179.877 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.656 HG22 ' O ' ' A' ' 27' ' ' ASN . 4.9 t -98.6 139.29 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.394 179.908 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.402 ' N ' HG11 ' A' ' 30' ' ' VAL . 10.8 mp -108.22 177.99 4.64 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.298 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.416 ' HG2' ' HZ1' ' A' ' 32' ' ' LYS . 22.6 tttm -75.55 -35.59 60.64 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.735 179.837 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -76.89 -9.35 58.63 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.102 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.453 ' OD1' HG13 ' A' ' 21' ' ' VAL . 3.7 t0 -65.33 -57.92 7.18 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.704 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.542 HG21 HG13 ' A' ' 16' ' ' VAL . 5.1 mt -70.2 -29.27 38.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.878 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -53.75 -41.22 66.9 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.873 -1.131 . . . . 0.0 109.58 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.29 -33.78 67.68 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.384 -0.826 . . . . 0.0 110.561 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.663 ' CD2' HG12 ' A' ' 16' ' ' VAL . 74.2 t80 -43.67 -68.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.471 -0.892 . . . . 0.0 111.251 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.806 ' C ' HD11 ' A' ' 39' ' ' LEU . 0.2 OUTLIER -70.92 -64.32 0.93 Allowed 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.595 -179.849 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -54.57 85.47 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.385 -0.926 . . . . 0.0 111.1 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -105.45 -76.53 1.06 Allowed Glycine 0 N--CA 1.506 3.324 0 C-N-CA 120.049 -1.072 . . . . 0.0 110.459 -179.932 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.01 35.18 16.11 Favored Glycine 0 N--CA 1.494 2.549 0 C-N-CA 119.61 -1.281 . . . . 0.0 110.367 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.387 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.686 179.922 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.565 HG23 ' N ' ' A' ' 3' ' ' ALA . 21.4 mm . . . . . 0 N--CA 1.482 1.133 0 CA-C-O 120.925 0.393 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.565 ' N ' HG23 ' A' ' 2' ' ' ILE . . . -80.26 64.0 4.93 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.952 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.61 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 62.1 mtt -116.64 -29.18 0.09 OUTLIER Pre-proline 0 N--CA 1.499 2.022 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.61 ' CD ' ' H ' ' A' ' 4' ' ' MET . 5.6 Cg_exo -62.23 80.28 0.1 OUTLIER 'Trans proline' 0 CA--C 1.541 0.874 0 CA-C-N 119.014 0.683 . . . . 0.0 111.325 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.449 ' N ' ' O ' ' A' ' 4' ' ' MET . 18.3 m 51.89 29.04 5.6 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.277 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 44.9 t -89.29 -63.66 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.802 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -66.23 -41.2 90.37 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.034 -1.066 . . . . 0.0 111.071 -179.922 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.0 mttp -53.09 -35.74 59.94 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.515 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -63.08 -51.54 66.22 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.049 179.83 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -42.15 53.17 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.186 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.9 mtp180 -62.17 -46.86 87.06 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.874 179.911 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -50.49 -50.82 51.74 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.051 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.926 ' HZ2' HD21 ' A' ' 39' ' ' LEU . 0.6 OUTLIER -78.78 -25.47 44.36 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.024 -179.963 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.46 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 96.73 68.75 0.98 Allowed Glycine 0 N--CA 1.505 3.278 0 C-N-CA 119.985 -1.102 . . . . 0.0 111.307 179.944 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.493 HG23 ' CD2' ' A' ' 38' ' ' PHE . 42.2 t -147.98 147.83 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.183 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -94.83 108.54 20.56 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.864 -0.734 . . . . 0.0 110.591 179.921 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.905 HG21 ' N ' ' A' ' 19' ' ' ARG . 10.4 tt -42.68 -41.93 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 120.019 -0.673 . . . . 0.0 111.51 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.905 ' N ' HG21 ' A' ' 18' ' ' ILE . 34.2 mtm-85 -52.42 -57.61 9.32 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.258 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.2 mt -52.88 -25.99 13.4 Favored 'General case' 0 N--CA 1.49 1.527 0 C-N-CA 119.611 -0.835 . . . . 0.0 111.918 -179.826 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.662 HG13 ' OD1' ' A' ' 34' ' ' ASP . 6.5 t -64.13 143.27 15.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.054 -1.058 . . . . 0.0 112.003 -179.817 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -136.63 63.0 1.59 Allowed 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.1 -113.18 0.61 Allowed Glycine 0 N--CA 1.497 2.707 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.775 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.438 ' HG1' HD12 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -74.26 -46.27 42.55 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.385 -179.941 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.17 110.46 0.44 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -75.21 61.05 1.12 Allowed 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.47 -0.892 . . . . 0.0 110.797 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.462 ' C ' ' H ' ' A' ' 29' ' ' ARG . 7.4 p30 -150.35 -164.85 2.12 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.284 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.06 -13.3 0.61 Allowed Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.38 -1.391 . . . . 0.0 110.581 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.462 ' H ' ' C ' ' A' ' 27' ' ' ASN . 1.0 OUTLIER -102.87 34.23 2.93 Favored 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 119.863 -0.735 . . . . 0.0 112.278 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.497 ' C ' HD11 ' A' ' 31' ' ' LEU . 2.7 t -75.34 149.86 6.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 C-N-CA 119.057 -1.057 . . . . 0.0 108.818 179.804 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.689 HD11 ' N ' ' A' ' 31' ' ' LEU . 11.0 mp -107.11 173.6 6.25 Favored 'General case' 0 N--CA 1.511 2.601 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.424 -179.878 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.4 tttm -77.16 -35.06 56.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.712 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.5 mm-40 -75.71 -9.12 58.32 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 114.961 -1.018 . . . . 0.0 108.582 179.794 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.662 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.6 t0 -63.77 -57.01 11.25 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.005 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 mp -65.16 -37.03 79.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.464 -0.894 . . . . 0.0 109.694 179.792 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -45.75 -44.65 13.95 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.353 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.05 76.21 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.471 -0.891 . . . . 0.0 110.493 179.92 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.493 ' CD2' HG23 ' A' ' 16' ' ' VAL . 57.2 t80 -46.29 -71.04 0.08 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.647 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.926 HD21 ' HZ2' ' A' ' 14' ' ' LYS . 12.6 tp -72.16 -53.73 11.82 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.416 -179.781 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -48.09 -72.06 0.06 Allowed 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 119.324 -0.951 . . . . 0.0 111.023 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 78.22 21.07 71.19 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.296 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 62.79 126.46 0.01 OUTLIER Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.541 -1.314 . . . . 0.0 110.371 179.989 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.293 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.877 -179.995 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.785 HG21 ' H ' ' A' ' 3' ' ' ALA . 10.1 mm . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 121.021 0.439 . . . . 0.0 111.002 . . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.785 ' H ' HG21 ' A' ' 2' ' ' ILE . . . 44.74 53.98 6.95 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.119 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.576 ' C ' ' H ' ' A' ' 6' ' ' SER . 30.3 mmm -44.56 160.54 0.23 Allowed Pre-proline 0 N--CA 1.487 1.424 0 C-N-CA 119.857 -0.737 . . . . 0.0 110.182 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -65.58 33.63 0.11 Allowed 'Trans proline' 0 CA--C 1.551 1.358 0 C-N-CA 120.724 0.949 . . . . 0.0 111.794 179.721 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.576 ' H ' ' C ' ' A' ' 4' ' ' MET . 44.6 t -139.97 -16.43 0.98 Allowed 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.341 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t -80.21 -64.52 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.689 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 41.3 ttp180 -63.57 -34.37 77.66 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 118.737 -1.185 . . . . 0.0 110.767 -179.937 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt -60.12 -41.66 93.12 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.757 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -57.28 -46.34 83.22 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.069 -1.052 . . . . 0.0 109.062 179.909 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.71 -45.99 63.76 Favored 'General case' 0 C--N 1.291 -1.948 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.485 179.867 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.2 mtp85 -59.11 -46.12 89.15 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.806 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -54.58 -39.33 67.69 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.457 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -89.38 -3.75 58.32 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.67 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.27 6.99 66.55 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.568 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.467 HG12 ' CD2' ' A' ' 38' ' ' PHE . 63.6 t -78.13 125.38 37.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.978 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -78.56 110.32 13.56 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.322 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.49 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -43.23 -40.02 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.117 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.49 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 55.0 mtt-85 -52.64 -59.46 4.44 Favored 'General case' 0 C--N 1.286 -2.153 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.228 -179.896 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.1 mt -52.15 -24.84 7.67 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.215 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.753 HG13 ' OD1' ' A' ' 34' ' ' ASP . 8.6 t -63.61 139.54 21.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 118.936 -1.106 . . . . 0.0 112.18 -179.813 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -131.88 64.54 1.59 Allowed 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 114.906 -1.043 . . . . 0.0 109.876 -179.929 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.11 -114.96 0.88 Allowed Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.437 -1.363 . . . . 0.0 110.499 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.452 ' HG1' HD12 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -82.32 -44.87 15.67 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.824 -0.75 . . . . 0.0 110.136 -179.935 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -147.45 103.8 0.28 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.995 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -76.33 60.38 1.53 Allowed 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.677 -179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.522 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.6 p-10 -157.05 -159.4 0.85 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.256 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.73 -9.09 0.67 Allowed Glycine 0 N--CA 1.484 1.876 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.522 ' H ' ' C ' ' A' ' 27' ' ' ASN . 10.9 mmt-85 -107.76 34.38 3.58 Favored 'General case' 0 N--CA 1.507 2.381 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.574 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -74.42 146.71 9.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.186 -1.006 . . . . 0.0 109.019 179.84 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.648 HD11 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -105.44 177.56 4.82 Favored 'General case' 0 N--CA 1.511 2.589 0 C-N-CA 119.597 -0.841 . . . . 0.0 112.131 -179.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 12.9 tmtt? -76.5 -41.02 48.43 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.09 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.28 -4.21 34.75 Favored 'General case' 0 C--N 1.311 -1.07 0 C-N-CA 119.37 -0.932 . . . . 0.0 109.183 179.823 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.753 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.7 t0 -67.37 -61.55 1.86 Allowed 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.748 179.94 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.7 mt -69.63 -30.57 45.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.486 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -52.25 -40.55 61.83 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.668 179.899 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.96 -35.64 72.24 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.258 179.875 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.467 ' CD2' HG12 ' A' ' 16' ' ' VAL . 57.6 t80 -44.73 -70.05 0.12 Allowed 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.373 179.921 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.4 tp -74.92 -53.39 9.11 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.896 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 43.48 -146.92 0.07 Allowed 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.688 -0.805 . . . . 0.0 111.071 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 165.58 34.31 0.02 OUTLIER Glycine 0 N--CA 1.485 1.942 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.417 -179.974 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 178.41 -60.53 0.09 OUTLIER Glycine 0 N--CA 1.484 1.861 0 C-N-CA 119.676 -1.25 . . . . 0.0 110.237 -179.922 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.577 0 C-N-CA 119.751 -0.78 . . . . 0.0 110.633 179.934 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 120.919 0.39 . . . . 0.0 110.22 . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.461 ' HB3' HG13 ' A' ' 7' ' ' VAL . . . 44.77 47.12 8.91 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.421 -0.912 . . . . 0.0 110.634 -179.987 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.647 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 14.1 ptt? -110.99 -14.49 0.12 Allowed Pre-proline 0 N--CA 1.505 2.29 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.647 ' CD ' ' N ' ' A' ' 4' ' ' MET . 3.8 Cg_exo -62.14 -59.12 0.29 Allowed 'Trans proline' 0 C--N 1.353 0.792 0 CA-C-N 120.089 1.068 . . . . 0.0 110.538 -179.905 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.8 p -162.31 24.01 0.11 Allowed 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.299 179.873 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.461 HG13 ' HB3' ' A' ' 3' ' ' ALA . 81.1 t -86.71 -68.92 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 CA-C-N 114.817 -1.083 . . . . 0.0 111.277 -179.964 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.5 ttp180 -63.8 -43.44 96.3 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.194 -1.002 . . . . 0.0 111.364 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.2 mttm -52.98 -37.63 61.51 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.646 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -63.45 -48.84 76.04 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.035 -1.066 . . . . 0.0 109.012 179.766 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.442 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -49.38 -42.65 42.85 Favored 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.573 179.898 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.6 mmm180 -58.66 -45.27 89.73 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.973 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -54.0 -45.03 71.36 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 118.99 -1.084 . . . . 0.0 110.147 179.978 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -82.21 -16.64 48.92 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.54 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 81.56 1.77 90.26 Favored Glycine 0 N--CA 1.494 2.522 0 C-N-CA 119.51 -1.329 . . . . 0.0 110.582 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.817 HG12 ' CD2' ' A' ' 38' ' ' PHE . 42.1 t -70.56 127.39 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.49 -0.884 . . . . 0.0 110.678 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 48.9 t0 -75.0 107.24 6.93 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.67 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.546 HG21 ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -42.55 -41.35 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.391 -179.88 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.546 ' N ' HG21 ' A' ' 18' ' ' ILE . 21.3 ttm105 -49.24 -53.08 23.27 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.185 -179.877 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -57.42 -41.3 80.15 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.193 -179.78 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.5 t -48.51 141.51 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.261 -179.827 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -141.58 55.13 1.51 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.719 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.45 -112.03 0.06 OUTLIER Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.974 -1.584 . . . . 0.0 109.96 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.477 ' HG1' HD11 ' A' ' 31' ' ' LEU . 1.1 p -78.29 -43.78 27.12 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.329 -0.948 . . . . 0.0 109.629 179.904 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.677 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -156.39 116.36 0.71 Allowed Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.934 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.6 pttm -76.58 45.83 0.42 Allowed 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.745 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.525 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.2 p-10 -142.58 -153.74 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.047 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.34 -9.07 0.9 Allowed Glycine 0 C--N 1.287 -2.171 0 C-N-CA 119.024 -1.56 . . . . 0.0 109.906 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.525 ' H ' ' C ' ' A' ' 27' ' ' ASN . 23.0 mmt180 -100.26 27.59 5.56 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 119.896 -0.722 . . . . 0.0 111.686 -179.972 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.677 HG21 ' O ' ' A' ' 25' ' ' GLY . 3.3 t -79.95 128.31 38.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 119.475 -0.89 . . . . 0.0 108.669 179.886 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.477 HD11 ' HG1' ' A' ' 24' ' ' THR . 10.8 mp -95.11 173.13 7.72 Favored 'General case' 0 N--CA 1.502 2.127 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.691 -179.811 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -73.94 -34.12 64.2 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 119.069 -1.053 . . . . 0.0 108.649 179.897 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -78.03 -6.62 55.11 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.699 -0.8 . . . . 0.0 108.924 179.878 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.34 -58.13 5.36 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.066 179.916 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.53 HG21 HG13 ' A' ' 16' ' ' VAL . 4.2 mt -74.07 -35.73 42.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.082 -179.894 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -50.24 -41.61 50.39 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.857 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.32 -35.0 71.09 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.731 -0.787 . . . . 0.0 110.66 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.817 ' CD2' HG12 ' A' ' 16' ' ' VAL . 69.0 t80 -42.6 -69.05 0.15 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.255 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.6 tp -71.61 -23.2 61.67 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.949 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 46.83 -168.38 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.5 -0.88 . . . . 0.0 111.07 -179.95 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.435 ' O ' ' N ' ' A' ' 43' ' ' ALA . . . 74.74 90.12 0.19 Allowed Glycine 0 N--CA 1.49 2.28 0 C-N-CA 119.36 -1.4 . . . . 0.0 110.388 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.68 88.57 0.02 OUTLIER Glycine 0 N--CA 1.489 2.18 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.488 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 41' ' ' GLY . . . . . . . . 0 C--N 1.306 -1.3 0 C-N-CA 119.463 -0.895 . . . . 0.0 110.872 -179.92 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.661 HG21 ' H ' ' A' ' 3' ' ' ALA . 17.3 mm . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 120.763 0.316 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.661 ' H ' HG21 ' A' ' 2' ' ' ILE . . . -54.16 157.35 2.66 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 119.239 -0.984 . . . . 0.0 110.132 179.925 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.516 ' O ' ' N ' ' A' ' 6' ' ' SER . 56.4 mmm -78.7 149.95 75.18 Favored Pre-proline 0 N--CA 1.487 1.378 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.449 179.99 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.1 77.79 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 120.601 0.867 . . . . 0.0 110.861 179.968 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.516 ' N ' ' O ' ' A' ' 4' ' ' MET . 13.5 t -172.88 -36.18 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.722 179.97 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t -85.35 -58.44 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 119.856 -0.738 . . . . 0.0 110.754 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 39.6 ttm-85 -61.08 -38.62 86.9 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.536 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.6 mmtt -56.99 -42.88 81.07 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.558 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -55.6 -47.3 76.74 Favored 'General case' 0 C--N 1.302 -1.499 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.464 179.912 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -53.43 -48.38 68.82 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.117 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mmm-85 -60.96 -43.83 98.2 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.217 179.908 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 56.3 mm-40 -58.23 -28.66 65.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.679 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 11.5 mmmt -101.42 -11.28 19.49 Favored 'General case' 0 N--CA 1.5 2.027 0 C-N-CA 119.874 -0.73 . . . . 0.0 110.655 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.42 63.53 1.7 Allowed Glycine 0 N--CA 1.496 2.635 0 C-N-CA 119.592 -1.289 . . . . 0.0 110.675 179.948 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.423 HG12 ' CD2' ' A' ' 38' ' ' PHE . 62.7 t -145.21 130.36 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.127 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -87.14 121.49 29.67 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.606 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.624 HG21 ' H ' ' A' ' 19' ' ' ARG . 3.8 tp -45.29 -44.1 3.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.78 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.624 ' H ' HG21 ' A' ' 18' ' ' ILE . 53.9 ttp180 -49.21 -58.71 4.55 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.434 -0.803 . . . . 0.0 112.331 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 57.7 mt -52.69 -29.54 27.18 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.784 -0.766 . . . . 0.0 112.033 -179.849 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 t -69.11 139.34 20.61 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 C-N-CA 118.783 -1.167 . . . . 0.0 111.362 -179.818 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 -145.82 54.03 1.16 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.153 -179.978 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.56 -106.46 0.03 OUTLIER Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.309 -1.424 . . . . 0.0 111.174 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.81 -65.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.574 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -138.72 107.02 0.54 Allowed Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.547 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttp -55.9 -163.34 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.379 -0.929 . . . . 0.0 110.545 179.971 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.547 ' ND2' ' O ' ' A' ' 26' ' ' LYS . 3.0 p30 57.66 -163.06 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 CA-C-O 121.362 0.601 . . . . 0.0 112.273 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.535 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -51.1 -21.22 5.31 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.55 -179.808 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.4 mmt85 -90.09 38.76 0.94 Allowed 'General case' 0 N--CA 1.505 2.289 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.256 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.5 HG11 ' N ' ' A' ' 31' ' ' LEU . 4.0 t -90.46 149.34 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.956 179.85 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.5 ' N ' HG11 ' A' ' 30' ' ' VAL . 7.6 mp -106.89 175.19 5.58 Favored 'General case' 0 N--CA 1.509 2.484 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.738 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.8 tttm -76.53 -38.21 55.49 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.43 -0.908 . . . . 0.0 109.425 179.849 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 57.9 mm-40 -73.69 -6.57 47.62 Favored 'General case' 0 C--N 1.307 -1.239 0 C-N-CA 119.441 -0.903 . . . . 0.0 108.966 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -67.57 -55.79 12.03 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.443 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.49 HG22 HD11 ' A' ' 35' ' ' ILE . 2.5 mt -73.18 -34.18 43.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.371 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -52.22 -40.03 61.06 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.448 179.926 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.24 -34.87 68.6 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.423 ' CD2' HG12 ' A' ' 16' ' ' VAL . 72.4 t80 -45.5 -70.3 0.11 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.454 -0.898 . . . . 0.0 111.184 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.771 ' C ' HD21 ' A' ' 39' ' ' LEU . 3.0 tt -71.17 -62.99 1.19 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.606 -179.903 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 40.86 -101.39 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 120.018 -0.673 . . . . 0.0 111.558 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -177.83 28.7 0.06 OUTLIER Glycine 0 N--CA 1.485 1.908 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.6 179.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 75.76 161.04 9.76 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.432 179.999 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.269 0 C-N-CA 119.346 -0.942 . . . . 0.0 110.83 -179.953 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.57 HG21 ' H ' ' A' ' 3' ' ' ALA . 9.8 mm . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 121.024 0.44 . . . . 0.0 110.895 . . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.57 ' H ' HG21 ' A' ' 2' ' ' ILE . . . -74.32 164.23 26.86 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.417 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 18.3 mmt -75.93 148.35 81.68 Favored Pre-proline 0 N--CA 1.485 1.29 0 C-N-CA 119.166 -1.014 . . . . 0.0 110.67 -179.955 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.436 ' O ' ' OG ' ' A' ' 6' ' ' SER . 10.2 Cg_endo -67.92 68.91 0.87 Allowed 'Trans proline' 0 CA--C 1.548 1.209 0 C-N-CA 120.821 1.014 . . . . 0.0 110.938 179.789 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' A' ' 5' ' ' PRO . 2.5 m -177.31 -57.19 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.667 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 92.5 t -64.54 -41.45 92.3 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 C-N-CA 119.166 -1.014 . . . . 0.0 110.587 179.901 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.9 ttp180 -63.65 -31.19 72.28 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.67 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.9 mmtp -55.31 -44.81 76.13 Favored 'General case' 0 C--N 1.306 -1.298 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.021 179.939 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.524 ' OH ' ' NZ ' ' A' ' 14' ' ' LYS . 9.6 t80 -57.98 -51.16 70.8 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.927 -1.109 . . . . 0.0 108.56 179.782 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -45.28 55.44 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.129 179.829 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -62.32 -47.12 85.65 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.447 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -52.12 -41.0 62.13 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.239 179.8 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.524 ' NZ ' ' OH ' ' A' ' 10' ' ' TYR . 3.2 mmmm -81.31 -69.17 0.63 Allowed 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.53 179.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 138.8 33.68 0.18 Allowed Glycine 0 N--CA 1.501 2.986 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.607 179.97 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.71 HG12 ' CD2' ' A' ' 38' ' ' PHE . 64.5 t -109.44 138.81 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.729 -180.0 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.438 ' N ' HG11 ' A' ' 16' ' ' VAL . 8.6 t70 -84.39 121.7 27.91 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.474 179.969 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.835 HG21 ' N ' ' A' ' 19' ' ' ARG . 3.0 tp -48.57 -44.13 13.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 119.934 -0.707 . . . . 0.0 111.541 -179.911 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.835 ' N ' HG21 ' A' ' 18' ' ' ILE . 32.9 ttm180 -54.07 -49.27 69.43 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.655 -179.908 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.4 mt -57.16 -34.72 68.73 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.52 -0.872 . . . . 0.0 112.102 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.474 HG13 ' OD1' ' A' ' 34' ' ' ASP . 9.8 t -66.7 139.62 20.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.394 -179.879 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -142.93 58.58 1.42 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.27 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.26 -104.36 0.23 Allowed Glycine 0 N--CA 1.496 2.666 0 C-N-CA 119.471 -1.347 . . . . 0.0 111.951 -179.838 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.34 -69.45 0.85 Allowed 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . -40.85 -52.79 3.88 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.03 -1.081 . . . . 0.0 110.559 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.521 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 5.2 mtmp? 48.36 -177.78 0.01 OUTLIER 'General case' 0 C--N 1.29 -2.012 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.925 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 25' ' ' GLY . 7.0 p30 43.13 -171.45 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.563 -179.94 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.92 -7.13 0.41 Allowed Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.178 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.514 ' H ' ' C ' ' A' ' 27' ' ' ASN . 42.2 mmt-85 -111.24 45.9 1.14 Allowed 'General case' 0 N--CA 1.503 2.201 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.794 -179.922 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.806 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.9 t -67.83 158.38 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.11 179.853 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.806 ' N ' HG11 ' A' ' 30' ' ' VAL . 8.8 mt -104.27 173.14 6.43 Favored 'General case' 0 N--CA 1.51 2.564 0 C-N-CA 119.516 -0.873 . . . . 0.0 111.395 -179.916 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.469 ' C ' ' H ' ' A' ' 34' ' ' ASP . 18.7 tptm -73.33 -52.77 12.67 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.381 -0.928 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -63.01 -5.5 3.02 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.224 -0.99 . . . . 0.0 109.849 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.474 ' OD1' HG13 ' A' ' 21' ' ' VAL . 4.5 t0 -66.11 -59.07 4.13 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.414 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.58 HD12 HD11 ' A' ' 18' ' ' ILE . 3.7 mt -73.24 -33.47 41.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.765 -0.774 . . . . 0.0 111.328 179.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -51.22 -41.53 60.36 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.917 179.916 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.96 -33.81 66.11 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.544 -0.863 . . . . 0.0 110.607 179.89 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.71 ' CD2' HG12 ' A' ' 16' ' ' VAL . 70.0 t80 -46.06 -70.93 0.08 Allowed 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.232 179.973 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt -74.59 -45.43 45.24 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.956 -179.97 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.421 ' HB2' ' H ' ' A' ' 41' ' ' GLY . . . 44.43 -101.06 0.04 OUTLIER 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.671 -0.812 . . . . 0.0 111.137 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.421 ' H ' ' HB2' ' A' ' 40' ' ' ALA . . . 62.72 13.27 45.47 Favored Glycine 0 N--CA 1.49 2.288 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.467 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 82.38 -16.56 23.36 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.604 -1.284 . . . . 0.0 110.378 179.972 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.314 0 C-N-CA 119.452 -0.899 . . . . 0.0 110.865 -179.963 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.424 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.6 OUTLIER -74.72 166.12 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.092 179.857 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.424 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 57.9 154.47 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.875 -179.955 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 60.5 mmm -79.08 147.53 69.86 Favored Pre-proline 0 N--CA 1.49 1.539 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.722 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.556 ' C ' ' H ' ' A' ' 7' ' ' VAL . 2.7 Cg_endo -62.26 173.2 3.48 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 120.766 0.977 . . . . 0.0 111.177 179.873 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 t 67.95 -21.03 0.13 Allowed 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 120.034 -0.666 . . . . 0.0 111.795 179.853 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.556 ' H ' ' C ' ' A' ' 5' ' ' PRO . 54.4 t -96.4 -55.45 6.07 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.806 -179.995 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -62.27 -29.02 70.12 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.185 -1.006 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mmtm -59.59 -42.99 93.8 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.145 -179.943 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.432 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 8.3 t80 -60.02 -49.51 77.39 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 118.743 -1.183 . . . . 0.0 108.664 179.863 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.17 -44.1 52.64 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.858 -179.981 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 57.7 mtp85 -62.25 -46.44 88.81 Favored 'General case' 0 C--N 1.295 -1.765 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.276 -179.869 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -52.96 -32.38 45.7 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.07 -1.052 . . . . 0.0 109.896 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 48.5 mmtt -94.47 -18.34 21.59 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 78.55 13.26 83.39 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.826 HG12 ' CD2' ' A' ' 38' ' ' PHE . 26.9 t -84.12 145.12 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.794 -179.83 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.5 ' N ' HG11 ' A' ' 16' ' ' VAL . 54.0 t0 -85.62 99.23 11.14 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.297 -179.961 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.595 ' HA ' HG22 ' A' ' 21' ' ' VAL . 17.3 tt -40.75 -42.65 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.842 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.525 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 43.9 ttt85 -50.24 -61.38 2.2 Favored 'General case' 0 C--N 1.287 -2.122 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.923 -179.938 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -52.18 -28.55 18.64 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.847 -0.741 . . . . 0.0 112.754 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.595 HG22 ' HA ' ' A' ' 18' ' ' ILE . 11.1 t -55.99 141.31 12.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.72 -1.192 . . . . 0.0 112.382 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -136.69 72.55 1.43 Allowed 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.719 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.6 -105.15 1.59 Allowed Glycine 0 N--CA 1.503 3.127 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.265 -179.86 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.811 ' HG1' HD13 ' A' ' 31' ' ' LEU . 1.3 p -93.7 -68.6 0.79 Allowed 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.115 -179.956 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.516 ' C ' HD21 ' A' ' 27' ' ' ASN . . . -105.42 83.41 0.37 Allowed Glycine 0 N--CA 1.501 3.023 0 C-N-CA 120.022 -1.085 . . . . 0.0 110.472 -179.888 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -69.56 74.48 0.39 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.262 -0.975 . . . . 0.0 110.154 179.992 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.546 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.0 OUTLIER -167.76 -161.52 0.39 Allowed 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.587 179.929 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.55 -4.08 1.25 Allowed Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.03 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.546 ' H ' ' C ' ' A' ' 27' ' ' ASN . 25.9 mmt180 -117.33 42.43 2.56 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.295 -0.562 . . . . 0.0 111.374 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -70.37 157.53 6.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 C-N-CA 119.28 -0.968 . . . . 0.0 108.74 179.841 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.811 HD13 ' HG1' ' A' ' 24' ' ' THR . 60.0 mt -107.01 175.06 5.62 Favored 'General case' 0 N--CA 1.513 2.676 0 C-N-CA 119.031 -1.068 . . . . 0.0 112.037 179.973 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -77.22 -32.95 56.21 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.524 179.932 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -79.13 -8.97 59.41 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 119.39 -0.924 . . . . 0.0 108.929 -179.967 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.584 ' OD1' HG13 ' A' ' 21' ' ' VAL . 1.9 t0 -64.4 -54.54 31.16 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.257 -179.931 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.4 mt -71.17 -34.22 53.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-N 114.588 -1.187 . . . . 0.0 110.867 179.874 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -49.7 -41.39 43.17 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.945 179.831 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.1 -34.83 71.48 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.646 179.79 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.826 ' CD2' HG12 ' A' ' 16' ' ' VAL . 69.3 t80 -42.43 -68.91 0.16 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.689 -0.804 . . . . 0.0 111.483 -179.961 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.8 tp -71.38 -64.26 0.95 Allowed 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 43.13 69.93 0.35 Allowed 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.605 -0.838 . . . . 0.0 111.407 -179.965 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 155.77 64.45 0.01 OUTLIER Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.792 -1.195 . . . . 0.0 110.159 179.973 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.6 112.17 4.75 Favored Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.483 179.928 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.361 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.916 -179.993 . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.433 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.501 2.089 0 CA-C-O 121.216 0.531 . . . . 0.0 110.476 . . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.433 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 49.81 177.37 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.738 -179.882 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 20.1 mtt -79.19 157.13 76.03 Favored Pre-proline 0 N--CA 1.491 1.607 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.326 179.957 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -69.32 66.62 1.51 Allowed 'Trans proline' 0 CA--C 1.551 1.337 0 C-N-CA 120.857 1.038 . . . . 0.0 110.553 179.807 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.2 t -168.88 -16.61 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.641 -0.824 . . . . 0.0 110.501 -179.964 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 69.3 t -88.84 -71.28 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.223 179.939 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.558 HH21 ' HE ' ' A' ' 12' ' ' ARG . 36.0 ttt85 -59.22 -27.74 66.02 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.802 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.1 mmmt -60.99 -44.82 96.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.753 -179.926 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -56.29 -48.33 76.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.266 179.816 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.94 -45.93 67.89 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.558 ' HE ' HH21 ' A' ' 8' ' ' ARG . 13.7 mmt85 -60.42 -43.47 96.72 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.681 -179.93 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -57.37 -54.98 40.72 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.114 179.993 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -71.34 -70.17 0.33 Allowed 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.759 -179.912 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.47 ' O ' HG21 ' A' ' 16' ' ' VAL . . . 137.67 69.59 0.05 OUTLIER Glycine 0 N--CA 1.499 2.849 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.996 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.822 HG12 ' CD2' ' A' ' 38' ' ' PHE . 25.0 t -144.41 129.03 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 C-N-CA 120.015 -0.674 . . . . 0.0 110.341 -179.973 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -73.55 106.61 5.4 Favored 'General case' 0 C--N 1.301 -1.508 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.387 179.849 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.8 tt -45.11 -42.27 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 119.938 -0.705 . . . . 0.0 111.468 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.526 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 71.8 mtm180 -46.29 -58.83 3.35 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.227 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.6 mt -55.46 -35.78 65.85 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.725 -0.79 . . . . 0.0 112.209 -179.798 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 t -53.88 140.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.881 -1.128 . . . . 0.0 111.513 -179.805 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -145.2 67.18 1.23 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.424 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . -81.15 -100.63 0.35 Allowed Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.32 -1.419 . . . . 0.0 109.946 179.962 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -78.15 -47.47 18.06 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.148 179.866 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.673 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -157.68 116.23 0.7 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.979 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 9.0 ptmm? -75.18 51.45 0.53 Allowed 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.991 179.953 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.534 ' C ' ' H ' ' A' ' 29' ' ' ARG . 2.9 p30 -147.6 -161.33 1.31 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.711 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.39 -10.89 0.12 Allowed Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.615 -1.279 . . . . 0.0 110.982 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.534 ' H ' ' C ' ' A' ' 27' ' ' ASN . 27.8 mmm-85 -106.0 38.73 1.94 Allowed 'General case' 0 N--CA 1.504 2.241 0 C-N-CA 120.044 -0.662 . . . . 0.0 112.259 -179.943 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.673 HG21 ' O ' ' A' ' 25' ' ' GLY . 4.1 t -82.3 145.62 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.725 179.79 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.424 HD11 ' N ' ' A' ' 31' ' ' LEU . 10.9 mp -106.78 174.49 5.86 Favored 'General case' 0 N--CA 1.51 2.572 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.185 -179.857 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -76.62 -34.31 58.34 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.368 -0.933 . . . . 0.0 108.926 179.743 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -77.0 -9.23 58.56 Favored 'General case' 0 C--N 1.312 -1.056 0 C-N-CA 119.521 -0.872 . . . . 0.0 108.912 179.84 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.424 ' OD1' ' N ' ' A' ' 23' ' ' GLY . 2.7 t0 -62.77 -49.58 74.43 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.232 179.933 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.569 HG21 HG13 ' A' ' 16' ' ' VAL . 4.8 mt -78.43 -33.53 17.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.259 179.889 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -52.29 -41.81 63.22 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.32 179.935 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.66 -35.88 75.56 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.704 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.822 ' CD2' HG12 ' A' ' 16' ' ' VAL . 64.7 t80 -43.08 -69.05 0.15 Allowed 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.335 -179.974 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 41' ' ' GLY . 37.6 tp -69.49 -38.17 77.54 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.366 -0.833 . . . . 0.0 112.643 -179.751 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -41.78 -20.81 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.897 0 C-N-CA 119.322 -0.951 . . . . 0.0 111.654 179.972 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -157.35 -65.49 0.01 OUTLIER Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.533 179.986 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.81 98.2 0.15 Allowed Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.341 -1.409 . . . . 0.0 110.466 179.952 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.49 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.872 179.997 . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.481 1.075 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -81.47 -176.34 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.694 -179.952 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.48 162.4 15.65 Favored 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.595 -179.93 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.448 ' O ' ' N ' ' A' ' 6' ' ' SER . 59.6 mtt -69.31 149.85 97.29 Favored Pre-proline 0 C--N 1.305 -1.349 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.671 179.928 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -63.03 77.35 0.11 Allowed 'Trans proline' 0 CA--C 1.539 0.741 0 C-N-CA 120.543 0.829 . . . . 0.0 110.54 179.993 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.448 ' N ' ' O ' ' A' ' 4' ' ' MET . 10.8 p -177.62 -27.65 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.606 -0.837 . . . . 0.0 110.551 -179.896 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t -82.91 -63.95 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 C-N-CA 119.618 -0.833 . . . . 0.0 110.796 179.914 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 28.5 ttp180 -60.83 -33.52 73.15 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.643 -179.939 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.0 mmtp -59.72 -41.13 90.19 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.334 179.895 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -58.49 -47.6 83.54 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.006 -1.078 . . . . 0.0 109.023 179.924 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.489 ' HB1' ' CD1' ' A' ' 35' ' ' ILE . . . -48.86 -46.07 41.84 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.966 179.746 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 59.2 mtp85 -57.53 -45.5 84.96 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.863 -179.875 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -53.36 -43.88 68.1 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.184 -1.007 . . . . 0.0 110.872 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 14.3 mmmt -81.43 -22.69 38.01 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.929 179.691 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.92 13.95 70.84 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.94 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.488 HG23 ' CD2' ' A' ' 38' ' ' PHE . 38.3 t -83.92 139.53 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.042 179.834 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 46.1 t0 -84.64 100.96 11.79 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.294 179.944 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.595 HG21 ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -39.28 -39.58 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 CA-C-O 121.437 0.636 . . . . 0.0 111.613 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.595 ' N ' HG21 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -50.33 -62.61 1.48 Allowed 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.092 179.911 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -50.61 -28.38 8.65 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.944 -0.703 . . . . 0.0 112.222 -179.704 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.0 t -60.4 141.34 17.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 118.888 -1.125 . . . . 0.0 112.071 -179.788 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.6 mt-30 -134.31 64.51 1.6 Allowed 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.602 -179.993 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.59 -115.61 0.71 Allowed Glycine 0 N--CA 1.498 2.828 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.435 -179.911 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -81.54 -68.12 0.72 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.009 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.64 ' O ' HG21 ' A' ' 30' ' ' VAL . . . -115.46 100.19 0.94 Allowed Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.887 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 7.4 ptmm? -76.09 50.67 0.62 Allowed 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.514 -0.874 . . . . 0.0 110.775 179.941 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.525 ' C ' ' H ' ' A' ' 29' ' ' ARG . 2.7 p30 -151.01 -155.65 0.64 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.902 -0.719 . . . . 0.0 110.583 -179.941 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.6 -7.73 0.71 Allowed Glycine 0 C--N 1.29 -1.982 0 C-N-CA 119.357 -1.401 . . . . 0.0 110.258 -179.859 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.525 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.5 mmt85 -111.56 39.25 2.38 Favored 'General case' 0 N--CA 1.506 2.353 0 C-N-CA 120.149 -0.621 . . . . 0.0 111.81 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.64 HG21 ' O ' ' A' ' 25' ' ' GLY . 2.9 t -76.64 155.45 5.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 C-N-CA 119.364 -0.934 . . . . 0.0 108.986 179.797 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.488 ' HA ' HD21 ' A' ' 31' ' ' LEU . 38.0 mt -109.44 175.43 5.45 Favored 'General case' 0 N--CA 1.514 2.732 0 C-N-CA 119.276 -0.97 . . . . 0.0 111.832 -179.902 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -78.21 -33.4 49.96 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.004 179.723 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 35.1 mm-40 -79.25 -4.99 53.33 Favored 'General case' 0 C--N 1.314 -0.955 0 C-N-CA 119.468 -0.893 . . . . 0.0 109.08 179.862 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -67.31 -58.4 4.87 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 114.687 -1.142 . . . . 0.0 109.249 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.49 HG22 HD11 ' A' ' 35' ' ' ILE . 6.0 mt -70.78 -31.33 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.738 179.703 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.626 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 15.9 t70 -51.97 -41.06 61.83 Favored 'General case' 0 C--N 1.309 -1.172 0 C-N-CA 118.906 -1.118 . . . . 0.0 110.101 -179.888 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.3 -33.37 65.16 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.619 179.906 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.488 ' CD2' HG23 ' A' ' 16' ' ' VAL . 68.3 t80 -44.68 -71.23 0.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.354 -0.939 . . . . 0.0 111.801 179.937 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.497 ' HA ' HD11 ' A' ' 39' ' ' LEU . 32.3 tp -66.87 -58.18 5.53 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.489 -179.797 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.626 ' HB1' ' O ' ' A' ' 36' ' ' ASP . . . -46.32 101.04 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.076 179.983 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -81.85 19.75 9.09 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 119.56 -1.305 . . . . 0.0 110.478 -179.924 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.44 164.92 45.93 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.289 179.982 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.443 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.86 -179.974 . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.608 ' O ' HG11 ' A' ' 1' ' ' VAL . 7.1 p . . . . . 0 N--CA 1.483 1.193 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 . . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.606 HG21 ' H ' ' A' ' 3' ' ' ALA . 10.3 mm -78.0 170.87 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 119.576 -0.849 . . . . 0.0 110.752 -179.942 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.606 ' H ' HG21 ' A' ' 2' ' ' ILE . . . -61.44 -176.82 0.08 Allowed 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.573 -0.851 . . . . 0.0 110.969 179.978 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.434 ' O ' ' N ' ' A' ' 6' ' ' SER . 45.9 mmm -69.34 149.72 97.27 Favored Pre-proline 0 C--N 1.305 -1.35 0 C-N-CA 119.504 -0.879 . . . . 0.0 110.111 -179.955 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.475 ' CB ' ' HZ1' ' A' ' 9' ' ' LYS . 6.4 Cg_endo -63.51 75.34 0.14 Allowed 'Trans proline' 0 CA--C 1.546 1.12 0 C-N-CA 120.681 0.92 . . . . 0.0 110.852 179.934 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.434 ' N ' ' O ' ' A' ' 4' ' ' MET . 5.2 t 176.94 -27.26 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.538 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.8 t -77.08 -60.12 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 119.628 -0.829 . . . . 0.0 111.166 179.987 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 24.9 ttt-85 -62.29 -48.9 77.85 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.208 -179.747 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.475 ' HZ1' ' CB ' ' A' ' 5' ' ' PRO . 54.5 mttt -52.43 -38.03 58.2 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.799 179.875 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -61.48 -46.15 91.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 118.669 -1.213 . . . . 0.0 108.91 179.836 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.0 -43.18 63.53 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.648 179.9 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -56.29 -45.14 80.32 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.759 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -54.33 -42.64 70.42 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.077 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.0 mmtt -90.04 0.5 57.08 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.274 179.878 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 61.63 16.49 51.0 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.684 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.892 HG12 ' CD2' ' A' ' 38' ' ' PHE . 52.5 t -79.03 137.22 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.773 179.99 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.422 ' N ' HG11 ' A' ' 16' ' ' VAL . 56.8 t0 -85.45 102.45 13.48 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.721 179.889 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.921 HG21 ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -42.76 -42.62 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.906 -0.718 . . . . 0.0 111.712 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.921 ' N ' HG21 ' A' ' 18' ' ' ILE . 56.4 ttt-85 -46.54 -60.06 2.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.689 179.901 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 50.6 mt -55.4 -37.54 67.73 Favored 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.683 -0.807 . . . . 0.0 112.255 -179.683 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.587 HG22 ' HA ' ' A' ' 18' ' ' ILE . 11.0 t -49.51 141.28 2.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.19 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -140.96 62.14 1.48 Allowed 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.485 179.95 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . -80.84 -103.74 0.31 Allowed Glycine 0 N--CA 1.499 2.85 0 C-N-CA 119.101 -1.524 . . . . 0.0 109.494 179.946 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.505 ' HG1' HD22 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -78.02 -36.01 49.2 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.291 -0.964 . . . . 0.0 108.718 179.791 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.07 -156.91 6.96 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 179.895 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.418 ' HZ3' ' HB3' ' A' ' 26' ' ' LYS . 14.7 ttpp -163.78 36.06 0.09 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.648 -0.821 . . . . 0.0 109.349 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -154.08 -158.46 0.87 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.818 -179.999 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.28 -21.63 1.99 Allowed Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.195 -1.478 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -93.09 34.44 1.12 Allowed 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.89 179.945 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.657 ' C ' HD21 ' A' ' 31' ' ' LEU . 3.4 t -82.68 155.08 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.525 -0.87 . . . . 0.0 109.57 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.855 HD21 ' N ' ' A' ' 31' ' ' LEU . 3.6 mm? -104.15 173.26 6.38 Favored 'General case' 0 N--CA 1.509 2.485 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -75.31 -43.75 49.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.419 -0.912 . . . . 0.0 108.916 179.798 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -71.27 -6.79 42.49 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.48 -0.888 . . . . 0.0 109.765 -179.948 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.575 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.7 t0 -62.92 -58.2 8.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.646 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.516 HG22 HD11 ' A' ' 35' ' ' ILE . 2.6 mt -69.99 -36.76 70.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.666 -0.814 . . . . 0.0 110.87 -179.92 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -48.56 -43.26 35.54 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.577 -1.249 . . . . 0.0 110.084 179.95 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.24 -35.48 78.0 Favored 'General case' 0 C--N 1.306 -1.316 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.567 -179.968 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.892 ' CD2' HG12 ' A' ' 16' ' ' VAL . 60.3 t80 -44.93 -68.04 0.23 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.385 179.984 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.2 tp -74.89 -69.24 0.48 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.137 -179.893 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.45 ' C ' ' H ' ' A' ' 42' ' ' GLY . . . -50.75 143.86 9.13 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.287 179.965 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -79.68 23.35 3.62 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.566 -1.302 . . . . 0.0 110.134 -179.952 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.45 ' H ' ' C ' ' A' ' 40' ' ' ALA . . . 86.83 18.31 58.36 Favored Glycine 0 N--CA 1.497 2.752 0 C-N-CA 119.704 -1.236 . . . . 0.0 110.474 -179.938 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.371 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.755 179.933 . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 34.0 t . . . . . 0 N--CA 1.481 1.111 0 CA-C-O 120.947 0.403 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.421 ' C ' HD11 ' A' ' 2' ' ' ILE . 0.8 OUTLIER -149.38 -175.78 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.8 179.928 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.06 -169.65 2.17 Favored 'General case' 0 N--CA 1.501 2.101 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.599 179.976 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.52 ' C ' ' H ' ' A' ' 6' ' ' SER . 49.2 mmm -87.44 148.05 43.46 Favored Pre-proline 0 N--CA 1.494 1.756 0 C-N-CA 119.54 -0.864 . . . . 0.0 110.727 -179.98 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -68.61 30.21 0.15 Allowed 'Trans proline' 0 CA--C 1.549 1.237 0 C-N-CA 120.96 1.107 . . . . 0.0 111.645 179.904 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.52 ' H ' ' C ' ' A' ' 4' ' ' MET . 5.6 m -143.85 -37.91 0.32 Allowed 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 119.217 -0.993 . . . . 0.0 111.749 -179.94 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.1 t -71.03 -50.22 43.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.067 -1.053 . . . . 0.0 111.114 -179.858 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 56.7 ttt180 -60.1 -36.07 76.61 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.076 -1.049 . . . . 0.0 111.268 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 51.4 mmtt -55.3 -45.63 76.27 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.212 -0.995 . . . . 0.0 110.336 179.87 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.71 ' CB ' ' HZ2' ' A' ' 32' ' ' LYS . 2.5 t80 -54.64 -46.64 73.98 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.101 179.906 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.53 -45.62 47.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.933 -179.863 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 -58.65 -43.39 89.8 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.18 -179.944 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 75.5 mt-10 -57.3 -31.43 65.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.301 -0.959 . . . . 0.0 110.935 -179.943 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.9 mmtt -96.71 -6.72 35.77 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.101 179.944 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 74.62 53.72 6.4 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.409 HG12 ' CD2' ' A' ' 38' ' ' PHE . 43.0 t -136.39 128.5 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.78 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.786 ' O ' HD13 ' A' ' 20' ' ' LEU . 39.1 t0 -88.28 94.42 9.83 Favored 'General case' 0 N--CA 1.494 1.768 0 C-N-CA 119.556 -0.858 . . . . 0.0 111.036 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.919 HG21 ' N ' ' A' ' 19' ' ' ARG . 15.0 tt -23.25 -41.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.437 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -179.95 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.919 ' N ' HG21 ' A' ' 18' ' ' ILE . 45.1 mtm-85 -45.59 -50.23 13.36 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -179.834 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.786 HD13 ' O ' ' A' ' 17' ' ' ASP . 0.3 OUTLIER -76.66 -2.25 31.85 Favored 'General case' 0 N--CA 1.5 2.061 0 C-N-CA 119.114 -1.035 . . . . 0.0 113.28 -179.665 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.535 HG13 ' OD1' ' A' ' 34' ' ' ASP . 85.2 t -74.75 146.25 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 C-N-CA 118.219 -1.392 . . . . 0.0 110.477 179.94 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.502 ' N ' HG11 ' A' ' 21' ' ' VAL . 53.5 mt-30 -135.3 62.92 1.62 Allowed 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.502 179.962 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.15 -118.88 0.44 Allowed Glycine 0 N--CA 1.498 2.825 0 C-N-CA 119.215 -1.469 . . . . 0.0 110.432 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -75.62 -45.83 35.16 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.432 179.968 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.99 106.49 0.3 Allowed Glycine 0 N--CA 1.486 2.009 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -74.39 64.69 1.16 Allowed 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.79 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.514 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.8 p-10 -152.48 -164.96 2.08 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.538 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.42 -8.63 0.83 Allowed Glycine 0 N--CA 1.485 1.953 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.228 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.514 ' H ' ' C ' ' A' ' 27' ' ' ASN . 12.3 mmt85 -108.57 37.86 2.4 Favored 'General case' 0 N--CA 1.503 2.214 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.537 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.588 HG11 ' N ' ' A' ' 31' ' ' LEU . 2.9 t -77.63 158.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 119.504 -0.879 . . . . 0.0 108.949 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.588 ' N ' HG11 ' A' ' 30' ' ' VAL . 9.9 mp -113.64 177.51 4.61 Favored 'General case' 0 N--CA 1.513 2.707 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.591 -179.954 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.71 ' HZ2' ' CB ' ' A' ' 10' ' ' TYR . 15.9 tptp -77.3 -40.3 44.91 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.871 179.692 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -74.64 -4.22 35.9 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.469 179.843 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.535 ' OD1' HG13 ' A' ' 21' ' ' VAL . 2.0 t70 -64.93 -54.01 37.49 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.529 179.965 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.461 HD12 HG22 ' A' ' 35' ' ' ILE . 4.3 mt -75.5 -36.97 36.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.698 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 55.6 t0 -48.93 -40.46 30.21 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 118.688 -1.205 . . . . 0.0 109.91 179.895 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.89 -35.73 69.83 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.357 -179.998 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.409 ' CD2' HG12 ' A' ' 16' ' ' VAL . 72.2 t80 -45.7 -71.48 0.07 Allowed 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.24 179.862 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.449 ' HA ' HD11 ' A' ' 39' ' ' LEU . 18.1 tp -71.29 -65.54 0.74 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.713 -179.841 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 41.45 -144.7 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.909 -0.716 . . . . 0.0 111.368 179.773 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.98 -56.69 0.01 OUTLIER Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.171 -179.878 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 68.56 82.72 0.17 Allowed Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.418 -179.911 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.317 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.728 179.989 . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' A' ' 2' ' ' ILE . 5.9 m . . . . . 0 N--CA 1.479 0.992 0 CA-C-O 120.839 0.352 . . . . 0.0 110.225 . . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.516 HG21 ' H ' ' A' ' 3' ' ' ALA . 11.0 mm 54.77 165.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 119.694 -0.802 . . . . 0.0 110.758 -179.93 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.516 ' H ' HG21 ' A' ' 2' ' ' ILE . . . -76.89 138.97 40.07 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.309 -0.956 . . . . 0.0 110.582 179.975 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.63 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 35.1 mtm -120.12 -31.96 0.06 OUTLIER Pre-proline 0 N--CA 1.508 2.454 0 N-CA-C 113.941 1.089 . . . . 0.0 113.941 -179.934 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.63 ' CD ' ' H ' ' A' ' 4' ' ' MET . 6.3 Cg_exo -64.91 -157.86 0.03 OUTLIER 'Trans proline' 0 C--O 1.213 -0.732 0 CA-C-N 118.826 0.617 . . . . 0.0 111.074 -179.937 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.2 m -69.32 72.5 0.31 Allowed 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.055 179.932 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.413 ' N ' ' O ' ' A' ' 5' ' ' PRO . 91.0 t -130.6 -66.84 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.721 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 27.8 ttm180 -58.36 -37.98 76.31 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 118.973 -1.091 . . . . 0.0 110.48 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -53.83 -44.81 70.58 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.289 -179.845 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.43 ' HE1' HG23 ' A' ' 35' ' ' ILE . 4.9 t80 -57.67 -48.44 79.5 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 118.991 -1.083 . . . . 0.0 109.299 179.785 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.533 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -50.82 -45.26 59.43 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.323 179.972 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -60.46 -45.83 92.28 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.433 -179.885 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -55.76 -29.42 59.56 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.796 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.1 mmtt -108.58 -5.31 16.55 Favored 'General case' 0 N--CA 1.502 2.158 0 C-N-CA 120.123 -0.631 . . . . 0.0 110.768 179.97 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 62.0 81.13 0.09 OUTLIER Glycine 0 N--CA 1.491 2.305 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.588 179.923 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.929 HG12 ' CD2' ' A' ' 38' ' ' PHE . 24.5 t -147.76 129.44 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.139 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -70.7 96.92 1.28 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.577 -179.975 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.776 HG21 ' H ' ' A' ' 19' ' ' ARG . 16.0 tt -40.52 -41.69 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.969 179.891 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.776 ' H ' HG21 ' A' ' 18' ' ' ILE . 10.0 tpt180 -55.14 -60.42 3.41 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.278 179.996 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.0 mt -49.42 -20.39 0.69 Allowed 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.964 -179.912 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.452 HG22 ' HA ' ' A' ' 18' ' ' ILE . 5.9 t -68.32 139.5 20.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.997 -179.846 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -142.61 52.56 1.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.012 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.4 -95.99 0.06 OUTLIER Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.651 -1.261 . . . . 0.0 111.036 -179.95 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.46 -46.3 16.14 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.38 -0.928 . . . . 0.0 110.291 -179.863 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -161.74 111.97 0.5 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.93 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.447 ' O ' ' OD1' ' A' ' 27' ' ' ASN . 17.5 ptmt -55.7 -163.5 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.77 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.64 ' ND2' ' N ' ' A' ' 28' ' ' GLY . 0.4 OUTLIER 50.82 -160.51 0.08 Allowed 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.416 -179.922 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.64 ' N ' ' ND2' ' A' ' 27' ' ' ASN . . . -50.2 -26.5 9.32 Favored Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.898 -1.144 . . . . 0.0 111.438 -179.823 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.435 ' O ' ' O ' ' A' ' 25' ' ' GLY . 22.0 mmt180 -75.19 29.59 0.1 Allowed 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.592 -179.883 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.52 ' H ' ' C ' ' A' ' 28' ' ' GLY . 2.9 t -90.74 133.72 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.375 179.901 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.469 HD11 ' N ' ' A' ' 31' ' ' LEU . 9.8 mp -104.18 178.82 4.45 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.786 179.943 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -74.43 -36.86 63.42 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.132 179.731 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -75.11 -8.55 56.87 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.189 179.872 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -66.07 -57.34 7.95 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.634 179.829 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.47 HG22 HD11 ' A' ' 35' ' ' ILE . 3.8 mt -66.58 -31.34 53.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.276 -179.951 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -51.57 -40.94 60.7 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.065 -1.054 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.84 -33.19 68.24 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.687 179.924 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.929 ' CD2' HG12 ' A' ' 16' ' ' VAL . 64.9 t80 -45.47 -69.39 0.14 Allowed 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.129 -179.967 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.459 HD11 ' HA ' ' A' ' 39' ' ' LEU . 18.8 tp -74.31 -54.23 8.09 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.821 -179.817 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.412 ' C ' ' H ' ' A' ' 42' ' ' GLY . . . 44.0 -156.92 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.656 -0.817 . . . . 0.0 111.271 -179.902 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -77.65 15.36 7.83 Favored Glycine 0 N--CA 1.493 2.465 0 C-N-CA 119.365 -1.398 . . . . 0.0 110.443 -179.899 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.412 ' H ' ' C ' ' A' ' 40' ' ' ALA . . . -77.07 173.91 54.71 Favored Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.321 -1.418 . . . . 0.0 110.339 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.315 0 C-N-CA 119.426 -0.909 . . . . 0.0 110.846 179.926 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.9 t . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 120.645 0.26 . . . . 0.0 111.372 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 25.1 ttm180 -61.45 -43.41 98.91 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.534 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -52.94 -39.61 63.01 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.936 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.532 ' OH ' ' NZ ' ' A' ' 14' ' ' LYS . 12.2 t80 -60.01 -50.5 73.48 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 118.7 -1.2 . . . . 0.0 109.196 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.91 -43.52 39.39 Favored 'General case' 0 C--N 1.29 -1.996 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.136 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.6 mtp180 -66.46 -45.46 79.66 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.308 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 39.1 mm-40 -46.73 -61.37 1.87 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.416 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.532 ' NZ ' ' OH ' ' A' ' 10' ' ' TYR . 11.4 ptpt -77.31 -22.99 51.11 Favored 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 118.599 -1.241 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 93.61 81.1 1.49 Allowed Glycine 0 N--CA 1.507 3.38 0 C-N-CA 119.731 -1.223 . . . . 0.0 111.477 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.557 HG13 ' CD2' ' A' ' 38' ' ' PHE . 18.7 t -148.42 129.6 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.266 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -74.03 104.52 4.89 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.651 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.535 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.5 tt -48.92 -44.2 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.928 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 19.4 ttm180 -47.88 -54.48 12.47 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.508 -0.769 . . . . 0.0 112.467 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.4 mt -57.54 -35.85 70.85 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 112.088 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 t -52.03 140.96 6.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.673 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.4 tt0 -142.56 66.45 1.33 Allowed 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.427 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.77 -101.26 0.27 Allowed Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.067 -1.539 . . . . 0.0 109.463 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.418 ' OG1' HD13 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -82.26 -42.31 19.04 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.151 179.922 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.91 119.0 0.86 Allowed Glycine 0 N--CA 1.477 1.424 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.7 pttp -75.07 46.29 0.3 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.966 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.484 ' C ' ' H ' ' A' ' 29' ' ' ARG . 14.9 p-10 -143.19 -152.34 0.41 Allowed 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.204 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.56 -8.46 0.54 Allowed Glycine 0 C--N 1.291 -1.959 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.388 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.484 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.8 mmt180 -102.95 34.91 2.68 Favored 'General case' 0 N--CA 1.503 2.184 0 C-N-CA 119.87 -0.732 . . . . 0.0 111.821 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.429 ' C ' HD12 ' A' ' 31' ' ' LEU . 6.3 t -85.27 127.38 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.643 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.6 mp -96.31 172.36 8.0 Favored 'General case' 0 N--CA 1.505 2.314 0 C-N-CA 119.239 -0.984 . . . . 0.0 112.486 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -71.32 -33.98 70.16 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.877 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -80.21 -8.27 59.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.266 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -65.53 -53.04 47.81 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.456 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 mt -75.54 -34.4 29.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.789 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -50.53 -41.96 54.51 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.934 -1.106 . . . . 0.0 109.848 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.59 67.5 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.979 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.557 ' CD2' HG13 ' A' ' 16' ' ' VAL . 77.9 t80 -42.9 -65.87 0.43 Allowed 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.581 -0.847 . . . . 0.0 112.232 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.1 tp . . . . . 0 C--N 1.302 -1.464 0 C-N-CA 119.367 -0.933 . . . . 0.0 112.548 -179.698 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.7 t . . . . . 0 N--CA 1.483 1.211 0 CA-C-O 120.813 0.339 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.0 ttt85 -64.36 -40.69 96.36 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.177 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 17.3 mttp -53.79 -37.96 64.01 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.083 -1.047 . . . . 0.0 110.539 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -60.71 -49.99 75.3 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.766 -1.173 . . . . 0.0 108.966 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.48 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.98 -43.63 40.2 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.573 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -59.45 -45.16 92.38 Favored 'General case' 0 C--N 1.294 -1.821 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.03 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -53.67 -40.05 65.61 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.308 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 15.4 mmmt -87.99 -3.24 58.93 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.612 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.75 3.08 48.55 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.359 -1.4 . . . . 0.0 110.331 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.483 HG13 ' CD2' ' A' ' 38' ' ' PHE . 54.2 t -74.4 133.05 32.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.778 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -84.3 108.9 17.42 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.655 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.517 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.7 tt -44.14 -41.2 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.383 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.517 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.4 tpm_? -48.73 -59.93 3.14 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 114.832 -1.076 . . . . 0.0 112.552 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.6 mt -55.49 -31.44 62.01 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.528 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -53.36 140.55 9.34 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.8 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -135.46 65.4 1.55 Allowed 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 114.997 -1.002 . . . . 0.0 109.801 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.68 -118.42 0.95 Allowed Glycine 0 N--CA 1.502 3.038 0 C-N-CA 119.633 -1.27 . . . . 0.0 111.805 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.16 -72.48 0.6 Allowed 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.086 -179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.489 ' O ' ' N ' ' A' ' 27' ' ' ASN . . . -91.29 69.34 2.08 Favored Glycine 0 N--CA 1.496 2.67 0 C-N-CA 119.761 -1.209 . . . . 0.0 110.397 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -64.49 73.87 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.564 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.496 ' C ' ' H ' ' A' ' 29' ' ' ARG . 33.1 p-10 -174.37 -159.86 0.09 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.829 -0.748 . . . . 0.0 110.259 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.9 -7.62 1.1 Allowed Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.061 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.496 ' H ' ' C ' ' A' ' 27' ' ' ASN . 47.9 mmt-85 -116.5 46.26 1.64 Allowed 'General case' 0 N--CA 1.504 2.263 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.564 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.7 t -72.89 157.89 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.282 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.405 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -104.62 172.84 6.58 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.213 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -79.6 -34.34 40.83 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.582 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 51.8 mm-40 -76.04 -6.57 51.68 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 119.367 -0.933 . . . . 0.0 108.512 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -66.0 -55.47 16.53 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.408 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.48 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.5 mt -75.07 -32.59 27.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.701 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -51.24 -40.49 58.94 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.727 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.79 -37.24 70.45 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.533 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.483 ' CD2' HG13 ' A' ' 16' ' ' VAL . 65.7 t80 -40.78 -67.78 0.22 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.756 -0.778 . . . . 0.0 111.719 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.9 tp . . . . . 0 C--N 1.304 -1.382 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.751 -179.862 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 120.842 0.353 . . . . 0.0 110.559 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -65.92 -30.82 71.46 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.007 -1.077 . . . . 0.0 110.72 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.9 mmtt -62.23 -40.03 94.8 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.014 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -57.92 -46.92 84.27 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.245 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.466 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -49.2 -45.17 43.92 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 115.111 -0.95 . . . . 0.0 111.008 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -58.5 -44.59 89.48 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.389 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 mt-10 -54.72 -51.92 64.09 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 118.986 -1.085 . . . . 0.0 110.989 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.2 mmmt -81.39 6.12 15.44 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.886 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 56.45 75.5 0.25 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.657 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.497 HG13 ' CD2' ' A' ' 38' ' ' PHE . 46.9 t -144.82 126.45 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.159 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 65.5 t0 -74.51 107.88 6.92 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.269 -0.972 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.494 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.3 tt -42.88 -40.94 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.585 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.494 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 32.7 mtm180 -54.89 -54.05 47.56 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.255 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -51.84 -36.52 48.47 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.52 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 t -56.56 142.72 11.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.843 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 41.8 tt0 -142.05 62.26 1.44 Allowed 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 120.098 -0.641 . . . . 0.0 111.647 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.9 -107.23 0.83 Allowed Glycine 0 N--CA 1.5 2.916 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.82 -45.9 40.24 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.467 -0.893 . . . . 0.0 109.626 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.5 120.65 0.99 Allowed Glycine 0 N--CA 1.485 1.91 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -79.99 44.4 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.262 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.479 ' C ' ' H ' ' A' ' 29' ' ' ARG . 1.8 p30 -149.14 -152.05 0.42 Allowed 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.474 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.52 -11.44 0.48 Allowed Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.151 -1.499 . . . . 0.0 110.29 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.479 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.6 mmt180 -102.43 32.85 3.38 Favored 'General case' 0 N--CA 1.503 2.216 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.815 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.6 t -85.57 135.86 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.376 179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.436 HD12 ' N ' ' A' ' 31' ' ' LEU . 11.0 mp -103.45 173.76 6.16 Favored 'General case' 0 N--CA 1.509 2.515 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -72.75 -37.85 67.55 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.649 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -74.46 -9.19 58.34 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.997 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -66.79 -58.24 5.45 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 114.579 -1.191 . . . . 0.0 109.551 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.466 HD13 ' HB2' ' A' ' 11' ' ' ALA . 4.1 mt -72.51 -36.79 55.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -47.24 -41.12 17.9 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 119.102 -1.039 . . . . 0.0 110.245 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.74 -35.86 67.61 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.528 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.497 ' CD2' HG13 ' A' ' 16' ' ' VAL . 67.2 t80 -43.09 -70.73 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.377 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 30.9 tp . . . . . 0 C--N 1.3 -1.568 0 C-N-CA 119.612 -0.835 . . . . 0.0 110.79 -179.96 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.6 t . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 120.937 0.399 . . . . 0.0 111.513 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.402 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 68.5 ttp85 -56.61 -43.79 80.52 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.319 -0.952 . . . . 0.0 111.594 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -48.39 -46.57 37.32 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.115 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -55.34 -49.55 71.93 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 118.866 -1.134 . . . . 0.0 109.385 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.402 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -50.99 -44.47 60.89 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.688 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -59.67 -43.48 93.98 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.825 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -57.7 -43.06 84.92 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.604 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.1 mmtt -82.3 -16.79 48.12 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.618 -0.833 . . . . 0.0 111.006 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.38 3.81 90.4 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.334 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.503 HG13 ' CD2' ' A' ' 38' ' ' PHE . 37.6 t -74.28 134.65 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.56 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -81.45 107.54 14.3 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.679 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.503 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -44.84 -41.11 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 C-N-CA 119.965 -0.694 . . . . 0.0 111.142 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.503 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 1.7 tmt_? -49.64 -59.0 4.19 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.491 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.2 mt -54.39 -25.8 26.65 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.77 -0.772 . . . . 0.0 112.401 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.422 HG12 ' OD1' ' A' ' 34' ' ' ASP . 8.2 t -62.58 139.9 20.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.691 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -136.49 54.63 1.87 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.5 -110.87 0.06 OUTLIER Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.065 -1.54 . . . . 0.0 109.536 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.05 -41.31 35.91 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.429 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -159.03 116.59 0.72 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.9 ptpp? -74.75 39.01 0.13 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.235 -0.986 . . . . 0.0 111.18 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.52 ' O ' ' N ' ' A' ' 29' ' ' ARG . 2.4 p30 -142.25 -152.74 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -47.44 -11.84 0.09 OUTLIER Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.205 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.52 ' N ' ' O ' ' A' ' 27' ' ' ASN . 17.4 mmt-85 -104.33 32.84 3.79 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.178 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.4 t -82.33 128.34 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 119.391 -0.924 . . . . 0.0 108.62 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.557 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -97.83 175.68 6.07 Favored 'General case' 0 N--CA 1.507 2.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.79 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -74.06 -35.99 64.31 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 119.517 -0.873 . . . . 0.0 108.825 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -76.49 -8.01 56.3 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 119.362 -0.935 . . . . 0.0 108.627 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.422 ' OD1' HG12 ' A' ' 21' ' ' VAL . 3.8 t0 -66.4 -59.25 3.85 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 114.66 -1.154 . . . . 0.0 109.581 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mt -70.48 -30.72 43.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.556 -0.857 . . . . 0.0 110.233 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -53.77 -41.36 67.1 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.486 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.64 -32.86 70.32 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.474 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.503 ' CD2' HG13 ' A' ' 16' ' ' VAL . 67.1 t80 -45.24 -70.07 0.11 Allowed 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.32 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 32.2 tp . . . . . 0 C--N 1.299 -1.588 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.713 -179.831 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.5 t . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 120.751 0.31 . . . . 0.0 111.28 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.403 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 57.3 ttp180 -62.17 -39.75 93.71 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.984 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mttp -54.52 -40.22 68.38 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.748 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.1 t80 -58.95 -47.06 86.44 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 118.802 -1.159 . . . . 0.0 108.926 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -49.09 -44.8 42.41 Favored 'General case' 0 C--N 1.291 -1.958 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.662 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 72.1 mtt85 -59.73 -47.12 86.92 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.902 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -50.88 -41.63 58.39 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.332 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 22.7 mmtp -85.49 -19.43 31.23 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.789 -0.764 . . . . 0.0 110.797 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.38 31.58 27.47 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.467 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 40.6 t -105.37 145.3 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 C-N-CA 120.199 -0.601 . . . . 0.0 110.779 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -91.11 105.56 17.9 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 120.029 -0.669 . . . . 0.0 110.299 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.516 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.7 tt -41.08 -41.71 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 CA-C-O 121.43 0.634 . . . . 0.0 111.797 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.516 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.4 ttt85 -52.08 -57.43 9.56 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-N 115.281 -0.872 . . . . 0.0 111.975 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -52.5 -30.24 29.11 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.878 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.2 t -61.59 143.65 14.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.599 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -142.15 52.61 1.47 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.297 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.45 -106.58 0.04 OUTLIER Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.699 -1.715 . . . . 0.0 109.311 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.79 -44.03 51.67 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.464 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.51 121.97 1.08 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttm -76.79 40.14 0.24 Allowed 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.101 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.499 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.2 p-10 -142.72 -150.36 0.31 Allowed 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.797 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.4 -8.77 0.55 Allowed Glycine 0 C--N 1.284 -2.335 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.226 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.499 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.6 28.72 5.8 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.899 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 t -83.01 128.53 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.748 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.541 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -100.07 176.67 5.33 Favored 'General case' 0 N--CA 1.505 2.309 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.957 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.4 tttt -74.41 -36.01 63.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.802 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -76.37 -7.82 55.82 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.883 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -66.26 -51.97 52.26 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.187 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -74.66 -33.19 30.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.994 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -52.07 -40.89 61.85 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 118.716 -1.193 . . . . 0.0 109.566 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.81 -32.88 68.04 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.547 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -44.93 -70.54 0.1 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.433 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.4 tp . . . . . 0 C--N 1.302 -1.49 0 C-N-CA 119.478 -0.889 . . . . 0.0 111.306 -179.809 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.0 t . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 120.868 0.366 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.416 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 64.0 ttt180 -61.42 -29.55 70.01 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.999 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 60.8 mmtt -59.5 -45.7 90.94 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.936 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -55.1 -46.67 75.52 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 119.341 -0.944 . . . . 0.0 109.04 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.555 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.93 -45.62 41.87 Favored 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.523 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 61.7 mtt-85 -64.11 -46.37 84.49 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.02 -0.991 . . . . 0.0 111.453 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 66.4 mt-10 -48.52 -48.74 38.11 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.366 -0.934 . . . . 0.0 111.344 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -83.34 -33.42 25.88 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.159 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.09 73.62 1.07 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.578 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.26 130.4 8.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 C-N-CA 120.019 -0.673 . . . . 0.0 110.193 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -76.26 103.04 6.09 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.08 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.522 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 14.1 tt -42.23 -42.61 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.707 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.522 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.7 ttp180 -45.46 -57.63 3.96 Favored 'General case' 0 C--N 1.289 -2.049 0 CA-C-N 115.264 -0.88 . . . . 0.0 112.415 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 53.1 mt -56.44 -35.97 68.47 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.647 -0.821 . . . . 0.0 112.3 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.8 t -50.18 141.44 3.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 C-N-CA 118.875 -1.13 . . . . 0.0 111.819 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -143.96 65.89 1.3 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.142 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.43 -105.55 0.6 Allowed Glycine 0 N--CA 1.499 2.84 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.07 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.94 -45.69 40.77 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.373 -0.931 . . . . 0.0 109.757 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.518 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -162.99 115.33 0.65 Allowed Glycine 0 N--CA 1.479 1.543 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -74.84 36.06 0.11 Allowed 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.091 -1.044 . . . . 0.0 110.769 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 26.3 t-20 -107.82 -179.82 4.01 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.98 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.52 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -50.01 -12.14 0.45 Allowed Glycine 0 N--CA 1.485 1.936 0 C-N-CA 119.112 -1.518 . . . . 0.0 110.016 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.49 ' N ' ' C ' ' A' ' 27' ' ' ASN . 14.7 mmt-85 -97.94 36.76 1.5 Allowed 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.624 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.4 t -71.11 153.0 8.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.001 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.407 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -105.56 173.21 6.41 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.332 -0.947 . . . . 0.0 111.312 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -77.18 -37.47 53.58 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.104 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -76.05 -5.58 47.1 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.396 -0.921 . . . . 0.0 109.066 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -65.12 -56.17 14.49 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.224 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.555 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 6.2 mt -69.59 -37.78 75.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.138 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -48.36 -40.46 25.58 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.985 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.21 -34.0 70.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.476 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -45.03 -71.9 0.07 Allowed 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.622 -0.831 . . . . 0.0 111.315 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 10.5 tp . . . . . 0 C--N 1.305 -1.345 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.622 -179.898 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.5 t . . . . . 0 N--CA 1.484 1.25 0 CA-C-O 120.932 0.396 . . . . 0.0 110.343 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -66.22 -44.28 84.26 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.551 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -52.65 -35.4 54.86 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.745 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -62.82 -49.83 73.38 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.863 -1.135 . . . . 0.0 108.894 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.404 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -51.49 -43.69 62.27 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.973 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 44.9 mtp180 -60.78 -47.09 87.87 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.721 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.96 -53.96 28.46 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.763 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 13.7 ptmt -76.51 -24.61 53.71 Favored 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.915 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.66 70.69 1.16 Allowed Glycine 0 N--CA 1.503 3.154 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.623 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.404 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 19.2 t -148.2 145.55 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.929 -0.709 . . . . 0.0 110.287 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -90.82 106.21 18.36 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.593 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.529 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 16.6 tt -42.12 -41.72 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.512 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.529 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 84.6 mtt-85 -50.08 -60.69 2.7 Favored 'General case' 0 C--N 1.285 -2.222 0 CA-C-N 115.021 -0.991 . . . . 0.0 112.421 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 75.6 mt -51.9 -18.1 1.21 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.467 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.2 t -72.34 139.8 19.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 C-N-CA 118.671 -1.212 . . . . 0.0 111.66 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 tt0 -138.68 55.39 1.73 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.858 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.54 -109.43 0.02 OUTLIER Glycine 0 N--CA 1.492 2.378 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.698 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -70.06 -44.31 69.42 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.312 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -168.68 121.36 0.94 Allowed Glycine 0 N--CA 1.48 1.614 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.079 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.43 ' CE ' ' O ' ' A' ' 19' ' ' ARG . 0.7 OUTLIER -73.05 66.1 0.8 Allowed 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.304 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.476 ' C ' ' H ' ' A' ' 29' ' ' ARG . 12.3 p30 -152.07 -164.89 2.08 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.243 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.1 -9.52 0.9 Allowed Glycine 0 N--CA 1.483 1.783 0 C-N-CA 119.212 -1.471 . . . . 0.0 110.045 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.476 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.3 mmm-85 -100.76 30.99 3.71 Favored 'General case' 0 N--CA 1.501 2.08 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.531 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.0 t -81.42 143.67 11.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 119.596 -0.841 . . . . 0.0 108.962 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.441 ' H ' ' HB2' ' A' ' 34' ' ' ASP . 5.4 mp -112.86 174.62 5.81 Favored 'General case' 0 N--CA 1.514 2.728 0 C-N-CA 119.49 -0.884 . . . . 0.0 112.302 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -73.29 -33.65 65.33 Favored 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.168 -1.013 . . . . 0.0 108.299 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -74.55 -12.88 60.58 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.124 -0.944 . . . . 0.0 108.912 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.441 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.2 t0 -63.87 -51.3 65.23 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.228 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mt -75.79 -32.11 23.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.243 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -52.63 -40.45 62.79 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.598 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.92 -34.43 71.52 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.308 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 61.9 t80 -42.92 -70.83 0.09 Allowed 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.77 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 53.5 tp . . . . . 0 C--N 1.301 -1.527 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.077 -179.925 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 85.7 t . . . . . 0 N--CA 1.486 1.354 0 CA-C-O 121.006 0.432 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 61.3 ttt180 -63.29 -37.21 86.35 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.85 -1.14 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.8 mmtt -55.81 -40.35 72.64 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.491 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -56.62 -51.11 69.95 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.631 -1.228 . . . . 0.0 108.977 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.24 -45.38 54.01 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.246 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtp180 -62.89 -46.69 86.63 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.823 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -52.07 -55.8 18.42 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.782 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.6 mmtt -67.7 -66.03 0.61 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 133.66 64.73 0.07 OUTLIER Glycine 0 N--CA 1.499 2.867 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.427 HG13 ' CD2' ' A' ' 38' ' ' PHE . 41.9 t -142.24 138.99 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.479 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 38.2 t0 -83.96 109.23 17.45 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.639 -0.825 . . . . 0.0 110.553 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.479 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 9.2 tt -44.05 -41.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.512 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.479 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 58.6 ttp180 -50.33 -58.16 6.3 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.33 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.2 mt -54.93 -28.21 49.22 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.325 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.404 ' H ' HG23 ' A' ' 21' ' ' VAL . 6.9 t -62.43 142.28 16.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 C-N-CA 118.754 -1.179 . . . . 0.0 111.308 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -142.23 66.24 1.34 Allowed 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.52 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.1 -103.22 0.66 Allowed Glycine 0 N--CA 1.5 2.93 0 C-N-CA 119.24 -1.457 . . . . 0.0 109.552 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -79.7 -51.81 8.75 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.486 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.25 114.19 0.63 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 pttm -76.0 55.95 0.95 Allowed 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.045 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.488 ' C ' ' N ' ' A' ' 29' ' ' ARG . 1.5 p30 -146.2 -162.34 1.5 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.259 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.46 -10.19 0.54 Allowed Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.303 -1.427 . . . . 0.0 110.153 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.488 ' N ' ' C ' ' A' ' 27' ' ' ASN . 13.2 mmt85 -104.39 35.25 2.78 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.751 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -78.07 145.24 10.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.296 -0.962 . . . . 0.0 108.625 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.1 mp -102.86 173.04 6.49 Favored 'General case' 0 N--CA 1.511 2.596 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.708 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.6 tttm -74.18 -43.49 57.09 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.242 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -70.95 -5.18 28.96 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.45 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -68.37 -56.79 7.29 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.177 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -71.45 -31.14 42.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.405 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -53.71 -42.33 67.92 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.602 -1.239 . . . . 0.0 109.531 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.8 -35.45 78.67 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.282 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.427 ' CD2' HG13 ' A' ' 16' ' ' VAL . 64.6 t80 -43.04 -70.47 0.11 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.266 -0.974 . . . . 0.0 111.342 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.1 tp . . . . . 0 C--N 1.302 -1.486 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.61 -179.831 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 84.9 t . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 120.865 0.364 . . . . 0.0 111.126 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 58.7 ttt-85 -58.09 -31.64 67.3 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.256 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -61.15 -39.97 92.1 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.206 -0.998 . . . . 0.0 110.511 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 6.1 t80 -59.08 -48.36 81.88 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 118.944 -1.102 . . . . 0.0 109.259 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.411 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -49.71 -42.38 45.74 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.791 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -61.96 -43.51 98.69 Favored 'General case' 0 C--N 1.292 -1.907 0 C-N-CA 119.484 -0.887 . . . . 0.0 111.082 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -55.04 -54.41 43.44 Favored 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.309 -0.956 . . . . 0.0 110.928 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.4 mmtp -79.82 -19.43 48.46 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.066 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 76.06 81.93 0.52 Allowed Glycine 0 N--CA 1.49 2.24 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.968 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.464 HG13 ' CE2' ' A' ' 38' ' ' PHE . 17.9 t -146.9 141.57 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.918 -0.713 . . . . 0.0 110.647 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -80.31 97.57 7.05 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.267 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.4 tt -40.19 -37.79 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.534 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.441 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 57.0 mtp180 -54.96 -62.72 1.48 Allowed 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.364 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.0 mt -51.17 -17.67 0.72 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.549 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.3 t -68.35 141.16 17.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 C-N-CA 118.502 -1.279 . . . . 0.0 111.447 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -139.83 67.77 1.37 Allowed 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.037 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.12 -114.01 1.34 Allowed Glycine 0 N--CA 1.498 2.814 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.025 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.34 -44.05 54.04 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.91 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.5 111.94 0.5 Allowed Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -75.85 53.07 0.73 Allowed 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.081 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.473 ' C ' ' N ' ' A' ' 29' ' ' ARG . 3.2 p30 -146.02 -164.09 1.88 Allowed 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 120.212 -0.595 . . . . 0.0 110.322 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -49.55 -13.57 0.5 Allowed Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.191 -1.48 . . . . 0.0 110.414 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.473 ' N ' ' C ' ' A' ' 27' ' ' ASN . 0.2 OUTLIER -101.11 33.95 2.69 Favored 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 119.917 -0.713 . . . . 0.0 112.152 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.7 t -76.66 150.18 6.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.047 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 9.6 mp -107.98 174.88 5.69 Favored 'General case' 0 N--CA 1.511 2.619 0 C-N-CA 119.482 -0.887 . . . . 0.0 111.033 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.5 tttm -77.32 -38.14 51.13 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.292 -0.963 . . . . 0.0 108.786 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -73.9 -7.49 52.52 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.563 -0.855 . . . . 0.0 108.876 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -64.31 -57.65 8.79 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.706 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.7 mt -72.28 -29.01 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.6 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -53.13 -43.41 66.92 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.627 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.56 -35.02 75.02 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.543 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.464 ' CE2' HG13 ' A' ' 16' ' ' VAL . 67.2 t80 -43.78 -68.62 0.18 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.341 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.567 ' C ' HD23 ' A' ' 39' ' ' LEU . 4.5 tt . . . . . 0 C--N 1.304 -1.406 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.901 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.9 t . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 120.749 0.309 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.58 HH22 HH21 ' A' ' 12' ' ' ARG . 48.7 ttt-85 -60.95 -40.18 92.32 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.528 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -56.41 -41.34 76.16 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.586 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -56.28 -46.46 79.71 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.029 -1.068 . . . . 0.0 109.149 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.02 -44.9 61.1 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.67 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.58 HH21 HH22 ' A' ' 8' ' ' ARG . 6.5 mmp_? -59.47 -42.83 92.92 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.179 -179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.425 ' C ' ' H ' ' A' ' 15' ' ' GLY . 48.2 mt-10 -58.14 -64.52 0.88 Allowed 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.344 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.2 mmtm -69.29 8.71 0.55 Allowed 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.295 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 13' ' ' GLU . . . 55.55 78.19 0.13 Allowed Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.787 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.512 HG13 ' CD2' ' A' ' 38' ' ' PHE . 37.1 t -147.71 137.32 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.075 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 68.6 t0 -87.43 106.4 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.7 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.534 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -43.85 -42.89 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.52 0.676 . . . . 0.0 111.862 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.534 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 46.0 mtt-85 -49.33 -59.72 3.45 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 114.999 -1.001 . . . . 0.0 113.119 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 49.3 mt -55.76 -24.68 36.85 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.961 -0.695 . . . . 0.0 112.668 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.5 t -57.86 141.1 15.29 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 C-N-CA 118.641 -1.224 . . . . 0.0 112.033 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.7 tt0 -136.4 59.18 1.71 Allowed 'General case' 0 N--CA 1.482 1.158 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.672 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.8 -110.41 0.09 OUTLIER Glycine 0 N--CA 1.494 2.551 0 C-N-CA 118.957 -1.592 . . . . 0.0 109.751 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.84 -43.59 29.93 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.322 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.453 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -159.84 114.82 0.63 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 ptmt -74.9 38.88 0.13 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.284 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.492 ' C ' ' H ' ' A' ' 29' ' ' ARG . 18.7 p-10 -124.43 -161.96 1.04 Allowed 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.207 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.06 -6.37 0.82 Allowed Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.156 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.492 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.44 34.93 2.59 Favored 'General case' 0 N--CA 1.502 2.126 0 C-N-CA 119.964 -0.695 . . . . 0.0 111.805 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -80.92 150.37 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 C-N-CA 119.341 -0.944 . . . . 0.0 108.934 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.444 ' H ' ' HB2' ' A' ' 34' ' ' ASP . 5.4 mp -120.26 -179.91 4.09 Favored 'General case' 0 N--CA 1.515 2.801 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.011 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 tttp -78.86 -33.2 46.05 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.75 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.62 ' CD ' ' H ' ' A' ' 33' ' ' GLU . 2.3 pm0 -75.3 -7.67 54.57 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.444 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.2 t0 -67.6 -54.71 17.49 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 114.523 -1.217 . . . . 0.0 109.369 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -72.98 -35.23 48.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.316 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -48.44 -40.71 27.09 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.208 -0.997 . . . . 0.0 110.177 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.14 -32.58 64.98 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.498 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.512 ' CD2' HG13 ' A' ' 16' ' ' VAL . 72.0 t80 -44.13 -69.08 0.15 Allowed 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.601 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.3 tp . . . . . 0 C--N 1.304 -1.412 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.12 -179.753 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t . . . . . 0 N--CA 1.496 1.87 0 CA-C-O 120.848 0.356 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 25.7 ttm-85 -60.73 -38.78 86.3 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.296 -0.961 . . . . 0.0 111.336 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -54.25 -42.31 69.79 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -57.19 -49.72 75.11 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 118.607 -1.237 . . . . 0.0 109.15 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -48.36 -42.32 31.26 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.184 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -63.55 -45.79 88.91 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 119.398 -0.921 . . . . 0.0 111.225 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -50.85 -56.17 13.5 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.951 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 55.5 mmtt -79.88 -22.55 42.73 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.114 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 83.4 80.71 1.0 Allowed Glycine 0 N--CA 1.497 2.711 0 C-N-CA 119.573 -1.299 . . . . 0.0 110.496 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.526 HG13 ' CD2' ' A' ' 38' ' ' PHE . 28.2 t -147.61 135.28 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.409 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -78.35 102.96 7.99 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.266 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.519 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -44.85 -42.99 2.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.663 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.519 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 17.5 tpp180 -52.62 -54.09 37.99 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.273 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.3 mt -55.7 -26.7 46.44 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.05 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.6 t -61.35 143.04 15.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.757 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -132.99 69.76 1.48 Allowed 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.613 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.81 -114.49 2.91 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.544 -1.313 . . . . 0.0 110.415 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.07 -46.03 31.13 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.293 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -153.4 109.82 0.42 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 11.8 pttm -77.28 61.07 2.08 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.81 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 14.2 p-10 -156.9 -161.59 1.11 Allowed 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.12 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -9.07 0.41 Allowed Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.59 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 14.9 mmt85 -111.9 40.95 2.04 Favored 'General case' 0 N--CA 1.507 2.385 0 C-N-CA 120.167 -0.613 . . . . 0.0 111.592 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.8 t -80.91 157.9 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.658 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 7.9 mp -113.42 173.39 6.43 Favored 'General case' 0 N--CA 1.509 2.522 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.948 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -76.3 -43.06 43.19 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.053 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -66.79 -10.06 43.56 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.44 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -66.2 -57.52 7.41 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.568 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 mt -72.33 -33.27 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.649 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 39.5 t0 -49.71 -41.38 43.28 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.191 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.18 -35.04 68.86 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.467 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' A' ' 16' ' ' VAL . 70.5 t80 -43.72 -70.2 0.11 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.631 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.508 ' C ' HD23 ' A' ' 39' ' ' LEU . 4.1 tt . . . . . 0 C--N 1.305 -1.368 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.745 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 82.0 t . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 121.018 0.437 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -66.71 -45.39 78.86 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.959 -1.096 . . . . 0.0 110.697 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mttm -53.83 -35.85 61.88 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.638 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -63.27 -47.14 83.61 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.405 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.06 -42.64 63.31 Favored 'General case' 0 C--N 1.291 -1.95 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.595 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 69.2 mtp180 -60.98 -46.48 90.56 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.678 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -54.59 -44.01 72.64 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.879 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.0 mmtt -86.14 -69.78 0.64 Allowed 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.692 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.75 73.35 0.06 OUTLIER Glycine 0 N--CA 1.502 3.076 0 C-N-CA 119.88 -1.153 . . . . 0.0 110.773 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 39.9 t -144.67 137.44 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.493 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.1 t0 -79.85 112.28 16.98 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.804 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 7.3 tp -43.11 -43.17 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.641 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.532 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.7 tpt180 -59.91 -56.25 24.07 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.595 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.407 HD23 ' HA ' ' A' ' 20' ' ' LEU . 74.0 mt -47.16 -21.17 0.22 Allowed 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.558 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.5 t -76.5 143.18 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.976 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -132.48 65.33 1.58 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.983 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.2 -121.99 2.62 Favored Glycine 0 N--CA 1.502 3.058 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.242 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.404 ' OG1' HD23 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -73.26 -60.15 2.38 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.987 179.87 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -134.9 109.7 0.79 Allowed Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt -76.49 55.46 1.02 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.03 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.479 ' C ' ' H ' ' A' ' 29' ' ' ARG . 16.1 p-10 -156.89 -157.84 0.72 Allowed 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.585 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.36 -10.52 0.56 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.239 -1.458 . . . . 0.0 110.236 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.479 ' H ' ' C ' ' A' ' 27' ' ' ASN . 28.0 mmt180 -107.71 37.27 2.47 Favored 'General case' 0 N--CA 1.506 2.34 0 C-N-CA 120.074 -0.651 . . . . 0.0 111.709 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.414 ' C ' HD22 ' A' ' 31' ' ' LEU . 2.7 t -80.68 156.62 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 119.545 -0.862 . . . . 0.0 109.619 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.414 HD22 ' C ' ' A' ' 30' ' ' VAL . 3.9 mm? -105.78 172.49 6.77 Favored 'General case' 0 N--CA 1.508 2.459 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.365 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 48.4 tttm -77.1 -42.89 36.28 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 118.863 -1.135 . . . . 0.0 109.245 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -70.89 -3.38 18.87 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.47 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -67.33 -59.73 3.17 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.959 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.2 mt -72.1 -30.5 36.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.534 -0.867 . . . . 0.0 110.881 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -53.23 -41.58 65.52 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.895 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.18 -31.56 62.73 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.823 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 74.4 t80 -47.92 -69.89 0.11 Allowed 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 119.219 -0.993 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.455 ' C ' HD23 ' A' ' 39' ' ' LEU . 3.6 tt . . . . . 0 C--N 1.304 -1.4 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.931 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 70.0 t . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 120.871 0.367 . . . . 0.0 110.714 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 34.0 ttm180 -60.62 -39.37 87.98 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.189 -1.005 . . . . 0.0 111.135 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.4 mttp -53.02 -42.84 66.06 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.9 t80 -57.61 -50.18 73.99 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.739 -1.184 . . . . 0.0 109.22 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.8 -45.01 49.5 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.811 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -60.49 -45.82 92.37 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.075 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -52.36 -51.95 56.09 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 18.2 mtpp -81.29 -8.58 59.77 Favored 'General case' 0 N--CA 1.489 1.515 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.89 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.52 75.4 0.61 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.358 -1.401 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.526 HG13 ' CD2' ' A' ' 38' ' ' PHE . 42.8 t -144.25 126.53 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.946 -0.701 . . . . 0.0 110.413 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -72.79 100.77 2.95 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.526 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.8 tt -41.25 -41.74 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.69 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 17.9 tpp180 -52.12 -53.06 47.31 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.327 -0.852 . . . . 0.0 112.207 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.4 mt -57.84 -28.98 64.59 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.156 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 t -59.08 140.28 17.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.559 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -140.55 63.2 1.47 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.853 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.26 -101.85 0.35 Allowed Glycine 0 N--CA 1.496 2.656 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.89 -42.7 21.02 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.631 -0.827 . . . . 0.0 110.098 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.93 114.77 0.62 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.1 pttt -75.87 57.33 1.03 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.963 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.48 ' C ' ' N ' ' A' ' 29' ' ' ARG . 41.3 p30 -149.89 -161.37 1.33 Allowed 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.633 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.09 -11.13 0.36 Allowed Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.597 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.48 ' N ' ' C ' ' A' ' 27' ' ' ASN . 18.9 mmt180 -104.58 35.52 2.72 Favored 'General case' 0 N--CA 1.504 2.258 0 C-N-CA 119.861 -0.735 . . . . 0.0 111.79 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -81.45 135.11 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.546 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.6 mp -101.52 174.01 6.17 Favored 'General case' 0 N--CA 1.511 2.616 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.795 -179.709 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 50.7 tttm -75.27 -34.18 61.32 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 119.137 -1.025 . . . . 0.0 108.304 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.1 tp10 -71.14 -16.21 62.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -63.22 -54.33 39.1 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 114.201 -1.363 . . . . 0.0 109.123 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.2 mt -73.34 -34.18 42.85 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.532 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -50.55 -41.31 53.92 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.502 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.46 -36.36 76.5 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.291 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' A' ' 16' ' ' VAL . 56.9 t80 -43.86 -69.96 0.12 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.374 -0.931 . . . . 0.0 111.489 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.434 ' O ' HD13 ' A' ' 39' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.305 -1.362 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.41 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.2 t . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 120.647 0.26 . . . . 0.0 111.483 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -62.94 -40.93 99.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 118.905 -1.118 . . . . 0.0 111.224 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.445 ' H ' ' CD ' ' A' ' 9' ' ' LYS . 0.4 OUTLIER -51.64 -40.34 59.78 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.411 179.977 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -61.04 -51.43 69.21 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 118.909 -1.116 . . . . 0.0 108.904 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.11 -43.14 51.54 Favored 'General case' 0 C--N 1.291 -1.945 0 CA-C-N 115.19 -0.913 . . . . 0.0 110.25 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -63.02 -47.32 83.56 Favored 'General case' 0 C--N 1.296 -1.749 0 CA-C-N 115.057 -0.974 . . . . 0.0 110.358 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -51.85 -31.4 27.68 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.153 -1.019 . . . . 0.0 110.108 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.3 mmtp -97.78 -10.1 25.4 Favored 'General case' 0 N--CA 1.495 1.796 0 C-N-CA 119.979 -0.689 . . . . 0.0 110.692 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.08 1.5 74.2 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.358 -1.401 . . . . 0.0 109.962 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.472 HG13 ' CE2' ' A' ' 38' ' ' PHE . 41.9 t -71.31 137.32 23.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.933 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -86.38 105.8 16.97 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.278 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 19' ' ' ARG . 16.4 tt -43.04 -43.04 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.994 -179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' HG23 ' A' ' 18' ' ' ILE . 37.8 mtp180 -48.81 -57.72 5.94 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.865 -179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.2 mt -54.43 -29.63 49.93 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 119.723 -0.791 . . . . 0.0 112.56 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -55.6 140.35 13.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.623 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -132.46 62.27 1.65 Allowed 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.397 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -83.92 -121.43 0.86 Allowed Glycine 0 N--CA 1.496 2.699 0 C-N-CA 119.098 -1.525 . . . . 0.0 110.54 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.52 -66.22 0.92 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.708 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.67 -62.94 5.68 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.897 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 66.9 tttt 56.43 38.86 30.06 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.554 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.507 ' C ' ' H ' ' A' ' 29' ' ' ARG . 38.2 p-10 -163.71 -160.77 0.6 Allowed 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.182 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.29 -5.41 0.71 Allowed Glycine 0 N--CA 1.484 1.885 0 C-N-CA 119.16 -1.495 . . . . 0.0 110.249 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.507 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -122.93 45.6 2.37 Favored 'General case' 0 N--CA 1.504 2.232 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.657 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -70.4 160.4 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 C-N-CA 119.089 -1.044 . . . . 0.0 108.946 179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 9.3 mp -105.79 172.66 6.68 Favored 'General case' 0 N--CA 1.513 2.679 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.08 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -79.01 -37.51 39.01 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.393 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -72.45 -7.44 49.86 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -66.1 -59.0 4.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 114.563 -1.199 . . . . 0.0 109.621 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -72.64 -28.54 27.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.548 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -53.41 -40.95 65.5 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.697 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.51 -35.54 68.14 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.583 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.472 ' CE2' HG13 ' A' ' 16' ' ' VAL . 67.0 t80 -42.19 -70.12 0.12 Allowed 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.666 -0.813 . . . . 0.0 112.284 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 32.2 tp . . . . . 0 C--N 1.303 -1.436 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.076 -179.716 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 60.7 t . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 120.854 0.359 . . . . 0.0 110.699 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.1 ttt85 -65.39 -43.97 88.99 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 118.782 -1.167 . . . . 0.0 110.254 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -56.09 -35.37 66.94 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.185 -1.006 . . . . 0.0 110.698 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -61.46 -45.5 93.99 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.837 -1.145 . . . . 0.0 109.111 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -48.32 -42.62 31.71 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.402 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -64.2 -44.82 90.8 Favored 'General case' 0 C--N 1.291 -1.935 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.061 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.8 mm-40 -51.29 -53.09 39.04 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.783 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -82.26 -22.62 35.71 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.646 -0.822 . . . . 0.0 111.012 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 83.36 78.85 1.06 Allowed Glycine 0 N--CA 1.497 2.702 0 C-N-CA 119.469 -1.348 . . . . 0.0 110.305 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.468 HG13 ' CD2' ' A' ' 38' ' ' PHE . 33.6 t -145.7 138.57 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 120.035 -0.666 . . . . 0.0 110.161 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.2 t0 -80.95 97.1 7.3 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.05 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.512 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.8 tt -41.2 -41.73 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.562 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.512 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 13.4 tpp180 -49.96 -57.92 6.52 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.713 -179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 51.2 mt -57.42 -36.62 71.58 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.547 -0.861 . . . . 0.0 112.163 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.432 ' H ' HG23 ' A' ' 21' ' ' VAL . 14.8 t -47.08 140.92 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.69 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -133.78 65.37 1.58 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.294 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.49 -114.17 0.78 Allowed Glycine 0 N--CA 1.496 2.678 0 C-N-CA 119.14 -1.505 . . . . 0.0 109.951 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.08 -61.01 2.03 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.01 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.35 102.62 0.59 Allowed Glycine 0 N--CA 1.5 2.947 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.2 pttp -74.59 61.5 0.96 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' N ' ' A' ' 29' ' ' ARG . 8.3 p30 -164.25 -154.97 0.27 Allowed 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.484 -0.887 . . . . 0.0 110.801 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.4 -9.99 0.5 Allowed Glycine 0 C--N 1.291 -1.964 0 C-N-CA 119.635 -1.269 . . . . 0.0 110.578 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.47 ' N ' ' C ' ' A' ' 27' ' ' ASN . 25.3 mmt180 -111.9 38.5 2.64 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.744 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -76.47 154.23 5.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 119.195 -1.002 . . . . 0.0 108.905 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 29.3 mt -117.52 178.87 4.23 Favored 'General case' 0 N--CA 1.513 2.69 0 C-N-CA 119.587 -0.845 . . . . 0.0 112.24 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' A' ' 36' ' ' ASP . 27.3 tptp -78.39 -33.55 48.73 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -73.86 -11.58 60.41 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.4 ' OD1' HG12 ' A' ' 21' ' ' VAL . 2.1 t0 -66.98 -67.54 0.44 Allowed 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.104 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.4 mt -67.39 -35.49 73.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 C-N-CA 119.656 -0.817 . . . . 0.0 111.44 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 32' ' ' LYS . 5.7 m-20 -49.38 -42.53 42.49 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.721 -1.192 . . . . 0.0 110.081 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.62 -32.98 71.99 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.612 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.468 ' CD2' HG13 ' A' ' 16' ' ' VAL . 68.4 t80 -45.2 -69.9 0.12 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.873 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.2 tp . . . . . 0 C--N 1.303 -1.429 0 CA-C-N 115.275 -0.875 . . . . 0.0 112.112 -179.759 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t . . . . . 0 N--CA 1.501 2.12 0 CA-C-O 120.841 0.353 . . . . 0.0 110.827 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 32.7 ttm180 -60.04 -45.62 92.23 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.31 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.9 mmmm -52.7 -41.78 64.23 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.632 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -57.85 -47.12 83.62 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 118.781 -1.167 . . . . 0.0 109.211 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.421 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -51.07 -45.47 61.42 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.793 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -56.56 -41.69 77.28 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.914 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -61.67 -33.54 74.16 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.911 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 50.6 mmtt -96.94 0.4 48.89 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.34 57.54 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.691 -1.242 . . . . 0.0 111.041 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.53 HG13 ' CD2' ' A' ' 38' ' ' PHE . 55.2 t -81.84 123.66 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.484 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -75.98 105.92 7.29 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.244 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.482 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 9.7 tt -41.62 -41.7 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.558 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.482 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.6 ttt85 -50.92 -53.87 29.06 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.987 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 74.6 mt -55.96 -28.17 55.84 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.818 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.422 HG12 ' OD1' ' A' ' 34' ' ' ASP . 10.6 t -65.31 142.6 16.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.687 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 47.3 tt0 -140.52 66.28 1.39 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.051 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -78.51 -107.56 0.2 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.095 -1.526 . . . . 0.0 110.428 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.442 ' OG1' ' CD1' ' A' ' 31' ' ' LEU . 0.7 OUTLIER -87.27 -53.02 5.06 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.473 -179.938 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 108.93 0.63 Allowed Glycine 0 N--CA 1.5 2.915 0 C-N-CA 119.857 -1.163 . . . . 0.0 110.404 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -76.58 61.41 1.78 Allowed 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.013 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.503 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.7 p-10 -152.83 -161.26 1.26 Allowed 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.434 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.76 -6.67 1.27 Allowed Glycine 0 N--CA 1.484 1.836 0 C-N-CA 119.123 -1.513 . . . . 0.0 109.909 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.503 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.8 mmt180 -108.17 31.82 5.25 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 120.187 -0.605 . . . . 0.0 111.523 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -70.08 156.11 7.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.434 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.442 ' CD1' ' OG1' ' A' ' 24' ' ' THR . 28.3 mt -108.53 173.78 6.17 Favored 'General case' 0 N--CA 1.509 2.499 0 C-N-CA 119.279 -0.969 . . . . 0.0 112.448 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 43.3 tptt -76.93 -32.23 57.22 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.063 -0.971 . . . . 0.0 108.574 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -82.58 -5.09 58.59 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.358 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.422 ' OD1' HG12 ' A' ' 21' ' ' VAL . 1.6 t0 -64.39 -53.95 40.51 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.237 -0.892 . . . . 0.0 108.933 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.421 HD13 ' HB2' ' A' ' 11' ' ' ALA . 3.3 mt -77.55 -37.89 25.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.678 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -47.17 -42.29 19.47 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.945 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.86 -37.08 73.08 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.6 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.53 ' CD2' HG13 ' A' ' 16' ' ' VAL . 66.1 t80 -42.67 -68.6 0.18 Allowed 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.463 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 11.2 tp . . . . . 0 C--N 1.303 -1.456 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.991 -179.87 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 79.9 t . . . . . 0 N--CA 1.507 2.416 0 CA-C-O 120.852 0.358 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.486 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 32.2 ttm180 -57.4 -38.09 73.74 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.239 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.7 mttp -52.43 -46.48 66.41 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.634 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -54.28 -47.74 72.02 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 118.9 -1.12 . . . . 0.0 109.092 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.503 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -49.48 -44.59 46.09 Favored 'General case' 0 C--N 1.288 -2.083 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.789 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 24.1 mmm180 -57.43 -43.86 84.2 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.745 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -57.57 -33.19 67.91 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.086 -1.045 . . . . 0.0 110.496 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.6 mmtt -93.51 -10.04 36.28 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.496 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 76.38 -0.9 62.61 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.458 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 54.7 t -70.77 124.4 26.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.772 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -77.08 105.88 8.44 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.048 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.1 tt -37.82 -42.63 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.266 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.526 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 51.7 ttp85 -49.36 -55.06 14.2 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.472 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 52.7 mt -53.07 -41.83 65.25 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.556 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.5 t -48.52 144.56 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 C-N-CA 119.267 -0.973 . . . . 0.0 111.863 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -137.95 60.85 1.61 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.476 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.32 -114.82 0.24 Allowed Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.927 -1.606 . . . . 0.0 109.943 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.1 -50.03 12.8 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.879 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.404 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -150.02 109.4 0.43 Allowed Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 pttt -75.97 43.51 0.28 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.177 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' H ' ' A' ' 29' ' ' ARG . 27.7 p-10 -119.05 -164.92 1.08 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.028 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.03 -4.2 2.21 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.196 -1.478 . . . . 0.0 110.332 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.47 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.1 mmt180 -110.71 41.42 1.79 Allowed 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.469 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -73.46 156.4 6.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.435 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.1 mp -105.74 173.0 6.5 Favored 'General case' 0 N--CA 1.511 2.577 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.142 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -76.94 -38.69 52.87 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 119.259 -0.977 . . . . 0.0 109.676 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -76.8 -2.91 35.61 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.222 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -67.18 -55.13 15.43 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.778 -1.101 . . . . 0.0 109.632 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.503 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.7 mt -75.17 -36.96 38.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.806 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.67 -40.54 53.89 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.421 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.35 -33.87 69.99 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.609 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -44.74 -69.65 0.13 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.067 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.419 ' C ' HD13 ' A' ' 39' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.609 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.441 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 121.079 0.466 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 71.2 ttt180 -71.02 -39.42 72.37 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.01 -1.076 . . . . 0.0 110.504 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttp -58.92 -26.61 64.51 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 118.988 -1.085 . . . . 0.0 110.467 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.408 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 7.6 t80 -69.62 -49.73 51.08 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 118.843 -1.143 . . . . 0.0 108.579 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.83 -41.47 23.91 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.43 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.37 -46.6 86.02 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.776 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -54.9 -35.35 64.02 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.976 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.8 mmtt -92.06 -16.79 25.94 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.849 -0.741 . . . . 0.0 110.72 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 80.46 4.75 90.07 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.523 -1.322 . . . . 0.0 110.623 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.1 t -76.46 138.55 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.651 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 36.8 t0 -81.37 104.4 11.79 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.761 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.524 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -40.87 -41.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.654 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.524 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.9 tpp180 -50.96 -59.56 4.02 Favored 'General case' 0 C--N 1.29 -2.007 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.308 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 84.8 mt -52.98 -28.44 23.84 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.013 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.413 ' H ' HG23 ' A' ' 21' ' ' VAL . 7.6 t -61.65 141.19 17.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 C-N-CA 118.915 -1.114 . . . . 0.0 112.181 -179.842 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 91.1 mt-30 -139.4 44.02 1.99 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.075 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.27 -104.25 0.01 OUTLIER Glycine 0 N--CA 1.492 2.37 0 C-N-CA 119.244 -1.455 . . . . 0.0 110.157 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.488 ' OG1' ' CD2' ' A' ' 31' ' ' LEU . 2.5 p -73.41 -37.84 65.8 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.08 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -179.65 121.13 0.72 Allowed Glycine 0 N--CA 1.479 1.517 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.423 ' O ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pttm -58.57 -157.31 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.507 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.517 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 25.4 t-20 59.31 176.29 0.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.013 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.517 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -46.12 -17.16 0.19 Allowed Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.733 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.482 ' N ' ' O ' ' A' ' 27' ' ' ASN . 14.5 mmt85 -80.13 35.41 0.32 Allowed 'General case' 0 N--CA 1.493 1.723 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.19 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 27' ' ' ASN . 11.7 t -101.6 156.48 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.442 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.488 ' CD2' ' OG1' ' A' ' 24' ' ' THR . 1.9 pt? -129.64 -170.71 2.35 Favored 'General case' 0 N--CA 1.512 2.634 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.633 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -71.02 -55.37 8.43 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.54 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 60.9 tt0 -61.03 -5.68 1.53 Allowed 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.9 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.85 -59.76 3.04 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.386 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.499 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.3 mp -66.55 -37.47 79.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.653 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -46.6 -42.78 16.6 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.348 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.17 -35.91 76.8 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.394 -0.923 . . . . 0.0 110.666 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -43.46 -67.54 0.27 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.467 -0.893 . . . . 0.0 112.171 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.4 tp . . . . . 0 C--N 1.302 -1.497 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.246 -179.719 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.5 t . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.024 0.44 . . . . 0.0 110.239 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 59.0 ttp85 -60.98 -51.5 68.98 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.093 -1.043 . . . . 0.0 110.749 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.1 mttt -51.26 -39.75 57.39 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.753 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -59.7 -45.95 90.56 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.206 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.451 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -53.12 -46.15 68.62 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.696 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -55.91 -40.96 73.83 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -63.08 -45.95 89.72 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.4 mmtt -78.31 -10.07 59.51 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.449 -0.901 . . . . 0.0 111.183 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.96 1.5 90.64 Favored Glycine 0 N--CA 1.496 2.642 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.899 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.536 HG13 ' CD2' ' A' ' 38' ' ' PHE . 57.8 t -74.5 130.54 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.507 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -83.22 110.01 17.71 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.155 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.551 HG23 ' N ' ' A' ' 19' ' ' ARG . 5.7 tp -42.26 -41.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.466 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.551 ' N ' HG23 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -48.07 -59.1 3.64 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.822 -179.83 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 46.8 mt -60.45 -18.41 51.01 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.2 t -70.64 139.73 19.56 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 118.552 -1.259 . . . . 0.0 111.649 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.401 ' O ' ' CD ' ' A' ' 22' ' ' GLN . 0.6 OUTLIER -145.7 79.44 1.56 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.706 179.901 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.18 -99.12 1.97 Allowed Glycine 0 N--CA 1.504 3.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.422 ' OG1' HD23 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -79.07 -38.97 35.05 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.428 179.819 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.475 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -170.61 116.16 0.63 Allowed Glycine 0 N--CA 1.485 1.932 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 pttp -74.1 38.64 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.001 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 25.0 t-20 -117.07 -179.59 3.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.712 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.513 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -47.57 -14.95 0.24 Allowed Glycine 0 N--CA 1.492 2.432 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.197 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.513 ' N ' ' O ' ' A' ' 27' ' ' ASN . 32.2 mmm-85 -95.47 37.22 1.2 Allowed 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.119 -0.632 . . . . 0.0 111.556 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 27' ' ' ASN . 2.6 t -70.99 154.64 7.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.105 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.422 HD23 ' OG1' ' A' ' 24' ' ' THR . 2.9 mm? -106.5 173.3 6.38 Favored 'General case' 0 N--CA 1.509 2.492 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.951 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.6 tmtt? -77.13 -41.43 41.96 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.386 -0.925 . . . . 0.0 108.926 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -71.78 -3.63 23.17 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.399 -0.818 . . . . 0.0 109.35 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -68.52 -56.04 9.68 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.079 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.479 HD11 ' CD1' ' A' ' 18' ' ' ILE . 1.8 mt -73.09 -37.54 53.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.643 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -51.22 -39.37 56.42 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.341 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.5 -33.62 71.42 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.347 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.536 ' CD2' HG13 ' A' ' 16' ' ' VAL . 65.9 t80 -45.07 -68.04 0.23 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.016 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 56.1 tp . . . . . 0 C--N 1.302 -1.481 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.995 -179.918 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.1 t . . . . . 0 N--CA 1.494 1.727 0 CA-C-O 120.938 0.399 . . . . 0.0 111.161 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.419 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 55.5 ttt180 -57.06 -36.05 70.07 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.384 -0.926 . . . . 0.0 111.199 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mmtm -54.85 -47.61 73.94 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 119.136 -1.026 . . . . 0.0 110.217 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -53.73 -46.94 71.02 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.073 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.422 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -52.12 -46.32 65.29 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.651 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.2 mtp180 -59.48 -44.29 93.08 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.679 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -56.69 -42.74 79.6 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.575 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -86.8 -13.92 43.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.834 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 75.91 67.84 1.64 Allowed Glycine 0 N--CA 1.488 2.134 0 C-N-CA 119.327 -1.416 . . . . 0.0 110.089 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.492 HG13 ' CD2' ' A' ' 38' ' ' PHE . 53.1 t -137.18 130.51 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.339 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -77.3 109.53 11.26 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.07 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.534 ' CD1' HD11 ' A' ' 35' ' ' ILE . 6.9 tp -44.69 -41.96 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.503 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.53 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 63.7 ttt-85 -56.15 -52.69 63.46 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.738 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.7 mt -57.18 -31.04 65.01 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.746 -0.781 . . . . 0.0 112.725 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.41 ' H ' HG23 ' A' ' 21' ' ' VAL . 7.8 t -57.46 141.87 13.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 118.437 -1.305 . . . . 0.0 111.868 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -136.77 77.71 1.66 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.933 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.26 -108.93 3.34 Favored Glycine 0 N--CA 1.51 3.596 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -77.02 -47.91 19.36 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.297 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.07 109.28 0.42 Allowed Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.9 pttp -76.07 55.36 0.92 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.601 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 15.8 p-10 -157.16 -154.95 0.49 Allowed 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 119.746 -0.782 . . . . 0.0 110.546 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.0 -8.2 0.59 Allowed Glycine 0 C--N 1.289 -2.04 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.246 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.6 mmt85 -109.09 37.34 2.59 Favored 'General case' 0 N--CA 1.504 2.24 0 C-N-CA 120.217 -0.593 . . . . 0.0 112.076 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.525 HG11 HD11 ' A' ' 18' ' ' ILE . 3.2 t -80.92 147.4 6.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.076 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.7 mp -109.37 177.34 4.77 Favored 'General case' 0 N--CA 1.511 2.604 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.51 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 3.6 tmtt? -75.47 -48.74 21.3 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.879 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -65.47 -5.45 7.84 Favored 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.207 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -69.5 -53.62 18.2 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.605 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.534 HD11 ' CD1' ' A' ' 18' ' ' ILE . 2.5 mt -72.46 -30.05 33.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 C-N-CA 119.676 -0.81 . . . . 0.0 110.757 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 36' ' ' ASP . 5.8 m-20 -55.5 -40.69 72.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.279 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.68 -34.81 76.31 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.284 179.691 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.492 ' CD2' HG13 ' A' ' 16' ' ' VAL . 70.1 t80 -44.55 -69.27 0.14 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.346 -0.942 . . . . 0.0 111.232 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 69.5 tp . . . . . 0 C--N 1.299 -1.604 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.916 -179.882 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.0 t . . . . . 0 N--CA 1.481 1.083 0 CA-C-O 120.978 0.418 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -61.94 -48.03 82.22 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 118.872 -1.131 . . . . 0.0 110.884 -179.906 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -53.76 -38.83 64.81 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.91 179.963 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -59.11 -44.73 92.0 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 118.883 -1.127 . . . . 0.0 109.36 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.427 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -52.05 -43.8 63.96 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.805 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -57.04 -43.49 81.98 Favored 'General case' 0 C--N 1.292 -1.893 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.886 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 59.9 mt-10 -59.06 -53.69 55.47 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.382 -0.927 . . . . 0.0 111.185 179.936 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -78.28 -14.48 59.41 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.115 -179.991 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 74.15 76.1 0.73 Allowed Glycine 0 N--CA 1.495 2.575 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.883 179.913 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.519 HG13 ' CD2' ' A' ' 38' ' ' PHE . 53.5 t -145.74 126.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 120.161 -0.616 . . . . 0.0 109.965 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -74.5 106.99 6.36 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.739 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.475 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 10.2 tt -44.64 -40.04 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.036 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.475 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.0 tpt85 -49.68 -54.3 19.44 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.411 -179.912 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 70.8 mt -63.21 -29.17 70.56 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.87 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.423 HG12 ' OD1' ' A' ' 34' ' ' ASP . 11.5 t -55.93 139.19 15.52 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 C-N-CA 118.812 -1.155 . . . . 0.0 111.987 -179.717 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 30.2 mm-40 -137.44 44.43 2.25 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.255 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.24 -107.48 0.01 OUTLIER Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.138 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -78.75 -42.45 28.09 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.81 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -166.17 124.05 1.2 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.599 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 14.9 ptmt -61.64 -156.87 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.009 -1.077 . . . . 0.0 110.678 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.599 ' ND2' ' O ' ' A' ' 26' ' ' LYS . 2.4 p30 43.4 -154.18 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.567 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.443 ' C ' ' H ' ' A' ' 30' ' ' VAL . . . -53.14 -20.91 10.0 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 120.074 -1.06 . . . . 0.0 111.63 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.436 ' O ' ' O ' ' A' ' 25' ' ' GLY . 22.2 mmt180 -78.25 27.03 0.2 Allowed 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 118.909 -1.116 . . . . 0.0 111.35 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.443 ' H ' ' C ' ' A' ' 28' ' ' GLY . 3.3 t -92.44 129.22 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 C-N-CA 120.028 -0.669 . . . . 0.0 110.914 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.508 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.6 mp -103.44 -177.58 3.41 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.432 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -75.8 -36.12 59.83 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.047 -1.061 . . . . 0.0 109.268 179.82 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -78.87 -2.68 40.96 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.375 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.435 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.3 t0 -68.78 -55.89 9.8 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.751 179.926 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -72.52 -39.21 61.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.481 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -47.8 -39.95 19.67 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 118.966 -1.093 . . . . 0.0 109.806 179.875 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.52 -34.19 67.42 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.586 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.519 ' CD2' HG13 ' A' ' 16' ' ' VAL . 76.7 t80 -40.88 -66.42 0.33 Allowed 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.086 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 10.1 tp . . . . . 0 C--N 1.302 -1.477 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.752 -179.949 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.5 t . . . . . 0 N--CA 1.498 1.95 0 CA-C-O 120.875 0.369 . . . . 0.0 111.242 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 56.1 ttp180 -60.92 -35.85 77.78 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.46 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.7 mmtp -55.65 -42.9 75.69 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.395 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.5 t80 -58.26 -48.65 79.75 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.799 -1.16 . . . . 0.0 109.329 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.27 -43.25 42.88 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.018 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 79.1 mtt180 -58.27 -43.81 88.11 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.977 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -55.68 -53.15 60.11 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.826 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.3 mmmt -80.4 0.38 33.47 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.148 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 58.51 70.89 0.86 Allowed Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.25 -1.452 . . . . 0.0 110.403 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.9 t -141.64 139.2 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.113 -179.968 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.0 t0 -85.99 107.95 18.0 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.507 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.3 tt -46.49 -40.97 4.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 119.769 -0.772 . . . . 0.0 110.92 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 5.1 tpm_? -48.16 -57.59 5.67 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.71 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.1 mt -54.0 -35.47 61.9 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.704 -0.799 . . . . 0.0 111.783 -179.87 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.6 t -56.38 139.5 15.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.432 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -138.94 53.91 1.75 Allowed 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.694 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.82 -114.79 0.06 OUTLIER Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.603 -1.284 . . . . 0.0 111.378 -179.851 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.5 p -92.96 -71.06 0.67 Allowed 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.884 -179.851 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.428 ' O ' ' OD1' ' A' ' 27' ' ' ASN . . . -58.93 -50.05 71.79 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.356 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.401 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 21.6 pttp 41.6 36.56 0.59 Allowed 'General case' 0 C--N 1.294 -1.806 0 CA-C-O 121.507 0.67 . . . . 0.0 110.79 -179.894 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' H ' ' A' ' 29' ' ' ARG . 13.6 p-10 -159.41 -160.21 0.81 Allowed 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.224 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.94 -7.79 1.18 Allowed Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.021 179.985 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.47 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -121.48 48.66 1.64 Allowed 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.39 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -69.69 158.18 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.344 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.8 mp -104.46 171.14 7.5 Favored 'General case' 0 N--CA 1.51 2.538 0 C-N-CA 119.408 -0.917 . . . . 0.0 111.154 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 36.0 tttp -76.77 -39.42 51.68 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.205 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -73.01 -6.37 45.01 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 119.337 -0.945 . . . . 0.0 108.879 179.819 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -65.32 -62.93 1.25 Allowed 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.026 -179.97 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mt -67.52 -31.29 52.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.801 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -51.27 -41.13 60.21 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.128 -1.029 . . . . 0.0 110.1 179.895 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -75.2 -32.71 61.28 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -43.82 -69.87 0.12 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.571 -0.852 . . . . 0.0 111.696 -179.954 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 24.1 tp . . . . . 0 C--N 1.298 -1.631 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.654 -179.824 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 N--CA 1.493 1.714 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.417 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 47.5 ttp85 -51.91 -51.56 56.04 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.702 -0.799 . . . . 0.0 112.947 -179.751 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.458 ' CG ' ' N ' ' A' ' 10' ' ' TYR . 0.2 OUTLIER -49.07 -49.47 41.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.688 -179.846 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.458 ' N ' ' CG ' ' A' ' 9' ' ' LYS . 2.3 t80 -51.93 -44.57 63.94 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.079 179.921 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -51.85 -43.9 63.4 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.58 -0.848 . . . . 0.0 110.928 179.997 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -59.64 -43.25 93.95 Favored 'General case' 0 C--N 1.293 -1.849 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.371 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -54.7 -60.01 3.94 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.55 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -75.17 11.07 1.26 Allowed 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.374 -179.896 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 53.59 75.84 0.21 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.596 -1.288 . . . . 0.0 111.611 179.933 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 22.4 t -147.84 135.38 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.843 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -82.99 111.32 18.74 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.563 -0.855 . . . . 0.0 111.015 179.923 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.514 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.7 tt -46.11 -40.48 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.943 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.514 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 52.4 ttt85 -51.86 -58.81 5.39 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 114.867 -1.06 . . . . 0.0 112.301 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.0 mt -50.45 -31.42 15.12 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.524 -179.83 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -62.03 140.74 18.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.781 -1.167 . . . . 0.0 111.159 -179.852 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.5 tt0 -134.9 57.15 1.82 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.644 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.4 -112.24 0.08 OUTLIER Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.132 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -73.79 -47.85 35.84 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.164 -1.014 . . . . 0.0 109.91 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.496 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -157.33 114.43 0.61 Allowed Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 12.0 ptmm? -74.83 36.9 0.11 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.728 179.983 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.51 ' CG ' ' H ' ' A' ' 28' ' ' GLY . 25.9 t-20 -109.5 -179.02 3.71 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.51 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -50.93 -11.07 0.5 Allowed Glycine 0 N--CA 1.488 2.124 0 C-N-CA 118.828 -1.653 . . . . 0.0 109.963 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.488 ' N ' ' C ' ' A' ' 27' ' ' ASN . 44.2 mmt-85 -101.01 43.58 1.05 Allowed 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.751 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 31' ' ' LEU . 3.0 t -76.52 163.17 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.397 179.852 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.441 ' N ' ' CG1' ' A' ' 30' ' ' VAL . 8.6 mp -112.37 174.36 5.92 Favored 'General case' 0 N--CA 1.512 2.655 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.329 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.9 tttp -78.02 -41.38 35.96 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.402 -0.919 . . . . 0.0 108.823 179.867 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -71.53 -5.5 33.7 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.213 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.0 -56.87 8.26 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.36 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.476 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.3 mp -72.06 -36.01 55.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.385 -0.926 . . . . 0.0 110.95 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -48.37 -42.12 30.74 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.177 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.48 -34.72 72.71 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.389 179.858 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.5 t80 -43.21 -70.63 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.602 179.916 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.6 tp . . . . . 0 C--N 1.299 -1.588 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.019 -179.782 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.894 0.378 . . . . 0.0 110.699 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 12' ' ' ARG . 53.2 ttp180 -65.04 -42.66 94.08 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.763 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.0 mttm -53.48 -36.55 61.79 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.603 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.6 t80 -61.38 -49.6 76.27 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 118.73 -1.188 . . . . 0.0 108.857 179.773 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.464 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -50.06 -43.32 51.12 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.995 179.771 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 8' ' ' ARG . 95.3 mtt180 -65.52 -47.05 77.25 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.025 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mm-40 -48.15 -50.72 27.77 Favored 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.504 -0.879 . . . . 0.0 111.274 -179.92 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -82.88 -36.66 25.17 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 119.403 -0.919 . . . . 0.0 111.5 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.23 75.47 1.04 Allowed Glycine 0 N--CA 1.505 3.252 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.0 t -147.75 131.45 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 C-N-CA 120.012 -0.675 . . . . 0.0 110.049 179.908 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -75.13 103.02 5.13 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.925 179.975 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.477 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.4 tt -42.34 -37.88 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 CA-C-O 121.688 0.756 . . . . 0.0 110.836 179.949 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.477 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 44.3 ttt85 -50.15 -58.5 5.43 Favored 'General case' 0 C--N 1.287 -2.132 0 CA-C-N 114.413 -1.267 . . . . 0.0 112.502 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 66.7 mt -59.99 -13.84 13.28 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.774 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.6 t -75.38 140.11 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 118.582 -1.247 . . . . 0.0 111.38 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 74.7 mt-30 -144.08 54.83 1.29 Allowed 'General case' 0 N--CA 1.49 1.527 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.017 -179.898 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -73.87 -96.74 0.1 OUTLIER Glycine 0 N--CA 1.495 2.57 0 C-N-CA 118.827 -1.654 . . . . 0.0 109.676 179.928 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.14 -43.11 29.74 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.419 -0.912 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -171.34 119.07 0.77 Allowed Glycine 0 N--CA 1.482 1.709 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.877 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.462 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttm -56.63 -163.23 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.868 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.484 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 8.8 p30 49.99 -157.71 0.09 Allowed 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.585 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.484 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -49.16 -30.74 10.87 Favored Glycine 0 N--CA 1.498 2.791 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.172 -179.825 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.444 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.0 mmt85 -74.34 34.44 0.09 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.963 -1.095 . . . . 0.0 111.711 -179.877 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 27' ' ' ASN . 4.9 t -98.6 139.29 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.394 179.908 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.481 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -108.22 177.99 4.64 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.298 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 22.6 tttm -75.55 -35.59 60.64 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.735 179.837 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -76.89 -9.35 58.63 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.102 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.403 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 3.7 t0 -65.33 -57.92 7.18 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.704 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.464 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 5.1 mt -70.2 -29.27 38.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.878 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -53.75 -41.22 66.9 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.873 -1.131 . . . . 0.0 109.58 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.29 -33.78 67.68 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.384 -0.826 . . . . 0.0 110.561 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -43.67 -68.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.471 -0.892 . . . . 0.0 111.251 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.404 ' C ' ' CD1' ' A' ' 39' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.301 -1.536 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.595 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 120.94 0.4 . . . . 0.0 110.802 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -66.23 -41.2 90.37 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.034 -1.066 . . . . 0.0 111.071 -179.922 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.0 mttp -53.09 -35.74 59.94 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.515 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -63.08 -51.54 66.22 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.049 179.83 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -42.15 53.17 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.186 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.9 mtp180 -62.17 -46.86 87.06 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.874 179.911 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -50.49 -50.82 51.74 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.051 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.5 ' HZ2' HD22 ' A' ' 39' ' ' LEU . 0.6 OUTLIER -78.78 -25.47 44.36 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.024 -179.963 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 96.73 68.75 0.98 Allowed Glycine 0 N--CA 1.505 3.278 0 C-N-CA 119.985 -1.102 . . . . 0.0 111.307 179.944 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.2 t -147.98 147.83 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.183 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -94.83 108.54 20.56 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.864 -0.734 . . . . 0.0 110.591 179.921 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 10.4 tt -42.68 -41.93 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 120.019 -0.673 . . . . 0.0 111.51 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.2 mtm-85 -52.42 -57.61 9.32 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.258 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.2 mt -52.88 -25.99 13.4 Favored 'General case' 0 N--CA 1.49 1.527 0 C-N-CA 119.611 -0.835 . . . . 0.0 111.918 -179.826 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.5 t -64.13 143.27 15.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.054 -1.058 . . . . 0.0 112.003 -179.817 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -136.63 63.0 1.59 Allowed 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.1 -113.18 0.61 Allowed Glycine 0 N--CA 1.497 2.707 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.775 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.26 -46.27 42.55 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.385 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.17 110.46 0.44 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -75.21 61.05 1.12 Allowed 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.47 -0.892 . . . . 0.0 110.797 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.457 ' C ' ' N ' ' A' ' 29' ' ' ARG . 7.4 p30 -150.35 -164.85 2.12 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.284 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.06 -13.3 0.61 Allowed Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.38 -1.391 . . . . 0.0 110.581 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.457 ' N ' ' C ' ' A' ' 27' ' ' ASN . 1.0 OUTLIER -102.87 34.23 2.93 Favored 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 119.863 -0.735 . . . . 0.0 112.278 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.418 ' C ' HD12 ' A' ' 31' ' ' LEU . 2.7 t -75.34 149.86 6.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 C-N-CA 119.057 -1.057 . . . . 0.0 108.818 179.804 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.418 HD12 ' C ' ' A' ' 30' ' ' VAL . 11.0 mp -107.11 173.6 6.25 Favored 'General case' 0 N--CA 1.511 2.601 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.424 -179.878 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.4 tttm -77.16 -35.06 56.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.712 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.5 mm-40 -75.71 -9.12 58.32 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 114.961 -1.018 . . . . 0.0 108.582 179.794 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -63.77 -57.01 11.25 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.005 179.958 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.533 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.8 mp -65.16 -37.03 79.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.464 -0.894 . . . . 0.0 109.694 179.792 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -45.75 -44.65 13.95 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.353 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.05 76.21 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.471 -0.891 . . . . 0.0 110.493 179.92 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -46.29 -71.04 0.08 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.647 -179.989 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.5 HD22 ' HZ2' ' A' ' 14' ' ' LYS . 12.6 tp . . . . . 0 C--N 1.305 -1.366 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.416 -179.781 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t . . . . . 0 N--CA 1.485 1.305 0 CA-C-O 120.839 0.352 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 41.3 ttp180 -63.57 -34.37 77.66 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 118.737 -1.185 . . . . 0.0 110.767 -179.937 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt -60.12 -41.66 93.12 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.757 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -57.28 -46.34 83.22 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.069 -1.052 . . . . 0.0 109.062 179.909 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.445 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -51.71 -45.99 63.76 Favored 'General case' 0 C--N 1.291 -1.948 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.485 179.867 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.2 mtp85 -59.11 -46.12 89.15 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.806 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -54.58 -39.33 67.69 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.457 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -89.38 -3.75 58.32 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.67 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.27 6.99 66.55 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.568 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.537 HG13 ' CD2' ' A' ' 38' ' ' PHE . 63.6 t -78.13 125.38 37.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.978 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -78.56 110.32 13.56 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.322 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.49 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -43.23 -40.02 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.117 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.49 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 55.0 mtt-85 -52.64 -59.46 4.44 Favored 'General case' 0 C--N 1.286 -2.153 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.228 -179.896 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.1 mt -52.15 -24.84 7.67 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.215 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.6 t -63.61 139.54 21.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 118.936 -1.106 . . . . 0.0 112.18 -179.813 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -131.88 64.54 1.59 Allowed 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 114.906 -1.043 . . . . 0.0 109.876 -179.929 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.11 -114.96 0.88 Allowed Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.437 -1.363 . . . . 0.0 110.499 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.32 -44.87 15.67 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.824 -0.75 . . . . 0.0 110.136 -179.935 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -147.45 103.8 0.28 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.995 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -76.33 60.38 1.53 Allowed 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.677 -179.986 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.475 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.6 p-10 -157.05 -159.4 0.85 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.256 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.73 -9.09 0.67 Allowed Glycine 0 N--CA 1.484 1.876 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.475 ' H ' ' C ' ' A' ' 27' ' ' ASN . 10.9 mmt-85 -107.76 34.38 3.58 Favored 'General case' 0 N--CA 1.507 2.381 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.574 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -74.42 146.71 9.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.186 -1.006 . . . . 0.0 109.019 179.84 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.7 mp -105.44 177.56 4.82 Favored 'General case' 0 N--CA 1.511 2.589 0 C-N-CA 119.597 -0.841 . . . . 0.0 112.131 -179.741 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 12.9 tmtt? -76.5 -41.02 48.43 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.09 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.28 -4.21 34.75 Favored 'General case' 0 C--N 1.311 -1.07 0 C-N-CA 119.37 -0.932 . . . . 0.0 109.183 179.823 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -67.37 -61.55 1.86 Allowed 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.748 179.94 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 2.7 mt -69.63 -30.57 45.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.486 179.855 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -52.25 -40.55 61.83 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.668 179.899 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.96 -35.64 72.24 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.258 179.875 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.537 ' CD2' HG13 ' A' ' 16' ' ' VAL . 57.6 t80 -44.73 -70.05 0.12 Allowed 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.373 179.921 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.4 tp . . . . . 0 C--N 1.304 -1.385 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.896 -179.964 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 81.1 t . . . . . 0 N--CA 1.479 0.99 0 CA-C-O 120.936 0.398 . . . . 0.0 111.277 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.5 ttp180 -63.8 -43.44 96.3 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.194 -1.002 . . . . 0.0 111.364 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.2 mttm -52.98 -37.63 61.51 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.646 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -63.45 -48.84 76.04 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.035 -1.066 . . . . 0.0 109.012 179.766 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.38 -42.65 42.85 Favored 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.573 179.898 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.6 mmm180 -58.66 -45.27 89.73 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.973 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -54.0 -45.03 71.36 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 118.99 -1.084 . . . . 0.0 110.147 179.978 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -82.21 -16.64 48.92 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.54 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 81.56 1.77 90.26 Favored Glycine 0 N--CA 1.494 2.522 0 C-N-CA 119.51 -1.329 . . . . 0.0 110.582 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.1 t -70.56 127.39 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.49 -0.884 . . . . 0.0 110.678 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 48.9 t0 -75.0 107.24 6.93 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.67 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.503 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -42.55 -41.35 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.391 -179.88 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.503 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 21.3 ttm105 -49.24 -53.08 23.27 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.185 -179.877 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -57.42 -41.3 80.15 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.193 -179.78 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.426 HG23 ' H ' ' A' ' 21' ' ' VAL . 16.5 t -48.51 141.51 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.261 -179.827 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -141.58 55.13 1.51 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.719 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.45 -112.03 0.06 OUTLIER Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.974 -1.584 . . . . 0.0 109.96 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.1 p -78.29 -43.78 27.12 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.329 -0.948 . . . . 0.0 109.629 179.904 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -156.39 116.36 0.71 Allowed Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.934 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.6 pttm -76.58 45.83 0.42 Allowed 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.745 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.2 p-10 -142.58 -153.74 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.047 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.34 -9.07 0.9 Allowed Glycine 0 C--N 1.287 -2.171 0 C-N-CA 119.024 -1.56 . . . . 0.0 109.906 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 23.0 mmt180 -100.26 27.59 5.56 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 119.896 -0.722 . . . . 0.0 111.686 -179.972 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.3 t -79.95 128.31 38.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 119.475 -0.89 . . . . 0.0 108.669 179.886 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.526 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -95.11 173.13 7.72 Favored 'General case' 0 N--CA 1.502 2.127 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.691 -179.811 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -73.94 -34.12 64.2 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 119.069 -1.053 . . . . 0.0 108.649 179.897 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -78.03 -6.62 55.11 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.699 -0.8 . . . . 0.0 108.924 179.878 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.34 -58.13 5.36 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.066 179.916 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.2 mt -74.07 -35.73 42.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.082 -179.894 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -50.24 -41.61 50.39 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.857 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.32 -35.0 71.09 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.731 -0.787 . . . . 0.0 110.66 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -42.6 -69.05 0.15 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.255 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.6 tp . . . . . 0 C--N 1.301 -1.509 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.949 -179.976 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 120.9 0.381 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 39.6 ttm-85 -61.08 -38.62 86.9 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.536 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.6 mmtt -56.99 -42.88 81.07 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.558 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -55.6 -47.3 76.74 Favored 'General case' 0 C--N 1.302 -1.499 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.464 179.912 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.513 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -53.43 -48.38 68.82 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.117 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mmm-85 -60.96 -43.83 98.2 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.217 179.908 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 56.3 mm-40 -58.23 -28.66 65.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.679 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 11.5 mmmt -101.42 -11.28 19.49 Favored 'General case' 0 N--CA 1.5 2.027 0 C-N-CA 119.874 -0.73 . . . . 0.0 110.655 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.42 63.53 1.7 Allowed Glycine 0 N--CA 1.496 2.635 0 C-N-CA 119.592 -1.289 . . . . 0.0 110.675 179.948 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.513 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 62.7 t -145.21 130.36 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.127 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -87.14 121.49 29.67 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.606 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 3.8 tp -45.29 -44.1 3.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.78 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.53 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 53.9 ttp180 -49.21 -58.71 4.55 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.434 -0.803 . . . . 0.0 112.331 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 57.7 mt -52.69 -29.54 27.18 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.784 -0.766 . . . . 0.0 112.033 -179.849 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 t -69.11 139.34 20.61 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 C-N-CA 118.783 -1.167 . . . . 0.0 111.362 -179.818 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 -145.82 54.03 1.16 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.153 -179.978 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.56 -106.46 0.03 OUTLIER Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.309 -1.424 . . . . 0.0 111.174 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.81 -65.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.574 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -138.72 107.02 0.54 Allowed Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.547 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttp -55.9 -163.34 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.379 -0.929 . . . . 0.0 110.545 179.971 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.547 ' ND2' ' O ' ' A' ' 26' ' ' LYS . 3.0 p30 57.66 -163.06 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 CA-C-O 121.362 0.601 . . . . 0.0 112.273 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.535 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -51.1 -21.22 5.31 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.55 -179.808 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.4 mmt85 -90.09 38.76 0.94 Allowed 'General case' 0 N--CA 1.505 2.289 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.256 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 27' ' ' ASN . 4.0 t -90.46 149.34 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.956 179.85 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 7.6 mp -106.89 175.19 5.58 Favored 'General case' 0 N--CA 1.509 2.484 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.738 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.8 tttm -76.53 -38.21 55.49 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.43 -0.908 . . . . 0.0 109.425 179.849 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 57.9 mm-40 -73.69 -6.57 47.62 Favored 'General case' 0 C--N 1.307 -1.239 0 C-N-CA 119.441 -0.903 . . . . 0.0 108.966 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -67.57 -55.79 12.03 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.443 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.497 HD13 ' HB2' ' A' ' 11' ' ' ALA . 2.5 mt -73.18 -34.18 43.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.371 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -52.22 -40.03 61.06 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.448 179.926 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.24 -34.87 68.6 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.415 ' CD2' HG13 ' A' ' 16' ' ' VAL . 72.4 t80 -45.5 -70.3 0.11 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.454 -0.898 . . . . 0.0 111.184 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.507 ' C ' HD23 ' A' ' 39' ' ' LEU . 3.0 tt . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.606 -179.903 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 92.5 t . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 121.024 0.44 . . . . 0.0 110.587 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.9 ttp180 -63.65 -31.19 72.28 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.67 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.9 mmtp -55.31 -44.81 76.13 Favored 'General case' 0 C--N 1.306 -1.298 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.021 179.939 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -57.98 -51.16 70.8 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.927 -1.109 . . . . 0.0 108.56 179.782 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -45.28 55.44 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.129 179.829 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -62.32 -47.12 85.65 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.447 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -52.12 -41.0 62.13 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.239 179.8 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -81.31 -69.17 0.63 Allowed 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.53 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 138.8 33.68 0.18 Allowed Glycine 0 N--CA 1.501 2.986 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.607 179.97 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 64.5 t -109.44 138.81 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.729 -180.0 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -84.39 121.7 27.91 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.474 179.969 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 3.0 tp -48.57 -44.13 13.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 119.934 -0.707 . . . . 0.0 111.541 -179.911 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.523 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 32.9 ttm180 -54.07 -49.27 69.43 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.655 -179.908 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.4 mt -57.16 -34.72 68.73 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.52 -0.872 . . . . 0.0 112.102 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.8 t -66.7 139.62 20.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.394 -179.879 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -142.93 58.58 1.42 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.27 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.26 -104.36 0.23 Allowed Glycine 0 N--CA 1.496 2.666 0 C-N-CA 119.471 -1.347 . . . . 0.0 111.951 -179.838 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.34 -69.45 0.85 Allowed 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . -40.85 -52.79 3.88 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.03 -1.081 . . . . 0.0 110.559 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.521 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 5.2 mtmp? 48.36 -177.78 0.01 OUTLIER 'General case' 0 C--N 1.29 -2.012 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.925 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 25' ' ' GLY . 7.0 p30 43.13 -171.45 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.563 -179.94 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.92 -7.13 0.41 Allowed Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.178 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.487 ' H ' ' C ' ' A' ' 27' ' ' ASN . 42.2 mmt-85 -111.24 45.9 1.14 Allowed 'General case' 0 N--CA 1.503 2.201 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.794 -179.922 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -67.83 158.38 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.11 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.8 mt -104.27 173.14 6.43 Favored 'General case' 0 N--CA 1.51 2.564 0 C-N-CA 119.516 -0.873 . . . . 0.0 111.395 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.426 ' C ' ' H ' ' A' ' 34' ' ' ASP . 18.7 tptm -73.33 -52.77 12.67 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.381 -0.928 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -63.01 -5.5 3.02 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.224 -0.99 . . . . 0.0 109.849 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.426 ' H ' ' C ' ' A' ' 32' ' ' LYS . 4.5 t0 -66.11 -59.07 4.13 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.414 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -73.24 -33.47 41.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.765 -0.774 . . . . 0.0 111.328 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -51.22 -41.53 60.36 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.917 179.916 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.96 -33.81 66.11 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.544 -0.863 . . . . 0.0 110.607 179.89 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.0 t80 -46.06 -70.93 0.08 Allowed 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.232 179.973 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt . . . . . 0 C--N 1.306 -1.309 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.956 -179.97 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 54.4 t . . . . . 0 N--CA 1.5 2.044 0 CA-C-O 120.796 0.332 . . . . 0.0 110.806 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -62.27 -29.02 70.12 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.185 -1.006 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mmtm -59.59 -42.99 93.8 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.145 -179.943 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.432 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 8.3 t80 -60.02 -49.51 77.39 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 118.743 -1.183 . . . . 0.0 108.664 179.863 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.442 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -50.17 -44.1 52.64 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.858 -179.981 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 57.7 mtp85 -62.25 -46.44 88.81 Favored 'General case' 0 C--N 1.295 -1.765 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.276 -179.869 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -52.96 -32.38 45.7 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.07 -1.052 . . . . 0.0 109.896 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 48.5 mmtt -94.47 -18.34 21.59 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 78.55 13.26 83.39 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 26.9 t -84.12 145.12 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.794 -179.83 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -85.62 99.23 11.14 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.297 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.525 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 17.3 tt -40.75 -42.65 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.842 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.525 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 43.9 ttt85 -50.24 -61.38 2.2 Favored 'General case' 0 C--N 1.287 -2.122 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.923 -179.938 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -52.18 -28.55 18.64 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.847 -0.741 . . . . 0.0 112.754 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.406 ' H ' HG23 ' A' ' 21' ' ' VAL . 11.1 t -55.99 141.31 12.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.72 -1.192 . . . . 0.0 112.382 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -136.69 72.55 1.43 Allowed 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.719 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.6 -105.15 1.59 Allowed Glycine 0 N--CA 1.503 3.127 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.265 -179.86 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.3 p -93.7 -68.6 0.79 Allowed 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.115 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -105.42 83.41 0.37 Allowed Glycine 0 N--CA 1.501 3.023 0 C-N-CA 120.022 -1.085 . . . . 0.0 110.472 -179.888 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -69.56 74.48 0.39 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.262 -0.975 . . . . 0.0 110.154 179.992 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.497 ' C ' ' H ' ' A' ' 29' ' ' ARG . 18.3 p-10 -167.76 -161.52 0.39 Allowed 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.587 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.55 -4.08 1.25 Allowed Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.03 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.497 ' H ' ' C ' ' A' ' 27' ' ' ASN . 25.9 mmt180 -117.33 42.43 2.56 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.295 -0.562 . . . . 0.0 111.374 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -70.37 157.53 6.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 C-N-CA 119.28 -0.968 . . . . 0.0 108.74 179.841 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 60.0 mt -107.01 175.06 5.62 Favored 'General case' 0 N--CA 1.513 2.676 0 C-N-CA 119.031 -1.068 . . . . 0.0 112.037 179.973 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -77.22 -32.95 56.21 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.524 179.932 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -79.13 -8.97 59.41 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 119.39 -0.924 . . . . 0.0 108.929 -179.967 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -64.4 -54.54 31.16 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.257 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.442 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.4 mt -71.17 -34.22 53.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-N 114.588 -1.187 . . . . 0.0 110.867 179.874 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -49.7 -41.39 43.17 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.945 179.831 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.1 -34.83 71.48 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.646 179.79 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.3 t80 -42.43 -68.91 0.16 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.689 -0.804 . . . . 0.0 111.483 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.8 tp . . . . . 0 C--N 1.302 -1.489 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.901 -179.98 . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 69.3 t . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 120.881 0.372 . . . . 0.0 110.223 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.626 HH21 ' HE ' ' A' ' 12' ' ' ARG . 36.0 ttt85 -59.22 -27.74 66.02 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.802 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.1 mmmt -60.99 -44.82 96.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.753 -179.926 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -56.29 -48.33 76.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.266 179.816 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.94 -45.93 67.89 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.626 ' HE ' HH21 ' A' ' 8' ' ' ARG . 13.7 mmt85 -60.42 -43.47 96.72 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.681 -179.93 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -57.37 -54.98 40.72 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.114 179.993 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -71.34 -70.17 0.33 Allowed 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.759 -179.912 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.67 69.59 0.05 OUTLIER Glycine 0 N--CA 1.499 2.849 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.996 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.0 t -144.41 129.03 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 C-N-CA 120.015 -0.674 . . . . 0.0 110.341 -179.973 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -73.55 106.61 5.4 Favored 'General case' 0 C--N 1.301 -1.508 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.387 179.849 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.8 tt -45.11 -42.27 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 119.938 -0.705 . . . . 0.0 111.468 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.526 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 71.8 mtm180 -46.29 -58.83 3.35 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.227 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.6 mt -55.46 -35.78 65.85 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.725 -0.79 . . . . 0.0 112.209 -179.798 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.42 HG23 ' H ' ' A' ' 21' ' ' VAL . 12.0 t -53.88 140.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.881 -1.128 . . . . 0.0 111.513 -179.805 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -145.2 67.18 1.23 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.403 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . -81.15 -100.63 0.35 Allowed Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.32 -1.419 . . . . 0.0 109.946 179.962 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -78.15 -47.47 18.06 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.148 179.866 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.68 116.23 0.7 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.979 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.4 ' HG2' ' H ' ' A' ' 26' ' ' LYS . 9.0 ptmm? -75.18 51.45 0.53 Allowed 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.991 179.953 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.507 ' O ' ' N ' ' A' ' 29' ' ' ARG . 2.9 p30 -147.6 -161.33 1.31 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.711 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.39 -10.89 0.12 Allowed Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.615 -1.279 . . . . 0.0 110.982 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.507 ' N ' ' O ' ' A' ' 27' ' ' ASN . 27.8 mmm-85 -106.0 38.73 1.94 Allowed 'General case' 0 N--CA 1.504 2.241 0 C-N-CA 120.044 -0.662 . . . . 0.0 112.259 -179.943 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -82.3 145.62 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.725 179.79 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.9 mp -106.78 174.49 5.86 Favored 'General case' 0 N--CA 1.51 2.572 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.185 -179.857 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -76.62 -34.31 58.34 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.368 -0.933 . . . . 0.0 108.926 179.743 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -77.0 -9.23 58.56 Favored 'General case' 0 C--N 1.312 -1.056 0 C-N-CA 119.521 -0.872 . . . . 0.0 108.912 179.84 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 23' ' ' GLY . 2.7 t0 -62.77 -49.58 74.43 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.232 179.933 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.8 mt -78.43 -33.53 17.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.259 179.889 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -52.29 -41.81 63.22 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.32 179.935 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.66 -35.88 75.56 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.704 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -43.08 -69.05 0.15 Allowed 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.335 -179.974 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.6 tp . . . . . 0 C--N 1.3 -1.558 0 CA-C-N 115.366 -0.833 . . . . 0.0 112.643 -179.751 . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t . . . . . 0 N--CA 1.488 1.452 0 CA-C-O 120.936 0.398 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 28.5 ttp180 -60.83 -33.52 73.15 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.643 -179.939 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.0 mmtp -59.72 -41.13 90.19 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.334 179.895 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -58.49 -47.6 83.54 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.006 -1.078 . . . . 0.0 109.023 179.924 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.525 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.86 -46.07 41.84 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.966 179.746 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 59.2 mtp85 -57.53 -45.5 84.96 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.863 -179.875 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -53.36 -43.88 68.1 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.184 -1.007 . . . . 0.0 110.872 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 14.3 mmmt -81.43 -22.69 38.01 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.929 179.691 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.92 13.95 70.84 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.94 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.408 HG13 ' CD2' ' A' ' 38' ' ' PHE . 38.3 t -83.92 139.53 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.042 179.834 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 46.1 t0 -84.64 100.96 11.79 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.294 179.944 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.489 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -39.28 -39.58 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 CA-C-O 121.437 0.636 . . . . 0.0 111.613 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.529 ' O ' ' NE ' ' A' ' 19' ' ' ARG . 0.0 OUTLIER -50.33 -62.61 1.48 Allowed 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.092 179.911 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -50.61 -28.38 8.65 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.944 -0.703 . . . . 0.0 112.222 -179.704 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.402 HG23 ' H ' ' A' ' 21' ' ' VAL . 9.0 t -60.4 141.34 17.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 118.888 -1.125 . . . . 0.0 112.071 -179.788 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.6 mt-30 -134.31 64.51 1.6 Allowed 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.602 -179.993 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.59 -115.61 0.71 Allowed Glycine 0 N--CA 1.498 2.828 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.435 -179.911 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -81.54 -68.12 0.72 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.009 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.46 100.19 0.94 Allowed Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.887 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.411 ' HG2' ' H ' ' A' ' 26' ' ' LYS . 7.4 ptmm? -76.09 50.67 0.62 Allowed 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.514 -0.874 . . . . 0.0 110.775 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.481 ' C ' ' H ' ' A' ' 29' ' ' ARG . 2.7 p30 -151.01 -155.65 0.64 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.902 -0.719 . . . . 0.0 110.583 -179.941 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.6 -7.73 0.71 Allowed Glycine 0 C--N 1.29 -1.982 0 C-N-CA 119.357 -1.401 . . . . 0.0 110.258 -179.859 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.481 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.5 mmt85 -111.56 39.25 2.38 Favored 'General case' 0 N--CA 1.506 2.353 0 C-N-CA 120.149 -0.621 . . . . 0.0 111.81 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -76.64 155.45 5.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 C-N-CA 119.364 -0.934 . . . . 0.0 108.986 179.797 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 38.0 mt -109.44 175.43 5.45 Favored 'General case' 0 N--CA 1.514 2.732 0 C-N-CA 119.276 -0.97 . . . . 0.0 111.832 -179.902 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -78.21 -33.4 49.96 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.004 179.723 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 35.1 mm-40 -79.25 -4.99 53.33 Favored 'General case' 0 C--N 1.314 -0.955 0 C-N-CA 119.468 -0.893 . . . . 0.0 109.08 179.862 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -67.31 -58.4 4.87 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 114.687 -1.142 . . . . 0.0 109.249 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.525 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 6.0 mt -70.78 -31.33 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.738 179.703 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -51.97 -41.06 61.83 Favored 'General case' 0 C--N 1.309 -1.172 0 C-N-CA 118.906 -1.118 . . . . 0.0 110.101 -179.888 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.3 -33.37 65.16 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.619 179.906 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.408 ' CD2' HG13 ' A' ' 16' ' ' VAL . 68.3 t80 -44.68 -71.23 0.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.354 -0.939 . . . . 0.0 111.801 179.937 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 32.3 tp . . . . . 0 C--N 1.3 -1.55 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.489 -179.797 . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 N--CA 1.485 1.3 0 CA-C-O 120.813 0.339 . . . . 0.0 111.166 . . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 24.9 ttt-85 -62.29 -48.9 77.85 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.208 -179.747 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 54.5 mttt -52.43 -38.03 58.2 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.799 179.875 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -61.48 -46.15 91.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 118.669 -1.213 . . . . 0.0 108.91 179.836 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.0 -43.18 63.53 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.648 179.9 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -56.29 -45.14 80.32 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.759 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -54.33 -42.64 70.42 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.077 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.0 mmtt -90.04 0.5 57.08 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.274 179.878 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 61.63 16.49 51.0 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.684 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.529 HG13 ' CD2' ' A' ' 38' ' ' PHE . 52.5 t -79.03 137.22 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.773 179.99 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -85.45 102.45 13.48 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.721 179.889 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.522 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -42.76 -42.62 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.906 -0.718 . . . . 0.0 111.712 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.522 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 56.4 ttt-85 -46.54 -60.06 2.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.689 179.901 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 50.6 mt -55.4 -37.54 67.73 Favored 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.683 -0.807 . . . . 0.0 112.255 -179.683 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.437 ' H ' HG23 ' A' ' 21' ' ' VAL . 11.0 t -49.51 141.28 2.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.19 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -140.96 62.14 1.48 Allowed 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.485 179.95 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.84 -103.74 0.31 Allowed Glycine 0 N--CA 1.499 2.85 0 C-N-CA 119.101 -1.524 . . . . 0.0 109.494 179.946 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -78.02 -36.01 49.2 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.291 -0.964 . . . . 0.0 108.718 179.791 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.07 -156.91 6.96 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 179.895 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.405 ' HZ2' ' HB3' ' A' ' 26' ' ' LYS . 14.7 ttpp -163.78 36.06 0.09 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.648 -0.821 . . . . 0.0 109.349 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.438 ' O ' HG23 ' A' ' 30' ' ' VAL . 10.8 p30 -154.08 -158.46 0.87 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.818 -179.999 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.28 -21.63 1.99 Allowed Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.195 -1.478 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -93.09 34.44 1.12 Allowed 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.89 179.945 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.438 HG23 ' O ' ' A' ' 27' ' ' ASN . 3.4 t -82.68 155.08 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.525 -0.87 . . . . 0.0 109.57 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.416 ' N ' ' CD2' ' A' ' 31' ' ' LEU . 3.6 mm? -104.15 173.26 6.38 Favored 'General case' 0 N--CA 1.509 2.485 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -75.31 -43.75 49.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.419 -0.912 . . . . 0.0 108.916 179.798 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -71.27 -6.79 42.49 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.48 -0.888 . . . . 0.0 109.765 -179.948 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.426 ' OD1' HG12 ' A' ' 21' ' ' VAL . 2.7 t0 -62.92 -58.2 8.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.646 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mt -69.99 -36.76 70.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.666 -0.814 . . . . 0.0 110.87 -179.92 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -48.56 -43.26 35.54 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.577 -1.249 . . . . 0.0 110.084 179.95 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.24 -35.48 78.0 Favored 'General case' 0 C--N 1.306 -1.316 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.567 -179.968 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.529 ' CD2' HG13 ' A' ' 16' ' ' VAL . 60.3 t80 -44.93 -68.04 0.23 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.385 179.984 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.2 tp . . . . . 0 C--N 1.302 -1.472 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.137 -179.893 . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.1 t . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.7 0.286 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.471 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 56.7 ttt180 -60.1 -36.07 76.61 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.076 -1.049 . . . . 0.0 111.268 -179.936 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 51.4 mmtt -55.3 -45.63 76.27 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.212 -0.995 . . . . 0.0 110.336 179.87 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.411 ' CG ' ' NZ ' ' A' ' 32' ' ' LYS . 2.5 t80 -54.64 -46.64 73.98 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.101 179.906 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.529 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -49.53 -45.62 47.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.933 -179.863 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 -58.65 -43.39 89.8 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.18 -179.944 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 75.5 mt-10 -57.3 -31.43 65.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.301 -0.959 . . . . 0.0 110.935 -179.943 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.9 mmtt -96.71 -6.72 35.77 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.101 179.944 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 74.62 53.72 6.4 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.529 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 43.0 t -136.39 128.5 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.78 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.548 ' O ' ' N ' ' A' ' 19' ' ' ARG . 39.1 t0 -88.28 94.42 9.83 Favored 'General case' 0 N--CA 1.494 1.768 0 C-N-CA 119.556 -0.858 . . . . 0.0 111.036 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.529 HG23 ' N ' ' A' ' 19' ' ' ARG . 15.0 tt -23.25 -41.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.437 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -179.95 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.548 ' N ' ' O ' ' A' ' 17' ' ' ASP . 45.1 mtm-85 -45.59 -50.23 13.36 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -179.834 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.461 ' CD1' ' O ' ' A' ' 17' ' ' ASP . 0.3 OUTLIER -76.66 -2.25 31.85 Favored 'General case' 0 N--CA 1.5 2.061 0 C-N-CA 119.114 -1.035 . . . . 0.0 113.28 -179.665 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 85.2 t -74.75 146.25 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 C-N-CA 118.219 -1.392 . . . . 0.0 110.477 179.94 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -135.3 62.92 1.62 Allowed 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.502 179.962 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.15 -118.88 0.44 Allowed Glycine 0 N--CA 1.498 2.825 0 C-N-CA 119.215 -1.469 . . . . 0.0 110.432 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -75.62 -45.83 35.16 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.432 179.968 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.99 106.49 0.3 Allowed Glycine 0 N--CA 1.486 2.009 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -74.39 64.69 1.16 Allowed 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.79 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.474 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.8 p-10 -152.48 -164.96 2.08 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.538 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.42 -8.63 0.83 Allowed Glycine 0 N--CA 1.485 1.953 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.228 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.474 ' H ' ' C ' ' A' ' 27' ' ' ASN . 12.3 mmt85 -108.57 37.86 2.4 Favored 'General case' 0 N--CA 1.503 2.214 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.537 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.431 ' C ' HD12 ' A' ' 31' ' ' LEU . 2.9 t -77.63 158.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 119.504 -0.879 . . . . 0.0 108.949 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.431 HD12 ' C ' ' A' ' 30' ' ' VAL . 9.9 mp -113.64 177.51 4.61 Favored 'General case' 0 N--CA 1.513 2.707 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.591 -179.954 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.411 ' NZ ' ' CG ' ' A' ' 10' ' ' TYR . 15.9 tptp -77.3 -40.3 44.91 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.871 179.692 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -74.64 -4.22 35.9 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.469 179.843 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -64.93 -54.01 37.49 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.529 179.965 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.469 HD13 ' HB2' ' A' ' 11' ' ' ALA . 4.3 mt -75.5 -36.97 36.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.698 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 55.6 t0 -48.93 -40.46 30.21 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 118.688 -1.205 . . . . 0.0 109.91 179.895 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.89 -35.73 69.83 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.357 -179.998 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -45.7 -71.48 0.07 Allowed 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.24 179.862 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.1 tp . . . . . 0 C--N 1.302 -1.486 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.713 -179.841 . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.0 t . . . . . 0 N--CA 1.492 1.665 0 CA-C-O 120.969 0.414 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 27.8 ttm180 -58.36 -37.98 76.31 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 118.973 -1.091 . . . . 0.0 110.48 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -53.83 -44.81 70.58 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.289 -179.845 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -57.67 -48.44 79.5 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 118.991 -1.083 . . . . 0.0 109.299 179.785 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.533 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -50.82 -45.26 59.43 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.323 179.972 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -60.46 -45.83 92.28 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.433 -179.885 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -55.76 -29.42 59.56 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.796 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.1 mmtt -108.58 -5.31 16.55 Favored 'General case' 0 N--CA 1.502 2.158 0 C-N-CA 120.123 -0.631 . . . . 0.0 110.768 179.97 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 62.0 81.13 0.09 OUTLIER Glycine 0 N--CA 1.491 2.305 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.588 179.923 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.553 HG13 ' CD2' ' A' ' 38' ' ' PHE . 24.5 t -147.76 129.44 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.139 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -70.7 96.92 1.28 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.577 -179.975 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 19' ' ' ARG . 16.0 tt -40.52 -41.69 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.969 179.891 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' HG23 ' A' ' 18' ' ' ILE . 10.0 tpt180 -55.14 -60.42 3.41 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.278 179.996 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.0 mt -49.42 -20.39 0.69 Allowed 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.964 -179.912 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 5.9 t -68.32 139.5 20.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.997 -179.846 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -142.61 52.56 1.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.012 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.4 -95.99 0.06 OUTLIER Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.651 -1.261 . . . . 0.0 111.036 -179.95 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.46 -46.3 16.14 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.38 -0.928 . . . . 0.0 110.291 -179.863 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -161.74 111.97 0.5 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.93 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.603 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 17.5 ptmt -55.7 -163.5 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.77 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.643 HD22 ' HG2' ' A' ' 29' ' ' ARG . 1.3 p30 50.82 -160.51 0.08 Allowed 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.416 -179.922 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.49 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -50.2 -26.5 9.32 Favored Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.898 -1.144 . . . . 0.0 111.438 -179.823 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.643 ' HG2' HD22 ' A' ' 27' ' ' ASN . 22.0 mmt180 -75.19 29.59 0.1 Allowed 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.592 -179.883 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.475 ' H ' ' C ' ' A' ' 28' ' ' GLY . 2.9 t -90.74 133.72 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.375 179.901 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.521 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.8 mp -104.18 178.82 4.45 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.786 179.943 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -74.43 -36.86 63.42 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.132 179.731 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -75.11 -8.55 56.87 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.189 179.872 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.415 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 3.3 t0 -66.07 -57.34 7.95 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.634 179.829 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 mt -66.58 -31.34 53.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.276 -179.951 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -51.57 -40.94 60.7 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.065 -1.054 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.84 -33.19 68.24 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.687 179.924 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.553 ' CD2' HG13 ' A' ' 16' ' ' VAL . 64.9 t80 -45.47 -69.39 0.14 Allowed 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.129 -179.967 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.8 tp . . . . . 0 C--N 1.303 -1.45 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.821 -179.817 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.482 1.172 0 CA-C-O 120.828 0.347 . . . . 0.0 110.277 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 3' ' ' ALA . 18.4 mm -55.37 159.98 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.912 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.426 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -56.88 164.7 1.46 Allowed 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.491 -0.884 . . . . 0.0 110.833 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 55.6 mtt -66.79 150.62 97.54 Favored Pre-proline 0 C--N 1.303 -1.443 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.465 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -61.11 -42.68 34.38 Favored 'Trans proline' 0 C--O 1.217 -0.562 0 C-N-CA 120.769 0.98 . . . . 0.0 110.76 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.6 m -47.17 -29.97 2.63 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.647 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.9 t -87.88 -42.38 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 C-N-CA 119.442 -0.903 . . . . 0.0 111.372 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 25.1 ttm180 -61.45 -43.41 98.91 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.534 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -52.94 -39.61 63.01 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.936 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.532 ' OH ' ' NZ ' ' A' ' 14' ' ' LYS . 12.2 t80 -60.01 -50.5 73.48 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 118.7 -1.2 . . . . 0.0 109.196 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.91 -43.52 39.39 Favored 'General case' 0 C--N 1.29 -1.996 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.136 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.6 mtp180 -66.46 -45.46 79.66 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.308 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 39.1 mm-40 -46.73 -61.37 1.87 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.416 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.532 ' NZ ' ' OH ' ' A' ' 10' ' ' TYR . 11.4 ptpt -77.31 -22.99 51.11 Favored 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 118.599 -1.241 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 93.61 81.1 1.49 Allowed Glycine 0 N--CA 1.507 3.38 0 C-N-CA 119.731 -1.223 . . . . 0.0 111.477 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.557 HG13 ' CD2' ' A' ' 38' ' ' PHE . 18.7 t -148.42 129.6 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.266 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -74.03 104.52 4.89 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.651 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.535 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.5 tt -48.92 -44.2 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.928 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 19.4 ttm180 -47.88 -54.48 12.47 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.508 -0.769 . . . . 0.0 112.467 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.4 mt -57.54 -35.85 70.85 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 112.088 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 t -52.03 140.96 6.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.673 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.4 tt0 -142.56 66.45 1.33 Allowed 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.427 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.77 -101.26 0.27 Allowed Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.067 -1.539 . . . . 0.0 109.463 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.418 ' OG1' HD13 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -82.26 -42.31 19.04 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.151 179.922 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.91 119.0 0.86 Allowed Glycine 0 N--CA 1.477 1.424 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.7 pttp -75.07 46.29 0.3 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.966 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.484 ' C ' ' H ' ' A' ' 29' ' ' ARG . 14.9 p-10 -143.19 -152.34 0.41 Allowed 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.204 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.56 -8.46 0.54 Allowed Glycine 0 C--N 1.291 -1.959 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.388 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.484 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.8 mmt180 -102.95 34.91 2.68 Favored 'General case' 0 N--CA 1.503 2.184 0 C-N-CA 119.87 -0.732 . . . . 0.0 111.821 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.429 ' C ' HD12 ' A' ' 31' ' ' LEU . 6.3 t -85.27 127.38 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.643 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.6 mp -96.31 172.36 8.0 Favored 'General case' 0 N--CA 1.505 2.314 0 C-N-CA 119.239 -0.984 . . . . 0.0 112.486 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -71.32 -33.98 70.16 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.877 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -80.21 -8.27 59.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.266 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -65.53 -53.04 47.81 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.456 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 mt -75.54 -34.4 29.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.789 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -50.53 -41.96 54.51 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.934 -1.106 . . . . 0.0 109.848 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.59 67.5 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.979 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.557 ' CD2' HG13 ' A' ' 16' ' ' VAL . 77.9 t80 -42.9 -65.87 0.43 Allowed 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.581 -0.847 . . . . 0.0 112.232 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.1 tp -72.12 -42.99 65.42 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.367 -0.933 . . . . 0.0 112.548 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -42.2 -46.56 4.47 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 119.351 -0.939 . . . . 0.0 111.454 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -47.04 -38.44 10.81 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.464 -1.351 . . . . 0.0 110.443 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.2 -92.14 1.69 Allowed Glycine 0 N--CA 1.494 2.54 0 C-N-CA 119.612 -1.28 . . . . 0.0 110.564 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.503 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.648 -179.941 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' A' ' 2' ' ' ILE . 16.5 m . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 120.904 0.383 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.449 ' O ' ' O ' ' A' ' 1' ' ' VAL . 13.6 mm 55.29 162.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.955 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.44 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -60.88 140.75 57.61 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.249 -0.981 . . . . 0.0 110.469 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 56.5 mtm -58.66 153.62 40.09 Favored Pre-proline 0 C--N 1.306 -1.308 0 C-N-CA 119.421 -0.912 . . . . 0.0 110.439 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -66.56 68.71 0.49 Allowed 'Trans proline' 0 CA--C 1.549 1.244 0 C-N-CA 120.884 1.056 . . . . 0.0 110.822 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.2 p -174.7 -39.31 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.572 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.7 t -75.02 -44.41 44.33 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.97 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.0 ttt85 -64.36 -40.69 96.36 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.177 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 17.3 mttp -53.79 -37.96 64.01 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.083 -1.047 . . . . 0.0 110.539 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -60.71 -49.99 75.3 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.766 -1.173 . . . . 0.0 108.966 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.48 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.98 -43.63 40.2 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.573 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -59.45 -45.16 92.38 Favored 'General case' 0 C--N 1.294 -1.821 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.03 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -53.67 -40.05 65.61 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.308 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 15.4 mmmt -87.99 -3.24 58.93 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.612 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.75 3.08 48.55 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.359 -1.4 . . . . 0.0 110.331 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.483 HG13 ' CD2' ' A' ' 38' ' ' PHE . 54.2 t -74.4 133.05 32.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.778 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -84.3 108.9 17.42 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.655 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.517 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.7 tt -44.14 -41.2 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.383 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.517 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.4 tpm_? -48.73 -59.93 3.14 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 114.832 -1.076 . . . . 0.0 112.552 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.6 mt -55.49 -31.44 62.01 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.528 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -53.36 140.55 9.34 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.8 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -135.46 65.4 1.55 Allowed 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 114.997 -1.002 . . . . 0.0 109.801 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.68 -118.42 0.95 Allowed Glycine 0 N--CA 1.502 3.038 0 C-N-CA 119.633 -1.27 . . . . 0.0 111.805 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.16 -72.48 0.6 Allowed 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.086 -179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.489 ' O ' ' N ' ' A' ' 27' ' ' ASN . . . -91.29 69.34 2.08 Favored Glycine 0 N--CA 1.496 2.67 0 C-N-CA 119.761 -1.209 . . . . 0.0 110.397 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -64.49 73.87 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.564 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.496 ' C ' ' H ' ' A' ' 29' ' ' ARG . 33.1 p-10 -174.37 -159.86 0.09 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.829 -0.748 . . . . 0.0 110.259 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.9 -7.62 1.1 Allowed Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.061 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.496 ' H ' ' C ' ' A' ' 27' ' ' ASN . 47.9 mmt-85 -116.5 46.26 1.64 Allowed 'General case' 0 N--CA 1.504 2.263 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.564 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.7 t -72.89 157.89 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.282 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.405 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -104.62 172.84 6.58 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.213 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -79.6 -34.34 40.83 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.582 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 51.8 mm-40 -76.04 -6.57 51.68 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 119.367 -0.933 . . . . 0.0 108.512 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -66.0 -55.47 16.53 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.408 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.48 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.5 mt -75.07 -32.59 27.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.701 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -51.24 -40.49 58.94 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.727 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.432 ' O ' ' N ' ' A' ' 41' ' ' GLY . . . -71.79 -37.24 70.45 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.533 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.483 ' CD2' HG13 ' A' ' 16' ' ' VAL . 65.7 t80 -40.78 -67.78 0.22 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.756 -0.778 . . . . 0.0 111.719 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.9 tp -73.99 -25.83 60.13 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.751 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -139.33 75.54 1.52 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.212 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 37' ' ' ALA . . . -93.76 29.66 8.3 Favored Glycine 0 N--CA 1.5 2.904 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.92 -176.84 46.55 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.533 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.345 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.857 -179.841 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 N--CA 1.48 1.047 0 CA-C-O 120.857 0.361 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.565 HG22 ' N ' ' A' ' 3' ' ' ALA . 25.0 mm -52.83 166.84 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 C-N-CA 119.532 -0.867 . . . . 0.0 110.835 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.565 ' N ' HG22 ' A' ' 2' ' ' ILE . . . 45.17 58.38 4.13 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.739 -0.784 . . . . 0.0 111.173 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.659 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 20.6 ptt? -125.45 -15.41 0.05 OUTLIER Pre-proline 0 N--CA 1.5 2.067 0 N-CA-C 114.855 1.428 . . . . 0.0 114.855 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.659 ' CD ' ' H ' ' A' ' 4' ' ' MET . 1.3 Cg_endo -66.23 -47.93 2.96 Favored 'Trans proline' 0 C--N 1.357 0.986 0 CA-C-N 120.18 1.1 . . . . 0.0 110.94 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.417 ' O ' ' OG ' ' A' ' 6' ' ' SER . 29.7 t -164.93 30.44 0.06 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.493 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 53.3 t -100.39 -76.63 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 C-N-CA 120.141 -0.624 . . . . 0.0 110.559 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -65.92 -30.82 71.46 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.007 -1.077 . . . . 0.0 110.72 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.9 mmtt -62.23 -40.03 94.8 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.014 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -57.92 -46.92 84.27 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.245 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.466 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -49.2 -45.17 43.92 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 115.111 -0.95 . . . . 0.0 111.008 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -58.5 -44.59 89.48 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.389 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 mt-10 -54.72 -51.92 64.09 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 118.986 -1.085 . . . . 0.0 110.989 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.2 mmmt -81.39 6.12 15.44 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.886 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 56.45 75.5 0.25 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.657 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.497 HG13 ' CD2' ' A' ' 38' ' ' PHE . 46.9 t -144.82 126.45 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.159 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 65.5 t0 -74.51 107.88 6.92 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.269 -0.972 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.494 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.3 tt -42.88 -40.94 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.585 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.494 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 32.7 mtm180 -54.89 -54.05 47.56 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.255 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -51.84 -36.52 48.47 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.52 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 t -56.56 142.72 11.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.843 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 41.8 tt0 -142.05 62.26 1.44 Allowed 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 120.098 -0.641 . . . . 0.0 111.647 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.9 -107.23 0.83 Allowed Glycine 0 N--CA 1.5 2.916 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.82 -45.9 40.24 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.467 -0.893 . . . . 0.0 109.626 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.5 120.65 0.99 Allowed Glycine 0 N--CA 1.485 1.91 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -79.99 44.4 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.262 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.479 ' C ' ' H ' ' A' ' 29' ' ' ARG . 1.8 p30 -149.14 -152.05 0.42 Allowed 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.474 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.52 -11.44 0.48 Allowed Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.151 -1.499 . . . . 0.0 110.29 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.479 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.6 mmt180 -102.43 32.85 3.38 Favored 'General case' 0 N--CA 1.503 2.216 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.815 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.6 t -85.57 135.86 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.376 179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.436 HD12 ' N ' ' A' ' 31' ' ' LEU . 11.0 mp -103.45 173.76 6.16 Favored 'General case' 0 N--CA 1.509 2.515 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -72.75 -37.85 67.55 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.649 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -74.46 -9.19 58.34 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.997 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -66.79 -58.24 5.45 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 114.579 -1.191 . . . . 0.0 109.551 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.466 HD13 ' HB2' ' A' ' 11' ' ' ALA . 4.1 mt -72.51 -36.79 55.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.48 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 25.0 t70 -47.24 -41.12 17.9 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 119.102 -1.039 . . . . 0.0 110.245 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.402 ' O ' ' N ' ' A' ' 41' ' ' GLY . . . -72.74 -35.86 67.61 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.528 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.497 ' CD2' HG13 ' A' ' 16' ' ' VAL . 67.2 t80 -43.09 -70.73 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.377 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 30.9 tp -69.74 -60.91 2.02 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.612 -0.835 . . . . 0.0 110.79 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.48 ' HB3' ' O ' ' A' ' 36' ' ' ASP . . . -47.27 -65.58 0.54 Allowed 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.344 -0.943 . . . . 0.0 111.107 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' A' ' 37' ' ' ALA . . . -51.74 -39.5 47.0 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.445 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.31 162.55 33.09 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 119.449 -1.357 . . . . 0.0 110.531 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.371 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.762 -180.0 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.0 p . . . . . 0 N--CA 1.479 1.014 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 15.6 mm -69.2 156.14 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.069 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -91.38 -171.35 2.91 Favored 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 119.953 -0.699 . . . . 0.0 110.85 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 28.0 mtt -76.05 154.01 84.65 Favored Pre-proline 0 N--CA 1.488 1.431 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.341 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -66.14 73.38 0.36 Allowed 'Trans proline' 0 CA--C 1.546 1.103 0 C-N-CA 120.875 1.05 . . . . 0.0 111.21 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 11.5 t -178.78 -26.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 119.297 -0.961 . . . . 0.0 111.246 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.6 t -84.17 -61.49 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.513 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.402 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 68.5 ttp85 -56.61 -43.79 80.52 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.319 -0.952 . . . . 0.0 111.594 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -48.39 -46.57 37.32 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.115 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -55.34 -49.55 71.93 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 118.866 -1.134 . . . . 0.0 109.385 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.402 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -50.99 -44.47 60.89 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.688 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -59.67 -43.48 93.98 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.825 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -57.7 -43.06 84.92 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.604 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.1 mmtt -82.3 -16.79 48.12 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.618 -0.833 . . . . 0.0 111.006 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.38 3.81 90.4 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.334 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.503 HG13 ' CD2' ' A' ' 38' ' ' PHE . 37.6 t -74.28 134.65 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.56 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -81.45 107.54 14.3 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.679 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.503 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -44.84 -41.11 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 C-N-CA 119.965 -0.694 . . . . 0.0 111.142 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.503 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 1.7 tmt_? -49.64 -59.0 4.19 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.491 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.2 mt -54.39 -25.8 26.65 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.77 -0.772 . . . . 0.0 112.401 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.422 HG12 ' OD1' ' A' ' 34' ' ' ASP . 8.2 t -62.58 139.9 20.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.691 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -136.49 54.63 1.87 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.5 -110.87 0.06 OUTLIER Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.065 -1.54 . . . . 0.0 109.536 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.05 -41.31 35.91 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.429 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -159.03 116.59 0.72 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.9 ptpp? -74.75 39.01 0.13 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.235 -0.986 . . . . 0.0 111.18 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.52 ' O ' ' N ' ' A' ' 29' ' ' ARG . 2.4 p30 -142.25 -152.74 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -47.44 -11.84 0.09 OUTLIER Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.205 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.52 ' N ' ' O ' ' A' ' 27' ' ' ASN . 17.4 mmt-85 -104.33 32.84 3.79 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.178 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.4 t -82.33 128.34 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 119.391 -0.924 . . . . 0.0 108.62 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.557 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -97.83 175.68 6.07 Favored 'General case' 0 N--CA 1.507 2.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.79 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -74.06 -35.99 64.31 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 119.517 -0.873 . . . . 0.0 108.825 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -76.49 -8.01 56.3 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 119.362 -0.935 . . . . 0.0 108.627 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.422 ' OD1' HG12 ' A' ' 21' ' ' VAL . 3.8 t0 -66.4 -59.25 3.85 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 114.66 -1.154 . . . . 0.0 109.581 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mt -70.48 -30.72 43.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.556 -0.857 . . . . 0.0 110.233 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.491 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 20.5 t70 -53.77 -41.36 67.1 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.486 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.64 -32.86 70.32 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.474 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.503 ' CD2' HG13 ' A' ' 16' ' ' VAL . 67.1 t80 -45.24 -70.07 0.11 Allowed 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.32 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.416 ' O ' ' O ' ' A' ' 40' ' ' ALA . 32.2 tp -70.92 -57.36 4.66 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.713 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 36' ' ' ASP . . . -59.76 -151.3 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.298 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.913 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.55 -46.83 2.62 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.589 -1.291 . . . . 0.0 110.516 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.77 14.68 38.01 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 119.293 -1.432 . . . . 0.0 110.243 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.396 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.894 179.95 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.451 HG22 ' N ' ' A' ' 2' ' ' ILE . 6.4 p . . . . . 0 N--CA 1.48 1.051 0 CA-C-O 120.936 0.398 . . . . 0.0 110.009 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.451 ' N ' HG22 ' A' ' 1' ' ' VAL . 11.7 mm -51.85 157.46 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.875 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.426 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -88.34 61.53 6.23 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.956 -0.698 . . . . 0.0 110.669 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.63 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 23.4 ptt? -115.6 -16.01 0.1 Allowed Pre-proline 0 N--CA 1.508 2.473 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.63 ' CD ' ' N ' ' A' ' 4' ' ' MET . 5.9 Cg_endo -70.18 -70.07 0.02 OUTLIER 'Trans proline' 0 C--N 1.356 0.942 0 CA-C-N 120.177 1.099 . . . . 0.0 110.716 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.1 t -146.55 28.9 1.05 Allowed 'General case' 0 N--CA 1.49 1.537 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.832 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.5 t -97.12 -60.49 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.28 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.403 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 57.3 ttp180 -62.17 -39.75 93.71 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.984 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mttp -54.52 -40.22 68.38 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.748 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.1 t80 -58.95 -47.06 86.44 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 118.802 -1.159 . . . . 0.0 108.926 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -49.09 -44.8 42.41 Favored 'General case' 0 C--N 1.291 -1.958 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.662 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 72.1 mtt85 -59.73 -47.12 86.92 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.902 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -50.88 -41.63 58.39 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.332 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 22.7 mmtp -85.49 -19.43 31.23 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.789 -0.764 . . . . 0.0 110.797 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.38 31.58 27.47 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.467 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 40.6 t -105.37 145.3 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 C-N-CA 120.199 -0.601 . . . . 0.0 110.779 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -91.11 105.56 17.9 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 120.029 -0.669 . . . . 0.0 110.299 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.516 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.7 tt -41.08 -41.71 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 CA-C-O 121.43 0.634 . . . . 0.0 111.797 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.516 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.4 ttt85 -52.08 -57.43 9.56 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-N 115.281 -0.872 . . . . 0.0 111.975 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -52.5 -30.24 29.11 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.878 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.2 t -61.59 143.65 14.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.599 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -142.15 52.61 1.47 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.297 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.45 -106.58 0.04 OUTLIER Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.699 -1.715 . . . . 0.0 109.311 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.79 -44.03 51.67 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.464 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.51 121.97 1.08 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttm -76.79 40.14 0.24 Allowed 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.101 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.499 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.2 p-10 -142.72 -150.36 0.31 Allowed 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.797 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.4 -8.77 0.55 Allowed Glycine 0 C--N 1.284 -2.335 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.226 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.499 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.6 28.72 5.8 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.899 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 t -83.01 128.53 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.748 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.541 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -100.07 176.67 5.33 Favored 'General case' 0 N--CA 1.505 2.309 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.957 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.4 tttt -74.41 -36.01 63.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.802 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -76.37 -7.82 55.82 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.883 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -66.26 -51.97 52.26 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.187 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -74.66 -33.19 30.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.994 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -52.07 -40.89 61.85 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 118.716 -1.193 . . . . 0.0 109.566 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.81 -32.88 68.04 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.547 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -44.93 -70.54 0.1 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.433 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.533 ' O ' ' N ' ' A' ' 41' ' ' GLY . 37.4 tp -68.05 -25.21 65.25 Favored 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.478 -0.889 . . . . 0.0 111.306 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.434 ' C ' ' H ' ' A' ' 42' ' ' GLY . . . 43.47 17.86 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.191 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -67.67 4.1 4.39 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 119.346 -1.407 . . . . 0.0 110.331 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 40' ' ' ALA . . . -166.59 -6.18 0.03 OUTLIER Glycine 0 N--CA 1.484 1.871 0 C-N-CA 119.405 -1.379 . . . . 0.0 110.59 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.401 ' H ' ' H ' ' A' ' 42' ' ' GLY . . . . . . . . 0 C--N 1.303 -1.435 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.774 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 34.7 m . . . . . 0 N--CA 1.483 1.197 0 CA-C-O 120.961 0.41 . . . . 0.0 110.111 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -70.61 -175.11 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.732 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -54.0 117.21 3.03 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.437 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.649 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 0.0 OUTLIER -116.87 -13.27 0.09 OUTLIER Pre-proline 0 N--CA 1.5 2.061 0 N-CA-C 114.925 1.454 . . . . 0.0 114.925 179.919 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.649 ' CD ' ' N ' ' A' ' 4' ' ' MET . 7.6 Cg_endo -70.63 79.11 1.24 Allowed 'Trans proline' 0 C--N 1.359 1.087 0 CA-C-N 120.1 1.071 . . . . 0.0 110.832 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.2 t 54.91 12.02 0.55 Allowed 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.369 -0.932 . . . . 0.0 111.311 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.0 t -82.32 -64.63 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.628 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.416 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 64.0 ttt180 -61.42 -29.55 70.01 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.999 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 60.8 mmtt -59.5 -45.7 90.94 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.936 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -55.1 -46.67 75.52 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 119.341 -0.944 . . . . 0.0 109.04 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.555 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.93 -45.62 41.87 Favored 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.523 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 61.7 mtt-85 -64.11 -46.37 84.49 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.02 -0.991 . . . . 0.0 111.453 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 66.4 mt-10 -48.52 -48.74 38.11 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.366 -0.934 . . . . 0.0 111.344 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -83.34 -33.42 25.88 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.159 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.09 73.62 1.07 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.578 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.26 130.4 8.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 C-N-CA 120.019 -0.673 . . . . 0.0 110.193 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -76.26 103.04 6.09 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.08 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.522 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 14.1 tt -42.23 -42.61 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.707 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.522 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.7 ttp180 -45.46 -57.63 3.96 Favored 'General case' 0 C--N 1.289 -2.049 0 CA-C-N 115.264 -0.88 . . . . 0.0 112.415 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 53.1 mt -56.44 -35.97 68.47 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.647 -0.821 . . . . 0.0 112.3 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.8 t -50.18 141.44 3.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 C-N-CA 118.875 -1.13 . . . . 0.0 111.819 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -143.96 65.89 1.3 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.142 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.43 -105.55 0.6 Allowed Glycine 0 N--CA 1.499 2.84 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.07 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.94 -45.69 40.77 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.373 -0.931 . . . . 0.0 109.757 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.518 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -162.99 115.33 0.65 Allowed Glycine 0 N--CA 1.479 1.543 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -74.84 36.06 0.11 Allowed 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.091 -1.044 . . . . 0.0 110.769 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 26.3 t-20 -107.82 -179.82 4.01 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.98 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.52 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -50.01 -12.14 0.45 Allowed Glycine 0 N--CA 1.485 1.936 0 C-N-CA 119.112 -1.518 . . . . 0.0 110.016 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.49 ' N ' ' C ' ' A' ' 27' ' ' ASN . 14.7 mmt-85 -97.94 36.76 1.5 Allowed 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.624 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.4 t -71.11 153.0 8.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.001 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.407 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -105.56 173.21 6.41 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.332 -0.947 . . . . 0.0 111.312 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -77.18 -37.47 53.58 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.104 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -76.05 -5.58 47.1 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.396 -0.921 . . . . 0.0 109.066 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -65.12 -56.17 14.49 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.224 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.555 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 6.2 mt -69.59 -37.78 75.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.138 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -48.36 -40.46 25.58 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.985 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.21 -34.0 70.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.476 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -45.03 -71.9 0.07 Allowed 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.622 -0.831 . . . . 0.0 111.315 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.506 ' O ' ' N ' ' A' ' 41' ' ' GLY . 10.5 tp -74.95 -53.76 8.42 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.622 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 45.21 16.87 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.16 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -62.4 -68.67 1.57 Allowed Glycine 0 N--CA 1.487 2.072 0 C-N-CA 119.361 -1.4 . . . . 0.0 110.27 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.63 -112.27 0.01 OUTLIER Glycine 0 N--CA 1.488 2.16 0 C-N-CA 119.366 -1.397 . . . . 0.0 110.364 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.311 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.724 179.951 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.526 HG12 ' N ' ' A' ' 2' ' ' ILE . 96.2 t . . . . . 0 N--CA 1.483 1.204 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.526 ' N ' HG12 ' A' ' 1' ' ' VAL . 9.9 mm -49.98 166.78 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.592 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.478 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -78.98 44.72 0.57 Allowed 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.723 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.642 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 42.8 mtt -91.21 -29.92 0.33 Allowed Pre-proline 0 N--CA 1.491 1.607 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.642 ' CD ' ' N ' ' A' ' 4' ' ' MET . 6.2 Cg_exo -65.67 -153.28 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 120.367 0.711 . . . . 0.0 110.939 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.0 m -71.96 32.08 0.05 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.031 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.523 ' H ' ' C ' ' A' ' 5' ' ' PRO . 73.5 t -79.0 -62.69 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 119.505 -0.878 . . . . 0.0 110.343 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -66.22 -44.28 84.26 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.551 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -52.65 -35.4 54.86 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.745 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -62.82 -49.83 73.38 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.863 -1.135 . . . . 0.0 108.894 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.404 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -51.49 -43.69 62.27 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.973 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 44.9 mtp180 -60.78 -47.09 87.87 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.721 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.96 -53.96 28.46 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.763 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 13.7 ptmt -76.51 -24.61 53.71 Favored 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.915 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.66 70.69 1.16 Allowed Glycine 0 N--CA 1.503 3.154 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.623 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.404 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 19.2 t -148.2 145.55 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.929 -0.709 . . . . 0.0 110.287 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -90.82 106.21 18.36 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.593 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.529 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 16.6 tt -42.12 -41.72 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.512 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.529 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 84.6 mtt-85 -50.08 -60.69 2.7 Favored 'General case' 0 C--N 1.285 -2.222 0 CA-C-N 115.021 -0.991 . . . . 0.0 112.421 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 75.6 mt -51.9 -18.1 1.21 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.467 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.2 t -72.34 139.8 19.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 C-N-CA 118.671 -1.212 . . . . 0.0 111.66 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 tt0 -138.68 55.39 1.73 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.858 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.54 -109.43 0.02 OUTLIER Glycine 0 N--CA 1.492 2.378 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.698 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -70.06 -44.31 69.42 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.312 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -168.68 121.36 0.94 Allowed Glycine 0 N--CA 1.48 1.614 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.079 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.43 ' CE ' ' O ' ' A' ' 19' ' ' ARG . 0.7 OUTLIER -73.05 66.1 0.8 Allowed 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.304 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.476 ' C ' ' H ' ' A' ' 29' ' ' ARG . 12.3 p30 -152.07 -164.89 2.08 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.243 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.1 -9.52 0.9 Allowed Glycine 0 N--CA 1.483 1.783 0 C-N-CA 119.212 -1.471 . . . . 0.0 110.045 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.476 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.3 mmm-85 -100.76 30.99 3.71 Favored 'General case' 0 N--CA 1.501 2.08 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.531 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.0 t -81.42 143.67 11.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 119.596 -0.841 . . . . 0.0 108.962 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.441 ' H ' ' HB2' ' A' ' 34' ' ' ASP . 5.4 mp -112.86 174.62 5.81 Favored 'General case' 0 N--CA 1.514 2.728 0 C-N-CA 119.49 -0.884 . . . . 0.0 112.302 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -73.29 -33.65 65.33 Favored 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.168 -1.013 . . . . 0.0 108.299 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -74.55 -12.88 60.58 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.124 -0.944 . . . . 0.0 108.912 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.441 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.2 t0 -63.87 -51.3 65.23 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.228 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mt -75.79 -32.11 23.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.243 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -52.63 -40.45 62.79 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.598 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.92 -34.43 71.52 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.308 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 61.9 t80 -42.92 -70.83 0.09 Allowed 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.77 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.496 ' O ' ' N ' ' A' ' 41' ' ' GLY . 53.5 tp -69.92 -53.85 16.03 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.077 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -48.86 -11.67 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.05 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . 50.79 46.55 48.34 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.259 -1.448 . . . . 0.0 110.447 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 70.4 90.9 0.08 OUTLIER Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.424 -1.37 . . . . 0.0 110.304 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 C-N-CA 119.505 -0.878 . . . . 0.0 111.122 -179.921 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.483 1.208 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.59 HG22 ' H ' ' A' ' 3' ' ' ALA . 12.7 mm -60.79 172.38 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.448 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.59 ' H ' HG22 ' A' ' 2' ' ' ILE . . . -158.57 -154.48 0.43 Allowed 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.964 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.48 ' C ' ' H ' ' A' ' 6' ' ' SER . 67.4 mtt -75.32 150.48 85.11 Favored Pre-proline 0 N--CA 1.484 1.24 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.629 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -68.3 31.1 0.15 Allowed 'Trans proline' 0 CA--C 1.548 1.214 0 C-N-CA 121.014 1.143 . . . . 0.0 111.674 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.48 ' H ' ' C ' ' A' ' 4' ' ' MET . 31.4 t -151.68 -25.63 0.19 Allowed 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 118.94 -1.104 . . . . 0.0 111.817 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 85.7 t -76.14 -60.38 2.39 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 C-N-CA 119.258 -0.977 . . . . 0.0 111.183 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 61.3 ttt180 -63.29 -37.21 86.35 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.85 -1.14 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.8 mmtt -55.81 -40.35 72.64 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.491 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -56.62 -51.11 69.95 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.631 -1.228 . . . . 0.0 108.977 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.24 -45.38 54.01 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.246 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtp180 -62.89 -46.69 86.63 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.823 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -52.07 -55.8 18.42 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.782 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.6 mmtt -67.7 -66.03 0.61 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 133.66 64.73 0.07 OUTLIER Glycine 0 N--CA 1.499 2.867 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.427 HG13 ' CD2' ' A' ' 38' ' ' PHE . 41.9 t -142.24 138.99 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.479 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 38.2 t0 -83.96 109.23 17.45 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.639 -0.825 . . . . 0.0 110.553 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.479 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 9.2 tt -44.05 -41.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.512 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.479 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 58.6 ttp180 -50.33 -58.16 6.3 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.33 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.2 mt -54.93 -28.21 49.22 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.325 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.404 ' H ' HG23 ' A' ' 21' ' ' VAL . 6.9 t -62.43 142.28 16.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 C-N-CA 118.754 -1.179 . . . . 0.0 111.308 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -142.23 66.24 1.34 Allowed 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.52 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.1 -103.22 0.66 Allowed Glycine 0 N--CA 1.5 2.93 0 C-N-CA 119.24 -1.457 . . . . 0.0 109.552 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -79.7 -51.81 8.75 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.486 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.25 114.19 0.63 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 pttm -76.0 55.95 0.95 Allowed 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.045 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.488 ' C ' ' N ' ' A' ' 29' ' ' ARG . 1.5 p30 -146.2 -162.34 1.5 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.259 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.46 -10.19 0.54 Allowed Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.303 -1.427 . . . . 0.0 110.153 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.488 ' N ' ' C ' ' A' ' 27' ' ' ASN . 13.2 mmt85 -104.39 35.25 2.78 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.751 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -78.07 145.24 10.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.296 -0.962 . . . . 0.0 108.625 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.1 mp -102.86 173.04 6.49 Favored 'General case' 0 N--CA 1.511 2.596 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.708 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.6 tttm -74.18 -43.49 57.09 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.242 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -70.95 -5.18 28.96 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.45 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -68.37 -56.79 7.29 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.177 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -71.45 -31.14 42.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.405 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.421 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 17.7 m-20 -53.71 -42.33 67.92 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.602 -1.239 . . . . 0.0 109.531 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.8 -35.45 78.67 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.282 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.427 ' CD2' HG13 ' A' ' 16' ' ' VAL . 64.6 t80 -43.04 -70.47 0.11 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.266 -0.974 . . . . 0.0 111.342 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.425 ' O ' ' O ' ' A' ' 40' ' ' ALA . 55.1 tp -71.05 -65.29 0.76 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.61 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.425 ' O ' ' O ' ' A' ' 39' ' ' LEU . . . -50.4 179.53 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.271 -0.971 . . . . 0.0 110.586 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 47.74 32.58 8.43 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.295 -1.431 . . . . 0.0 110.288 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 163.21 -176.08 39.45 Favored Glycine 0 N--CA 1.485 1.916 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.076 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.322 0 C-N-CA 119.258 -0.977 . . . . 0.0 110.907 -179.97 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.5 m . . . . . 0 N--CA 1.483 1.203 0 CA-C-O 120.938 0.399 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.9 OUTLIER -103.6 -176.17 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.235 0 CA-C-O 121.376 0.608 . . . . 0.0 111.283 179.934 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.429 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 45.33 -174.9 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.279 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.5 ' C ' ' H ' ' A' ' 6' ' ' SER . 92.1 mtp -84.76 154.79 61.74 Favored Pre-proline 0 N--CA 1.487 1.384 0 C-N-CA 119.934 -0.706 . . . . 0.0 110.242 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -66.43 30.98 0.11 Allowed 'Trans proline' 0 CA--C 1.55 1.302 0 C-N-CA 120.924 1.082 . . . . 0.0 111.998 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.5 ' H ' ' C ' ' A' ' 4' ' ' MET . 21.0 t -142.52 -20.81 0.68 Allowed 'General case' 0 N--CA 1.5 2.07 0 C-N-CA 119.484 -0.886 . . . . 0.0 111.237 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 84.9 t -82.23 -52.78 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 C-N-CA 119.427 -0.909 . . . . 0.0 111.126 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 58.7 ttt-85 -58.09 -31.64 67.3 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.256 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -61.15 -39.97 92.1 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.206 -0.998 . . . . 0.0 110.511 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 6.1 t80 -59.08 -48.36 81.88 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 118.944 -1.102 . . . . 0.0 109.259 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.411 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -49.71 -42.38 45.74 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.791 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -61.96 -43.51 98.69 Favored 'General case' 0 C--N 1.292 -1.907 0 C-N-CA 119.484 -0.887 . . . . 0.0 111.082 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -55.04 -54.41 43.44 Favored 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.309 -0.956 . . . . 0.0 110.928 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.4 mmtp -79.82 -19.43 48.46 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.066 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 76.06 81.93 0.52 Allowed Glycine 0 N--CA 1.49 2.24 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.968 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.464 HG13 ' CE2' ' A' ' 38' ' ' PHE . 17.9 t -146.9 141.57 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.918 -0.713 . . . . 0.0 110.647 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -80.31 97.57 7.05 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.267 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.4 tt -40.19 -37.79 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.534 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.441 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 57.0 mtp180 -54.96 -62.72 1.48 Allowed 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.364 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.0 mt -51.17 -17.67 0.72 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.549 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.3 t -68.35 141.16 17.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 C-N-CA 118.502 -1.279 . . . . 0.0 111.447 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -139.83 67.77 1.37 Allowed 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.037 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.12 -114.01 1.34 Allowed Glycine 0 N--CA 1.498 2.814 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.025 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.34 -44.05 54.04 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.91 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.5 111.94 0.5 Allowed Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -75.85 53.07 0.73 Allowed 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.081 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.473 ' C ' ' N ' ' A' ' 29' ' ' ARG . 3.2 p30 -146.02 -164.09 1.88 Allowed 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 120.212 -0.595 . . . . 0.0 110.322 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -49.55 -13.57 0.5 Allowed Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.191 -1.48 . . . . 0.0 110.414 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.473 ' N ' ' C ' ' A' ' 27' ' ' ASN . 0.2 OUTLIER -101.11 33.95 2.69 Favored 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 119.917 -0.713 . . . . 0.0 112.152 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.7 t -76.66 150.18 6.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.047 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 9.6 mp -107.98 174.88 5.69 Favored 'General case' 0 N--CA 1.511 2.619 0 C-N-CA 119.482 -0.887 . . . . 0.0 111.033 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.5 tttm -77.32 -38.14 51.13 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.292 -0.963 . . . . 0.0 108.786 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -73.9 -7.49 52.52 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.563 -0.855 . . . . 0.0 108.876 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -64.31 -57.65 8.79 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.706 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.7 mt -72.28 -29.01 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.6 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -53.13 -43.41 66.92 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.627 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.418 ' O ' ' O ' ' A' ' 40' ' ' ALA . . . -69.56 -35.02 75.02 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.543 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.464 ' CE2' HG13 ' A' ' 16' ' ' VAL . 67.2 t80 -43.78 -68.62 0.18 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.341 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.567 ' C ' HD23 ' A' ' 39' ' ' LEU . 4.5 tt -73.78 -68.65 0.49 Allowed 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.901 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.418 ' O ' ' O ' ' A' ' 37' ' ' ALA . . . -66.62 -173.85 0.26 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.334 -0.946 . . . . 0.0 111.025 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -161.51 46.63 0.37 Allowed Glycine 0 N--CA 1.485 1.9 0 C-N-CA 119.711 -1.233 . . . . 0.0 110.208 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -71.57 75.06 0.71 Allowed Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.551 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.324 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.905 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.482 1.142 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.479 HG22 ' N ' ' A' ' 3' ' ' ALA . 18.0 mm -66.25 165.54 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.444 -0.902 . . . . 0.0 110.404 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.479 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -64.83 92.42 0.1 Allowed 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.576 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.496 ' O ' ' N ' ' A' ' 6' ' ' SER . 34.1 mtm -67.38 151.01 97.57 Favored Pre-proline 0 C--N 1.306 -1.294 0 C-N-CA 119.242 -0.983 . . . . 0.0 109.947 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -62.51 72.86 0.11 Allowed 'Trans proline' 0 CA--C 1.545 1.032 0 C-N-CA 120.683 0.922 . . . . 0.0 110.616 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.496 ' N ' ' O ' ' A' ' 4' ' ' MET . 8.8 t -175.63 -16.95 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.217 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.9 t -88.64 -48.92 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.079 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.58 HH22 HH21 ' A' ' 12' ' ' ARG . 48.7 ttt-85 -60.95 -40.18 92.32 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.528 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -56.41 -41.34 76.16 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.586 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -56.28 -46.46 79.71 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.029 -1.068 . . . . 0.0 109.149 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.02 -44.9 61.1 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.67 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.58 HH21 HH22 ' A' ' 8' ' ' ARG . 6.5 mmp_? -59.47 -42.83 92.92 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.179 -179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.425 ' C ' ' H ' ' A' ' 15' ' ' GLY . 48.2 mt-10 -58.14 -64.52 0.88 Allowed 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.344 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.2 mmtm -69.29 8.71 0.55 Allowed 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.295 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 13' ' ' GLU . . . 55.55 78.19 0.13 Allowed Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.787 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.512 HG13 ' CD2' ' A' ' 38' ' ' PHE . 37.1 t -147.71 137.32 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.075 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 68.6 t0 -87.43 106.4 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.7 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.534 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -43.85 -42.89 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.52 0.676 . . . . 0.0 111.862 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.534 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 46.0 mtt-85 -49.33 -59.72 3.45 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 114.999 -1.001 . . . . 0.0 113.119 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 49.3 mt -55.76 -24.68 36.85 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.961 -0.695 . . . . 0.0 112.668 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.5 t -57.86 141.1 15.29 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 C-N-CA 118.641 -1.224 . . . . 0.0 112.033 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.7 tt0 -136.4 59.18 1.71 Allowed 'General case' 0 N--CA 1.482 1.158 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.672 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.8 -110.41 0.09 OUTLIER Glycine 0 N--CA 1.494 2.551 0 C-N-CA 118.957 -1.592 . . . . 0.0 109.751 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.84 -43.59 29.93 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.322 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.453 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -159.84 114.82 0.63 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 ptmt -74.9 38.88 0.13 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.284 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.492 ' C ' ' H ' ' A' ' 29' ' ' ARG . 18.7 p-10 -124.43 -161.96 1.04 Allowed 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.207 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.06 -6.37 0.82 Allowed Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.156 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.492 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.44 34.93 2.59 Favored 'General case' 0 N--CA 1.502 2.126 0 C-N-CA 119.964 -0.695 . . . . 0.0 111.805 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -80.92 150.37 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 C-N-CA 119.341 -0.944 . . . . 0.0 108.934 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.444 ' H ' ' HB2' ' A' ' 34' ' ' ASP . 5.4 mp -120.26 -179.91 4.09 Favored 'General case' 0 N--CA 1.515 2.801 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.011 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 tttp -78.86 -33.2 46.05 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.75 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.62 ' CD ' ' H ' ' A' ' 33' ' ' GLU . 2.3 pm0 -75.3 -7.67 54.57 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.444 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.2 t0 -67.6 -54.71 17.49 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 114.523 -1.217 . . . . 0.0 109.369 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -72.98 -35.23 48.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.316 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -48.44 -40.71 27.09 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.208 -0.997 . . . . 0.0 110.177 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.14 -32.58 64.98 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.498 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.512 ' CD2' HG13 ' A' ' 16' ' ' VAL . 72.0 t80 -44.13 -69.08 0.15 Allowed 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.601 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.3 tp -73.04 -50.23 24.21 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.12 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 45.5 54.09 7.81 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.65 -0.82 . . . . 0.0 111.125 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -158.29 16.42 0.29 Allowed Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.371 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.76 -29.81 11.37 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.301 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.327 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.865 -179.962 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 N--CA 1.481 1.097 0 CA-C-O 121.005 0.431 . . . . 0.0 109.912 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.453 ' H ' HD12 ' A' ' 2' ' ' ILE . 0.8 OUTLIER -143.7 176.02 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 C-N-CA 119.795 -0.762 . . . . 0.0 110.321 179.982 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -56.19 120.19 7.15 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.219 -0.992 . . . . 0.0 110.345 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.401 ' O ' ' N ' ' A' ' 6' ' ' SER . 61.7 mtt -64.2 150.68 92.05 Favored Pre-proline 0 C--N 1.306 -1.289 0 C-N-CA 119.08 -1.048 . . . . 0.0 110.839 -179.854 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -61.78 80.88 0.09 OUTLIER 'Trans proline' 0 CA--C 1.543 0.972 0 C-N-CA 120.874 1.049 . . . . 0.0 110.932 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.401 ' N ' ' O ' ' A' ' 4' ' ' MET . 3.9 t 175.9 -8.48 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 C-N-CA 119.569 -0.852 . . . . 0.0 110.611 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t -103.51 -66.56 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 C-N-CA 120.14 -0.624 . . . . 0.0 111.263 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 25.7 ttm-85 -60.73 -38.78 86.3 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.296 -0.961 . . . . 0.0 111.336 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -54.25 -42.31 69.79 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -57.19 -49.72 75.11 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 118.607 -1.237 . . . . 0.0 109.15 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -48.36 -42.32 31.26 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.184 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -63.55 -45.79 88.91 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 119.398 -0.921 . . . . 0.0 111.225 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -50.85 -56.17 13.5 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.951 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 55.5 mmtt -79.88 -22.55 42.73 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.114 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 83.4 80.71 1.0 Allowed Glycine 0 N--CA 1.497 2.711 0 C-N-CA 119.573 -1.299 . . . . 0.0 110.496 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.526 HG13 ' CD2' ' A' ' 38' ' ' PHE . 28.2 t -147.61 135.28 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.409 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -78.35 102.96 7.99 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.266 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.519 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -44.85 -42.99 2.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.663 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.519 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 17.5 tpp180 -52.62 -54.09 37.99 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.273 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.3 mt -55.7 -26.7 46.44 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.05 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.6 t -61.35 143.04 15.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.757 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -132.99 69.76 1.48 Allowed 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.613 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.81 -114.49 2.91 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.544 -1.313 . . . . 0.0 110.415 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.07 -46.03 31.13 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.293 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -153.4 109.82 0.42 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 11.8 pttm -77.28 61.07 2.08 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.81 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 14.2 p-10 -156.9 -161.59 1.11 Allowed 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.12 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -9.07 0.41 Allowed Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.59 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 14.9 mmt85 -111.9 40.95 2.04 Favored 'General case' 0 N--CA 1.507 2.385 0 C-N-CA 120.167 -0.613 . . . . 0.0 111.592 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.8 t -80.91 157.9 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.658 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 7.9 mp -113.42 173.39 6.43 Favored 'General case' 0 N--CA 1.509 2.522 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.948 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -76.3 -43.06 43.19 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.053 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -66.79 -10.06 43.56 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.44 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -66.2 -57.52 7.41 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.568 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 mt -72.33 -33.27 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.649 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 39.5 t0 -49.71 -41.38 43.28 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.191 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.18 -35.04 68.86 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.467 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' A' ' 16' ' ' VAL . 70.5 t80 -43.72 -70.2 0.11 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.631 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' A' ' 41' ' ' GLY . 4.1 tt -69.4 -57.05 5.77 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.745 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -49.44 90.04 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.491 -0.884 . . . . 0.0 110.461 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . 137.42 -36.2 1.98 Allowed Glycine 0 N--CA 1.5 2.916 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 51.5 -105.12 0.19 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.329 -1.415 . . . . 0.0 110.505 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.363 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.661 -179.978 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.489 ' O ' ' SD ' ' A' ' 4' ' ' MET . 13.4 t . . . . . 0 N--CA 1.482 1.142 0 CA-C-O 120.938 0.399 . . . . 0.0 109.942 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.435 ' O ' ' O ' ' A' ' 3' ' ' ALA . 19.9 mm -75.38 156.28 6.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.996 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.435 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 52.42 104.6 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.637 -0.825 . . . . 0.0 111.136 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.673 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 60.9 mmm -114.34 -32.73 0.1 Allowed Pre-proline 0 N--CA 1.508 2.44 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.673 ' CD ' ' H ' ' A' ' 4' ' ' MET . 2.6 Cg_endo -72.61 -161.6 0.11 Allowed 'Trans proline' 0 C--O 1.216 -0.598 0 N-CA-C 110.325 -0.683 . . . . 0.0 110.325 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 73.0 m -77.69 53.23 1.08 Allowed 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.303 -0.959 . . . . 0.0 109.902 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 82.0 t -102.93 -83.23 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.642 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -66.71 -45.39 78.86 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.959 -1.096 . . . . 0.0 110.697 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mttm -53.83 -35.85 61.88 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.638 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -63.27 -47.14 83.61 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.405 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.06 -42.64 63.31 Favored 'General case' 0 C--N 1.291 -1.95 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.595 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 69.2 mtp180 -60.98 -46.48 90.56 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.678 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -54.59 -44.01 72.64 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.879 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.0 mmtt -86.14 -69.78 0.64 Allowed 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.692 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.75 73.35 0.06 OUTLIER Glycine 0 N--CA 1.502 3.076 0 C-N-CA 119.88 -1.153 . . . . 0.0 110.773 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 39.9 t -144.67 137.44 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.493 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.1 t0 -79.85 112.28 16.98 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.804 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 7.3 tp -43.11 -43.17 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.641 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.532 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.7 tpt180 -59.91 -56.25 24.07 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.595 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.407 HD23 ' HA ' ' A' ' 20' ' ' LEU . 74.0 mt -47.16 -21.17 0.22 Allowed 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.558 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.5 t -76.5 143.18 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.976 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -132.48 65.33 1.58 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.983 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.2 -121.99 2.62 Favored Glycine 0 N--CA 1.502 3.058 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.242 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.404 ' OG1' HD23 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -73.26 -60.15 2.38 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.987 179.87 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -134.9 109.7 0.79 Allowed Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt -76.49 55.46 1.02 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.03 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.479 ' C ' ' H ' ' A' ' 29' ' ' ARG . 16.1 p-10 -156.89 -157.84 0.72 Allowed 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.585 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.36 -10.52 0.56 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.239 -1.458 . . . . 0.0 110.236 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.479 ' H ' ' C ' ' A' ' 27' ' ' ASN . 28.0 mmt180 -107.71 37.27 2.47 Favored 'General case' 0 N--CA 1.506 2.34 0 C-N-CA 120.074 -0.651 . . . . 0.0 111.709 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.414 ' C ' HD22 ' A' ' 31' ' ' LEU . 2.7 t -80.68 156.62 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 119.545 -0.862 . . . . 0.0 109.619 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.414 HD22 ' C ' ' A' ' 30' ' ' VAL . 3.9 mm? -105.78 172.49 6.77 Favored 'General case' 0 N--CA 1.508 2.459 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.365 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 48.4 tttm -77.1 -42.89 36.28 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 118.863 -1.135 . . . . 0.0 109.245 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -70.89 -3.38 18.87 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.47 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -67.33 -59.73 3.17 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.959 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.2 mt -72.1 -30.5 36.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.534 -0.867 . . . . 0.0 110.881 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -53.23 -41.58 65.52 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.895 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.18 -31.56 62.73 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.823 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 74.4 t80 -47.92 -69.89 0.11 Allowed 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 119.219 -0.993 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.455 ' C ' HD23 ' A' ' 39' ' ' LEU . 3.6 tt -71.63 -54.49 10.22 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.931 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 46.28 63.6 1.81 Allowed 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 119.629 -0.828 . . . . 0.0 111.039 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -62.92 -81.37 0.1 OUTLIER Glycine 0 N--CA 1.49 2.253 0 C-N-CA 119.33 -1.414 . . . . 0.0 110.366 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 57.11 -103.35 0.28 Allowed Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.285 -1.436 . . . . 0.0 110.276 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.785 179.972 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.887 HG22 ' H ' ' A' ' 3' ' ' ALA . 13.1 mt . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.695 0.283 . . . . 0.0 110.429 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.887 ' H ' HG22 ' A' ' 2' ' ' ILE . . . 55.11 162.21 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.935 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 36.7 mtm -61.76 152.96 73.93 Favored Pre-proline 0 C--N 1.306 -1.312 0 C-N-CA 119.007 -1.077 . . . . 0.0 110.333 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.494 ' C ' ' H ' ' A' ' 7' ' ' VAL . 3.6 Cg_endo -62.62 172.01 5.04 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 120.942 1.094 . . . . 0.0 111.452 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m 64.37 -10.06 0.15 Allowed 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.102 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.494 ' H ' ' C ' ' A' ' 5' ' ' PRO . 70.0 t -82.27 -65.08 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.714 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 34.0 ttm180 -60.62 -39.37 87.98 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.189 -1.005 . . . . 0.0 111.135 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.4 mttp -53.02 -42.84 66.06 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.9 t80 -57.61 -50.18 73.99 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.739 -1.184 . . . . 0.0 109.22 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.8 -45.01 49.5 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.811 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -60.49 -45.82 92.37 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.075 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -52.36 -51.95 56.09 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 18.2 mtpp -81.29 -8.58 59.77 Favored 'General case' 0 N--CA 1.489 1.515 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.89 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.52 75.4 0.61 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.358 -1.401 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.526 HG13 ' CD2' ' A' ' 38' ' ' PHE . 42.8 t -144.25 126.53 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.946 -0.701 . . . . 0.0 110.413 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -72.79 100.77 2.95 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.526 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.8 tt -41.25 -41.74 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.69 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 17.9 tpp180 -52.12 -53.06 47.31 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.327 -0.852 . . . . 0.0 112.207 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.4 mt -57.84 -28.98 64.59 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.156 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 t -59.08 140.28 17.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.559 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -140.55 63.2 1.47 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.853 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.26 -101.85 0.35 Allowed Glycine 0 N--CA 1.496 2.656 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.89 -42.7 21.02 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.631 -0.827 . . . . 0.0 110.098 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.93 114.77 0.62 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.1 pttt -75.87 57.33 1.03 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.963 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.48 ' C ' ' N ' ' A' ' 29' ' ' ARG . 41.3 p30 -149.89 -161.37 1.33 Allowed 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.633 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.09 -11.13 0.36 Allowed Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.597 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.48 ' N ' ' C ' ' A' ' 27' ' ' ASN . 18.9 mmt180 -104.58 35.52 2.72 Favored 'General case' 0 N--CA 1.504 2.258 0 C-N-CA 119.861 -0.735 . . . . 0.0 111.79 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -81.45 135.11 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.546 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.6 mp -101.52 174.01 6.17 Favored 'General case' 0 N--CA 1.511 2.616 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.795 -179.709 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 50.7 tttm -75.27 -34.18 61.32 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 119.137 -1.025 . . . . 0.0 108.304 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.1 tp10 -71.14 -16.21 62.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -63.22 -54.33 39.1 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 114.201 -1.363 . . . . 0.0 109.123 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.2 mt -73.34 -34.18 42.85 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.532 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -50.55 -41.31 53.92 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.502 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.46 -36.36 76.5 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.291 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' A' ' 16' ' ' VAL . 56.9 t80 -43.86 -69.96 0.12 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.374 -0.931 . . . . 0.0 111.489 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.434 ' O ' HD13 ' A' ' 39' ' ' LEU . 0.2 OUTLIER -76.08 -50.15 15.5 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.41 -179.905 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 51.02 47.88 24.08 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.715 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -81.61 3.52 78.28 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.363 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -68.72 74.84 0.31 Allowed Glycine 0 N--CA 1.491 2.319 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.383 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.387 0 C-N-CA 119.299 -0.961 . . . . 0.0 110.726 179.987 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.45 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 121.249 0.547 . . . . 0.0 110.914 . . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 53.75 164.35 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.078 -0.965 . . . . 0.0 111.243 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 79.1 mtp -75.48 150.66 84.84 Favored Pre-proline 0 C--N 1.305 -1.327 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.03 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -63.85 83.38 0.14 Allowed 'Trans proline' 0 CA--C 1.54 0.804 0 C-N-CA 120.665 0.91 . . . . 0.0 110.808 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 172.42 -31.21 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.469 -0.893 . . . . 0.0 110.821 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.2 t -88.25 -41.47 14.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.483 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -62.94 -40.93 99.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 118.905 -1.118 . . . . 0.0 111.224 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.445 ' H ' ' CD ' ' A' ' 9' ' ' LYS . 0.4 OUTLIER -51.64 -40.34 59.78 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.411 179.977 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -61.04 -51.43 69.21 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 118.909 -1.116 . . . . 0.0 108.904 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.11 -43.14 51.54 Favored 'General case' 0 C--N 1.291 -1.945 0 CA-C-N 115.19 -0.913 . . . . 0.0 110.25 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -63.02 -47.32 83.56 Favored 'General case' 0 C--N 1.296 -1.749 0 CA-C-N 115.057 -0.974 . . . . 0.0 110.358 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -51.85 -31.4 27.68 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.153 -1.019 . . . . 0.0 110.108 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.3 mmtp -97.78 -10.1 25.4 Favored 'General case' 0 N--CA 1.495 1.796 0 C-N-CA 119.979 -0.689 . . . . 0.0 110.692 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.08 1.5 74.2 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.358 -1.401 . . . . 0.0 109.962 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.472 HG13 ' CE2' ' A' ' 38' ' ' PHE . 41.9 t -71.31 137.32 23.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.933 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -86.38 105.8 16.97 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.278 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 19' ' ' ARG . 16.4 tt -43.04 -43.04 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.994 -179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' HG23 ' A' ' 18' ' ' ILE . 37.8 mtp180 -48.81 -57.72 5.94 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.865 -179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.2 mt -54.43 -29.63 49.93 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 119.723 -0.791 . . . . 0.0 112.56 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -55.6 140.35 13.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.623 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -132.46 62.27 1.65 Allowed 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.397 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -83.92 -121.43 0.86 Allowed Glycine 0 N--CA 1.496 2.699 0 C-N-CA 119.098 -1.525 . . . . 0.0 110.54 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.52 -66.22 0.92 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.708 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.67 -62.94 5.68 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.897 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 66.9 tttt 56.43 38.86 30.06 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.554 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.507 ' C ' ' H ' ' A' ' 29' ' ' ARG . 38.2 p-10 -163.71 -160.77 0.6 Allowed 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.182 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.29 -5.41 0.71 Allowed Glycine 0 N--CA 1.484 1.885 0 C-N-CA 119.16 -1.495 . . . . 0.0 110.249 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.507 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -122.93 45.6 2.37 Favored 'General case' 0 N--CA 1.504 2.232 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.657 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -70.4 160.4 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 C-N-CA 119.089 -1.044 . . . . 0.0 108.946 179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 9.3 mp -105.79 172.66 6.68 Favored 'General case' 0 N--CA 1.513 2.679 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.08 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -79.01 -37.51 39.01 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.393 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -72.45 -7.44 49.86 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -66.1 -59.0 4.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 114.563 -1.199 . . . . 0.0 109.621 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -72.64 -28.54 27.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.548 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -53.41 -40.95 65.5 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.697 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.51 -35.54 68.14 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.583 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.472 ' CE2' HG13 ' A' ' 16' ' ' VAL . 67.0 t80 -42.19 -70.12 0.12 Allowed 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.666 -0.813 . . . . 0.0 112.284 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.435 ' O ' ' O ' ' A' ' 40' ' ' ALA . 32.2 tp -67.35 -46.0 74.71 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.076 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.435 ' O ' ' O ' ' A' ' 39' ' ' LEU . . . -48.42 177.6 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.016 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 57.46 15.06 15.26 Favored Glycine 0 N--CA 1.489 2.224 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.211 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 77.99 -52.93 3.71 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.151 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.26 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.888 180.0 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 2' ' ' ILE . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.413 0 CA-C-O 121.082 0.467 . . . . 0.0 110.517 . . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -58.44 135.56 57.27 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.681 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 13.8 mmt -50.45 153.19 2.77 Favored Pre-proline 0 C--N 1.305 -1.352 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.261 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.419 ' O ' ' CB ' ' A' ' 6' ' ' SER . 2.5 Cg_endo -56.94 169.9 1.7 Allowed 'Trans proline' 0 C--O 1.212 -0.799 0 C-N-CA 120.634 0.89 . . . . 0.0 110.961 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.419 ' CB ' ' O ' ' A' ' 5' ' ' PRO . 1.4 p 72.45 -11.73 0.79 Allowed 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.982 -0.687 . . . . 0.0 111.894 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 60.7 t -89.08 -71.41 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.699 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.1 ttt85 -65.39 -43.97 88.99 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 118.782 -1.167 . . . . 0.0 110.254 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -56.09 -35.37 66.94 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.185 -1.006 . . . . 0.0 110.698 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -61.46 -45.5 93.99 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.837 -1.145 . . . . 0.0 109.111 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -48.32 -42.62 31.71 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.402 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -64.2 -44.82 90.8 Favored 'General case' 0 C--N 1.291 -1.935 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.061 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.8 mm-40 -51.29 -53.09 39.04 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.783 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -82.26 -22.62 35.71 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.646 -0.822 . . . . 0.0 111.012 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 83.36 78.85 1.06 Allowed Glycine 0 N--CA 1.497 2.702 0 C-N-CA 119.469 -1.348 . . . . 0.0 110.305 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.468 HG13 ' CD2' ' A' ' 38' ' ' PHE . 33.6 t -145.7 138.57 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 120.035 -0.666 . . . . 0.0 110.161 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.2 t0 -80.95 97.1 7.3 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.05 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.512 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.8 tt -41.2 -41.73 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.562 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.512 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 13.4 tpp180 -49.96 -57.92 6.52 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.713 -179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 51.2 mt -57.42 -36.62 71.58 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.547 -0.861 . . . . 0.0 112.163 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.432 ' H ' HG23 ' A' ' 21' ' ' VAL . 14.8 t -47.08 140.92 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.69 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -133.78 65.37 1.58 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.294 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.49 -114.17 0.78 Allowed Glycine 0 N--CA 1.496 2.678 0 C-N-CA 119.14 -1.505 . . . . 0.0 109.951 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.08 -61.01 2.03 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.01 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.35 102.62 0.59 Allowed Glycine 0 N--CA 1.5 2.947 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.2 pttp -74.59 61.5 0.96 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' N ' ' A' ' 29' ' ' ARG . 8.3 p30 -164.25 -154.97 0.27 Allowed 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.484 -0.887 . . . . 0.0 110.801 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.4 -9.99 0.5 Allowed Glycine 0 C--N 1.291 -1.964 0 C-N-CA 119.635 -1.269 . . . . 0.0 110.578 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.47 ' N ' ' C ' ' A' ' 27' ' ' ASN . 25.3 mmt180 -111.9 38.5 2.64 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.744 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -76.47 154.23 5.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 119.195 -1.002 . . . . 0.0 108.905 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 29.3 mt -117.52 178.87 4.23 Favored 'General case' 0 N--CA 1.513 2.69 0 C-N-CA 119.587 -0.845 . . . . 0.0 112.24 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' A' ' 36' ' ' ASP . 27.3 tptp -78.39 -33.55 48.73 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -73.86 -11.58 60.41 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.4 ' OD1' HG12 ' A' ' 21' ' ' VAL . 2.1 t0 -66.98 -67.54 0.44 Allowed 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.104 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.4 mt -67.39 -35.49 73.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 C-N-CA 119.656 -0.817 . . . . 0.0 111.44 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 32' ' ' LYS . 5.7 m-20 -49.38 -42.53 42.49 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.721 -1.192 . . . . 0.0 110.081 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.62 -32.98 71.99 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.612 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.468 ' CD2' HG13 ' A' ' 16' ' ' VAL . 68.4 t80 -45.2 -69.9 0.12 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.873 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.2 tp -68.36 -27.91 66.66 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.275 -0.875 . . . . 0.0 112.112 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -46.24 -39.7 10.3 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.092 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.92 -0.88 4.56 Favored Glycine 0 N--CA 1.503 3.128 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.28 132.11 50.14 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.326 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.345 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.837 179.965 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 121.209 0.528 . . . . 0.0 110.596 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.11 157.3 23.12 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.566 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 69.1 mtm -52.07 148.0 11.9 Favored Pre-proline 0 N--CA 1.484 1.269 0 C-N-CA 119.161 -1.015 . . . . 0.0 110.727 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -64.67 156.06 63.42 Favored 'Trans proline' 0 CA--C 1.54 0.815 0 C-N-CA 120.975 1.117 . . . . 0.0 111.699 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 66.44 30.97 8.44 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.87 -0.732 . . . . 0.0 111.745 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t -130.3 -69.26 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.827 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 32.7 ttm180 -60.04 -45.62 92.23 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.31 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.9 mmmm -52.7 -41.78 64.23 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.632 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -57.85 -47.12 83.62 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 118.781 -1.167 . . . . 0.0 109.211 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.421 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -51.07 -45.47 61.42 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.793 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -56.56 -41.69 77.28 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.914 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -61.67 -33.54 74.16 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.911 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 50.6 mmtt -96.94 0.4 48.89 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.34 57.54 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.691 -1.242 . . . . 0.0 111.041 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.53 HG13 ' CD2' ' A' ' 38' ' ' PHE . 55.2 t -81.84 123.66 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.484 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -75.98 105.92 7.29 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.244 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.482 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 9.7 tt -41.62 -41.7 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.558 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.482 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.6 ttt85 -50.92 -53.87 29.06 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.987 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 74.6 mt -55.96 -28.17 55.84 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.818 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.422 HG12 ' OD1' ' A' ' 34' ' ' ASP . 10.6 t -65.31 142.6 16.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.687 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 47.3 tt0 -140.52 66.28 1.39 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.051 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -78.51 -107.56 0.2 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.095 -1.526 . . . . 0.0 110.428 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.442 ' OG1' ' CD1' ' A' ' 31' ' ' LEU . 0.7 OUTLIER -87.27 -53.02 5.06 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.473 -179.938 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 108.93 0.63 Allowed Glycine 0 N--CA 1.5 2.915 0 C-N-CA 119.857 -1.163 . . . . 0.0 110.404 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -76.58 61.41 1.78 Allowed 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.013 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.503 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.7 p-10 -152.83 -161.26 1.26 Allowed 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.434 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.76 -6.67 1.27 Allowed Glycine 0 N--CA 1.484 1.836 0 C-N-CA 119.123 -1.513 . . . . 0.0 109.909 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.503 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.8 mmt180 -108.17 31.82 5.25 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 120.187 -0.605 . . . . 0.0 111.523 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -70.08 156.11 7.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.434 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.442 ' CD1' ' OG1' ' A' ' 24' ' ' THR . 28.3 mt -108.53 173.78 6.17 Favored 'General case' 0 N--CA 1.509 2.499 0 C-N-CA 119.279 -0.969 . . . . 0.0 112.448 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 43.3 tptt -76.93 -32.23 57.22 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.063 -0.971 . . . . 0.0 108.574 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -82.58 -5.09 58.59 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.358 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.422 ' OD1' HG12 ' A' ' 21' ' ' VAL . 1.6 t0 -64.39 -53.95 40.51 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.237 -0.892 . . . . 0.0 108.933 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.421 HD13 ' HB2' ' A' ' 11' ' ' ALA . 3.3 mt -77.55 -37.89 25.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.678 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.416 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 19.8 t70 -47.17 -42.29 19.47 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.945 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.86 -37.08 73.08 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.6 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.53 ' CD2' HG13 ' A' ' 16' ' ' VAL . 66.1 t80 -42.67 -68.6 0.18 Allowed 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.463 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 11.2 tp -72.0 -66.97 0.57 Allowed 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.991 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.416 ' HB3' ' O ' ' A' ' 36' ' ' ASP . . . -54.9 118.02 3.92 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.9 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' A' ' 43' ' ' ALA . . . -56.08 -58.44 14.15 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.391 -1.385 . . . . 0.0 110.442 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 56.29 -85.6 0.01 OUTLIER Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.261 -1.447 . . . . 0.0 110.341 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 41' ' ' GLY . . . . . . . . 0 C--N 1.306 -1.294 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.919 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.44 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.413 0.625 . . . . 0.0 111.466 . . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 43.24 101.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.839 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.439 ' O ' ' N ' ' A' ' 6' ' ' SER . 14.2 mmt -47.99 152.8 1.31 Allowed Pre-proline 0 C--N 1.307 -1.242 0 C-N-CA 119.251 -0.98 . . . . 0.0 110.074 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -63.32 73.24 0.14 Allowed 'Trans proline' 0 CA--C 1.55 1.277 0 C-N-CA 120.844 1.03 . . . . 0.0 111.021 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.439 ' N ' ' O ' ' A' ' 4' ' ' MET . 2.1 p 175.55 3.36 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.291 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 79.9 t -113.44 -70.49 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.507 2.416 0 C-N-CA 120.091 -0.644 . . . . 0.0 111.127 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.486 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 32.2 ttm180 -57.4 -38.09 73.74 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.239 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.7 mttp -52.43 -46.48 66.41 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.634 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -54.28 -47.74 72.02 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 118.9 -1.12 . . . . 0.0 109.092 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.503 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -49.48 -44.59 46.09 Favored 'General case' 0 C--N 1.288 -2.083 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.789 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 24.1 mmm180 -57.43 -43.86 84.2 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.745 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -57.57 -33.19 67.91 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.086 -1.045 . . . . 0.0 110.496 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.6 mmtt -93.51 -10.04 36.28 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.496 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 76.38 -0.9 62.61 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.458 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 54.7 t -70.77 124.4 26.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.772 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -77.08 105.88 8.44 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.048 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.1 tt -37.82 -42.63 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.266 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.526 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 51.7 ttp85 -49.36 -55.06 14.2 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.472 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 52.7 mt -53.07 -41.83 65.25 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.556 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.5 t -48.52 144.56 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 C-N-CA 119.267 -0.973 . . . . 0.0 111.863 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -137.95 60.85 1.61 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.476 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.32 -114.82 0.24 Allowed Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.927 -1.606 . . . . 0.0 109.943 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.1 -50.03 12.8 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.879 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.404 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -150.02 109.4 0.43 Allowed Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 pttt -75.97 43.51 0.28 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.177 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' H ' ' A' ' 29' ' ' ARG . 27.7 p-10 -119.05 -164.92 1.08 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.028 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.03 -4.2 2.21 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.196 -1.478 . . . . 0.0 110.332 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.47 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.1 mmt180 -110.71 41.42 1.79 Allowed 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.469 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -73.46 156.4 6.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.435 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.1 mp -105.74 173.0 6.5 Favored 'General case' 0 N--CA 1.511 2.577 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.142 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -76.94 -38.69 52.87 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 119.259 -0.977 . . . . 0.0 109.676 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -76.8 -2.91 35.61 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.222 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -67.18 -55.13 15.43 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.778 -1.101 . . . . 0.0 109.632 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.503 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.7 mt -75.17 -36.96 38.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.806 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.67 -40.54 53.89 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.421 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' A' ' 40' ' ' ALA . . . -71.35 -33.87 69.99 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.609 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -44.74 -69.65 0.13 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.067 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.419 ' C ' HD13 ' A' ' 39' ' ' LEU . 0.3 OUTLIER -66.5 -65.9 0.62 Allowed 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.441 -179.851 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' A' ' 37' ' ' ALA . . . -71.03 126.53 29.81 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.911 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 55.17 82.91 0.05 OUTLIER Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.305 -1.426 . . . . 0.0 110.324 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -154.98 98.83 0.18 Allowed Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.691 -1.242 . . . . 0.0 110.366 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.302 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.021 179.928 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.453 ' O ' ' O ' ' A' ' 3' ' ' ALA . 17.8 mm . . . . . 0 N--CA 1.485 1.304 0 CA-C-O 120.947 0.403 . . . . 0.0 111.231 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.453 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 46.24 103.03 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.669 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 15.9 mmt -46.29 149.1 1.39 Allowed Pre-proline 0 N--CA 1.485 1.317 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.23 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.444 ' C ' ' H ' ' A' ' 7' ' ' VAL . 2.3 Cg_endo -56.99 174.62 0.4 Allowed 'Trans proline' 0 C--O 1.214 -0.691 0 C-N-CA 120.707 0.938 . . . . 0.0 111.235 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 5' ' ' PRO . 1.3 t 72.3 -15.69 0.47 Allowed 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 120.046 -0.661 . . . . 0.0 111.457 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.444 ' H ' ' C ' ' A' ' 5' ' ' PRO . 47.8 t -88.99 -68.6 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.889 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 71.2 ttt180 -71.02 -39.42 72.37 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.01 -1.076 . . . . 0.0 110.504 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttp -58.92 -26.61 64.51 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 118.988 -1.085 . . . . 0.0 110.467 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.408 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 7.6 t80 -69.62 -49.73 51.08 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 118.843 -1.143 . . . . 0.0 108.579 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.83 -41.47 23.91 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.43 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.37 -46.6 86.02 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.776 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -54.9 -35.35 64.02 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.976 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.8 mmtt -92.06 -16.79 25.94 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.849 -0.741 . . . . 0.0 110.72 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 80.46 4.75 90.07 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.523 -1.322 . . . . 0.0 110.623 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.1 t -76.46 138.55 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.651 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 36.8 t0 -81.37 104.4 11.79 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.761 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.524 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -40.87 -41.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.654 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.524 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.9 tpp180 -50.96 -59.56 4.02 Favored 'General case' 0 C--N 1.29 -2.007 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.308 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 84.8 mt -52.98 -28.44 23.84 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.013 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.413 ' H ' HG23 ' A' ' 21' ' ' VAL . 7.6 t -61.65 141.19 17.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 C-N-CA 118.915 -1.114 . . . . 0.0 112.181 -179.842 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 91.1 mt-30 -139.4 44.02 1.99 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.075 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.27 -104.25 0.01 OUTLIER Glycine 0 N--CA 1.492 2.37 0 C-N-CA 119.244 -1.455 . . . . 0.0 110.157 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.488 ' OG1' ' CD2' ' A' ' 31' ' ' LEU . 2.5 p -73.41 -37.84 65.8 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.08 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -179.65 121.13 0.72 Allowed Glycine 0 N--CA 1.479 1.517 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.423 ' O ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pttm -58.57 -157.31 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.507 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.517 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 25.4 t-20 59.31 176.29 0.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.013 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.517 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -46.12 -17.16 0.19 Allowed Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.733 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.482 ' N ' ' O ' ' A' ' 27' ' ' ASN . 14.5 mmt85 -80.13 35.41 0.32 Allowed 'General case' 0 N--CA 1.493 1.723 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.19 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 27' ' ' ASN . 11.7 t -101.6 156.48 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.442 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.488 ' CD2' ' OG1' ' A' ' 24' ' ' THR . 1.9 pt? -129.64 -170.71 2.35 Favored 'General case' 0 N--CA 1.512 2.634 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.633 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -71.02 -55.37 8.43 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.54 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 60.9 tt0 -61.03 -5.68 1.53 Allowed 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.9 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.85 -59.76 3.04 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.386 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.499 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.3 mp -66.55 -37.47 79.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.653 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -46.6 -42.78 16.6 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.348 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.17 -35.91 76.8 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.394 -0.923 . . . . 0.0 110.666 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -43.46 -67.54 0.27 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.467 -0.893 . . . . 0.0 112.171 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.4 tp -72.48 -25.82 61.56 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.246 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -44.9 -25.29 0.29 Allowed 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.085 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -60.18 -84.31 0.05 OUTLIER Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.405 -1.378 . . . . 0.0 110.483 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -71.11 102.85 1.13 Allowed Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.367 -1.396 . . . . 0.0 110.452 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.355 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.731 -179.959 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.589 HG22 ' H ' ' A' ' 3' ' ' ALA . 11.7 mm . . . . . 0 N--CA 1.485 1.292 0 CA-C-O 120.944 0.402 . . . . 0.0 111.128 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.589 ' H ' HG22 ' A' ' 2' ' ' ILE . . . 56.0 79.41 0.17 Allowed 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.489 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.699 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 71.0 mtp -121.84 -30.32 0.05 OUTLIER Pre-proline 0 N--CA 1.508 2.461 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.699 ' CD ' ' H ' ' A' ' 4' ' ' MET . 2.3 Cg_endo -66.36 76.3 0.36 Allowed 'Trans proline' 0 CA--C 1.543 0.974 0 CA-C-N 119.073 0.705 . . . . 0.0 111.493 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 93.9 p 40.65 52.2 3.07 Favored 'General case' 0 N--CA 1.493 1.684 0 C-N-CA 119.965 -0.694 . . . . 0.0 111.661 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.5 t -96.73 -77.41 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 C-N-CA 119.831 -0.748 . . . . 0.0 110.239 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 59.0 ttp85 -60.98 -51.5 68.98 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.093 -1.043 . . . . 0.0 110.749 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.1 mttt -51.26 -39.75 57.39 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.753 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -59.7 -45.95 90.56 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.206 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.451 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -53.12 -46.15 68.62 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.696 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -55.91 -40.96 73.83 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -63.08 -45.95 89.72 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.4 mmtt -78.31 -10.07 59.51 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.449 -0.901 . . . . 0.0 111.183 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.96 1.5 90.64 Favored Glycine 0 N--CA 1.496 2.642 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.899 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.536 HG13 ' CD2' ' A' ' 38' ' ' PHE . 57.8 t -74.5 130.54 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.507 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -83.22 110.01 17.71 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.155 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.551 HG23 ' N ' ' A' ' 19' ' ' ARG . 5.7 tp -42.26 -41.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.466 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.551 ' N ' HG23 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -48.07 -59.1 3.64 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.822 -179.83 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 46.8 mt -60.45 -18.41 51.01 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.2 t -70.64 139.73 19.56 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 118.552 -1.259 . . . . 0.0 111.649 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.401 ' O ' ' CD ' ' A' ' 22' ' ' GLN . 0.6 OUTLIER -145.7 79.44 1.56 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.706 179.901 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.18 -99.12 1.97 Allowed Glycine 0 N--CA 1.504 3.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.422 ' OG1' HD23 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -79.07 -38.97 35.05 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.428 179.819 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.475 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -170.61 116.16 0.63 Allowed Glycine 0 N--CA 1.485 1.932 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 pttp -74.1 38.64 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.001 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 25.0 t-20 -117.07 -179.59 3.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.712 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.513 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -47.57 -14.95 0.24 Allowed Glycine 0 N--CA 1.492 2.432 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.197 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.513 ' N ' ' O ' ' A' ' 27' ' ' ASN . 32.2 mmm-85 -95.47 37.22 1.2 Allowed 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.119 -0.632 . . . . 0.0 111.556 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 27' ' ' ASN . 2.6 t -70.99 154.64 7.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.105 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.422 HD23 ' OG1' ' A' ' 24' ' ' THR . 2.9 mm? -106.5 173.3 6.38 Favored 'General case' 0 N--CA 1.509 2.492 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.951 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.6 tmtt? -77.13 -41.43 41.96 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.386 -0.925 . . . . 0.0 108.926 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -71.78 -3.63 23.17 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.399 -0.818 . . . . 0.0 109.35 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -68.52 -56.04 9.68 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.079 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.479 HD11 ' CD1' ' A' ' 18' ' ' ILE . 1.8 mt -73.09 -37.54 53.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.643 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -51.22 -39.37 56.42 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.341 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.5 -33.62 71.42 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.347 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.536 ' CD2' HG13 ' A' ' 16' ' ' VAL . 65.9 t80 -45.07 -68.04 0.23 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.016 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 56.1 tp -74.0 -67.19 0.63 Allowed 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.995 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 41.44 55.78 3.35 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.897 -0.721 . . . . 0.0 111.575 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 76.6 -44.33 1.98 Allowed Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.491 -1.337 . . . . 0.0 110.677 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 70.05 157.03 1.73 Allowed Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.318 -1.42 . . . . 0.0 110.158 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.394 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.944 -179.966 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.4 m . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.818 0.342 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.491 HG22 ' N ' ' A' ' 3' ' ' ALA . 18.4 mm -73.24 162.77 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 C-N-CA 119.232 -0.987 . . . . 0.0 111.006 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.491 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -55.9 148.59 16.75 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.798 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 4.2 mmt -67.91 153.96 94.41 Favored Pre-proline 0 C--N 1.304 -1.402 0 C-N-CA 119.364 -0.934 . . . . 0.0 109.93 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.414 ' O ' ' OG ' ' A' ' 6' ' ' SER . 9.2 Cg_endo -70.19 52.96 1.19 Allowed 'Trans proline' 0 CA--C 1.558 1.687 0 C-N-CA 120.79 0.993 . . . . 0.0 111.56 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.414 ' OG ' ' O ' ' A' ' 5' ' ' PRO . 27.2 m -166.24 -1.89 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.142 -1.023 . . . . 0.0 110.869 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.1 t -88.25 -66.46 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 C-N-CA 119.683 -0.807 . . . . 0.0 111.161 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.419 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 55.5 ttt180 -57.06 -36.05 70.07 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.384 -0.926 . . . . 0.0 111.199 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mmtm -54.85 -47.61 73.94 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 119.136 -1.026 . . . . 0.0 110.217 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -53.73 -46.94 71.02 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.073 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.422 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -52.12 -46.32 65.29 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.651 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.2 mtp180 -59.48 -44.29 93.08 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.679 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -56.69 -42.74 79.6 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.575 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -86.8 -13.92 43.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.834 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 75.91 67.84 1.64 Allowed Glycine 0 N--CA 1.488 2.134 0 C-N-CA 119.327 -1.416 . . . . 0.0 110.089 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.492 HG13 ' CD2' ' A' ' 38' ' ' PHE . 53.1 t -137.18 130.51 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.339 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -77.3 109.53 11.26 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.07 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.534 ' CD1' HD11 ' A' ' 35' ' ' ILE . 6.9 tp -44.69 -41.96 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.503 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.53 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 63.7 ttt-85 -56.15 -52.69 63.46 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.738 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.7 mt -57.18 -31.04 65.01 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.746 -0.781 . . . . 0.0 112.725 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.41 ' H ' HG23 ' A' ' 21' ' ' VAL . 7.8 t -57.46 141.87 13.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 118.437 -1.305 . . . . 0.0 111.868 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -136.77 77.71 1.66 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.933 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.26 -108.93 3.34 Favored Glycine 0 N--CA 1.51 3.596 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -77.02 -47.91 19.36 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.297 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.07 109.28 0.42 Allowed Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.9 pttp -76.07 55.36 0.92 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.601 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 15.8 p-10 -157.16 -154.95 0.49 Allowed 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 119.746 -0.782 . . . . 0.0 110.546 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.0 -8.2 0.59 Allowed Glycine 0 C--N 1.289 -2.04 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.246 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.6 mmt85 -109.09 37.34 2.59 Favored 'General case' 0 N--CA 1.504 2.24 0 C-N-CA 120.217 -0.593 . . . . 0.0 112.076 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.525 HG11 HD11 ' A' ' 18' ' ' ILE . 3.2 t -80.92 147.4 6.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.076 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.7 mp -109.37 177.34 4.77 Favored 'General case' 0 N--CA 1.511 2.604 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.51 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 3.6 tmtt? -75.47 -48.74 21.3 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.879 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -65.47 -5.45 7.84 Favored 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.207 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -69.5 -53.62 18.2 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.605 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.534 HD11 ' CD1' ' A' ' 18' ' ' ILE . 2.5 mt -72.46 -30.05 33.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 C-N-CA 119.676 -0.81 . . . . 0.0 110.757 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 36' ' ' ASP . 5.8 m-20 -55.5 -40.69 72.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.279 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.68 -34.81 76.31 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.284 179.691 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.492 ' CD2' HG13 ' A' ' 16' ' ' VAL . 70.1 t80 -44.55 -69.27 0.14 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.346 -0.942 . . . . 0.0 111.232 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.448 ' O ' ' O ' ' A' ' 40' ' ' ALA . 69.5 tp -66.49 -53.95 29.42 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.916 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.448 ' O ' ' O ' ' A' ' 39' ' ' LEU . . . -57.54 -113.7 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.87 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 154.63 33.6 0.03 OUTLIER Glycine 0 N--CA 1.493 2.448 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.372 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.72 -66.75 1.73 Allowed Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.551 -1.309 . . . . 0.0 110.303 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.406 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.815 179.946 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.479 HG22 ' N ' ' A' ' 3' ' ' ALA . 18.2 mm . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 121.044 0.45 . . . . 0.0 111.272 . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.479 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -45.94 142.17 2.77 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.604 179.851 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.743 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 14.3 mtt -124.82 -31.97 0.04 OUTLIER Pre-proline 0 N--CA 1.509 2.483 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.743 ' CD ' ' H ' ' A' ' 4' ' ' MET . 5.7 Cg_exo -65.07 -159.47 0.04 OUTLIER 'Trans proline' 0 C--O 1.217 -0.574 0 C-N-CA 120.476 0.784 . . . . 0.0 111.439 -179.911 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.4 t -77.35 45.18 0.45 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.026 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.4 ' H ' ' C ' ' A' ' 5' ' ' PRO . 32.0 t -86.46 -71.79 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.689 179.989 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -61.94 -48.03 82.22 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 118.872 -1.131 . . . . 0.0 110.884 -179.906 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -53.76 -38.83 64.81 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.91 179.963 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -59.11 -44.73 92.0 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 118.883 -1.127 . . . . 0.0 109.36 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.427 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -52.05 -43.8 63.96 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.805 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -57.04 -43.49 81.98 Favored 'General case' 0 C--N 1.292 -1.893 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.886 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 59.9 mt-10 -59.06 -53.69 55.47 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.382 -0.927 . . . . 0.0 111.185 179.936 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -78.28 -14.48 59.41 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.115 -179.991 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 74.15 76.1 0.73 Allowed Glycine 0 N--CA 1.495 2.575 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.883 179.913 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.519 HG13 ' CD2' ' A' ' 38' ' ' PHE . 53.5 t -145.74 126.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 120.161 -0.616 . . . . 0.0 109.965 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -74.5 106.99 6.36 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.739 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.475 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 10.2 tt -44.64 -40.04 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.036 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.475 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.0 tpt85 -49.68 -54.3 19.44 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.411 -179.912 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 70.8 mt -63.21 -29.17 70.56 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.87 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.423 HG12 ' OD1' ' A' ' 34' ' ' ASP . 11.5 t -55.93 139.19 15.52 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 C-N-CA 118.812 -1.155 . . . . 0.0 111.987 -179.717 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 30.2 mm-40 -137.44 44.43 2.25 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.255 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.24 -107.48 0.01 OUTLIER Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.138 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -78.75 -42.45 28.09 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.81 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -166.17 124.05 1.2 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.599 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 14.9 ptmt -61.64 -156.87 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.009 -1.077 . . . . 0.0 110.678 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.599 ' ND2' ' O ' ' A' ' 26' ' ' LYS . 2.4 p30 43.4 -154.18 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.567 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.443 ' C ' ' H ' ' A' ' 30' ' ' VAL . . . -53.14 -20.91 10.0 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 120.074 -1.06 . . . . 0.0 111.63 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.436 ' O ' ' O ' ' A' ' 25' ' ' GLY . 22.2 mmt180 -78.25 27.03 0.2 Allowed 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 118.909 -1.116 . . . . 0.0 111.35 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.443 ' H ' ' C ' ' A' ' 28' ' ' GLY . 3.3 t -92.44 129.22 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 C-N-CA 120.028 -0.669 . . . . 0.0 110.914 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.508 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.6 mp -103.44 -177.58 3.41 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.432 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -75.8 -36.12 59.83 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.047 -1.061 . . . . 0.0 109.268 179.82 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -78.87 -2.68 40.96 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.375 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.435 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.3 t0 -68.78 -55.89 9.8 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.751 179.926 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -72.52 -39.21 61.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.481 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -47.8 -39.95 19.67 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 118.966 -1.093 . . . . 0.0 109.806 179.875 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.52 -34.19 67.42 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.586 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.519 ' CD2' HG13 ' A' ' 16' ' ' VAL . 76.7 t80 -40.88 -66.42 0.33 Allowed 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.086 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 10.1 tp -75.08 -61.09 2.01 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.752 -179.949 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.46 -160.04 0.02 OUTLIER 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 119.624 -0.831 . . . . 0.0 110.721 179.965 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.67 -0.69 2.25 Favored Glycine 0 N--CA 1.502 3.041 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.741 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -96.24 -152.44 29.0 Favored Glycine 0 N--CA 1.504 3.198 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.487 179.951 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.25 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.753 -179.998 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 26.7 mm . . . . . 0 N--CA 1.484 1.249 0 CA-C-O 121.126 0.489 . . . . 0.0 110.965 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.82 177.58 6.96 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.134 179.936 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.432 ' HG2' ' H ' ' A' ' 4' ' ' MET . 4.3 ptp -63.98 152.29 87.71 Favored Pre-proline 0 C--N 1.303 -1.442 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.352 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.46 ' C ' ' H ' ' A' ' 7' ' ' VAL . 1.1 Cg_endo -59.11 -179.5 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 120.956 1.104 . . . . 0.0 111.219 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.6 p 71.91 -20.69 0.24 Allowed 'General case' 0 N--CA 1.49 1.564 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.599 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.46 ' H ' ' C ' ' A' ' 5' ' ' PRO . 94.5 t -95.2 -56.64 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 C-N-CA 119.581 -0.848 . . . . 0.0 111.242 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 56.1 ttp180 -60.92 -35.85 77.78 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.46 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.7 mmtp -55.65 -42.9 75.69 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.395 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.5 t80 -58.26 -48.65 79.75 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.799 -1.16 . . . . 0.0 109.329 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.27 -43.25 42.88 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.018 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 79.1 mtt180 -58.27 -43.81 88.11 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.977 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -55.68 -53.15 60.11 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.826 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.3 mmmt -80.4 0.38 33.47 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.148 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 58.51 70.89 0.86 Allowed Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.25 -1.452 . . . . 0.0 110.403 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.9 t -141.64 139.2 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.113 -179.968 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.0 t0 -85.99 107.95 18.0 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.507 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.3 tt -46.49 -40.97 4.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 119.769 -0.772 . . . . 0.0 110.92 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 5.1 tpm_? -48.16 -57.59 5.67 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.71 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.1 mt -54.0 -35.47 61.9 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.704 -0.799 . . . . 0.0 111.783 -179.87 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.6 t -56.38 139.5 15.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.432 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -138.94 53.91 1.75 Allowed 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.694 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.82 -114.79 0.06 OUTLIER Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.603 -1.284 . . . . 0.0 111.378 -179.851 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.5 p -92.96 -71.06 0.67 Allowed 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.884 -179.851 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.428 ' O ' ' OD1' ' A' ' 27' ' ' ASN . . . -58.93 -50.05 71.79 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.356 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.401 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 21.6 pttp 41.6 36.56 0.59 Allowed 'General case' 0 C--N 1.294 -1.806 0 CA-C-O 121.507 0.67 . . . . 0.0 110.79 -179.894 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' H ' ' A' ' 29' ' ' ARG . 13.6 p-10 -159.41 -160.21 0.81 Allowed 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.224 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.94 -7.79 1.18 Allowed Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.021 179.985 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.47 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -121.48 48.66 1.64 Allowed 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.39 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -69.69 158.18 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.344 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.8 mp -104.46 171.14 7.5 Favored 'General case' 0 N--CA 1.51 2.538 0 C-N-CA 119.408 -0.917 . . . . 0.0 111.154 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 36.0 tttp -76.77 -39.42 51.68 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.205 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -73.01 -6.37 45.01 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 119.337 -0.945 . . . . 0.0 108.879 179.819 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -65.32 -62.93 1.25 Allowed 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.026 -179.97 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mt -67.52 -31.29 52.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.801 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -51.27 -41.13 60.21 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.128 -1.029 . . . . 0.0 110.1 179.895 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -75.2 -32.71 61.28 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -43.82 -69.87 0.12 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.571 -0.852 . . . . 0.0 111.696 -179.954 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.483 ' C ' ' H ' ' A' ' 41' ' ' GLY . 24.1 tp -65.43 -49.86 67.6 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.654 -179.824 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -50.61 -10.15 0.06 Allowed 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.26 -0.976 . . . . 0.0 110.996 -179.936 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.483 ' H ' ' C ' ' A' ' 39' ' ' LEU . . . -45.19 -57.07 5.77 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.642 -1.266 . . . . 0.0 110.758 179.994 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -71.5 -87.3 0.14 Allowed Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.275 -1.441 . . . . 0.0 110.535 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.256 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.756 179.968 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 120.946 0.403 . . . . 0.0 110.146 . . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.426 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 48.74 -179.01 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.879 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.446 ' C ' ' H ' ' A' ' 6' ' ' SER . 16.1 mmt -87.91 151.13 49.21 Favored Pre-proline 0 N--CA 1.49 1.557 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.314 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -69.43 36.62 0.22 Allowed 'Trans proline' 0 CA--C 1.55 1.29 0 C-N-CA 120.82 1.013 . . . . 0.0 111.448 179.91 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.446 ' H ' ' C ' ' A' ' 4' ' ' MET . 13.8 t -154.87 33.7 0.4 Allowed 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 119.364 -0.934 . . . . 0.0 111.312 179.909 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 48.5 t -142.63 -79.03 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 119.455 -0.898 . . . . 0.0 112.32 179.973 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.417 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 47.5 ttp85 -51.91 -51.56 56.04 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.702 -0.799 . . . . 0.0 112.947 -179.751 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.458 ' CG ' ' N ' ' A' ' 10' ' ' TYR . 0.2 OUTLIER -49.07 -49.47 41.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.688 -179.846 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.458 ' N ' ' CG ' ' A' ' 9' ' ' LYS . 2.3 t80 -51.93 -44.57 63.94 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.079 179.921 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -51.85 -43.9 63.4 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.58 -0.848 . . . . 0.0 110.928 179.997 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -59.64 -43.25 93.95 Favored 'General case' 0 C--N 1.293 -1.849 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.371 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -54.7 -60.01 3.94 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.55 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -75.17 11.07 1.26 Allowed 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.374 -179.896 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 53.59 75.84 0.21 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.596 -1.288 . . . . 0.0 111.611 179.933 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 22.4 t -147.84 135.38 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.843 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -82.99 111.32 18.74 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.563 -0.855 . . . . 0.0 111.015 179.923 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.514 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.7 tt -46.11 -40.48 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.943 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.514 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 52.4 ttt85 -51.86 -58.81 5.39 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 114.867 -1.06 . . . . 0.0 112.301 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.0 mt -50.45 -31.42 15.12 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.524 -179.83 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -62.03 140.74 18.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.781 -1.167 . . . . 0.0 111.159 -179.852 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.5 tt0 -134.9 57.15 1.82 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.644 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.4 -112.24 0.08 OUTLIER Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.132 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -73.79 -47.85 35.84 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.164 -1.014 . . . . 0.0 109.91 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.496 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -157.33 114.43 0.61 Allowed Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 12.0 ptmm? -74.83 36.9 0.11 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.728 179.983 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.51 ' CG ' ' H ' ' A' ' 28' ' ' GLY . 25.9 t-20 -109.5 -179.02 3.71 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.51 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -50.93 -11.07 0.5 Allowed Glycine 0 N--CA 1.488 2.124 0 C-N-CA 118.828 -1.653 . . . . 0.0 109.963 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.488 ' N ' ' C ' ' A' ' 27' ' ' ASN . 44.2 mmt-85 -101.01 43.58 1.05 Allowed 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.751 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 31' ' ' LEU . 3.0 t -76.52 163.17 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.397 179.852 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.441 ' N ' ' CG1' ' A' ' 30' ' ' VAL . 8.6 mp -112.37 174.36 5.92 Favored 'General case' 0 N--CA 1.512 2.655 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.329 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.9 tttp -78.02 -41.38 35.96 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.402 -0.919 . . . . 0.0 108.823 179.867 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -71.53 -5.5 33.7 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.213 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.0 -56.87 8.26 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.36 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.476 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.3 mp -72.06 -36.01 55.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.385 -0.926 . . . . 0.0 110.95 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -48.37 -42.12 30.74 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.177 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.48 -34.72 72.71 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.389 179.858 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.5 t80 -43.21 -70.63 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.602 179.916 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.6 tp -69.01 -60.85 2.08 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.019 -179.782 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -49.23 168.95 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.4 -0.92 . . . . 0.0 110.836 179.928 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -161.81 19.04 0.18 Allowed Glycine 0 N--CA 1.487 2.037 0 C-N-CA 119.488 -1.339 . . . . 0.0 110.55 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.89 34.79 52.05 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.394 -1.384 . . . . 0.0 110.534 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.387 -0.925 . . . . 0.0 110.77 -179.963 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.51 HG22 ' N ' ' A' ' 3' ' ' ALA . 17.0 mm . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 120.877 0.37 . . . . 0.0 110.813 . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.51 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -78.56 174.52 11.27 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.668 179.979 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.465 ' O ' ' N ' ' A' ' 6' ' ' SER . 64.9 mtm -68.81 149.02 98.02 Favored Pre-proline 0 C--N 1.307 -1.26 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.615 -179.941 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -62.37 77.23 0.1 Allowed 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 120.547 0.831 . . . . 0.0 110.394 179.82 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.465 ' N ' ' O ' ' A' ' 4' ' ' MET . 7.6 p -176.76 -15.87 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 119.666 -0.813 . . . . 0.0 110.094 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.6 t -95.87 -47.85 12.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.699 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 12' ' ' ARG . 53.2 ttp180 -65.04 -42.66 94.08 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.763 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.0 mttm -53.48 -36.55 61.79 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.603 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.6 t80 -61.38 -49.6 76.27 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 118.73 -1.188 . . . . 0.0 108.857 179.773 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.464 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -50.06 -43.32 51.12 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.995 179.771 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 8' ' ' ARG . 95.3 mtt180 -65.52 -47.05 77.25 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.025 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mm-40 -48.15 -50.72 27.77 Favored 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.504 -0.879 . . . . 0.0 111.274 -179.92 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -82.88 -36.66 25.17 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 119.403 -0.919 . . . . 0.0 111.5 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.23 75.47 1.04 Allowed Glycine 0 N--CA 1.505 3.252 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.0 t -147.75 131.45 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 C-N-CA 120.012 -0.675 . . . . 0.0 110.049 179.908 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -75.13 103.02 5.13 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.925 179.975 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.477 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.4 tt -42.34 -37.88 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 CA-C-O 121.688 0.756 . . . . 0.0 110.836 179.949 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.477 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 44.3 ttt85 -50.15 -58.5 5.43 Favored 'General case' 0 C--N 1.287 -2.132 0 CA-C-N 114.413 -1.267 . . . . 0.0 112.502 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 66.7 mt -59.99 -13.84 13.28 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.774 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.6 t -75.38 140.11 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 118.582 -1.247 . . . . 0.0 111.38 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 74.7 mt-30 -144.08 54.83 1.29 Allowed 'General case' 0 N--CA 1.49 1.527 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.017 -179.898 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -73.87 -96.74 0.1 OUTLIER Glycine 0 N--CA 1.495 2.57 0 C-N-CA 118.827 -1.654 . . . . 0.0 109.676 179.928 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.14 -43.11 29.74 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.419 -0.912 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -171.34 119.07 0.77 Allowed Glycine 0 N--CA 1.482 1.709 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.877 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.462 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttm -56.63 -163.23 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.868 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.484 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 8.8 p30 49.99 -157.71 0.09 Allowed 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.585 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.484 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -49.16 -30.74 10.87 Favored Glycine 0 N--CA 1.498 2.791 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.172 -179.825 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.444 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.0 mmt85 -74.34 34.44 0.09 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.963 -1.095 . . . . 0.0 111.711 -179.877 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 27' ' ' ASN . 4.9 t -98.6 139.29 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.394 179.908 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.481 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -108.22 177.99 4.64 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.298 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 22.6 tttm -75.55 -35.59 60.64 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.735 179.837 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -76.89 -9.35 58.63 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.102 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.403 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 3.7 t0 -65.33 -57.92 7.18 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.704 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.464 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 5.1 mt -70.2 -29.27 38.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.878 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -53.75 -41.22 66.9 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.873 -1.131 . . . . 0.0 109.58 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.29 -33.78 67.68 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.384 -0.826 . . . . 0.0 110.561 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -43.67 -68.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.471 -0.892 . . . . 0.0 111.251 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 41' ' ' GLY . 0.2 OUTLIER -70.92 -64.32 0.93 Allowed 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.595 -179.849 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -54.57 85.47 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.385 -0.926 . . . . 0.0 111.1 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -105.45 -76.53 1.06 Allowed Glycine 0 N--CA 1.506 3.324 0 C-N-CA 120.049 -1.072 . . . . 0.0 110.459 -179.932 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.01 35.18 16.11 Favored Glycine 0 N--CA 1.494 2.549 0 C-N-CA 119.61 -1.281 . . . . 0.0 110.367 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.387 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.686 179.922 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.645 HG22 ' N ' ' A' ' 3' ' ' ALA . 21.4 mm . . . . . 0 N--CA 1.482 1.133 0 CA-C-O 120.925 0.393 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.645 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -80.26 64.0 4.93 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.952 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.67 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 62.1 mtt -116.64 -29.18 0.09 OUTLIER Pre-proline 0 N--CA 1.499 2.022 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.67 ' CD ' ' H ' ' A' ' 4' ' ' MET . 5.6 Cg_exo -62.23 80.28 0.1 OUTLIER 'Trans proline' 0 CA--C 1.541 0.874 0 CA-C-N 119.014 0.683 . . . . 0.0 111.325 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.449 ' N ' ' O ' ' A' ' 4' ' ' MET . 18.3 m 51.89 29.04 5.6 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.277 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 44.9 t -89.29 -63.66 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.802 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -66.23 -41.2 90.37 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.034 -1.066 . . . . 0.0 111.071 -179.922 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.0 mttp -53.09 -35.74 59.94 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.515 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -63.08 -51.54 66.22 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.049 179.83 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -42.15 53.17 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.186 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.9 mtp180 -62.17 -46.86 87.06 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.874 179.911 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -50.49 -50.82 51.74 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.051 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.5 ' HZ2' HD22 ' A' ' 39' ' ' LEU . 0.6 OUTLIER -78.78 -25.47 44.36 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.024 -179.963 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 96.73 68.75 0.98 Allowed Glycine 0 N--CA 1.505 3.278 0 C-N-CA 119.985 -1.102 . . . . 0.0 111.307 179.944 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.2 t -147.98 147.83 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.183 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -94.83 108.54 20.56 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.864 -0.734 . . . . 0.0 110.591 179.921 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 10.4 tt -42.68 -41.93 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 120.019 -0.673 . . . . 0.0 111.51 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.2 mtm-85 -52.42 -57.61 9.32 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.258 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.2 mt -52.88 -25.99 13.4 Favored 'General case' 0 N--CA 1.49 1.527 0 C-N-CA 119.611 -0.835 . . . . 0.0 111.918 -179.826 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.5 t -64.13 143.27 15.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.054 -1.058 . . . . 0.0 112.003 -179.817 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -136.63 63.0 1.59 Allowed 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.1 -113.18 0.61 Allowed Glycine 0 N--CA 1.497 2.707 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.775 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.26 -46.27 42.55 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.385 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.17 110.46 0.44 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -75.21 61.05 1.12 Allowed 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.47 -0.892 . . . . 0.0 110.797 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.457 ' C ' ' N ' ' A' ' 29' ' ' ARG . 7.4 p30 -150.35 -164.85 2.12 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.284 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.06 -13.3 0.61 Allowed Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.38 -1.391 . . . . 0.0 110.581 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.457 ' N ' ' C ' ' A' ' 27' ' ' ASN . 1.0 OUTLIER -102.87 34.23 2.93 Favored 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 119.863 -0.735 . . . . 0.0 112.278 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.418 ' C ' HD12 ' A' ' 31' ' ' LEU . 2.7 t -75.34 149.86 6.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 C-N-CA 119.057 -1.057 . . . . 0.0 108.818 179.804 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.418 HD12 ' C ' ' A' ' 30' ' ' VAL . 11.0 mp -107.11 173.6 6.25 Favored 'General case' 0 N--CA 1.511 2.601 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.424 -179.878 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.4 tttm -77.16 -35.06 56.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.712 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.5 mm-40 -75.71 -9.12 58.32 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 114.961 -1.018 . . . . 0.0 108.582 179.794 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -63.77 -57.01 11.25 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.005 179.958 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.533 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.8 mp -65.16 -37.03 79.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.464 -0.894 . . . . 0.0 109.694 179.792 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.435 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 12.3 t0 -45.75 -44.65 13.95 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.353 179.998 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.05 76.21 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.471 -0.891 . . . . 0.0 110.493 179.92 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -46.29 -71.04 0.08 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.647 -179.989 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.5 HD22 ' HZ2' ' A' ' 14' ' ' LYS . 12.6 tp -72.16 -53.73 11.82 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.416 -179.781 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 36' ' ' ASP . . . -48.09 -72.06 0.06 Allowed 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 119.324 -0.951 . . . . 0.0 111.023 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 78.22 21.07 71.19 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.296 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 62.79 126.46 0.01 OUTLIER Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.541 -1.314 . . . . 0.0 110.371 179.989 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.293 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.877 -179.995 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.765 HG22 ' H ' ' A' ' 3' ' ' ALA . 10.1 mm . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 121.021 0.439 . . . . 0.0 111.002 . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.765 ' H ' HG22 ' A' ' 2' ' ' ILE . . . 44.74 53.98 6.95 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.119 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.54 ' C ' ' H ' ' A' ' 6' ' ' SER . 30.3 mmm -44.56 160.54 0.23 Allowed Pre-proline 0 N--CA 1.487 1.424 0 C-N-CA 119.857 -0.737 . . . . 0.0 110.182 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -65.58 33.63 0.11 Allowed 'Trans proline' 0 CA--C 1.551 1.358 0 C-N-CA 120.724 0.949 . . . . 0.0 111.794 179.721 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.54 ' H ' ' C ' ' A' ' 4' ' ' MET . 44.6 t -139.97 -16.43 0.98 Allowed 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.341 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t -80.21 -64.52 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.689 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 41.3 ttp180 -63.57 -34.37 77.66 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 118.737 -1.185 . . . . 0.0 110.767 -179.937 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt -60.12 -41.66 93.12 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.757 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -57.28 -46.34 83.22 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.069 -1.052 . . . . 0.0 109.062 179.909 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.445 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -51.71 -45.99 63.76 Favored 'General case' 0 C--N 1.291 -1.948 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.485 179.867 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.2 mtp85 -59.11 -46.12 89.15 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.806 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -54.58 -39.33 67.69 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.457 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -89.38 -3.75 58.32 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.67 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.27 6.99 66.55 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.568 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.537 HG13 ' CD2' ' A' ' 38' ' ' PHE . 63.6 t -78.13 125.38 37.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.978 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -78.56 110.32 13.56 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.322 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.49 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -43.23 -40.02 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.117 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.49 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 55.0 mtt-85 -52.64 -59.46 4.44 Favored 'General case' 0 C--N 1.286 -2.153 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.228 -179.896 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.1 mt -52.15 -24.84 7.67 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.215 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.6 t -63.61 139.54 21.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 118.936 -1.106 . . . . 0.0 112.18 -179.813 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -131.88 64.54 1.59 Allowed 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 114.906 -1.043 . . . . 0.0 109.876 -179.929 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.11 -114.96 0.88 Allowed Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.437 -1.363 . . . . 0.0 110.499 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.32 -44.87 15.67 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.824 -0.75 . . . . 0.0 110.136 -179.935 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -147.45 103.8 0.28 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.995 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -76.33 60.38 1.53 Allowed 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.677 -179.986 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.475 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.6 p-10 -157.05 -159.4 0.85 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.256 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.73 -9.09 0.67 Allowed Glycine 0 N--CA 1.484 1.876 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.475 ' H ' ' C ' ' A' ' 27' ' ' ASN . 10.9 mmt-85 -107.76 34.38 3.58 Favored 'General case' 0 N--CA 1.507 2.381 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.574 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -74.42 146.71 9.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.186 -1.006 . . . . 0.0 109.019 179.84 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.7 mp -105.44 177.56 4.82 Favored 'General case' 0 N--CA 1.511 2.589 0 C-N-CA 119.597 -0.841 . . . . 0.0 112.131 -179.741 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 12.9 tmtt? -76.5 -41.02 48.43 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.09 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.28 -4.21 34.75 Favored 'General case' 0 C--N 1.311 -1.07 0 C-N-CA 119.37 -0.932 . . . . 0.0 109.183 179.823 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -67.37 -61.55 1.86 Allowed 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.748 179.94 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 2.7 mt -69.63 -30.57 45.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.486 179.855 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -52.25 -40.55 61.83 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.668 179.899 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.96 -35.64 72.24 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.258 179.875 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.537 ' CD2' HG13 ' A' ' 16' ' ' VAL . 57.6 t80 -44.73 -70.05 0.12 Allowed 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.373 179.921 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.4 tp -74.92 -53.39 9.11 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.896 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 43.48 -146.92 0.07 Allowed 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.688 -0.805 . . . . 0.0 111.071 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 165.58 34.31 0.02 OUTLIER Glycine 0 N--CA 1.485 1.942 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.417 -179.974 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 178.41 -60.53 0.09 OUTLIER Glycine 0 N--CA 1.484 1.861 0 C-N-CA 119.676 -1.25 . . . . 0.0 110.237 -179.922 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.577 0 C-N-CA 119.751 -0.78 . . . . 0.0 110.633 179.934 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 120.919 0.39 . . . . 0.0 110.22 . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 44.77 47.12 8.91 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.421 -0.912 . . . . 0.0 110.634 -179.987 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.647 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 14.1 ptt? -110.99 -14.49 0.12 Allowed Pre-proline 0 N--CA 1.505 2.29 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.647 ' CD ' ' N ' ' A' ' 4' ' ' MET . 3.8 Cg_exo -62.14 -59.12 0.29 Allowed 'Trans proline' 0 C--N 1.353 0.792 0 CA-C-N 120.089 1.068 . . . . 0.0 110.538 -179.905 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.8 p -162.31 24.01 0.11 Allowed 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.299 179.873 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 81.1 t -86.71 -68.92 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 CA-C-N 114.817 -1.083 . . . . 0.0 111.277 -179.964 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.5 ttp180 -63.8 -43.44 96.3 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.194 -1.002 . . . . 0.0 111.364 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.2 mttm -52.98 -37.63 61.51 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.646 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -63.45 -48.84 76.04 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.035 -1.066 . . . . 0.0 109.012 179.766 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.38 -42.65 42.85 Favored 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.573 179.898 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.6 mmm180 -58.66 -45.27 89.73 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.973 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -54.0 -45.03 71.36 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 118.99 -1.084 . . . . 0.0 110.147 179.978 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -82.21 -16.64 48.92 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.54 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 81.56 1.77 90.26 Favored Glycine 0 N--CA 1.494 2.522 0 C-N-CA 119.51 -1.329 . . . . 0.0 110.582 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.1 t -70.56 127.39 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.49 -0.884 . . . . 0.0 110.678 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 48.9 t0 -75.0 107.24 6.93 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.67 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.503 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -42.55 -41.35 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.391 -179.88 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.503 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 21.3 ttm105 -49.24 -53.08 23.27 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.185 -179.877 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -57.42 -41.3 80.15 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.193 -179.78 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.426 HG23 ' H ' ' A' ' 21' ' ' VAL . 16.5 t -48.51 141.51 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.261 -179.827 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -141.58 55.13 1.51 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.719 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.45 -112.03 0.06 OUTLIER Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.974 -1.584 . . . . 0.0 109.96 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.1 p -78.29 -43.78 27.12 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.329 -0.948 . . . . 0.0 109.629 179.904 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -156.39 116.36 0.71 Allowed Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.934 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.6 pttm -76.58 45.83 0.42 Allowed 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.745 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.2 p-10 -142.58 -153.74 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.047 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.34 -9.07 0.9 Allowed Glycine 0 C--N 1.287 -2.171 0 C-N-CA 119.024 -1.56 . . . . 0.0 109.906 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 23.0 mmt180 -100.26 27.59 5.56 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 119.896 -0.722 . . . . 0.0 111.686 -179.972 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.3 t -79.95 128.31 38.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 119.475 -0.89 . . . . 0.0 108.669 179.886 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.526 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -95.11 173.13 7.72 Favored 'General case' 0 N--CA 1.502 2.127 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.691 -179.811 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -73.94 -34.12 64.2 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 119.069 -1.053 . . . . 0.0 108.649 179.897 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -78.03 -6.62 55.11 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.699 -0.8 . . . . 0.0 108.924 179.878 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.34 -58.13 5.36 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.066 179.916 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.2 mt -74.07 -35.73 42.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.082 -179.894 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -50.24 -41.61 50.39 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.857 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.32 -35.0 71.09 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.731 -0.787 . . . . 0.0 110.66 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -42.6 -69.05 0.15 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.255 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.6 tp -71.61 -23.2 61.67 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.949 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 46.83 -168.38 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.5 -0.88 . . . . 0.0 111.07 -179.95 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.435 ' O ' ' N ' ' A' ' 43' ' ' ALA . . . 74.74 90.12 0.19 Allowed Glycine 0 N--CA 1.49 2.28 0 C-N-CA 119.36 -1.4 . . . . 0.0 110.388 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.68 88.57 0.02 OUTLIER Glycine 0 N--CA 1.489 2.18 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.488 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 41' ' ' GLY . . . . . . . . 0 C--N 1.306 -1.3 0 C-N-CA 119.463 -0.895 . . . . 0.0 110.872 -179.92 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.516 HG22 ' N ' ' A' ' 3' ' ' ALA . 17.3 mm . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 120.763 0.316 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.516 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -54.16 157.35 2.66 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 119.239 -0.984 . . . . 0.0 110.132 179.925 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.516 ' O ' ' N ' ' A' ' 6' ' ' SER . 56.4 mmm -78.7 149.95 75.18 Favored Pre-proline 0 N--CA 1.487 1.378 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.449 179.99 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.1 77.79 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 120.601 0.867 . . . . 0.0 110.861 179.968 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.516 ' N ' ' O ' ' A' ' 4' ' ' MET . 13.5 t -172.88 -36.18 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.722 179.97 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t -85.35 -58.44 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 119.856 -0.738 . . . . 0.0 110.754 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 39.6 ttm-85 -61.08 -38.62 86.9 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.536 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.6 mmtt -56.99 -42.88 81.07 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.558 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -55.6 -47.3 76.74 Favored 'General case' 0 C--N 1.302 -1.499 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.464 179.912 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.513 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -53.43 -48.38 68.82 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.117 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mmm-85 -60.96 -43.83 98.2 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.217 179.908 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 56.3 mm-40 -58.23 -28.66 65.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.679 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 11.5 mmmt -101.42 -11.28 19.49 Favored 'General case' 0 N--CA 1.5 2.027 0 C-N-CA 119.874 -0.73 . . . . 0.0 110.655 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.42 63.53 1.7 Allowed Glycine 0 N--CA 1.496 2.635 0 C-N-CA 119.592 -1.289 . . . . 0.0 110.675 179.948 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.513 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 62.7 t -145.21 130.36 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.127 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -87.14 121.49 29.67 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.606 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 3.8 tp -45.29 -44.1 3.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.78 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.53 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 53.9 ttp180 -49.21 -58.71 4.55 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.434 -0.803 . . . . 0.0 112.331 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 57.7 mt -52.69 -29.54 27.18 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.784 -0.766 . . . . 0.0 112.033 -179.849 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 t -69.11 139.34 20.61 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 C-N-CA 118.783 -1.167 . . . . 0.0 111.362 -179.818 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 -145.82 54.03 1.16 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.153 -179.978 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.56 -106.46 0.03 OUTLIER Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.309 -1.424 . . . . 0.0 111.174 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.81 -65.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.574 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -138.72 107.02 0.54 Allowed Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.547 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttp -55.9 -163.34 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.379 -0.929 . . . . 0.0 110.545 179.971 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.547 ' ND2' ' O ' ' A' ' 26' ' ' LYS . 3.0 p30 57.66 -163.06 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 CA-C-O 121.362 0.601 . . . . 0.0 112.273 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.535 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -51.1 -21.22 5.31 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.55 -179.808 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.4 mmt85 -90.09 38.76 0.94 Allowed 'General case' 0 N--CA 1.505 2.289 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.256 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 27' ' ' ASN . 4.0 t -90.46 149.34 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.956 179.85 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 7.6 mp -106.89 175.19 5.58 Favored 'General case' 0 N--CA 1.509 2.484 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.738 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.8 tttm -76.53 -38.21 55.49 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.43 -0.908 . . . . 0.0 109.425 179.849 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 57.9 mm-40 -73.69 -6.57 47.62 Favored 'General case' 0 C--N 1.307 -1.239 0 C-N-CA 119.441 -0.903 . . . . 0.0 108.966 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -67.57 -55.79 12.03 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.443 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.497 HD13 ' HB2' ' A' ' 11' ' ' ALA . 2.5 mt -73.18 -34.18 43.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.371 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -52.22 -40.03 61.06 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.448 179.926 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.24 -34.87 68.6 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.415 ' CD2' HG13 ' A' ' 16' ' ' VAL . 72.4 t80 -45.5 -70.3 0.11 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.454 -0.898 . . . . 0.0 111.184 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.507 ' C ' HD23 ' A' ' 39' ' ' LEU . 3.0 tt -71.17 -62.99 1.19 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.606 -179.903 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 40.86 -101.39 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 120.018 -0.673 . . . . 0.0 111.558 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -177.83 28.7 0.06 OUTLIER Glycine 0 N--CA 1.485 1.908 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.6 179.962 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 75.76 161.04 9.76 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.432 179.999 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.269 0 C-N-CA 119.346 -0.942 . . . . 0.0 110.83 -179.953 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.517 HG22 ' N ' ' A' ' 3' ' ' ALA . 9.8 mm . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 121.024 0.44 . . . . 0.0 110.895 . . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.517 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -74.32 164.23 26.86 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.417 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 18.3 mmt -75.93 148.35 81.68 Favored Pre-proline 0 N--CA 1.485 1.29 0 C-N-CA 119.166 -1.014 . . . . 0.0 110.67 -179.955 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.427 ' O ' ' OG ' ' A' ' 6' ' ' SER . 10.2 Cg_endo -67.92 68.91 0.87 Allowed 'Trans proline' 0 CA--C 1.548 1.209 0 C-N-CA 120.821 1.014 . . . . 0.0 110.938 179.789 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 5' ' ' PRO . 2.5 m -177.31 -57.19 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.667 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 92.5 t -64.54 -41.45 92.3 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 C-N-CA 119.166 -1.014 . . . . 0.0 110.587 179.901 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.9 ttp180 -63.65 -31.19 72.28 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.67 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.9 mmtp -55.31 -44.81 76.13 Favored 'General case' 0 C--N 1.306 -1.298 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.021 179.939 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -57.98 -51.16 70.8 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.927 -1.109 . . . . 0.0 108.56 179.782 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -45.28 55.44 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.129 179.829 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -62.32 -47.12 85.65 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.447 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -52.12 -41.0 62.13 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.239 179.8 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -81.31 -69.17 0.63 Allowed 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.53 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 138.8 33.68 0.18 Allowed Glycine 0 N--CA 1.501 2.986 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.607 179.97 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 64.5 t -109.44 138.81 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.729 -180.0 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -84.39 121.7 27.91 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.474 179.969 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 3.0 tp -48.57 -44.13 13.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 119.934 -0.707 . . . . 0.0 111.541 -179.911 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.523 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 32.9 ttm180 -54.07 -49.27 69.43 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.655 -179.908 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.4 mt -57.16 -34.72 68.73 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.52 -0.872 . . . . 0.0 112.102 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.8 t -66.7 139.62 20.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.394 -179.879 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -142.93 58.58 1.42 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.27 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.26 -104.36 0.23 Allowed Glycine 0 N--CA 1.496 2.666 0 C-N-CA 119.471 -1.347 . . . . 0.0 111.951 -179.838 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.34 -69.45 0.85 Allowed 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . -40.85 -52.79 3.88 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.03 -1.081 . . . . 0.0 110.559 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.521 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 5.2 mtmp? 48.36 -177.78 0.01 OUTLIER 'General case' 0 C--N 1.29 -2.012 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.925 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 25' ' ' GLY . 7.0 p30 43.13 -171.45 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.563 -179.94 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.92 -7.13 0.41 Allowed Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.178 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.487 ' H ' ' C ' ' A' ' 27' ' ' ASN . 42.2 mmt-85 -111.24 45.9 1.14 Allowed 'General case' 0 N--CA 1.503 2.201 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.794 -179.922 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -67.83 158.38 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.11 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.8 mt -104.27 173.14 6.43 Favored 'General case' 0 N--CA 1.51 2.564 0 C-N-CA 119.516 -0.873 . . . . 0.0 111.395 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.426 ' C ' ' H ' ' A' ' 34' ' ' ASP . 18.7 tptm -73.33 -52.77 12.67 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.381 -0.928 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -63.01 -5.5 3.02 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.224 -0.99 . . . . 0.0 109.849 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.426 ' H ' ' C ' ' A' ' 32' ' ' LYS . 4.5 t0 -66.11 -59.07 4.13 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.414 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -73.24 -33.47 41.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.765 -0.774 . . . . 0.0 111.328 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -51.22 -41.53 60.36 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.917 179.916 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.96 -33.81 66.11 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.544 -0.863 . . . . 0.0 110.607 179.89 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.0 t80 -46.06 -70.93 0.08 Allowed 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.232 179.973 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt -74.59 -45.43 45.24 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.956 -179.97 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 44.43 -101.06 0.04 OUTLIER 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.671 -0.812 . . . . 0.0 111.137 -179.954 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 62.72 13.27 45.47 Favored Glycine 0 N--CA 1.49 2.288 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.467 -179.955 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 82.38 -16.56 23.36 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.604 -1.284 . . . . 0.0 110.378 179.972 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.314 0 C-N-CA 119.452 -0.899 . . . . 0.0 110.865 -179.963 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.424 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.6 OUTLIER -74.72 166.12 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.092 179.857 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.424 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 57.9 154.47 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.875 -179.955 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 60.5 mmm -79.08 147.53 69.86 Favored Pre-proline 0 N--CA 1.49 1.539 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.722 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.51 ' C ' ' H ' ' A' ' 7' ' ' VAL . 2.7 Cg_endo -62.26 173.2 3.48 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 120.766 0.977 . . . . 0.0 111.177 179.873 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 t 67.95 -21.03 0.13 Allowed 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 120.034 -0.666 . . . . 0.0 111.795 179.853 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.51 ' H ' ' C ' ' A' ' 5' ' ' PRO . 54.4 t -96.4 -55.45 6.07 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.806 -179.995 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -62.27 -29.02 70.12 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.185 -1.006 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mmtm -59.59 -42.99 93.8 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.145 -179.943 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.432 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 8.3 t80 -60.02 -49.51 77.39 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 118.743 -1.183 . . . . 0.0 108.664 179.863 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.442 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -50.17 -44.1 52.64 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.858 -179.981 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 57.7 mtp85 -62.25 -46.44 88.81 Favored 'General case' 0 C--N 1.295 -1.765 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.276 -179.869 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -52.96 -32.38 45.7 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.07 -1.052 . . . . 0.0 109.896 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 48.5 mmtt -94.47 -18.34 21.59 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 78.55 13.26 83.39 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 26.9 t -84.12 145.12 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.794 -179.83 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -85.62 99.23 11.14 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.297 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.525 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 17.3 tt -40.75 -42.65 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.842 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.525 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 43.9 ttt85 -50.24 -61.38 2.2 Favored 'General case' 0 C--N 1.287 -2.122 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.923 -179.938 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -52.18 -28.55 18.64 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.847 -0.741 . . . . 0.0 112.754 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.406 ' H ' HG23 ' A' ' 21' ' ' VAL . 11.1 t -55.99 141.31 12.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.72 -1.192 . . . . 0.0 112.382 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -136.69 72.55 1.43 Allowed 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.719 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.6 -105.15 1.59 Allowed Glycine 0 N--CA 1.503 3.127 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.265 -179.86 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.3 p -93.7 -68.6 0.79 Allowed 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.115 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -105.42 83.41 0.37 Allowed Glycine 0 N--CA 1.501 3.023 0 C-N-CA 120.022 -1.085 . . . . 0.0 110.472 -179.888 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -69.56 74.48 0.39 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.262 -0.975 . . . . 0.0 110.154 179.992 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.497 ' C ' ' H ' ' A' ' 29' ' ' ARG . 18.3 p-10 -167.76 -161.52 0.39 Allowed 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.587 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.55 -4.08 1.25 Allowed Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.03 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.497 ' H ' ' C ' ' A' ' 27' ' ' ASN . 25.9 mmt180 -117.33 42.43 2.56 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.295 -0.562 . . . . 0.0 111.374 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -70.37 157.53 6.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 C-N-CA 119.28 -0.968 . . . . 0.0 108.74 179.841 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 60.0 mt -107.01 175.06 5.62 Favored 'General case' 0 N--CA 1.513 2.676 0 C-N-CA 119.031 -1.068 . . . . 0.0 112.037 179.973 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -77.22 -32.95 56.21 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.524 179.932 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -79.13 -8.97 59.41 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 119.39 -0.924 . . . . 0.0 108.929 -179.967 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -64.4 -54.54 31.16 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.257 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.442 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.4 mt -71.17 -34.22 53.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-N 114.588 -1.187 . . . . 0.0 110.867 179.874 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -49.7 -41.39 43.17 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.945 179.831 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.1 -34.83 71.48 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.646 179.79 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.3 t80 -42.43 -68.91 0.16 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.689 -0.804 . . . . 0.0 111.483 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.8 tp -71.38 -64.26 0.95 Allowed 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 43.13 69.93 0.35 Allowed 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.605 -0.838 . . . . 0.0 111.407 -179.965 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 155.77 64.45 0.01 OUTLIER Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.792 -1.195 . . . . 0.0 110.159 179.973 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.6 112.17 4.75 Favored Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.483 179.928 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.361 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.916 -179.993 . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.433 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.501 2.089 0 CA-C-O 121.216 0.531 . . . . 0.0 110.476 . . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.433 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 49.81 177.37 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.738 -179.882 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 20.1 mtt -79.19 157.13 76.03 Favored Pre-proline 0 N--CA 1.491 1.607 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.326 179.957 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -69.32 66.62 1.51 Allowed 'Trans proline' 0 CA--C 1.551 1.337 0 C-N-CA 120.857 1.038 . . . . 0.0 110.553 179.807 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.2 t -168.88 -16.61 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.641 -0.824 . . . . 0.0 110.501 -179.964 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 69.3 t -88.84 -71.28 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.223 179.939 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.626 HH21 ' HE ' ' A' ' 12' ' ' ARG . 36.0 ttt85 -59.22 -27.74 66.02 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.802 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.1 mmmt -60.99 -44.82 96.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.753 -179.926 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -56.29 -48.33 76.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.266 179.816 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.94 -45.93 67.89 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.626 ' HE ' HH21 ' A' ' 8' ' ' ARG . 13.7 mmt85 -60.42 -43.47 96.72 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.681 -179.93 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -57.37 -54.98 40.72 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.114 179.993 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -71.34 -70.17 0.33 Allowed 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.759 -179.912 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.67 69.59 0.05 OUTLIER Glycine 0 N--CA 1.499 2.849 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.996 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.0 t -144.41 129.03 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 C-N-CA 120.015 -0.674 . . . . 0.0 110.341 -179.973 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -73.55 106.61 5.4 Favored 'General case' 0 C--N 1.301 -1.508 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.387 179.849 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.8 tt -45.11 -42.27 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 119.938 -0.705 . . . . 0.0 111.468 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.526 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 71.8 mtm180 -46.29 -58.83 3.35 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.227 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.6 mt -55.46 -35.78 65.85 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.725 -0.79 . . . . 0.0 112.209 -179.798 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.42 HG23 ' H ' ' A' ' 21' ' ' VAL . 12.0 t -53.88 140.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.881 -1.128 . . . . 0.0 111.513 -179.805 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -145.2 67.18 1.23 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.403 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . -81.15 -100.63 0.35 Allowed Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.32 -1.419 . . . . 0.0 109.946 179.962 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -78.15 -47.47 18.06 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.148 179.866 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.68 116.23 0.7 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.979 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.4 ' HG2' ' H ' ' A' ' 26' ' ' LYS . 9.0 ptmm? -75.18 51.45 0.53 Allowed 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.991 179.953 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.507 ' O ' ' N ' ' A' ' 29' ' ' ARG . 2.9 p30 -147.6 -161.33 1.31 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.711 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.39 -10.89 0.12 Allowed Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.615 -1.279 . . . . 0.0 110.982 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.507 ' N ' ' O ' ' A' ' 27' ' ' ASN . 27.8 mmm-85 -106.0 38.73 1.94 Allowed 'General case' 0 N--CA 1.504 2.241 0 C-N-CA 120.044 -0.662 . . . . 0.0 112.259 -179.943 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -82.3 145.62 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.725 179.79 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.9 mp -106.78 174.49 5.86 Favored 'General case' 0 N--CA 1.51 2.572 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.185 -179.857 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -76.62 -34.31 58.34 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.368 -0.933 . . . . 0.0 108.926 179.743 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -77.0 -9.23 58.56 Favored 'General case' 0 C--N 1.312 -1.056 0 C-N-CA 119.521 -0.872 . . . . 0.0 108.912 179.84 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 23' ' ' GLY . 2.7 t0 -62.77 -49.58 74.43 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.232 179.933 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.8 mt -78.43 -33.53 17.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.259 179.889 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -52.29 -41.81 63.22 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.32 179.935 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.66 -35.88 75.56 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.704 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -43.08 -69.05 0.15 Allowed 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.335 -179.974 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 41' ' ' GLY . 37.6 tp -69.49 -38.17 77.54 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.366 -0.833 . . . . 0.0 112.643 -179.751 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -41.78 -20.81 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.897 0 C-N-CA 119.322 -0.951 . . . . 0.0 111.654 179.972 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -157.35 -65.49 0.01 OUTLIER Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.533 179.986 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.81 98.2 0.15 Allowed Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.341 -1.409 . . . . 0.0 110.466 179.952 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.49 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.872 179.997 . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.481 1.075 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 2' ' ' ILE . 0.7 OUTLIER -81.47 -176.34 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.694 -179.952 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.48 162.4 15.65 Favored 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.595 -179.93 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.455 ' O ' ' N ' ' A' ' 6' ' ' SER . 59.6 mtt -69.31 149.85 97.29 Favored Pre-proline 0 C--N 1.305 -1.349 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.671 179.928 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -63.03 77.35 0.11 Allowed 'Trans proline' 0 CA--C 1.539 0.741 0 C-N-CA 120.543 0.829 . . . . 0.0 110.54 179.993 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.455 ' N ' ' O ' ' A' ' 4' ' ' MET . 10.8 p -177.62 -27.65 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.606 -0.837 . . . . 0.0 110.551 -179.896 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t -82.91 -63.95 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 C-N-CA 119.618 -0.833 . . . . 0.0 110.796 179.914 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 28.5 ttp180 -60.83 -33.52 73.15 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.643 -179.939 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.0 mmtp -59.72 -41.13 90.19 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.334 179.895 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -58.49 -47.6 83.54 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.006 -1.078 . . . . 0.0 109.023 179.924 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.525 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.86 -46.07 41.84 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.966 179.746 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 59.2 mtp85 -57.53 -45.5 84.96 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.863 -179.875 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -53.36 -43.88 68.1 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.184 -1.007 . . . . 0.0 110.872 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 14.3 mmmt -81.43 -22.69 38.01 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.929 179.691 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.92 13.95 70.84 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.94 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.408 HG13 ' CD2' ' A' ' 38' ' ' PHE . 38.3 t -83.92 139.53 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.042 179.834 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 46.1 t0 -84.64 100.96 11.79 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.294 179.944 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.489 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -39.28 -39.58 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 CA-C-O 121.437 0.636 . . . . 0.0 111.613 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.529 ' O ' ' NE ' ' A' ' 19' ' ' ARG . 0.0 OUTLIER -50.33 -62.61 1.48 Allowed 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.092 179.911 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -50.61 -28.38 8.65 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.944 -0.703 . . . . 0.0 112.222 -179.704 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.402 HG23 ' H ' ' A' ' 21' ' ' VAL . 9.0 t -60.4 141.34 17.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 118.888 -1.125 . . . . 0.0 112.071 -179.788 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.6 mt-30 -134.31 64.51 1.6 Allowed 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.602 -179.993 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.59 -115.61 0.71 Allowed Glycine 0 N--CA 1.498 2.828 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.435 -179.911 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -81.54 -68.12 0.72 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.009 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.46 100.19 0.94 Allowed Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.887 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.411 ' HG2' ' H ' ' A' ' 26' ' ' LYS . 7.4 ptmm? -76.09 50.67 0.62 Allowed 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.514 -0.874 . . . . 0.0 110.775 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.481 ' C ' ' H ' ' A' ' 29' ' ' ARG . 2.7 p30 -151.01 -155.65 0.64 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.902 -0.719 . . . . 0.0 110.583 -179.941 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.6 -7.73 0.71 Allowed Glycine 0 C--N 1.29 -1.982 0 C-N-CA 119.357 -1.401 . . . . 0.0 110.258 -179.859 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.481 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.5 mmt85 -111.56 39.25 2.38 Favored 'General case' 0 N--CA 1.506 2.353 0 C-N-CA 120.149 -0.621 . . . . 0.0 111.81 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -76.64 155.45 5.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 C-N-CA 119.364 -0.934 . . . . 0.0 108.986 179.797 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 38.0 mt -109.44 175.43 5.45 Favored 'General case' 0 N--CA 1.514 2.732 0 C-N-CA 119.276 -0.97 . . . . 0.0 111.832 -179.902 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -78.21 -33.4 49.96 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.004 179.723 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 35.1 mm-40 -79.25 -4.99 53.33 Favored 'General case' 0 C--N 1.314 -0.955 0 C-N-CA 119.468 -0.893 . . . . 0.0 109.08 179.862 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -67.31 -58.4 4.87 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 114.687 -1.142 . . . . 0.0 109.249 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.525 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 6.0 mt -70.78 -31.33 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.738 179.703 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -51.97 -41.06 61.83 Favored 'General case' 0 C--N 1.309 -1.172 0 C-N-CA 118.906 -1.118 . . . . 0.0 110.101 -179.888 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.3 -33.37 65.16 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.619 179.906 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.408 ' CD2' HG13 ' A' ' 16' ' ' VAL . 68.3 t80 -44.68 -71.23 0.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.354 -0.939 . . . . 0.0 111.801 179.937 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 32.3 tp -66.87 -58.18 5.53 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.489 -179.797 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -46.32 101.04 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.076 179.983 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -81.85 19.75 9.09 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 119.56 -1.305 . . . . 0.0 110.478 -179.924 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.44 164.92 45.93 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.289 179.982 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.443 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.86 -179.974 . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.425 ' O ' HG13 ' A' ' 1' ' ' VAL . 7.1 p . . . . . 0 N--CA 1.483 1.193 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 . . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.561 HG22 ' N ' ' A' ' 3' ' ' ALA . 10.3 mm -78.0 170.87 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 119.576 -0.849 . . . . 0.0 110.752 -179.942 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.561 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -61.44 -176.82 0.08 Allowed 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.573 -0.851 . . . . 0.0 110.969 179.978 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.443 ' O ' ' N ' ' A' ' 6' ' ' SER . 45.9 mmm -69.34 149.72 97.27 Favored Pre-proline 0 C--N 1.305 -1.35 0 C-N-CA 119.504 -0.879 . . . . 0.0 110.111 -179.955 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -63.51 75.34 0.14 Allowed 'Trans proline' 0 CA--C 1.546 1.12 0 C-N-CA 120.681 0.92 . . . . 0.0 110.852 179.934 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.443 ' N ' ' O ' ' A' ' 4' ' ' MET . 5.2 t 176.94 -27.26 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.538 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.8 t -77.08 -60.12 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 119.628 -0.829 . . . . 0.0 111.166 179.987 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 24.9 ttt-85 -62.29 -48.9 77.85 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.208 -179.747 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 54.5 mttt -52.43 -38.03 58.2 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.799 179.875 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -61.48 -46.15 91.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 118.669 -1.213 . . . . 0.0 108.91 179.836 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.0 -43.18 63.53 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.648 179.9 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -56.29 -45.14 80.32 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.759 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -54.33 -42.64 70.42 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.077 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.0 mmtt -90.04 0.5 57.08 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.274 179.878 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 61.63 16.49 51.0 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.684 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.529 HG13 ' CD2' ' A' ' 38' ' ' PHE . 52.5 t -79.03 137.22 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.773 179.99 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -85.45 102.45 13.48 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.721 179.889 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.522 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -42.76 -42.62 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.906 -0.718 . . . . 0.0 111.712 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.522 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 56.4 ttt-85 -46.54 -60.06 2.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.689 179.901 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 50.6 mt -55.4 -37.54 67.73 Favored 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.683 -0.807 . . . . 0.0 112.255 -179.683 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.437 ' H ' HG23 ' A' ' 21' ' ' VAL . 11.0 t -49.51 141.28 2.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.19 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -140.96 62.14 1.48 Allowed 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.485 179.95 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.84 -103.74 0.31 Allowed Glycine 0 N--CA 1.499 2.85 0 C-N-CA 119.101 -1.524 . . . . 0.0 109.494 179.946 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -78.02 -36.01 49.2 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.291 -0.964 . . . . 0.0 108.718 179.791 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.07 -156.91 6.96 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 179.895 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.405 ' HZ2' ' HB3' ' A' ' 26' ' ' LYS . 14.7 ttpp -163.78 36.06 0.09 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.648 -0.821 . . . . 0.0 109.349 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.438 ' O ' HG23 ' A' ' 30' ' ' VAL . 10.8 p30 -154.08 -158.46 0.87 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.818 -179.999 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.28 -21.63 1.99 Allowed Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.195 -1.478 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -93.09 34.44 1.12 Allowed 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.89 179.945 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.438 HG23 ' O ' ' A' ' 27' ' ' ASN . 3.4 t -82.68 155.08 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.525 -0.87 . . . . 0.0 109.57 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.416 ' N ' ' CD2' ' A' ' 31' ' ' LEU . 3.6 mm? -104.15 173.26 6.38 Favored 'General case' 0 N--CA 1.509 2.485 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -75.31 -43.75 49.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.419 -0.912 . . . . 0.0 108.916 179.798 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -71.27 -6.79 42.49 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.48 -0.888 . . . . 0.0 109.765 -179.948 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.426 ' OD1' HG12 ' A' ' 21' ' ' VAL . 2.7 t0 -62.92 -58.2 8.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.646 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mt -69.99 -36.76 70.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.666 -0.814 . . . . 0.0 110.87 -179.92 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.465 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 23.3 t70 -48.56 -43.26 35.54 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.577 -1.249 . . . . 0.0 110.084 179.95 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.24 -35.48 78.0 Favored 'General case' 0 C--N 1.306 -1.316 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.567 -179.968 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.529 ' CD2' HG13 ' A' ' 16' ' ' VAL . 60.3 t80 -44.93 -68.04 0.23 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.385 179.984 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.2 tp -74.89 -69.24 0.48 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.137 -179.893 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.465 ' HB3' ' O ' ' A' ' 36' ' ' ASP . . . -50.75 143.86 9.13 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.287 179.965 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -79.68 23.35 3.62 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.566 -1.302 . . . . 0.0 110.134 -179.952 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.41 ' H ' ' C ' ' A' ' 40' ' ' ALA . . . 86.83 18.31 58.36 Favored Glycine 0 N--CA 1.497 2.752 0 C-N-CA 119.704 -1.236 . . . . 0.0 110.474 -179.938 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.371 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.755 179.933 . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 34.0 t . . . . . 0 N--CA 1.481 1.111 0 CA-C-O 120.947 0.403 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.424 ' H ' HD12 ' A' ' 2' ' ' ILE . 0.8 OUTLIER -149.38 -175.78 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.8 179.928 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.06 -169.65 2.17 Favored 'General case' 0 N--CA 1.501 2.101 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.599 179.976 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.484 ' C ' ' H ' ' A' ' 6' ' ' SER . 49.2 mmm -87.44 148.05 43.46 Favored Pre-proline 0 N--CA 1.494 1.756 0 C-N-CA 119.54 -0.864 . . . . 0.0 110.727 -179.98 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -68.61 30.21 0.15 Allowed 'Trans proline' 0 CA--C 1.549 1.237 0 C-N-CA 120.96 1.107 . . . . 0.0 111.645 179.904 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.484 ' H ' ' C ' ' A' ' 4' ' ' MET . 5.6 m -143.85 -37.91 0.32 Allowed 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 119.217 -0.993 . . . . 0.0 111.749 -179.94 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.1 t -71.03 -50.22 43.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.067 -1.053 . . . . 0.0 111.114 -179.858 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.471 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 56.7 ttt180 -60.1 -36.07 76.61 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.076 -1.049 . . . . 0.0 111.268 -179.936 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 51.4 mmtt -55.3 -45.63 76.27 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.212 -0.995 . . . . 0.0 110.336 179.87 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.411 ' CG ' ' NZ ' ' A' ' 32' ' ' LYS . 2.5 t80 -54.64 -46.64 73.98 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.101 179.906 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.529 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -49.53 -45.62 47.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.933 -179.863 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 -58.65 -43.39 89.8 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.18 -179.944 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 75.5 mt-10 -57.3 -31.43 65.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.301 -0.959 . . . . 0.0 110.935 -179.943 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.9 mmtt -96.71 -6.72 35.77 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.101 179.944 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 74.62 53.72 6.4 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.529 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 43.0 t -136.39 128.5 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.78 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.548 ' O ' ' N ' ' A' ' 19' ' ' ARG . 39.1 t0 -88.28 94.42 9.83 Favored 'General case' 0 N--CA 1.494 1.768 0 C-N-CA 119.556 -0.858 . . . . 0.0 111.036 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.529 HG23 ' N ' ' A' ' 19' ' ' ARG . 15.0 tt -23.25 -41.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.437 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -179.95 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.548 ' N ' ' O ' ' A' ' 17' ' ' ASP . 45.1 mtm-85 -45.59 -50.23 13.36 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -179.834 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.461 ' CD1' ' O ' ' A' ' 17' ' ' ASP . 0.3 OUTLIER -76.66 -2.25 31.85 Favored 'General case' 0 N--CA 1.5 2.061 0 C-N-CA 119.114 -1.035 . . . . 0.0 113.28 -179.665 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 85.2 t -74.75 146.25 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 C-N-CA 118.219 -1.392 . . . . 0.0 110.477 179.94 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -135.3 62.92 1.62 Allowed 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.502 179.962 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.15 -118.88 0.44 Allowed Glycine 0 N--CA 1.498 2.825 0 C-N-CA 119.215 -1.469 . . . . 0.0 110.432 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -75.62 -45.83 35.16 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.432 179.968 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.99 106.49 0.3 Allowed Glycine 0 N--CA 1.486 2.009 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -74.39 64.69 1.16 Allowed 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.79 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.474 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.8 p-10 -152.48 -164.96 2.08 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.538 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.42 -8.63 0.83 Allowed Glycine 0 N--CA 1.485 1.953 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.228 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.474 ' H ' ' C ' ' A' ' 27' ' ' ASN . 12.3 mmt85 -108.57 37.86 2.4 Favored 'General case' 0 N--CA 1.503 2.214 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.537 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.431 ' C ' HD12 ' A' ' 31' ' ' LEU . 2.9 t -77.63 158.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 119.504 -0.879 . . . . 0.0 108.949 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.431 HD12 ' C ' ' A' ' 30' ' ' VAL . 9.9 mp -113.64 177.51 4.61 Favored 'General case' 0 N--CA 1.513 2.707 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.591 -179.954 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.411 ' NZ ' ' CG ' ' A' ' 10' ' ' TYR . 15.9 tptp -77.3 -40.3 44.91 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.871 179.692 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -74.64 -4.22 35.9 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.469 179.843 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -64.93 -54.01 37.49 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.529 179.965 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.469 HD13 ' HB2' ' A' ' 11' ' ' ALA . 4.3 mt -75.5 -36.97 36.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.698 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 55.6 t0 -48.93 -40.46 30.21 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 118.688 -1.205 . . . . 0.0 109.91 179.895 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.89 -35.73 69.83 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.357 -179.998 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -45.7 -71.48 0.07 Allowed 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.24 179.862 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.1 tp -71.29 -65.54 0.74 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.713 -179.841 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 41.45 -144.7 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.909 -0.716 . . . . 0.0 111.368 179.773 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.98 -56.69 0.01 OUTLIER Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.171 -179.878 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 68.56 82.72 0.17 Allowed Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.418 -179.911 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.317 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.728 179.989 . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' A' ' 2' ' ' ILE . 5.9 m . . . . . 0 N--CA 1.479 0.992 0 CA-C-O 120.839 0.352 . . . . 0.0 110.225 . . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.438 HG22 ' N ' ' A' ' 3' ' ' ALA . 11.0 mm 54.77 165.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 119.694 -0.802 . . . . 0.0 110.758 -179.93 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.438 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -76.89 138.97 40.07 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.309 -0.956 . . . . 0.0 110.582 179.975 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.695 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 35.1 mtm -120.12 -31.96 0.06 OUTLIER Pre-proline 0 N--CA 1.508 2.454 0 N-CA-C 113.941 1.089 . . . . 0.0 113.941 -179.934 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.695 ' CD ' ' H ' ' A' ' 4' ' ' MET . 6.3 Cg_exo -64.91 -157.86 0.03 OUTLIER 'Trans proline' 0 C--O 1.213 -0.732 0 CA-C-N 118.826 0.617 . . . . 0.0 111.074 -179.937 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.2 m -69.32 72.5 0.31 Allowed 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.055 179.932 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.413 ' N ' ' O ' ' A' ' 5' ' ' PRO . 91.0 t -130.6 -66.84 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.721 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 27.8 ttm180 -58.36 -37.98 76.31 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 118.973 -1.091 . . . . 0.0 110.48 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -53.83 -44.81 70.58 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.289 -179.845 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -57.67 -48.44 79.5 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 118.991 -1.083 . . . . 0.0 109.299 179.785 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.533 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -50.82 -45.26 59.43 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.323 179.972 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -60.46 -45.83 92.28 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.433 -179.885 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -55.76 -29.42 59.56 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.796 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.1 mmtt -108.58 -5.31 16.55 Favored 'General case' 0 N--CA 1.502 2.158 0 C-N-CA 120.123 -0.631 . . . . 0.0 110.768 179.97 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 62.0 81.13 0.09 OUTLIER Glycine 0 N--CA 1.491 2.305 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.588 179.923 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.553 HG13 ' CD2' ' A' ' 38' ' ' PHE . 24.5 t -147.76 129.44 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.139 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -70.7 96.92 1.28 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.577 -179.975 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 19' ' ' ARG . 16.0 tt -40.52 -41.69 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.969 179.891 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' HG23 ' A' ' 18' ' ' ILE . 10.0 tpt180 -55.14 -60.42 3.41 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.278 179.996 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.0 mt -49.42 -20.39 0.69 Allowed 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.964 -179.912 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 5.9 t -68.32 139.5 20.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.997 -179.846 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -142.61 52.56 1.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.012 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.4 -95.99 0.06 OUTLIER Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.651 -1.261 . . . . 0.0 111.036 -179.95 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.46 -46.3 16.14 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.38 -0.928 . . . . 0.0 110.291 -179.863 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -161.74 111.97 0.5 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.93 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.603 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 17.5 ptmt -55.7 -163.5 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.77 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.643 HD22 ' HG2' ' A' ' 29' ' ' ARG . 1.3 p30 50.82 -160.51 0.08 Allowed 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.416 -179.922 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.49 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -50.2 -26.5 9.32 Favored Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.898 -1.144 . . . . 0.0 111.438 -179.823 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.643 ' HG2' HD22 ' A' ' 27' ' ' ASN . 22.0 mmt180 -75.19 29.59 0.1 Allowed 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.592 -179.883 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.475 ' H ' ' C ' ' A' ' 28' ' ' GLY . 2.9 t -90.74 133.72 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.375 179.901 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.521 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.8 mp -104.18 178.82 4.45 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.786 179.943 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -74.43 -36.86 63.42 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.132 179.731 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -75.11 -8.55 56.87 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.189 179.872 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.415 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 3.3 t0 -66.07 -57.34 7.95 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.634 179.829 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 mt -66.58 -31.34 53.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.276 -179.951 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -51.57 -40.94 60.7 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.065 -1.054 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.84 -33.19 68.24 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.687 179.924 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.553 ' CD2' HG13 ' A' ' 16' ' ' VAL . 64.9 t80 -45.47 -69.39 0.14 Allowed 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.129 -179.967 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.8 tp -74.31 -54.23 8.09 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.821 -179.817 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 44.0 -156.92 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.656 -0.817 . . . . 0.0 111.271 -179.902 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -77.65 15.36 7.83 Favored Glycine 0 N--CA 1.493 2.465 0 C-N-CA 119.365 -1.398 . . . . 0.0 110.443 -179.899 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.07 173.91 54.71 Favored Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.321 -1.418 . . . . 0.0 110.339 179.944 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.315 0 C-N-CA 119.426 -0.909 . . . . 0.0 110.846 179.926 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.9 t . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 120.645 0.26 . . . . 0.0 111.372 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 25.1 ttm180 -61.45 -43.41 98.91 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.534 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -52.94 -39.61 63.01 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.936 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.532 ' OH ' ' NZ ' ' A' ' 14' ' ' LYS . 12.2 t80 -60.01 -50.5 73.48 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 118.7 -1.2 . . . . 0.0 109.196 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.91 -43.52 39.39 Favored 'General case' 0 C--N 1.29 -1.996 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.136 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.6 mtp180 -66.46 -45.46 79.66 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.308 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 39.1 mm-40 -46.73 -61.37 1.87 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.416 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.532 ' NZ ' ' OH ' ' A' ' 10' ' ' TYR . 11.4 ptpt -77.31 -22.99 51.11 Favored 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 118.599 -1.241 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 93.61 81.1 1.49 Allowed Glycine 0 N--CA 1.507 3.38 0 C-N-CA 119.731 -1.223 . . . . 0.0 111.477 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.557 HG13 ' CD2' ' A' ' 38' ' ' PHE . 18.7 t -148.42 129.6 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.266 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -74.03 104.52 4.89 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.651 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.535 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.5 tt -48.92 -44.2 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.928 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 19.4 ttm180 -47.88 -54.48 12.47 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.508 -0.769 . . . . 0.0 112.467 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.4 mt -57.54 -35.85 70.85 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 112.088 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 t -52.03 140.96 6.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.673 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -142.56 66.45 1.33 Allowed 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.427 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.77 -101.26 0.27 Allowed Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.067 -1.539 . . . . 0.0 109.463 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.418 ' OG1' HD13 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -82.26 -42.31 19.04 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.151 179.922 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.91 119.0 0.86 Allowed Glycine 0 N--CA 1.477 1.424 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.7 pttp -75.07 46.29 0.3 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.966 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.484 ' C ' ' H ' ' A' ' 29' ' ' ARG . 14.9 p-10 -143.19 -152.34 0.41 Allowed 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.204 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.56 -8.46 0.54 Allowed Glycine 0 C--N 1.291 -1.959 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.388 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.484 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.8 mmt180 -102.95 34.91 2.68 Favored 'General case' 0 N--CA 1.503 2.184 0 C-N-CA 119.87 -0.732 . . . . 0.0 111.821 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.429 ' C ' HD12 ' A' ' 31' ' ' LEU . 6.3 t -85.27 127.38 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.643 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.6 mp -96.31 172.36 8.0 Favored 'General case' 0 N--CA 1.505 2.314 0 C-N-CA 119.239 -0.984 . . . . 0.0 112.486 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -71.32 -33.98 70.16 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.877 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -80.21 -8.27 59.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.266 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -65.53 -53.04 47.81 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.456 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 mt -75.54 -34.4 29.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.789 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -50.53 -41.96 54.51 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.934 -1.106 . . . . 0.0 109.848 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.59 67.5 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.979 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.557 ' CD2' HG13 ' A' ' 16' ' ' VAL . 77.9 t80 -42.9 -65.87 0.43 Allowed 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.581 -0.847 . . . . 0.0 112.232 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.1 tp . . . . . 0 C--N 1.302 -1.464 0 C-N-CA 119.367 -0.933 . . . . 0.0 112.548 -179.698 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.7 t . . . . . 0 N--CA 1.483 1.211 0 CA-C-O 120.813 0.339 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.0 ttt85 -64.36 -40.69 96.36 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.177 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 17.3 mttp -53.79 -37.96 64.01 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.083 -1.047 . . . . 0.0 110.539 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -60.71 -49.99 75.3 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.766 -1.173 . . . . 0.0 108.966 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.48 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.98 -43.63 40.2 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.573 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -59.45 -45.16 92.38 Favored 'General case' 0 C--N 1.294 -1.821 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.03 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -53.67 -40.05 65.61 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.308 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 15.4 mmmt -87.99 -3.24 58.93 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.612 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.75 3.08 48.55 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.359 -1.4 . . . . 0.0 110.331 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.483 HG13 ' CD2' ' A' ' 38' ' ' PHE . 54.2 t -74.4 133.05 32.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.778 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -84.3 108.9 17.42 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.655 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.517 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.7 tt -44.14 -41.2 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.383 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.517 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.4 tpm_? -48.73 -59.93 3.14 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 114.832 -1.076 . . . . 0.0 112.552 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.6 mt -55.49 -31.44 62.01 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.528 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -53.36 140.55 9.34 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.8 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -135.46 65.4 1.55 Allowed 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 114.997 -1.002 . . . . 0.0 109.801 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.68 -118.42 0.95 Allowed Glycine 0 N--CA 1.502 3.038 0 C-N-CA 119.633 -1.27 . . . . 0.0 111.805 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.16 -72.48 0.6 Allowed 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.086 -179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.489 ' O ' ' N ' ' A' ' 27' ' ' ASN . . . -91.29 69.34 2.08 Favored Glycine 0 N--CA 1.496 2.67 0 C-N-CA 119.761 -1.209 . . . . 0.0 110.397 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -64.49 73.87 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.564 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.496 ' C ' ' H ' ' A' ' 29' ' ' ARG . 33.1 p-10 -174.37 -159.86 0.09 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.829 -0.748 . . . . 0.0 110.259 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.9 -7.62 1.1 Allowed Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.061 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.496 ' H ' ' C ' ' A' ' 27' ' ' ASN . 47.9 mmt-85 -116.5 46.26 1.64 Allowed 'General case' 0 N--CA 1.504 2.263 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.564 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.7 t -72.89 157.89 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.282 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.405 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -104.62 172.84 6.58 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.213 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -79.6 -34.34 40.83 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.582 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 51.8 mm-40 -76.04 -6.57 51.68 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 119.367 -0.933 . . . . 0.0 108.512 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -66.0 -55.47 16.53 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.408 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.48 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.5 mt -75.07 -32.59 27.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.701 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -51.24 -40.49 58.94 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.727 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.79 -37.24 70.45 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.533 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.483 ' CD2' HG13 ' A' ' 16' ' ' VAL . 65.7 t80 -40.78 -67.78 0.22 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.756 -0.778 . . . . 0.0 111.719 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.9 tp . . . . . 0 C--N 1.304 -1.382 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.751 -179.862 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 120.842 0.353 . . . . 0.0 110.559 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -65.92 -30.82 71.46 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.007 -1.077 . . . . 0.0 110.72 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.9 mmtt -62.23 -40.03 94.8 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.014 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -57.92 -46.92 84.27 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.245 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.466 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -49.2 -45.17 43.92 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 115.111 -0.95 . . . . 0.0 111.008 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -58.5 -44.59 89.48 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.389 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 mt-10 -54.72 -51.92 64.09 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 118.986 -1.085 . . . . 0.0 110.989 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.2 mmmt -81.39 6.12 15.44 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.886 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 56.45 75.5 0.25 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.657 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.497 HG13 ' CD2' ' A' ' 38' ' ' PHE . 46.9 t -144.82 126.45 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.159 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 65.5 t0 -74.51 107.88 6.92 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.269 -0.972 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.494 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.3 tt -42.88 -40.94 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.585 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.494 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 32.7 mtm180 -54.89 -54.05 47.56 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.255 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -51.84 -36.52 48.47 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.52 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 t -56.56 142.72 11.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.843 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -142.05 62.26 1.44 Allowed 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 120.098 -0.641 . . . . 0.0 111.647 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.9 -107.23 0.83 Allowed Glycine 0 N--CA 1.5 2.916 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.82 -45.9 40.24 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.467 -0.893 . . . . 0.0 109.626 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.5 120.65 0.99 Allowed Glycine 0 N--CA 1.485 1.91 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -79.99 44.4 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.262 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.479 ' C ' ' H ' ' A' ' 29' ' ' ARG . 1.8 p30 -149.14 -152.05 0.42 Allowed 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.474 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.52 -11.44 0.48 Allowed Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.151 -1.499 . . . . 0.0 110.29 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.479 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.6 mmt180 -102.43 32.85 3.38 Favored 'General case' 0 N--CA 1.503 2.216 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.815 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.6 t -85.57 135.86 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.376 179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.436 HD12 ' N ' ' A' ' 31' ' ' LEU . 11.0 mp -103.45 173.76 6.16 Favored 'General case' 0 N--CA 1.509 2.515 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -72.75 -37.85 67.55 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.649 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -74.46 -9.19 58.34 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.997 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -66.79 -58.24 5.45 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 114.579 -1.191 . . . . 0.0 109.551 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.466 HD13 ' HB2' ' A' ' 11' ' ' ALA . 4.1 mt -72.51 -36.79 55.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -47.24 -41.12 17.9 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 119.102 -1.039 . . . . 0.0 110.245 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.74 -35.86 67.61 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.528 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.497 ' CD2' HG13 ' A' ' 16' ' ' VAL . 67.2 t80 -43.09 -70.73 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.377 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 30.9 tp . . . . . 0 C--N 1.3 -1.568 0 C-N-CA 119.612 -0.835 . . . . 0.0 110.79 -179.96 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.6 t . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 120.937 0.399 . . . . 0.0 111.513 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.402 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 68.5 ttp85 -56.61 -43.79 80.52 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.319 -0.952 . . . . 0.0 111.594 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -48.39 -46.57 37.32 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.115 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -55.34 -49.55 71.93 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 118.866 -1.134 . . . . 0.0 109.385 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.402 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -50.99 -44.47 60.89 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.688 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -59.67 -43.48 93.98 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.825 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -57.7 -43.06 84.92 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.604 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.1 mmtt -82.3 -16.79 48.12 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.618 -0.833 . . . . 0.0 111.006 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.38 3.81 90.4 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.334 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.503 HG13 ' CD2' ' A' ' 38' ' ' PHE . 37.6 t -74.28 134.65 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.56 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -81.45 107.54 14.3 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.679 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.503 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -44.84 -41.11 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 C-N-CA 119.965 -0.694 . . . . 0.0 111.142 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.503 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 1.7 tmt_? -49.64 -59.0 4.19 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.491 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.2 mt -54.39 -25.8 26.65 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.77 -0.772 . . . . 0.0 112.401 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.422 HG12 ' OD1' ' A' ' 34' ' ' ASP . 8.2 t -62.58 139.9 20.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.691 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -136.49 54.63 1.87 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.5 -110.87 0.06 OUTLIER Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.065 -1.54 . . . . 0.0 109.536 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.05 -41.31 35.91 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.429 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -159.03 116.59 0.72 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.9 ptpp? -74.75 39.01 0.13 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.235 -0.986 . . . . 0.0 111.18 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.52 ' O ' ' N ' ' A' ' 29' ' ' ARG . 2.4 p30 -142.25 -152.74 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -47.44 -11.84 0.09 OUTLIER Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.205 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.52 ' N ' ' O ' ' A' ' 27' ' ' ASN . 17.4 mmt-85 -104.33 32.84 3.79 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.178 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.4 t -82.33 128.34 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 119.391 -0.924 . . . . 0.0 108.62 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.557 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -97.83 175.68 6.07 Favored 'General case' 0 N--CA 1.507 2.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.79 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -74.06 -35.99 64.31 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 119.517 -0.873 . . . . 0.0 108.825 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -76.49 -8.01 56.3 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 119.362 -0.935 . . . . 0.0 108.627 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.422 ' OD1' HG12 ' A' ' 21' ' ' VAL . 3.8 t0 -66.4 -59.25 3.85 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 114.66 -1.154 . . . . 0.0 109.581 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mt -70.48 -30.72 43.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.556 -0.857 . . . . 0.0 110.233 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -53.77 -41.36 67.1 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.486 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.64 -32.86 70.32 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.474 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.503 ' CD2' HG13 ' A' ' 16' ' ' VAL . 67.1 t80 -45.24 -70.07 0.11 Allowed 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.32 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 32.2 tp . . . . . 0 C--N 1.299 -1.588 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.713 -179.831 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.5 t . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 120.751 0.31 . . . . 0.0 111.28 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.403 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 57.3 ttp180 -62.17 -39.75 93.71 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.984 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mttp -54.52 -40.22 68.38 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.748 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.1 t80 -58.95 -47.06 86.44 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 118.802 -1.159 . . . . 0.0 108.926 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -49.09 -44.8 42.41 Favored 'General case' 0 C--N 1.291 -1.958 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.662 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 72.1 mtt85 -59.73 -47.12 86.92 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.902 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -50.88 -41.63 58.39 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.332 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 22.7 mmtp -85.49 -19.43 31.23 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.789 -0.764 . . . . 0.0 110.797 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.38 31.58 27.47 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.467 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 40.6 t -105.37 145.3 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 C-N-CA 120.199 -0.601 . . . . 0.0 110.779 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -91.11 105.56 17.9 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 120.029 -0.669 . . . . 0.0 110.299 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.516 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.7 tt -41.08 -41.71 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 CA-C-O 121.43 0.634 . . . . 0.0 111.797 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.516 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.4 ttt85 -52.08 -57.43 9.56 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-N 115.281 -0.872 . . . . 0.0 111.975 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -52.5 -30.24 29.11 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.878 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.2 t -61.59 143.65 14.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.599 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -142.15 52.61 1.47 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.297 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.45 -106.58 0.04 OUTLIER Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.699 -1.715 . . . . 0.0 109.311 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.79 -44.03 51.67 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.464 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.51 121.97 1.08 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttm -76.79 40.14 0.24 Allowed 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.101 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.499 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.2 p-10 -142.72 -150.36 0.31 Allowed 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.797 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.4 -8.77 0.55 Allowed Glycine 0 C--N 1.284 -2.335 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.226 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.499 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.6 28.72 5.8 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.899 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 t -83.01 128.53 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.748 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.541 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -100.07 176.67 5.33 Favored 'General case' 0 N--CA 1.505 2.309 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.957 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.4 tttt -74.41 -36.01 63.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.802 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -76.37 -7.82 55.82 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.883 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -66.26 -51.97 52.26 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.187 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -74.66 -33.19 30.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.994 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -52.07 -40.89 61.85 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 118.716 -1.193 . . . . 0.0 109.566 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.81 -32.88 68.04 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.547 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -44.93 -70.54 0.1 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.433 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.4 tp . . . . . 0 C--N 1.302 -1.49 0 C-N-CA 119.478 -0.889 . . . . 0.0 111.306 -179.809 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.0 t . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 120.868 0.366 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.416 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 64.0 ttt180 -61.42 -29.55 70.01 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.999 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 60.8 mmtt -59.5 -45.7 90.94 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.936 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -55.1 -46.67 75.52 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 119.341 -0.944 . . . . 0.0 109.04 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.555 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.93 -45.62 41.87 Favored 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.523 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 61.7 mtt-85 -64.11 -46.37 84.49 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.02 -0.991 . . . . 0.0 111.453 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 66.4 mt-10 -48.52 -48.74 38.11 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.366 -0.934 . . . . 0.0 111.344 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -83.34 -33.42 25.88 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.159 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.09 73.62 1.07 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.578 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.26 130.4 8.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 C-N-CA 120.019 -0.673 . . . . 0.0 110.193 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -76.26 103.04 6.09 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.08 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.522 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 14.1 tt -42.23 -42.61 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.707 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.522 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.7 ttp180 -45.46 -57.63 3.96 Favored 'General case' 0 C--N 1.289 -2.049 0 CA-C-N 115.264 -0.88 . . . . 0.0 112.415 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 53.1 mt -56.44 -35.97 68.47 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.647 -0.821 . . . . 0.0 112.3 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.8 t -50.18 141.44 3.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 C-N-CA 118.875 -1.13 . . . . 0.0 111.819 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -143.96 65.89 1.3 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.142 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.43 -105.55 0.6 Allowed Glycine 0 N--CA 1.499 2.84 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.07 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.94 -45.69 40.77 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.373 -0.931 . . . . 0.0 109.757 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.518 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -162.99 115.33 0.65 Allowed Glycine 0 N--CA 1.479 1.543 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -74.84 36.06 0.11 Allowed 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.091 -1.044 . . . . 0.0 110.769 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 26.3 t-20 -107.82 -179.82 4.01 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.98 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.52 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -50.01 -12.14 0.45 Allowed Glycine 0 N--CA 1.485 1.936 0 C-N-CA 119.112 -1.518 . . . . 0.0 110.016 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.49 ' N ' ' C ' ' A' ' 27' ' ' ASN . 14.7 mmt-85 -97.94 36.76 1.5 Allowed 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.624 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.4 t -71.11 153.0 8.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.001 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.407 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -105.56 173.21 6.41 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.332 -0.947 . . . . 0.0 111.312 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -77.18 -37.47 53.58 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.104 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -76.05 -5.58 47.1 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.396 -0.921 . . . . 0.0 109.066 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -65.12 -56.17 14.49 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.224 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.555 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 6.2 mt -69.59 -37.78 75.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.138 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -48.36 -40.46 25.58 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.985 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.21 -34.0 70.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.476 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -45.03 -71.9 0.07 Allowed 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.622 -0.831 . . . . 0.0 111.315 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 10.5 tp . . . . . 0 C--N 1.305 -1.345 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.622 -179.898 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.5 t . . . . . 0 N--CA 1.484 1.25 0 CA-C-O 120.932 0.396 . . . . 0.0 110.343 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -66.22 -44.28 84.26 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.551 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -52.65 -35.4 54.86 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.745 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -62.82 -49.83 73.38 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.863 -1.135 . . . . 0.0 108.894 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.404 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -51.49 -43.69 62.27 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.973 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 44.9 mtp180 -60.78 -47.09 87.87 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.721 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.96 -53.96 28.46 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.763 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 13.7 ptmt -76.51 -24.61 53.71 Favored 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.915 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.66 70.69 1.16 Allowed Glycine 0 N--CA 1.503 3.154 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.623 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.404 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 19.2 t -148.2 145.55 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.929 -0.709 . . . . 0.0 110.287 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -90.82 106.21 18.36 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.593 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.529 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 16.6 tt -42.12 -41.72 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.512 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.529 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 84.6 mtt-85 -50.08 -60.69 2.7 Favored 'General case' 0 C--N 1.285 -2.222 0 CA-C-N 115.021 -0.991 . . . . 0.0 112.421 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 75.6 mt -51.9 -18.1 1.21 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.467 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.2 t -72.34 139.8 19.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 C-N-CA 118.671 -1.212 . . . . 0.0 111.66 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 tt0 -138.68 55.39 1.73 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.858 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.54 -109.43 0.02 OUTLIER Glycine 0 N--CA 1.492 2.378 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.698 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -70.06 -44.31 69.42 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.312 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -168.68 121.36 0.94 Allowed Glycine 0 N--CA 1.48 1.614 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.079 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.43 ' CE ' ' O ' ' A' ' 19' ' ' ARG . 0.7 OUTLIER -73.05 66.1 0.8 Allowed 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.304 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.476 ' C ' ' H ' ' A' ' 29' ' ' ARG . 12.3 p30 -152.07 -164.89 2.08 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.243 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.1 -9.52 0.9 Allowed Glycine 0 N--CA 1.483 1.783 0 C-N-CA 119.212 -1.471 . . . . 0.0 110.045 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.476 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.3 mmm-85 -100.76 30.99 3.71 Favored 'General case' 0 N--CA 1.501 2.08 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.531 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.0 t -81.42 143.67 11.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 119.596 -0.841 . . . . 0.0 108.962 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.441 ' H ' ' HB2' ' A' ' 34' ' ' ASP . 5.4 mp -112.86 174.62 5.81 Favored 'General case' 0 N--CA 1.514 2.728 0 C-N-CA 119.49 -0.884 . . . . 0.0 112.302 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -73.29 -33.65 65.33 Favored 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.168 -1.013 . . . . 0.0 108.299 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -74.55 -12.88 60.58 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.124 -0.944 . . . . 0.0 108.912 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.441 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.2 t0 -63.87 -51.3 65.23 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.228 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mt -75.79 -32.11 23.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.243 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -52.63 -40.45 62.79 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.598 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.92 -34.43 71.52 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.308 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 61.9 t80 -42.92 -70.83 0.09 Allowed 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.77 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 53.5 tp . . . . . 0 C--N 1.301 -1.527 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.077 -179.925 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 85.7 t . . . . . 0 N--CA 1.486 1.354 0 CA-C-O 121.006 0.432 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 61.3 ttt180 -63.29 -37.21 86.35 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.85 -1.14 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.8 mmtt -55.81 -40.35 72.64 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.491 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -56.62 -51.11 69.95 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.631 -1.228 . . . . 0.0 108.977 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.24 -45.38 54.01 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.246 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtp180 -62.89 -46.69 86.63 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.823 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -52.07 -55.8 18.42 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.782 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.6 mmtt -67.7 -66.03 0.61 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 133.66 64.73 0.07 OUTLIER Glycine 0 N--CA 1.499 2.867 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.427 HG13 ' CD2' ' A' ' 38' ' ' PHE . 41.9 t -142.24 138.99 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.479 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 38.2 t0 -83.96 109.23 17.45 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.639 -0.825 . . . . 0.0 110.553 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.479 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 9.2 tt -44.05 -41.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.512 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.479 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 58.6 ttp180 -50.33 -58.16 6.3 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.33 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.2 mt -54.93 -28.21 49.22 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.325 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.404 ' H ' HG23 ' A' ' 21' ' ' VAL . 6.9 t -62.43 142.28 16.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 C-N-CA 118.754 -1.179 . . . . 0.0 111.308 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -142.23 66.24 1.34 Allowed 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.52 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.1 -103.22 0.66 Allowed Glycine 0 N--CA 1.5 2.93 0 C-N-CA 119.24 -1.457 . . . . 0.0 109.552 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -79.7 -51.81 8.75 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.486 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.25 114.19 0.63 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 pttm -76.0 55.95 0.95 Allowed 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.045 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.488 ' C ' ' N ' ' A' ' 29' ' ' ARG . 1.5 p30 -146.2 -162.34 1.5 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.259 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.46 -10.19 0.54 Allowed Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.303 -1.427 . . . . 0.0 110.153 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.488 ' N ' ' C ' ' A' ' 27' ' ' ASN . 13.2 mmt85 -104.39 35.25 2.78 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.751 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -78.07 145.24 10.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.296 -0.962 . . . . 0.0 108.625 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.1 mp -102.86 173.04 6.49 Favored 'General case' 0 N--CA 1.511 2.596 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.708 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.6 tttm -74.18 -43.49 57.09 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.242 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -70.95 -5.18 28.96 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.45 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -68.37 -56.79 7.29 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.177 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -71.45 -31.14 42.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.405 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -53.71 -42.33 67.92 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.602 -1.239 . . . . 0.0 109.531 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.8 -35.45 78.67 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.282 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.427 ' CD2' HG13 ' A' ' 16' ' ' VAL . 64.6 t80 -43.04 -70.47 0.11 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.266 -0.974 . . . . 0.0 111.342 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.1 tp . . . . . 0 C--N 1.302 -1.486 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.61 -179.831 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 84.9 t . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 120.865 0.364 . . . . 0.0 111.126 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 58.7 ttt-85 -58.09 -31.64 67.3 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.256 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -61.15 -39.97 92.1 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.206 -0.998 . . . . 0.0 110.511 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 6.1 t80 -59.08 -48.36 81.88 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 118.944 -1.102 . . . . 0.0 109.259 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.411 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -49.71 -42.38 45.74 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.791 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -61.96 -43.51 98.69 Favored 'General case' 0 C--N 1.292 -1.907 0 C-N-CA 119.484 -0.887 . . . . 0.0 111.082 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -55.04 -54.41 43.44 Favored 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.309 -0.956 . . . . 0.0 110.928 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.4 mmtp -79.82 -19.43 48.46 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.066 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 76.06 81.93 0.52 Allowed Glycine 0 N--CA 1.49 2.24 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.968 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.464 HG13 ' CE2' ' A' ' 38' ' ' PHE . 17.9 t -146.9 141.57 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.918 -0.713 . . . . 0.0 110.647 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -80.31 97.57 7.05 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.267 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.4 tt -40.19 -37.79 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.534 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.441 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 57.0 mtp180 -54.96 -62.72 1.48 Allowed 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.364 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.0 mt -51.17 -17.67 0.72 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.549 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.3 t -68.35 141.16 17.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 C-N-CA 118.502 -1.279 . . . . 0.0 111.447 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -139.83 67.77 1.37 Allowed 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.037 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.12 -114.01 1.34 Allowed Glycine 0 N--CA 1.498 2.814 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.025 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.34 -44.05 54.04 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.91 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.5 111.94 0.5 Allowed Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -75.85 53.07 0.73 Allowed 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.081 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.473 ' C ' ' N ' ' A' ' 29' ' ' ARG . 3.2 p30 -146.02 -164.09 1.88 Allowed 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 120.212 -0.595 . . . . 0.0 110.322 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -49.55 -13.57 0.5 Allowed Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.191 -1.48 . . . . 0.0 110.414 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.473 ' N ' ' C ' ' A' ' 27' ' ' ASN . 0.2 OUTLIER -101.11 33.95 2.69 Favored 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 119.917 -0.713 . . . . 0.0 112.152 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.7 t -76.66 150.18 6.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.047 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 9.6 mp -107.98 174.88 5.69 Favored 'General case' 0 N--CA 1.511 2.619 0 C-N-CA 119.482 -0.887 . . . . 0.0 111.033 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.5 tttm -77.32 -38.14 51.13 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.292 -0.963 . . . . 0.0 108.786 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -73.9 -7.49 52.52 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.563 -0.855 . . . . 0.0 108.876 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -64.31 -57.65 8.79 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.706 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.7 mt -72.28 -29.01 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.6 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -53.13 -43.41 66.92 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.627 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.56 -35.02 75.02 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.543 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.464 ' CE2' HG13 ' A' ' 16' ' ' VAL . 67.2 t80 -43.78 -68.62 0.18 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.341 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.567 ' C ' HD23 ' A' ' 39' ' ' LEU . 4.5 tt . . . . . 0 C--N 1.304 -1.406 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.901 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.9 t . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 120.749 0.309 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.58 HH22 HH21 ' A' ' 12' ' ' ARG . 48.7 ttt-85 -60.95 -40.18 92.32 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.528 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -56.41 -41.34 76.16 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.586 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -56.28 -46.46 79.71 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.029 -1.068 . . . . 0.0 109.149 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.02 -44.9 61.1 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.67 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.58 HH21 HH22 ' A' ' 8' ' ' ARG . 6.5 mmp_? -59.47 -42.83 92.92 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.179 -179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.425 ' C ' ' H ' ' A' ' 15' ' ' GLY . 48.2 mt-10 -58.14 -64.52 0.88 Allowed 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.344 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.2 mmtm -69.29 8.71 0.55 Allowed 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.295 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 13' ' ' GLU . . . 55.55 78.19 0.13 Allowed Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.787 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.512 HG13 ' CD2' ' A' ' 38' ' ' PHE . 37.1 t -147.71 137.32 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.075 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 68.6 t0 -87.43 106.4 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.7 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.534 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -43.85 -42.89 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.52 0.676 . . . . 0.0 111.862 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.534 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 46.0 mtt-85 -49.33 -59.72 3.45 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 114.999 -1.001 . . . . 0.0 113.119 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 49.3 mt -55.76 -24.68 36.85 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.961 -0.695 . . . . 0.0 112.668 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.5 t -57.86 141.1 15.29 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 C-N-CA 118.641 -1.224 . . . . 0.0 112.033 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -136.4 59.18 1.71 Allowed 'General case' 0 N--CA 1.482 1.158 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.672 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.8 -110.41 0.09 OUTLIER Glycine 0 N--CA 1.494 2.551 0 C-N-CA 118.957 -1.592 . . . . 0.0 109.751 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.84 -43.59 29.93 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.322 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.453 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -159.84 114.82 0.63 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 ptmt -74.9 38.88 0.13 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.284 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.492 ' C ' ' H ' ' A' ' 29' ' ' ARG . 18.7 p-10 -124.43 -161.96 1.04 Allowed 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.207 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.06 -6.37 0.82 Allowed Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.156 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.492 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.44 34.93 2.59 Favored 'General case' 0 N--CA 1.502 2.126 0 C-N-CA 119.964 -0.695 . . . . 0.0 111.805 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -80.92 150.37 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 C-N-CA 119.341 -0.944 . . . . 0.0 108.934 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.444 ' H ' ' HB2' ' A' ' 34' ' ' ASP . 5.4 mp -120.26 -179.91 4.09 Favored 'General case' 0 N--CA 1.515 2.801 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.011 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 tttp -78.86 -33.2 46.05 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.75 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.62 ' CD ' ' H ' ' A' ' 33' ' ' GLU . 2.3 pm0 -75.3 -7.67 54.57 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.444 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.2 t0 -67.6 -54.71 17.49 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 114.523 -1.217 . . . . 0.0 109.369 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -72.98 -35.23 48.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.316 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -48.44 -40.71 27.09 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.208 -0.997 . . . . 0.0 110.177 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.14 -32.58 64.98 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.498 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.512 ' CD2' HG13 ' A' ' 16' ' ' VAL . 72.0 t80 -44.13 -69.08 0.15 Allowed 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.601 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.3 tp . . . . . 0 C--N 1.304 -1.412 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.12 -179.753 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t . . . . . 0 N--CA 1.496 1.87 0 CA-C-O 120.848 0.356 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 25.7 ttm-85 -60.73 -38.78 86.3 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.296 -0.961 . . . . 0.0 111.336 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -54.25 -42.31 69.79 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -57.19 -49.72 75.11 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 118.607 -1.237 . . . . 0.0 109.15 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -48.36 -42.32 31.26 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.184 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -63.55 -45.79 88.91 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 119.398 -0.921 . . . . 0.0 111.225 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -50.85 -56.17 13.5 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.951 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 55.5 mmtt -79.88 -22.55 42.73 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.114 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 83.4 80.71 1.0 Allowed Glycine 0 N--CA 1.497 2.711 0 C-N-CA 119.573 -1.299 . . . . 0.0 110.496 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.526 HG13 ' CD2' ' A' ' 38' ' ' PHE . 28.2 t -147.61 135.28 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.409 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -78.35 102.96 7.99 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.266 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.519 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -44.85 -42.99 2.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.663 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.519 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 17.5 tpp180 -52.62 -54.09 37.99 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.273 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.3 mt -55.7 -26.7 46.44 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.05 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.6 t -61.35 143.04 15.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.757 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -132.99 69.76 1.48 Allowed 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.613 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.81 -114.49 2.91 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.544 -1.313 . . . . 0.0 110.415 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.07 -46.03 31.13 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.293 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -153.4 109.82 0.42 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 11.8 pttm -77.28 61.07 2.08 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.81 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.5 OUTLIER -156.9 -161.59 1.11 Allowed 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.12 179.901 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -9.07 0.41 Allowed Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.59 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 14.9 mmt85 -111.9 40.95 2.04 Favored 'General case' 0 N--CA 1.507 2.385 0 C-N-CA 120.167 -0.613 . . . . 0.0 111.592 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.8 t -80.91 157.9 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.658 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 7.9 mp -113.42 173.39 6.43 Favored 'General case' 0 N--CA 1.509 2.522 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.948 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -76.3 -43.06 43.19 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.053 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -66.79 -10.06 43.56 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.44 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -66.2 -57.52 7.41 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.568 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 mt -72.33 -33.27 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.649 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 39.5 t0 -49.71 -41.38 43.28 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.191 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.18 -35.04 68.86 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.467 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' A' ' 16' ' ' VAL . 70.5 t80 -43.72 -70.2 0.11 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.631 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.508 ' C ' HD23 ' A' ' 39' ' ' LEU . 4.1 tt . . . . . 0 C--N 1.305 -1.368 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.745 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 82.0 t . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 121.018 0.437 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -66.71 -45.39 78.86 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.959 -1.096 . . . . 0.0 110.697 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mttm -53.83 -35.85 61.88 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.638 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -63.27 -47.14 83.61 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.405 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.06 -42.64 63.31 Favored 'General case' 0 C--N 1.291 -1.95 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.595 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 69.2 mtp180 -60.98 -46.48 90.56 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.678 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -54.59 -44.01 72.64 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.879 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.0 mmtt -86.14 -69.78 0.64 Allowed 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.692 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.75 73.35 0.06 OUTLIER Glycine 0 N--CA 1.502 3.076 0 C-N-CA 119.88 -1.153 . . . . 0.0 110.773 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 39.9 t -144.67 137.44 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.493 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.1 t0 -79.85 112.28 16.98 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.804 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 7.3 tp -43.11 -43.17 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.641 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.532 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.7 tpt180 -59.91 -56.25 24.07 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.595 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.407 HD23 ' HA ' ' A' ' 20' ' ' LEU . 74.0 mt -47.16 -21.17 0.22 Allowed 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.558 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.5 t -76.5 143.18 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.976 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -132.48 65.33 1.58 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.983 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.2 -121.99 2.62 Favored Glycine 0 N--CA 1.502 3.058 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.242 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.404 ' OG1' HD23 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -73.26 -60.15 2.38 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.987 179.87 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -134.9 109.7 0.79 Allowed Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt -76.49 55.46 1.02 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.03 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.479 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.4 OUTLIER -156.89 -157.84 0.72 Allowed 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.585 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.36 -10.52 0.56 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.239 -1.458 . . . . 0.0 110.236 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.479 ' H ' ' C ' ' A' ' 27' ' ' ASN . 28.0 mmt180 -107.71 37.27 2.47 Favored 'General case' 0 N--CA 1.506 2.34 0 C-N-CA 120.074 -0.651 . . . . 0.0 111.709 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.414 ' C ' HD22 ' A' ' 31' ' ' LEU . 2.7 t -80.68 156.62 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 119.545 -0.862 . . . . 0.0 109.619 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.414 HD22 ' C ' ' A' ' 30' ' ' VAL . 3.9 mm? -105.78 172.49 6.77 Favored 'General case' 0 N--CA 1.508 2.459 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.365 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 48.4 tttm -77.1 -42.89 36.28 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 118.863 -1.135 . . . . 0.0 109.245 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -70.89 -3.38 18.87 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.47 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -67.33 -59.73 3.17 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.959 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.2 mt -72.1 -30.5 36.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.534 -0.867 . . . . 0.0 110.881 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -53.23 -41.58 65.52 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.895 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.18 -31.56 62.73 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.823 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 74.4 t80 -47.92 -69.89 0.11 Allowed 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 119.219 -0.993 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.455 ' C ' HD23 ' A' ' 39' ' ' LEU . 3.6 tt . . . . . 0 C--N 1.304 -1.4 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.931 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 70.0 t . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 120.871 0.367 . . . . 0.0 110.714 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 34.0 ttm180 -60.62 -39.37 87.98 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.189 -1.005 . . . . 0.0 111.135 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.4 mttp -53.02 -42.84 66.06 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.9 t80 -57.61 -50.18 73.99 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.739 -1.184 . . . . 0.0 109.22 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.8 -45.01 49.5 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.811 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -60.49 -45.82 92.37 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.075 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -52.36 -51.95 56.09 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 18.2 mtpp -81.29 -8.58 59.77 Favored 'General case' 0 N--CA 1.489 1.515 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.89 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.52 75.4 0.61 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.358 -1.401 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.526 HG13 ' CD2' ' A' ' 38' ' ' PHE . 42.8 t -144.25 126.53 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.946 -0.701 . . . . 0.0 110.413 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -72.79 100.77 2.95 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.526 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.8 tt -41.25 -41.74 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.69 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 17.9 tpp180 -52.12 -53.06 47.31 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.327 -0.852 . . . . 0.0 112.207 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.4 mt -57.84 -28.98 64.59 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.156 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 t -59.08 140.28 17.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.559 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -140.55 63.2 1.47 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.853 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.26 -101.85 0.35 Allowed Glycine 0 N--CA 1.496 2.656 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.89 -42.7 21.02 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.631 -0.827 . . . . 0.0 110.098 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.93 114.77 0.62 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.1 pttt -75.87 57.33 1.03 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.963 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.48 ' C ' ' N ' ' A' ' 29' ' ' ARG . 41.3 p30 -149.89 -161.37 1.33 Allowed 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.633 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.09 -11.13 0.36 Allowed Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.597 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.48 ' N ' ' C ' ' A' ' 27' ' ' ASN . 18.9 mmt180 -104.58 35.52 2.72 Favored 'General case' 0 N--CA 1.504 2.258 0 C-N-CA 119.861 -0.735 . . . . 0.0 111.79 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -81.45 135.11 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.546 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.6 mp -101.52 174.01 6.17 Favored 'General case' 0 N--CA 1.511 2.616 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.795 -179.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 50.7 tttm -75.27 -34.18 61.32 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 119.137 -1.025 . . . . 0.0 108.304 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.1 tp10 -71.14 -16.21 62.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -63.22 -54.33 39.1 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 114.201 -1.363 . . . . 0.0 109.123 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.2 mt -73.34 -34.18 42.85 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.532 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -50.55 -41.31 53.92 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.502 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.46 -36.36 76.5 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.291 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' A' ' 16' ' ' VAL . 56.9 t80 -43.86 -69.96 0.12 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.374 -0.931 . . . . 0.0 111.489 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.434 ' O ' HD13 ' A' ' 39' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.305 -1.362 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.41 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.2 t . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 120.647 0.26 . . . . 0.0 111.483 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -62.94 -40.93 99.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 118.905 -1.118 . . . . 0.0 111.224 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.445 ' H ' ' CD ' ' A' ' 9' ' ' LYS . 0.4 OUTLIER -51.64 -40.34 59.78 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.411 179.977 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -61.04 -51.43 69.21 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 118.909 -1.116 . . . . 0.0 108.904 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.11 -43.14 51.54 Favored 'General case' 0 C--N 1.291 -1.945 0 CA-C-N 115.19 -0.913 . . . . 0.0 110.25 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -63.02 -47.32 83.56 Favored 'General case' 0 C--N 1.296 -1.749 0 CA-C-N 115.057 -0.974 . . . . 0.0 110.358 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -51.85 -31.4 27.68 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.153 -1.019 . . . . 0.0 110.108 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.3 mmtp -97.78 -10.1 25.4 Favored 'General case' 0 N--CA 1.495 1.796 0 C-N-CA 119.979 -0.689 . . . . 0.0 110.692 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.08 1.5 74.2 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.358 -1.401 . . . . 0.0 109.962 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.472 HG13 ' CE2' ' A' ' 38' ' ' PHE . 41.9 t -71.31 137.32 23.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.933 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -86.38 105.8 16.97 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.278 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 19' ' ' ARG . 16.4 tt -43.04 -43.04 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.994 -179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' HG23 ' A' ' 18' ' ' ILE . 37.8 mtp180 -48.81 -57.72 5.94 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.865 -179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.2 mt -54.43 -29.63 49.93 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 119.723 -0.791 . . . . 0.0 112.56 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -55.6 140.35 13.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.623 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -132.46 62.27 1.65 Allowed 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.397 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -83.92 -121.43 0.86 Allowed Glycine 0 N--CA 1.496 2.699 0 C-N-CA 119.098 -1.525 . . . . 0.0 110.54 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.52 -66.22 0.92 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.708 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.67 -62.94 5.68 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.897 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 66.9 tttt 56.43 38.86 30.06 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.554 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.507 ' C ' ' H ' ' A' ' 29' ' ' ARG . 38.2 p-10 -163.71 -160.77 0.6 Allowed 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.182 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.29 -5.41 0.71 Allowed Glycine 0 N--CA 1.484 1.885 0 C-N-CA 119.16 -1.495 . . . . 0.0 110.249 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.507 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -122.93 45.6 2.37 Favored 'General case' 0 N--CA 1.504 2.232 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.657 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -70.4 160.4 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 C-N-CA 119.089 -1.044 . . . . 0.0 108.946 179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 9.3 mp -105.79 172.66 6.68 Favored 'General case' 0 N--CA 1.513 2.679 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.08 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -79.01 -37.51 39.01 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.393 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -72.45 -7.44 49.86 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -66.1 -59.0 4.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 114.563 -1.199 . . . . 0.0 109.621 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -72.64 -28.54 27.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.548 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -53.41 -40.95 65.5 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.697 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.51 -35.54 68.14 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.583 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.472 ' CE2' HG13 ' A' ' 16' ' ' VAL . 67.0 t80 -42.19 -70.12 0.12 Allowed 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.666 -0.813 . . . . 0.0 112.284 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 32.2 tp . . . . . 0 C--N 1.303 -1.436 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.076 -179.716 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 60.7 t . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 120.854 0.359 . . . . 0.0 110.699 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.1 ttt85 -65.39 -43.97 88.99 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 118.782 -1.167 . . . . 0.0 110.254 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -56.09 -35.37 66.94 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.185 -1.006 . . . . 0.0 110.698 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -61.46 -45.5 93.99 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.837 -1.145 . . . . 0.0 109.111 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -48.32 -42.62 31.71 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.402 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -64.2 -44.82 90.8 Favored 'General case' 0 C--N 1.291 -1.935 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.061 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.8 mm-40 -51.29 -53.09 39.04 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.783 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -82.26 -22.62 35.71 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.646 -0.822 . . . . 0.0 111.012 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 83.36 78.85 1.06 Allowed Glycine 0 N--CA 1.497 2.702 0 C-N-CA 119.469 -1.348 . . . . 0.0 110.305 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.468 HG13 ' CD2' ' A' ' 38' ' ' PHE . 33.6 t -145.7 138.57 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 120.035 -0.666 . . . . 0.0 110.161 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.2 t0 -80.95 97.1 7.3 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.05 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.512 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.8 tt -41.2 -41.73 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.562 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.512 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 13.4 tpp180 -49.96 -57.92 6.52 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.713 -179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 51.2 mt -57.42 -36.62 71.58 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.547 -0.861 . . . . 0.0 112.163 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.432 ' H ' HG23 ' A' ' 21' ' ' VAL . 14.8 t -47.08 140.92 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.69 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -133.78 65.37 1.58 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.294 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.49 -114.17 0.78 Allowed Glycine 0 N--CA 1.496 2.678 0 C-N-CA 119.14 -1.505 . . . . 0.0 109.951 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.08 -61.01 2.03 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.01 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.35 102.62 0.59 Allowed Glycine 0 N--CA 1.5 2.947 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.2 pttp -74.59 61.5 0.96 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' N ' ' A' ' 29' ' ' ARG . 8.3 p30 -164.25 -154.97 0.27 Allowed 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.484 -0.887 . . . . 0.0 110.801 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.4 -9.99 0.5 Allowed Glycine 0 C--N 1.291 -1.964 0 C-N-CA 119.635 -1.269 . . . . 0.0 110.578 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.47 ' N ' ' C ' ' A' ' 27' ' ' ASN . 25.3 mmt180 -111.9 38.5 2.64 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.744 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -76.47 154.23 5.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 119.195 -1.002 . . . . 0.0 108.905 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 29.3 mt -117.52 178.87 4.23 Favored 'General case' 0 N--CA 1.513 2.69 0 C-N-CA 119.587 -0.845 . . . . 0.0 112.24 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' A' ' 36' ' ' ASP . 27.3 tptp -78.39 -33.55 48.73 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -73.86 -11.58 60.41 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.4 ' OD1' HG12 ' A' ' 21' ' ' VAL . 2.1 t0 -66.98 -67.54 0.44 Allowed 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.104 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.4 mt -67.39 -35.49 73.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 C-N-CA 119.656 -0.817 . . . . 0.0 111.44 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 32' ' ' LYS . 5.7 m-20 -49.38 -42.53 42.49 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.721 -1.192 . . . . 0.0 110.081 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.62 -32.98 71.99 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.612 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.468 ' CD2' HG13 ' A' ' 16' ' ' VAL . 68.4 t80 -45.2 -69.9 0.12 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.873 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.2 tp . . . . . 0 C--N 1.303 -1.429 0 CA-C-N 115.275 -0.875 . . . . 0.0 112.112 -179.759 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t . . . . . 0 N--CA 1.501 2.12 0 CA-C-O 120.841 0.353 . . . . 0.0 110.827 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 32.7 ttm180 -60.04 -45.62 92.23 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.31 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.9 mmmm -52.7 -41.78 64.23 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.632 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -57.85 -47.12 83.62 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 118.781 -1.167 . . . . 0.0 109.211 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.421 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -51.07 -45.47 61.42 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.793 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -56.56 -41.69 77.28 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.914 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -61.67 -33.54 74.16 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.911 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 50.6 mmtt -96.94 0.4 48.89 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.34 57.54 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.691 -1.242 . . . . 0.0 111.041 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.53 HG13 ' CD2' ' A' ' 38' ' ' PHE . 55.2 t -81.84 123.66 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.484 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -75.98 105.92 7.29 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.244 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.482 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 9.7 tt -41.62 -41.7 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.558 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.482 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.6 ttt85 -50.92 -53.87 29.06 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.987 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 74.6 mt -55.96 -28.17 55.84 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.818 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.422 HG12 ' OD1' ' A' ' 34' ' ' ASP . 10.6 t -65.31 142.6 16.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.687 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -140.52 66.28 1.39 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.051 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -78.51 -107.56 0.2 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.095 -1.526 . . . . 0.0 110.428 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.442 ' OG1' ' CD1' ' A' ' 31' ' ' LEU . 0.7 OUTLIER -87.27 -53.02 5.06 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.473 -179.938 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 108.93 0.63 Allowed Glycine 0 N--CA 1.5 2.915 0 C-N-CA 119.857 -1.163 . . . . 0.0 110.404 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -76.58 61.41 1.78 Allowed 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.013 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.503 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.7 p-10 -152.83 -161.26 1.26 Allowed 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.434 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.76 -6.67 1.27 Allowed Glycine 0 N--CA 1.484 1.836 0 C-N-CA 119.123 -1.513 . . . . 0.0 109.909 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.503 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.8 mmt180 -108.17 31.82 5.25 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 120.187 -0.605 . . . . 0.0 111.523 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -70.08 156.11 7.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.434 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.442 ' CD1' ' OG1' ' A' ' 24' ' ' THR . 28.3 mt -108.53 173.78 6.17 Favored 'General case' 0 N--CA 1.509 2.499 0 C-N-CA 119.279 -0.969 . . . . 0.0 112.448 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 43.3 tptt -76.93 -32.23 57.22 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.063 -0.971 . . . . 0.0 108.574 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -82.58 -5.09 58.59 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.358 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.422 ' OD1' HG12 ' A' ' 21' ' ' VAL . 1.6 t0 -64.39 -53.95 40.51 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.237 -0.892 . . . . 0.0 108.933 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.421 HD13 ' HB2' ' A' ' 11' ' ' ALA . 3.3 mt -77.55 -37.89 25.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.678 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -47.17 -42.29 19.47 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.945 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.86 -37.08 73.08 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.6 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.53 ' CD2' HG13 ' A' ' 16' ' ' VAL . 66.1 t80 -42.67 -68.6 0.18 Allowed 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.463 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 11.2 tp . . . . . 0 C--N 1.303 -1.456 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.991 -179.87 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 79.9 t . . . . . 0 N--CA 1.507 2.416 0 CA-C-O 120.852 0.358 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.486 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 32.2 ttm180 -57.4 -38.09 73.74 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.239 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.7 mttp -52.43 -46.48 66.41 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.634 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -54.28 -47.74 72.02 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 118.9 -1.12 . . . . 0.0 109.092 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.503 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -49.48 -44.59 46.09 Favored 'General case' 0 C--N 1.288 -2.083 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.789 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 24.1 mmm180 -57.43 -43.86 84.2 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.745 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -57.57 -33.19 67.91 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.086 -1.045 . . . . 0.0 110.496 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.6 mmtt -93.51 -10.04 36.28 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.496 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 76.38 -0.9 62.61 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.458 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 54.7 t -70.77 124.4 26.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.772 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -77.08 105.88 8.44 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.048 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.1 tt -37.82 -42.63 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.266 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.526 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 51.7 ttp85 -49.36 -55.06 14.2 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.472 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 52.7 mt -53.07 -41.83 65.25 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.556 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.5 t -48.52 144.56 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 C-N-CA 119.267 -0.973 . . . . 0.0 111.863 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -137.95 60.85 1.61 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.476 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.32 -114.82 0.24 Allowed Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.927 -1.606 . . . . 0.0 109.943 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.1 -50.03 12.8 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.879 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.404 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -150.02 109.4 0.43 Allowed Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 pttt -75.97 43.51 0.28 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.177 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' H ' ' A' ' 29' ' ' ARG . 27.7 p-10 -119.05 -164.92 1.08 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.028 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.03 -4.2 2.21 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.196 -1.478 . . . . 0.0 110.332 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.47 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.1 mmt180 -110.71 41.42 1.79 Allowed 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.469 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -73.46 156.4 6.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.435 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.1 mp -105.74 173.0 6.5 Favored 'General case' 0 N--CA 1.511 2.577 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.142 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -76.94 -38.69 52.87 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 119.259 -0.977 . . . . 0.0 109.676 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -76.8 -2.91 35.61 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.222 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -67.18 -55.13 15.43 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.778 -1.101 . . . . 0.0 109.632 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.503 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.7 mt -75.17 -36.96 38.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.806 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.67 -40.54 53.89 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.421 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.35 -33.87 69.99 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.609 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -44.74 -69.65 0.13 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.067 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.419 ' C ' HD13 ' A' ' 39' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.609 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.441 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 121.079 0.466 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 71.2 ttt180 -71.02 -39.42 72.37 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.01 -1.076 . . . . 0.0 110.504 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttp -58.92 -26.61 64.51 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 118.988 -1.085 . . . . 0.0 110.467 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.408 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 7.6 t80 -69.62 -49.73 51.08 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 118.843 -1.143 . . . . 0.0 108.579 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.83 -41.47 23.91 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.43 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.37 -46.6 86.02 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.776 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -54.9 -35.35 64.02 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.976 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.8 mmtt -92.06 -16.79 25.94 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.849 -0.741 . . . . 0.0 110.72 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 80.46 4.75 90.07 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.523 -1.322 . . . . 0.0 110.623 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.1 t -76.46 138.55 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.651 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 36.8 t0 -81.37 104.4 11.79 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.761 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.524 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -40.87 -41.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.654 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.524 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.9 tpp180 -50.96 -59.56 4.02 Favored 'General case' 0 C--N 1.29 -2.007 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.308 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 84.8 mt -52.98 -28.44 23.84 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.013 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.413 ' H ' HG23 ' A' ' 21' ' ' VAL . 7.6 t -61.65 141.19 17.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 C-N-CA 118.915 -1.114 . . . . 0.0 112.181 -179.842 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -139.4 44.02 1.99 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.075 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.27 -104.25 0.01 OUTLIER Glycine 0 N--CA 1.492 2.37 0 C-N-CA 119.244 -1.455 . . . . 0.0 110.157 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.488 ' OG1' ' CD2' ' A' ' 31' ' ' LEU . 2.5 p -73.41 -37.84 65.8 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.08 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -179.65 121.13 0.72 Allowed Glycine 0 N--CA 1.479 1.517 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.423 ' O ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pttm -58.57 -157.31 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.507 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.517 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 25.4 t-20 59.31 176.29 0.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.013 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.517 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -46.12 -17.16 0.19 Allowed Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.733 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.482 ' N ' ' O ' ' A' ' 27' ' ' ASN . 14.5 mmt85 -80.13 35.41 0.32 Allowed 'General case' 0 N--CA 1.493 1.723 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.19 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 27' ' ' ASN . 11.7 t -101.6 156.48 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.442 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.488 ' CD2' ' OG1' ' A' ' 24' ' ' THR . 1.9 pt? -129.64 -170.71 2.35 Favored 'General case' 0 N--CA 1.512 2.634 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.633 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -71.02 -55.37 8.43 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.54 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 60.9 tt0 -61.03 -5.68 1.53 Allowed 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.9 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.85 -59.76 3.04 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.386 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.499 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.3 mp -66.55 -37.47 79.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.653 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -46.6 -42.78 16.6 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.348 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.17 -35.91 76.8 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.394 -0.923 . . . . 0.0 110.666 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -43.46 -67.54 0.27 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.467 -0.893 . . . . 0.0 112.171 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.4 tp . . . . . 0 C--N 1.302 -1.497 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.246 -179.719 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.5 t . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.024 0.44 . . . . 0.0 110.239 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 59.0 ttp85 -60.98 -51.5 68.98 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.093 -1.043 . . . . 0.0 110.749 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.1 mttt -51.26 -39.75 57.39 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.753 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -59.7 -45.95 90.56 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.206 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.451 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -53.12 -46.15 68.62 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.696 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -55.91 -40.96 73.83 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -63.08 -45.95 89.72 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.4 mmtt -78.31 -10.07 59.51 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.449 -0.901 . . . . 0.0 111.183 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.96 1.5 90.64 Favored Glycine 0 N--CA 1.496 2.642 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.899 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.536 HG13 ' CD2' ' A' ' 38' ' ' PHE . 57.8 t -74.5 130.54 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.507 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -83.22 110.01 17.71 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.155 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.551 HG23 ' N ' ' A' ' 19' ' ' ARG . 5.7 tp -42.26 -41.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.466 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.551 ' N ' HG23 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -48.07 -59.1 3.64 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.822 -179.83 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 46.8 mt -60.45 -18.41 51.01 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.2 t -70.64 139.73 19.56 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 118.552 -1.259 . . . . 0.0 111.649 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.401 ' O ' ' CD ' ' A' ' 22' ' ' GLN . 0.6 OUTLIER -145.7 79.44 1.56 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.706 179.901 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.18 -99.12 1.97 Allowed Glycine 0 N--CA 1.504 3.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.422 ' OG1' HD23 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -79.07 -38.97 35.05 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.428 179.819 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.475 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -170.61 116.16 0.63 Allowed Glycine 0 N--CA 1.485 1.932 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 pttp -74.1 38.64 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.001 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 25.0 t-20 -117.07 -179.59 3.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.712 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.513 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -47.57 -14.95 0.24 Allowed Glycine 0 N--CA 1.492 2.432 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.197 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.513 ' N ' ' O ' ' A' ' 27' ' ' ASN . 32.2 mmm-85 -95.47 37.22 1.2 Allowed 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.119 -0.632 . . . . 0.0 111.556 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 27' ' ' ASN . 2.6 t -70.99 154.64 7.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.105 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.422 HD23 ' OG1' ' A' ' 24' ' ' THR . 2.9 mm? -106.5 173.3 6.38 Favored 'General case' 0 N--CA 1.509 2.492 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.951 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.6 tmtt? -77.13 -41.43 41.96 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.386 -0.925 . . . . 0.0 108.926 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -71.78 -3.63 23.17 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.399 -0.818 . . . . 0.0 109.35 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -68.52 -56.04 9.68 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.079 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.479 HD11 ' CD1' ' A' ' 18' ' ' ILE . 1.8 mt -73.09 -37.54 53.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.643 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -51.22 -39.37 56.42 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.341 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.5 -33.62 71.42 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.347 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.536 ' CD2' HG13 ' A' ' 16' ' ' VAL . 65.9 t80 -45.07 -68.04 0.23 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.016 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 56.1 tp . . . . . 0 C--N 1.302 -1.481 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.995 -179.918 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.1 t . . . . . 0 N--CA 1.494 1.727 0 CA-C-O 120.938 0.399 . . . . 0.0 111.161 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.419 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 55.5 ttt180 -57.06 -36.05 70.07 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.384 -0.926 . . . . 0.0 111.199 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mmtm -54.85 -47.61 73.94 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 119.136 -1.026 . . . . 0.0 110.217 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -53.73 -46.94 71.02 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.073 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.422 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -52.12 -46.32 65.29 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.651 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.2 mtp180 -59.48 -44.29 93.08 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.679 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -56.69 -42.74 79.6 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.575 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -86.8 -13.92 43.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.834 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 75.91 67.84 1.64 Allowed Glycine 0 N--CA 1.488 2.134 0 C-N-CA 119.327 -1.416 . . . . 0.0 110.089 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.492 HG13 ' CD2' ' A' ' 38' ' ' PHE . 53.1 t -137.18 130.51 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.339 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -77.3 109.53 11.26 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.07 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.534 ' CD1' HD11 ' A' ' 35' ' ' ILE . 6.9 tp -44.69 -41.96 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.503 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.53 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 63.7 ttt-85 -56.15 -52.69 63.46 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.738 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.7 mt -57.18 -31.04 65.01 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.746 -0.781 . . . . 0.0 112.725 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.41 ' H ' HG23 ' A' ' 21' ' ' VAL . 7.8 t -57.46 141.87 13.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 118.437 -1.305 . . . . 0.0 111.868 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -136.77 77.71 1.66 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.933 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.26 -108.93 3.34 Favored Glycine 0 N--CA 1.51 3.596 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -77.02 -47.91 19.36 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.297 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.07 109.28 0.42 Allowed Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.9 pttp -76.07 55.36 0.92 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.601 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.4 OUTLIER -157.16 -154.95 0.49 Allowed 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 119.746 -0.782 . . . . 0.0 110.546 179.886 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.0 -8.2 0.59 Allowed Glycine 0 C--N 1.289 -2.04 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.246 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.6 mmt85 -109.09 37.34 2.59 Favored 'General case' 0 N--CA 1.504 2.24 0 C-N-CA 120.217 -0.593 . . . . 0.0 112.076 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.525 HG11 HD11 ' A' ' 18' ' ' ILE . 3.2 t -80.92 147.4 6.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.076 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.7 mp -109.37 177.34 4.77 Favored 'General case' 0 N--CA 1.511 2.604 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.51 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 3.6 tmtt? -75.47 -48.74 21.3 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.879 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -65.47 -5.45 7.84 Favored 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.207 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -69.5 -53.62 18.2 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.605 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.534 HD11 ' CD1' ' A' ' 18' ' ' ILE . 2.5 mt -72.46 -30.05 33.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 C-N-CA 119.676 -0.81 . . . . 0.0 110.757 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 36' ' ' ASP . 5.8 m-20 -55.5 -40.69 72.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.279 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.68 -34.81 76.31 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.284 179.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.492 ' CD2' HG13 ' A' ' 16' ' ' VAL . 70.1 t80 -44.55 -69.27 0.14 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.346 -0.942 . . . . 0.0 111.232 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 69.5 tp . . . . . 0 C--N 1.299 -1.604 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.916 -179.882 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.0 t . . . . . 0 N--CA 1.481 1.083 0 CA-C-O 120.978 0.418 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -61.94 -48.03 82.22 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 118.872 -1.131 . . . . 0.0 110.884 -179.906 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -53.76 -38.83 64.81 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.91 179.963 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -59.11 -44.73 92.0 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 118.883 -1.127 . . . . 0.0 109.36 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.427 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -52.05 -43.8 63.96 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.805 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -57.04 -43.49 81.98 Favored 'General case' 0 C--N 1.292 -1.893 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.886 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 59.9 mt-10 -59.06 -53.69 55.47 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.382 -0.927 . . . . 0.0 111.185 179.936 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -78.28 -14.48 59.41 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.115 -179.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 74.15 76.1 0.73 Allowed Glycine 0 N--CA 1.495 2.575 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.883 179.913 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.519 HG13 ' CD2' ' A' ' 38' ' ' PHE . 53.5 t -145.74 126.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 120.161 -0.616 . . . . 0.0 109.965 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -74.5 106.99 6.36 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.739 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.475 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 10.2 tt -44.64 -40.04 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.036 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.475 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.0 tpt85 -49.68 -54.3 19.44 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.411 -179.912 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 70.8 mt -63.21 -29.17 70.56 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.87 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.423 HG12 ' OD1' ' A' ' 34' ' ' ASP . 11.5 t -55.93 139.19 15.52 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 C-N-CA 118.812 -1.155 . . . . 0.0 111.987 -179.717 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.1 mm100 -137.44 44.43 2.25 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.255 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.24 -107.48 0.01 OUTLIER Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.138 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -78.75 -42.45 28.09 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.81 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -166.17 124.05 1.2 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 27' ' ' ASN . 14.9 ptmt -61.64 -156.87 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.009 -1.077 . . . . 0.0 110.678 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.553 ' ND2' ' N ' ' A' ' 28' ' ' GLY . 1.8 p-10 43.4 -154.18 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.567 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.553 ' N ' ' ND2' ' A' ' 27' ' ' ASN . . . -53.14 -20.91 10.0 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 120.074 -1.06 . . . . 0.0 111.63 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.436 ' O ' ' O ' ' A' ' 25' ' ' GLY . 22.2 mmt180 -78.25 27.03 0.2 Allowed 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 118.909 -1.116 . . . . 0.0 111.35 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.443 ' H ' ' C ' ' A' ' 28' ' ' GLY . 3.3 t -92.44 129.22 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 C-N-CA 120.028 -0.669 . . . . 0.0 110.914 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.508 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.6 mp -103.44 -177.58 3.41 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.432 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -75.8 -36.12 59.83 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.047 -1.061 . . . . 0.0 109.268 179.82 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -78.87 -2.68 40.96 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.375 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.435 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.3 t0 -68.78 -55.89 9.8 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.751 179.926 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -72.52 -39.21 61.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.481 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -47.8 -39.95 19.67 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 118.966 -1.093 . . . . 0.0 109.806 179.875 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.52 -34.19 67.42 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.586 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.519 ' CD2' HG13 ' A' ' 16' ' ' VAL . 76.7 t80 -40.88 -66.42 0.33 Allowed 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.086 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 10.1 tp . . . . . 0 C--N 1.302 -1.477 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.752 -179.949 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.5 t . . . . . 0 N--CA 1.498 1.95 0 CA-C-O 120.875 0.369 . . . . 0.0 111.242 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 56.1 ttp180 -60.92 -35.85 77.78 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.46 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.7 mmtp -55.65 -42.9 75.69 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.395 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.5 t80 -58.26 -48.65 79.75 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.799 -1.16 . . . . 0.0 109.329 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.27 -43.25 42.88 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.018 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 79.1 mtt180 -58.27 -43.81 88.11 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.977 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -55.68 -53.15 60.11 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.826 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.3 mmmt -80.4 0.38 33.47 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.148 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 58.51 70.89 0.86 Allowed Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.25 -1.452 . . . . 0.0 110.403 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.9 t -141.64 139.2 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.113 -179.968 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.0 t0 -85.99 107.95 18.0 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.507 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.3 tt -46.49 -40.97 4.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 119.769 -0.772 . . . . 0.0 110.92 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 5.1 tpm_? -48.16 -57.59 5.67 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.71 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.1 mt -54.0 -35.47 61.9 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.704 -0.799 . . . . 0.0 111.783 -179.87 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.6 t -56.38 139.5 15.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.432 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -138.94 53.91 1.75 Allowed 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.694 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.82 -114.79 0.06 OUTLIER Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.603 -1.284 . . . . 0.0 111.378 -179.851 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.5 p -92.96 -71.06 0.67 Allowed 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.884 -179.851 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.428 ' O ' ' OD1' ' A' ' 27' ' ' ASN . . . -58.93 -50.05 71.79 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.356 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.401 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 21.6 pttp 41.6 36.56 0.59 Allowed 'General case' 0 C--N 1.294 -1.806 0 CA-C-O 121.507 0.67 . . . . 0.0 110.79 -179.894 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' H ' ' A' ' 29' ' ' ARG . 13.6 p-10 -159.41 -160.21 0.81 Allowed 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.224 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.94 -7.79 1.18 Allowed Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.021 179.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.47 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -121.48 48.66 1.64 Allowed 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.39 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -69.69 158.18 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.344 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.8 mp -104.46 171.14 7.5 Favored 'General case' 0 N--CA 1.51 2.538 0 C-N-CA 119.408 -0.917 . . . . 0.0 111.154 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 36.0 tttp -76.77 -39.42 51.68 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.205 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -73.01 -6.37 45.01 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 119.337 -0.945 . . . . 0.0 108.879 179.819 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -65.32 -62.93 1.25 Allowed 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.026 -179.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mt -67.52 -31.29 52.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.801 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -51.27 -41.13 60.21 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.128 -1.029 . . . . 0.0 110.1 179.895 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -75.2 -32.71 61.28 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -43.82 -69.87 0.12 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.571 -0.852 . . . . 0.0 111.696 -179.954 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 24.1 tp . . . . . 0 C--N 1.298 -1.631 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.654 -179.824 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 N--CA 1.493 1.714 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.417 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 47.5 ttp85 -51.91 -51.56 56.04 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.702 -0.799 . . . . 0.0 112.947 -179.751 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.458 ' CG ' ' N ' ' A' ' 10' ' ' TYR . 0.2 OUTLIER -49.07 -49.47 41.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.688 -179.846 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.458 ' N ' ' CG ' ' A' ' 9' ' ' LYS . 2.3 t80 -51.93 -44.57 63.94 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.079 179.921 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -51.85 -43.9 63.4 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.58 -0.848 . . . . 0.0 110.928 179.997 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -59.64 -43.25 93.95 Favored 'General case' 0 C--N 1.293 -1.849 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.371 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -54.7 -60.01 3.94 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.55 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -75.17 11.07 1.26 Allowed 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.374 -179.896 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 53.59 75.84 0.21 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.596 -1.288 . . . . 0.0 111.611 179.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 22.4 t -147.84 135.38 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.843 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -82.99 111.32 18.74 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.563 -0.855 . . . . 0.0 111.015 179.923 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.514 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.7 tt -46.11 -40.48 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.943 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.514 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 52.4 ttt85 -51.86 -58.81 5.39 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 114.867 -1.06 . . . . 0.0 112.301 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.0 mt -50.45 -31.42 15.12 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.524 -179.83 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -62.03 140.74 18.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.781 -1.167 . . . . 0.0 111.159 -179.852 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -134.9 57.15 1.82 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.644 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.4 -112.24 0.08 OUTLIER Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.132 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -73.79 -47.85 35.84 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.164 -1.014 . . . . 0.0 109.91 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.496 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -157.33 114.43 0.61 Allowed Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 12.0 ptmm? -74.83 36.9 0.11 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.728 179.983 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.51 ' CG ' ' H ' ' A' ' 28' ' ' GLY . 25.9 t-20 -109.5 -179.02 3.71 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.51 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -50.93 -11.07 0.5 Allowed Glycine 0 N--CA 1.488 2.124 0 C-N-CA 118.828 -1.653 . . . . 0.0 109.963 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.488 ' N ' ' C ' ' A' ' 27' ' ' ASN . 44.2 mmt-85 -101.01 43.58 1.05 Allowed 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.751 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 31' ' ' LEU . 3.0 t -76.52 163.17 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.397 179.852 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.441 ' N ' ' CG1' ' A' ' 30' ' ' VAL . 8.6 mp -112.37 174.36 5.92 Favored 'General case' 0 N--CA 1.512 2.655 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.329 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.9 tttp -78.02 -41.38 35.96 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.402 -0.919 . . . . 0.0 108.823 179.867 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -71.53 -5.5 33.7 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.213 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.0 -56.87 8.26 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.36 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.476 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.3 mp -72.06 -36.01 55.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.385 -0.926 . . . . 0.0 110.95 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -48.37 -42.12 30.74 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.177 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.48 -34.72 72.71 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.389 179.858 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.5 t80 -43.21 -70.63 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.602 179.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.6 tp . . . . . 0 C--N 1.299 -1.588 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.019 -179.782 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.894 0.378 . . . . 0.0 110.699 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 12' ' ' ARG . 53.2 ttp180 -65.04 -42.66 94.08 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.763 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.0 mttm -53.48 -36.55 61.79 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.603 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.6 t80 -61.38 -49.6 76.27 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 118.73 -1.188 . . . . 0.0 108.857 179.773 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.464 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -50.06 -43.32 51.12 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.995 179.771 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 8' ' ' ARG . 95.3 mtt180 -65.52 -47.05 77.25 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.025 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mm-40 -48.15 -50.72 27.77 Favored 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.504 -0.879 . . . . 0.0 111.274 -179.92 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -82.88 -36.66 25.17 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 119.403 -0.919 . . . . 0.0 111.5 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.23 75.47 1.04 Allowed Glycine 0 N--CA 1.505 3.252 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.0 t -147.75 131.45 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 C-N-CA 120.012 -0.675 . . . . 0.0 110.049 179.908 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -75.13 103.02 5.13 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.925 179.975 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.477 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.4 tt -42.34 -37.88 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 CA-C-O 121.688 0.756 . . . . 0.0 110.836 179.949 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.477 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 44.3 ttt85 -50.15 -58.5 5.43 Favored 'General case' 0 C--N 1.287 -2.132 0 CA-C-N 114.413 -1.267 . . . . 0.0 112.502 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 66.7 mt -59.99 -13.84 13.28 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.774 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.6 t -75.38 140.11 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 118.582 -1.247 . . . . 0.0 111.38 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.7 mt-30 -144.08 54.83 1.29 Allowed 'General case' 0 N--CA 1.49 1.527 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.017 -179.898 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -73.87 -96.74 0.1 OUTLIER Glycine 0 N--CA 1.495 2.57 0 C-N-CA 118.827 -1.654 . . . . 0.0 109.676 179.928 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.14 -43.11 29.74 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.419 -0.912 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -171.34 119.07 0.77 Allowed Glycine 0 N--CA 1.482 1.709 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.877 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.462 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttm -56.63 -163.23 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.868 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.484 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 8.8 p30 49.99 -157.71 0.09 Allowed 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.585 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.484 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -49.16 -30.74 10.87 Favored Glycine 0 N--CA 1.498 2.791 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.172 -179.825 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.444 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.0 mmt85 -74.34 34.44 0.09 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.963 -1.095 . . . . 0.0 111.711 -179.877 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 27' ' ' ASN . 4.9 t -98.6 139.29 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.394 179.908 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.481 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -108.22 177.99 4.64 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.298 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 22.6 tttm -75.55 -35.59 60.64 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.735 179.837 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -76.89 -9.35 58.63 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.102 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.403 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 3.7 t0 -65.33 -57.92 7.18 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.704 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.464 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 5.1 mt -70.2 -29.27 38.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.878 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -53.75 -41.22 66.9 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.873 -1.131 . . . . 0.0 109.58 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.29 -33.78 67.68 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.384 -0.826 . . . . 0.0 110.561 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -43.67 -68.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.471 -0.892 . . . . 0.0 111.251 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.404 ' C ' ' CD1' ' A' ' 39' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.301 -1.536 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.595 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 120.94 0.4 . . . . 0.0 110.802 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -66.23 -41.2 90.37 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.034 -1.066 . . . . 0.0 111.071 -179.922 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.0 mttp -53.09 -35.74 59.94 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.515 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -63.08 -51.54 66.22 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.049 179.83 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -42.15 53.17 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.186 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.9 mtp180 -62.17 -46.86 87.06 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.874 179.911 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -50.49 -50.82 51.74 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.051 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.5 ' HZ2' HD22 ' A' ' 39' ' ' LEU . 0.6 OUTLIER -78.78 -25.47 44.36 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.024 -179.963 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 96.73 68.75 0.98 Allowed Glycine 0 N--CA 1.505 3.278 0 C-N-CA 119.985 -1.102 . . . . 0.0 111.307 179.944 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.2 t -147.98 147.83 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.183 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -94.83 108.54 20.56 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.864 -0.734 . . . . 0.0 110.591 179.921 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 10.4 tt -42.68 -41.93 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 120.019 -0.673 . . . . 0.0 111.51 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.2 mtm-85 -52.42 -57.61 9.32 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.258 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.2 mt -52.88 -25.99 13.4 Favored 'General case' 0 N--CA 1.49 1.527 0 C-N-CA 119.611 -0.835 . . . . 0.0 111.918 -179.826 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.5 t -64.13 143.27 15.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.054 -1.058 . . . . 0.0 112.003 -179.817 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -136.63 63.0 1.59 Allowed 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.1 -113.18 0.61 Allowed Glycine 0 N--CA 1.497 2.707 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.775 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.26 -46.27 42.55 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.385 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.17 110.46 0.44 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -75.21 61.05 1.12 Allowed 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.47 -0.892 . . . . 0.0 110.797 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.457 ' C ' ' N ' ' A' ' 29' ' ' ARG . 7.4 p30 -150.35 -164.85 2.12 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.284 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.06 -13.3 0.61 Allowed Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.38 -1.391 . . . . 0.0 110.581 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.457 ' N ' ' C ' ' A' ' 27' ' ' ASN . 1.0 OUTLIER -102.87 34.23 2.93 Favored 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 119.863 -0.735 . . . . 0.0 112.278 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.418 ' C ' HD12 ' A' ' 31' ' ' LEU . 2.7 t -75.34 149.86 6.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 C-N-CA 119.057 -1.057 . . . . 0.0 108.818 179.804 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.418 HD12 ' C ' ' A' ' 30' ' ' VAL . 11.0 mp -107.11 173.6 6.25 Favored 'General case' 0 N--CA 1.511 2.601 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.424 -179.878 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.4 tttm -77.16 -35.06 56.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.712 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.5 mm-40 -75.71 -9.12 58.32 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 114.961 -1.018 . . . . 0.0 108.582 179.794 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -63.77 -57.01 11.25 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.005 179.958 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.533 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.8 mp -65.16 -37.03 79.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.464 -0.894 . . . . 0.0 109.694 179.792 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -45.75 -44.65 13.95 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.353 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.05 76.21 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.471 -0.891 . . . . 0.0 110.493 179.92 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -46.29 -71.04 0.08 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.647 -179.989 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.5 HD22 ' HZ2' ' A' ' 14' ' ' LYS . 12.6 tp . . . . . 0 C--N 1.305 -1.366 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.416 -179.781 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t . . . . . 0 N--CA 1.485 1.305 0 CA-C-O 120.839 0.352 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 41.3 ttp180 -63.57 -34.37 77.66 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 118.737 -1.185 . . . . 0.0 110.767 -179.937 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt -60.12 -41.66 93.12 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.757 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -57.28 -46.34 83.22 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.069 -1.052 . . . . 0.0 109.062 179.909 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.445 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -51.71 -45.99 63.76 Favored 'General case' 0 C--N 1.291 -1.948 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.485 179.867 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.2 mtp85 -59.11 -46.12 89.15 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.806 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -54.58 -39.33 67.69 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.457 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -89.38 -3.75 58.32 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.67 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.27 6.99 66.55 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.568 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.537 HG13 ' CD2' ' A' ' 38' ' ' PHE . 63.6 t -78.13 125.38 37.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.978 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -78.56 110.32 13.56 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.322 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.49 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -43.23 -40.02 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.117 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.49 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 55.0 mtt-85 -52.64 -59.46 4.44 Favored 'General case' 0 C--N 1.286 -2.153 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.228 -179.896 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.1 mt -52.15 -24.84 7.67 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.215 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.6 t -63.61 139.54 21.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 118.936 -1.106 . . . . 0.0 112.18 -179.813 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -131.88 64.54 1.59 Allowed 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 114.906 -1.043 . . . . 0.0 109.876 -179.929 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.11 -114.96 0.88 Allowed Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.437 -1.363 . . . . 0.0 110.499 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.32 -44.87 15.67 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.824 -0.75 . . . . 0.0 110.136 -179.935 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -147.45 103.8 0.28 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.995 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -76.33 60.38 1.53 Allowed 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.677 -179.986 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.475 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.6 p-10 -157.05 -159.4 0.85 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.256 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.73 -9.09 0.67 Allowed Glycine 0 N--CA 1.484 1.876 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.475 ' H ' ' C ' ' A' ' 27' ' ' ASN . 10.9 mmt-85 -107.76 34.38 3.58 Favored 'General case' 0 N--CA 1.507 2.381 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.574 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -74.42 146.71 9.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.186 -1.006 . . . . 0.0 109.019 179.84 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.7 mp -105.44 177.56 4.82 Favored 'General case' 0 N--CA 1.511 2.589 0 C-N-CA 119.597 -0.841 . . . . 0.0 112.131 -179.741 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 12.9 tmtt? -76.5 -41.02 48.43 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.09 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.28 -4.21 34.75 Favored 'General case' 0 C--N 1.311 -1.07 0 C-N-CA 119.37 -0.932 . . . . 0.0 109.183 179.823 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -67.37 -61.55 1.86 Allowed 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.748 179.94 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 2.7 mt -69.63 -30.57 45.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.486 179.855 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -52.25 -40.55 61.83 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.668 179.899 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.96 -35.64 72.24 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.258 179.875 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.537 ' CD2' HG13 ' A' ' 16' ' ' VAL . 57.6 t80 -44.73 -70.05 0.12 Allowed 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.373 179.921 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.4 tp . . . . . 0 C--N 1.304 -1.385 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.896 -179.964 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 81.1 t . . . . . 0 N--CA 1.479 0.99 0 CA-C-O 120.936 0.398 . . . . 0.0 111.277 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.5 ttp180 -63.8 -43.44 96.3 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.194 -1.002 . . . . 0.0 111.364 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.2 mttm -52.98 -37.63 61.51 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.646 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -63.45 -48.84 76.04 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.035 -1.066 . . . . 0.0 109.012 179.766 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.38 -42.65 42.85 Favored 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.573 179.898 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.6 mmm180 -58.66 -45.27 89.73 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.973 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -54.0 -45.03 71.36 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 118.99 -1.084 . . . . 0.0 110.147 179.978 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -82.21 -16.64 48.92 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.54 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 81.56 1.77 90.26 Favored Glycine 0 N--CA 1.494 2.522 0 C-N-CA 119.51 -1.329 . . . . 0.0 110.582 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.1 t -70.56 127.39 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.49 -0.884 . . . . 0.0 110.678 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 48.9 t0 -75.0 107.24 6.93 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.67 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.503 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -42.55 -41.35 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.391 -179.88 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.503 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 21.3 ttm105 -49.24 -53.08 23.27 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.185 -179.877 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -57.42 -41.3 80.15 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.193 -179.78 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.426 HG23 ' H ' ' A' ' 21' ' ' VAL . 16.5 t -48.51 141.51 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.261 -179.827 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -141.58 55.13 1.51 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.719 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.45 -112.03 0.06 OUTLIER Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.974 -1.584 . . . . 0.0 109.96 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.1 p -78.29 -43.78 27.12 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.329 -0.948 . . . . 0.0 109.629 179.904 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -156.39 116.36 0.71 Allowed Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.934 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.6 pttm -76.58 45.83 0.42 Allowed 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.745 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.2 p-10 -142.58 -153.74 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.047 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.34 -9.07 0.9 Allowed Glycine 0 C--N 1.287 -2.171 0 C-N-CA 119.024 -1.56 . . . . 0.0 109.906 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 23.0 mmt180 -100.26 27.59 5.56 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 119.896 -0.722 . . . . 0.0 111.686 -179.972 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.3 t -79.95 128.31 38.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 119.475 -0.89 . . . . 0.0 108.669 179.886 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.526 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -95.11 173.13 7.72 Favored 'General case' 0 N--CA 1.502 2.127 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.691 -179.811 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -73.94 -34.12 64.2 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 119.069 -1.053 . . . . 0.0 108.649 179.897 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -78.03 -6.62 55.11 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.699 -0.8 . . . . 0.0 108.924 179.878 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.34 -58.13 5.36 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.066 179.916 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.2 mt -74.07 -35.73 42.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.082 -179.894 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -50.24 -41.61 50.39 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.857 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.32 -35.0 71.09 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.731 -0.787 . . . . 0.0 110.66 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -42.6 -69.05 0.15 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.255 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.6 tp . . . . . 0 C--N 1.301 -1.509 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.949 -179.976 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 120.9 0.381 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 39.6 ttm-85 -61.08 -38.62 86.9 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.536 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.6 mmtt -56.99 -42.88 81.07 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.558 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -55.6 -47.3 76.74 Favored 'General case' 0 C--N 1.302 -1.499 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.464 179.912 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.513 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -53.43 -48.38 68.82 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.117 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mmm-85 -60.96 -43.83 98.2 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.217 179.908 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 56.3 mm-40 -58.23 -28.66 65.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.679 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 11.5 mmmt -101.42 -11.28 19.49 Favored 'General case' 0 N--CA 1.5 2.027 0 C-N-CA 119.874 -0.73 . . . . 0.0 110.655 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.42 63.53 1.7 Allowed Glycine 0 N--CA 1.496 2.635 0 C-N-CA 119.592 -1.289 . . . . 0.0 110.675 179.948 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.513 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 62.7 t -145.21 130.36 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.127 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -87.14 121.49 29.67 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.606 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 3.8 tp -45.29 -44.1 3.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.78 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.53 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 53.9 ttp180 -49.21 -58.71 4.55 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.434 -0.803 . . . . 0.0 112.331 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 57.7 mt -52.69 -29.54 27.18 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.784 -0.766 . . . . 0.0 112.033 -179.849 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 t -69.11 139.34 20.61 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 C-N-CA 118.783 -1.167 . . . . 0.0 111.362 -179.818 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 -145.82 54.03 1.16 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.153 -179.978 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.56 -106.46 0.03 OUTLIER Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.309 -1.424 . . . . 0.0 111.174 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.81 -65.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.574 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -138.72 107.02 0.54 Allowed Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.547 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttp -55.9 -163.34 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.379 -0.929 . . . . 0.0 110.545 179.971 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.547 ' ND2' ' O ' ' A' ' 26' ' ' LYS . 3.0 p30 57.66 -163.06 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 CA-C-O 121.362 0.601 . . . . 0.0 112.273 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.535 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -51.1 -21.22 5.31 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.55 -179.808 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.4 mmt85 -90.09 38.76 0.94 Allowed 'General case' 0 N--CA 1.505 2.289 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.256 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 27' ' ' ASN . 4.0 t -90.46 149.34 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.956 179.85 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 7.6 mp -106.89 175.19 5.58 Favored 'General case' 0 N--CA 1.509 2.484 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.738 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.8 tttm -76.53 -38.21 55.49 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.43 -0.908 . . . . 0.0 109.425 179.849 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 57.9 mm-40 -73.69 -6.57 47.62 Favored 'General case' 0 C--N 1.307 -1.239 0 C-N-CA 119.441 -0.903 . . . . 0.0 108.966 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -67.57 -55.79 12.03 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.443 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.497 HD13 ' HB2' ' A' ' 11' ' ' ALA . 2.5 mt -73.18 -34.18 43.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.371 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -52.22 -40.03 61.06 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.448 179.926 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.24 -34.87 68.6 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.415 ' CD2' HG13 ' A' ' 16' ' ' VAL . 72.4 t80 -45.5 -70.3 0.11 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.454 -0.898 . . . . 0.0 111.184 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.507 ' C ' HD23 ' A' ' 39' ' ' LEU . 3.0 tt . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.606 -179.903 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 92.5 t . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 121.024 0.44 . . . . 0.0 110.587 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.9 ttp180 -63.65 -31.19 72.28 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.67 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.9 mmtp -55.31 -44.81 76.13 Favored 'General case' 0 C--N 1.306 -1.298 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.021 179.939 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -57.98 -51.16 70.8 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.927 -1.109 . . . . 0.0 108.56 179.782 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -45.28 55.44 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.129 179.829 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -62.32 -47.12 85.65 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.447 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -52.12 -41.0 62.13 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.239 179.8 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -81.31 -69.17 0.63 Allowed 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.53 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 138.8 33.68 0.18 Allowed Glycine 0 N--CA 1.501 2.986 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.607 179.97 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 64.5 t -109.44 138.81 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.729 -180.0 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -84.39 121.7 27.91 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.474 179.969 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 3.0 tp -48.57 -44.13 13.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 119.934 -0.707 . . . . 0.0 111.541 -179.911 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.523 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 32.9 ttm180 -54.07 -49.27 69.43 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.655 -179.908 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.4 mt -57.16 -34.72 68.73 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.52 -0.872 . . . . 0.0 112.102 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.8 t -66.7 139.62 20.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.394 -179.879 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -142.93 58.58 1.42 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.27 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.26 -104.36 0.23 Allowed Glycine 0 N--CA 1.496 2.666 0 C-N-CA 119.471 -1.347 . . . . 0.0 111.951 -179.838 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.34 -69.45 0.85 Allowed 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . -40.85 -52.79 3.88 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.03 -1.081 . . . . 0.0 110.559 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.521 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 5.2 mtmp? 48.36 -177.78 0.01 OUTLIER 'General case' 0 C--N 1.29 -2.012 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.925 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 25' ' ' GLY . 7.0 p30 43.13 -171.45 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.563 -179.94 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.92 -7.13 0.41 Allowed Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.178 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.487 ' H ' ' C ' ' A' ' 27' ' ' ASN . 42.2 mmt-85 -111.24 45.9 1.14 Allowed 'General case' 0 N--CA 1.503 2.201 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.794 -179.922 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -67.83 158.38 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.11 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.8 mt -104.27 173.14 6.43 Favored 'General case' 0 N--CA 1.51 2.564 0 C-N-CA 119.516 -0.873 . . . . 0.0 111.395 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.426 ' C ' ' H ' ' A' ' 34' ' ' ASP . 18.7 tptm -73.33 -52.77 12.67 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.381 -0.928 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -63.01 -5.5 3.02 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.224 -0.99 . . . . 0.0 109.849 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.426 ' H ' ' C ' ' A' ' 32' ' ' LYS . 4.5 t0 -66.11 -59.07 4.13 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.414 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -73.24 -33.47 41.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.765 -0.774 . . . . 0.0 111.328 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -51.22 -41.53 60.36 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.917 179.916 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.96 -33.81 66.11 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.544 -0.863 . . . . 0.0 110.607 179.89 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.0 t80 -46.06 -70.93 0.08 Allowed 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.232 179.973 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt . . . . . 0 C--N 1.306 -1.309 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.956 -179.97 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 54.4 t . . . . . 0 N--CA 1.5 2.044 0 CA-C-O 120.796 0.332 . . . . 0.0 110.806 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -62.27 -29.02 70.12 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.185 -1.006 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mmtm -59.59 -42.99 93.8 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.145 -179.943 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.432 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 8.3 t80 -60.02 -49.51 77.39 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 118.743 -1.183 . . . . 0.0 108.664 179.863 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.442 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -50.17 -44.1 52.64 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.858 -179.981 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 57.7 mtp85 -62.25 -46.44 88.81 Favored 'General case' 0 C--N 1.295 -1.765 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.276 -179.869 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -52.96 -32.38 45.7 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.07 -1.052 . . . . 0.0 109.896 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 48.5 mmtt -94.47 -18.34 21.59 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 78.55 13.26 83.39 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 26.9 t -84.12 145.12 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.794 -179.83 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -85.62 99.23 11.14 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.297 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.525 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 17.3 tt -40.75 -42.65 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.842 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.525 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 43.9 ttt85 -50.24 -61.38 2.2 Favored 'General case' 0 C--N 1.287 -2.122 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.923 -179.938 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -52.18 -28.55 18.64 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.847 -0.741 . . . . 0.0 112.754 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.406 ' H ' HG23 ' A' ' 21' ' ' VAL . 11.1 t -55.99 141.31 12.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.72 -1.192 . . . . 0.0 112.382 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -136.69 72.55 1.43 Allowed 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.719 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.6 -105.15 1.59 Allowed Glycine 0 N--CA 1.503 3.127 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.265 -179.86 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.3 p -93.7 -68.6 0.79 Allowed 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.115 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.547 ' C ' HD22 ' A' ' 27' ' ' ASN . . . -105.42 83.41 0.37 Allowed Glycine 0 N--CA 1.501 3.023 0 C-N-CA 120.022 -1.085 . . . . 0.0 110.472 -179.888 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -69.56 74.48 0.39 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.262 -0.975 . . . . 0.0 110.154 179.992 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.562 HD22 ' N ' ' A' ' 27' ' ' ASN . 0.0 OUTLIER -167.76 -161.52 0.39 Allowed 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.587 179.929 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.55 -4.08 1.25 Allowed Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.03 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.497 ' H ' ' C ' ' A' ' 27' ' ' ASN . 25.9 mmt180 -117.33 42.43 2.56 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.295 -0.562 . . . . 0.0 111.374 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -70.37 157.53 6.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 C-N-CA 119.28 -0.968 . . . . 0.0 108.74 179.841 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 60.0 mt -107.01 175.06 5.62 Favored 'General case' 0 N--CA 1.513 2.676 0 C-N-CA 119.031 -1.068 . . . . 0.0 112.037 179.973 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -77.22 -32.95 56.21 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.524 179.932 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -79.13 -8.97 59.41 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 119.39 -0.924 . . . . 0.0 108.929 -179.967 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -64.4 -54.54 31.16 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.257 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.442 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.4 mt -71.17 -34.22 53.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-N 114.588 -1.187 . . . . 0.0 110.867 179.874 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -49.7 -41.39 43.17 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.945 179.831 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.1 -34.83 71.48 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.646 179.79 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.3 t80 -42.43 -68.91 0.16 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.689 -0.804 . . . . 0.0 111.483 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.8 tp . . . . . 0 C--N 1.302 -1.489 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.901 -179.98 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 69.3 t . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 120.881 0.372 . . . . 0.0 110.223 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.626 HH21 ' HE ' ' A' ' 12' ' ' ARG . 36.0 ttt85 -59.22 -27.74 66.02 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.802 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.1 mmmt -60.99 -44.82 96.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.753 -179.926 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -56.29 -48.33 76.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.266 179.816 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.94 -45.93 67.89 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.626 ' HE ' HH21 ' A' ' 8' ' ' ARG . 13.7 mmt85 -60.42 -43.47 96.72 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.681 -179.93 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -57.37 -54.98 40.72 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.114 179.993 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -71.34 -70.17 0.33 Allowed 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.759 -179.912 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.67 69.59 0.05 OUTLIER Glycine 0 N--CA 1.499 2.849 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.996 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.0 t -144.41 129.03 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 C-N-CA 120.015 -0.674 . . . . 0.0 110.341 -179.973 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -73.55 106.61 5.4 Favored 'General case' 0 C--N 1.301 -1.508 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.387 179.849 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.8 tt -45.11 -42.27 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 119.938 -0.705 . . . . 0.0 111.468 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.526 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 71.8 mtm180 -46.29 -58.83 3.35 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.227 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.6 mt -55.46 -35.78 65.85 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.725 -0.79 . . . . 0.0 112.209 -179.798 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.42 HG23 ' H ' ' A' ' 21' ' ' VAL . 12.0 t -53.88 140.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.881 -1.128 . . . . 0.0 111.513 -179.805 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -145.2 67.18 1.23 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.403 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . -81.15 -100.63 0.35 Allowed Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.32 -1.419 . . . . 0.0 109.946 179.962 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -78.15 -47.47 18.06 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.148 179.866 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.68 116.23 0.7 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.979 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.4 ' HG2' ' H ' ' A' ' 26' ' ' LYS . 9.0 ptmm? -75.18 51.45 0.53 Allowed 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.991 179.953 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.507 ' O ' ' N ' ' A' ' 29' ' ' ARG . 2.9 p30 -147.6 -161.33 1.31 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.711 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.39 -10.89 0.12 Allowed Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.615 -1.279 . . . . 0.0 110.982 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.507 ' N ' ' O ' ' A' ' 27' ' ' ASN . 27.8 mmm-85 -106.0 38.73 1.94 Allowed 'General case' 0 N--CA 1.504 2.241 0 C-N-CA 120.044 -0.662 . . . . 0.0 112.259 -179.943 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -82.3 145.62 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.725 179.79 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.9 mp -106.78 174.49 5.86 Favored 'General case' 0 N--CA 1.51 2.572 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.185 -179.857 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -76.62 -34.31 58.34 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.368 -0.933 . . . . 0.0 108.926 179.743 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -77.0 -9.23 58.56 Favored 'General case' 0 C--N 1.312 -1.056 0 C-N-CA 119.521 -0.872 . . . . 0.0 108.912 179.84 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 23' ' ' GLY . 2.7 t0 -62.77 -49.58 74.43 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.232 179.933 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.8 mt -78.43 -33.53 17.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.259 179.889 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -52.29 -41.81 63.22 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.32 179.935 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.66 -35.88 75.56 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.704 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -43.08 -69.05 0.15 Allowed 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.335 -179.974 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.6 tp . . . . . 0 C--N 1.3 -1.558 0 CA-C-N 115.366 -0.833 . . . . 0.0 112.643 -179.751 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t . . . . . 0 N--CA 1.488 1.452 0 CA-C-O 120.936 0.398 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 28.5 ttp180 -60.83 -33.52 73.15 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.643 -179.939 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.0 mmtp -59.72 -41.13 90.19 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.334 179.895 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -58.49 -47.6 83.54 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.006 -1.078 . . . . 0.0 109.023 179.924 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.525 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.86 -46.07 41.84 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.966 179.746 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 59.2 mtp85 -57.53 -45.5 84.96 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.863 -179.875 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -53.36 -43.88 68.1 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.184 -1.007 . . . . 0.0 110.872 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 14.3 mmmt -81.43 -22.69 38.01 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.929 179.691 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.92 13.95 70.84 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.94 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.408 HG13 ' CD2' ' A' ' 38' ' ' PHE . 38.3 t -83.92 139.53 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.042 179.834 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 46.1 t0 -84.64 100.96 11.79 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.294 179.944 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.489 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -39.28 -39.58 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 CA-C-O 121.437 0.636 . . . . 0.0 111.613 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.529 ' O ' ' NE ' ' A' ' 19' ' ' ARG . 0.0 OUTLIER -50.33 -62.61 1.48 Allowed 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.092 179.911 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -50.61 -28.38 8.65 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.944 -0.703 . . . . 0.0 112.222 -179.704 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.402 HG23 ' H ' ' A' ' 21' ' ' VAL . 9.0 t -60.4 141.34 17.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 118.888 -1.125 . . . . 0.0 112.071 -179.788 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.6 mt-30 -134.31 64.51 1.6 Allowed 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.602 -179.993 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.59 -115.61 0.71 Allowed Glycine 0 N--CA 1.498 2.828 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.435 -179.911 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -81.54 -68.12 0.72 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.009 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.46 100.19 0.94 Allowed Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.887 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.411 ' HG2' ' H ' ' A' ' 26' ' ' LYS . 7.4 ptmm? -76.09 50.67 0.62 Allowed 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.514 -0.874 . . . . 0.0 110.775 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.481 ' C ' ' H ' ' A' ' 29' ' ' ARG . 2.7 p30 -151.01 -155.65 0.64 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.902 -0.719 . . . . 0.0 110.583 -179.941 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.6 -7.73 0.71 Allowed Glycine 0 C--N 1.29 -1.982 0 C-N-CA 119.357 -1.401 . . . . 0.0 110.258 -179.859 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.481 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.5 mmt85 -111.56 39.25 2.38 Favored 'General case' 0 N--CA 1.506 2.353 0 C-N-CA 120.149 -0.621 . . . . 0.0 111.81 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -76.64 155.45 5.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 C-N-CA 119.364 -0.934 . . . . 0.0 108.986 179.797 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 38.0 mt -109.44 175.43 5.45 Favored 'General case' 0 N--CA 1.514 2.732 0 C-N-CA 119.276 -0.97 . . . . 0.0 111.832 -179.902 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -78.21 -33.4 49.96 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.004 179.723 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 35.1 mm-40 -79.25 -4.99 53.33 Favored 'General case' 0 C--N 1.314 -0.955 0 C-N-CA 119.468 -0.893 . . . . 0.0 109.08 179.862 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -67.31 -58.4 4.87 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 114.687 -1.142 . . . . 0.0 109.249 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.525 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 6.0 mt -70.78 -31.33 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.738 179.703 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -51.97 -41.06 61.83 Favored 'General case' 0 C--N 1.309 -1.172 0 C-N-CA 118.906 -1.118 . . . . 0.0 110.101 -179.888 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.3 -33.37 65.16 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.619 179.906 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.408 ' CD2' HG13 ' A' ' 16' ' ' VAL . 68.3 t80 -44.68 -71.23 0.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.354 -0.939 . . . . 0.0 111.801 179.937 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 32.3 tp . . . . . 0 C--N 1.3 -1.55 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.489 -179.797 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 N--CA 1.485 1.3 0 CA-C-O 120.813 0.339 . . . . 0.0 111.166 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 24.9 ttt-85 -62.29 -48.9 77.85 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.208 -179.747 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 54.5 mttt -52.43 -38.03 58.2 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.799 179.875 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -61.48 -46.15 91.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 118.669 -1.213 . . . . 0.0 108.91 179.836 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.0 -43.18 63.53 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.648 179.9 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -56.29 -45.14 80.32 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.759 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -54.33 -42.64 70.42 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.077 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.0 mmtt -90.04 0.5 57.08 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.274 179.878 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 61.63 16.49 51.0 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.684 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.529 HG13 ' CD2' ' A' ' 38' ' ' PHE . 52.5 t -79.03 137.22 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.773 179.99 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -85.45 102.45 13.48 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.721 179.889 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.522 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -42.76 -42.62 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.906 -0.718 . . . . 0.0 111.712 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.522 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 56.4 ttt-85 -46.54 -60.06 2.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.689 179.901 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 50.6 mt -55.4 -37.54 67.73 Favored 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.683 -0.807 . . . . 0.0 112.255 -179.683 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.437 ' H ' HG23 ' A' ' 21' ' ' VAL . 11.0 t -49.51 141.28 2.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.19 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -140.96 62.14 1.48 Allowed 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.485 179.95 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.84 -103.74 0.31 Allowed Glycine 0 N--CA 1.499 2.85 0 C-N-CA 119.101 -1.524 . . . . 0.0 109.494 179.946 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -78.02 -36.01 49.2 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.291 -0.964 . . . . 0.0 108.718 179.791 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.07 -156.91 6.96 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 179.895 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.405 ' HZ2' ' HB3' ' A' ' 26' ' ' LYS . 14.7 ttpp -163.78 36.06 0.09 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.648 -0.821 . . . . 0.0 109.349 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.438 ' O ' HG23 ' A' ' 30' ' ' VAL . 10.8 p30 -154.08 -158.46 0.87 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.818 -179.999 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.28 -21.63 1.99 Allowed Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.195 -1.478 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -93.09 34.44 1.12 Allowed 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.89 179.945 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.438 HG23 ' O ' ' A' ' 27' ' ' ASN . 3.4 t -82.68 155.08 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.525 -0.87 . . . . 0.0 109.57 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.416 ' N ' ' CD2' ' A' ' 31' ' ' LEU . 3.6 mm? -104.15 173.26 6.38 Favored 'General case' 0 N--CA 1.509 2.485 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -75.31 -43.75 49.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.419 -0.912 . . . . 0.0 108.916 179.798 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -71.27 -6.79 42.49 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.48 -0.888 . . . . 0.0 109.765 -179.948 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.426 ' OD1' HG12 ' A' ' 21' ' ' VAL . 2.7 t0 -62.92 -58.2 8.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.646 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mt -69.99 -36.76 70.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.666 -0.814 . . . . 0.0 110.87 -179.92 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -48.56 -43.26 35.54 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.577 -1.249 . . . . 0.0 110.084 179.95 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.24 -35.48 78.0 Favored 'General case' 0 C--N 1.306 -1.316 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.567 -179.968 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.529 ' CD2' HG13 ' A' ' 16' ' ' VAL . 60.3 t80 -44.93 -68.04 0.23 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.385 179.984 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.2 tp . . . . . 0 C--N 1.302 -1.472 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.137 -179.893 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.1 t . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.7 0.286 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.471 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 56.7 ttt180 -60.1 -36.07 76.61 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.076 -1.049 . . . . 0.0 111.268 -179.936 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 51.4 mmtt -55.3 -45.63 76.27 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.212 -0.995 . . . . 0.0 110.336 179.87 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.411 ' CG ' ' NZ ' ' A' ' 32' ' ' LYS . 2.5 t80 -54.64 -46.64 73.98 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.101 179.906 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.529 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -49.53 -45.62 47.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.933 -179.863 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 -58.65 -43.39 89.8 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.18 -179.944 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 75.5 mt-10 -57.3 -31.43 65.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.301 -0.959 . . . . 0.0 110.935 -179.943 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.9 mmtt -96.71 -6.72 35.77 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.101 179.944 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 74.62 53.72 6.4 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.529 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 43.0 t -136.39 128.5 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.78 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.548 ' O ' ' N ' ' A' ' 19' ' ' ARG . 39.1 t0 -88.28 94.42 9.83 Favored 'General case' 0 N--CA 1.494 1.768 0 C-N-CA 119.556 -0.858 . . . . 0.0 111.036 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.529 HG23 ' N ' ' A' ' 19' ' ' ARG . 15.0 tt -23.25 -41.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.437 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -179.95 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.548 ' N ' ' O ' ' A' ' 17' ' ' ASP . 45.1 mtm-85 -45.59 -50.23 13.36 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -179.834 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.461 ' CD1' ' O ' ' A' ' 17' ' ' ASP . 0.3 OUTLIER -76.66 -2.25 31.85 Favored 'General case' 0 N--CA 1.5 2.061 0 C-N-CA 119.114 -1.035 . . . . 0.0 113.28 -179.665 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 85.2 t -74.75 146.25 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 C-N-CA 118.219 -1.392 . . . . 0.0 110.477 179.94 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -135.3 62.92 1.62 Allowed 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.502 179.962 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.15 -118.88 0.44 Allowed Glycine 0 N--CA 1.498 2.825 0 C-N-CA 119.215 -1.469 . . . . 0.0 110.432 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -75.62 -45.83 35.16 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.432 179.968 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.99 106.49 0.3 Allowed Glycine 0 N--CA 1.486 2.009 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -74.39 64.69 1.16 Allowed 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.79 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.474 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.8 p-10 -152.48 -164.96 2.08 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.538 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.42 -8.63 0.83 Allowed Glycine 0 N--CA 1.485 1.953 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.228 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.474 ' H ' ' C ' ' A' ' 27' ' ' ASN . 12.3 mmt85 -108.57 37.86 2.4 Favored 'General case' 0 N--CA 1.503 2.214 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.537 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.431 ' C ' HD12 ' A' ' 31' ' ' LEU . 2.9 t -77.63 158.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 119.504 -0.879 . . . . 0.0 108.949 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.431 HD12 ' C ' ' A' ' 30' ' ' VAL . 9.9 mp -113.64 177.51 4.61 Favored 'General case' 0 N--CA 1.513 2.707 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.591 -179.954 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.411 ' NZ ' ' CG ' ' A' ' 10' ' ' TYR . 15.9 tptp -77.3 -40.3 44.91 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.871 179.692 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -74.64 -4.22 35.9 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.469 179.843 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -64.93 -54.01 37.49 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.529 179.965 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.469 HD13 ' HB2' ' A' ' 11' ' ' ALA . 4.3 mt -75.5 -36.97 36.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.698 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 55.6 t0 -48.93 -40.46 30.21 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 118.688 -1.205 . . . . 0.0 109.91 179.895 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.89 -35.73 69.83 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.357 -179.998 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -45.7 -71.48 0.07 Allowed 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.24 179.862 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.1 tp . . . . . 0 C--N 1.302 -1.486 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.713 -179.841 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.0 t . . . . . 0 N--CA 1.492 1.665 0 CA-C-O 120.969 0.414 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 27.8 ttm180 -58.36 -37.98 76.31 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 118.973 -1.091 . . . . 0.0 110.48 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -53.83 -44.81 70.58 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.289 -179.845 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -57.67 -48.44 79.5 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 118.991 -1.083 . . . . 0.0 109.299 179.785 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.533 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -50.82 -45.26 59.43 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.323 179.972 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -60.46 -45.83 92.28 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.433 -179.885 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -55.76 -29.42 59.56 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.796 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.1 mmtt -108.58 -5.31 16.55 Favored 'General case' 0 N--CA 1.502 2.158 0 C-N-CA 120.123 -0.631 . . . . 0.0 110.768 179.97 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 62.0 81.13 0.09 OUTLIER Glycine 0 N--CA 1.491 2.305 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.588 179.923 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.553 HG13 ' CD2' ' A' ' 38' ' ' PHE . 24.5 t -147.76 129.44 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.139 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -70.7 96.92 1.28 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.577 -179.975 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 19' ' ' ARG . 16.0 tt -40.52 -41.69 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.969 179.891 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' HG23 ' A' ' 18' ' ' ILE . 10.0 tpt180 -55.14 -60.42 3.41 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.278 179.996 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.0 mt -49.42 -20.39 0.69 Allowed 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.964 -179.912 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 5.9 t -68.32 139.5 20.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.997 -179.846 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -142.61 52.56 1.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.012 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.4 -95.99 0.06 OUTLIER Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.651 -1.261 . . . . 0.0 111.036 -179.95 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.46 -46.3 16.14 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.38 -0.928 . . . . 0.0 110.291 -179.863 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -161.74 111.97 0.5 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.93 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.447 ' O ' ' OD1' ' A' ' 27' ' ' ASN . 17.5 ptmt -55.7 -163.5 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.77 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.64 ' ND2' ' N ' ' A' ' 28' ' ' GLY . 0.4 OUTLIER 50.82 -160.51 0.08 Allowed 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.416 -179.922 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.64 ' N ' ' ND2' ' A' ' 27' ' ' ASN . . . -50.2 -26.5 9.32 Favored Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.898 -1.144 . . . . 0.0 111.438 -179.823 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.435 ' O ' ' O ' ' A' ' 25' ' ' GLY . 22.0 mmt180 -75.19 29.59 0.1 Allowed 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.592 -179.883 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.475 ' H ' ' C ' ' A' ' 28' ' ' GLY . 2.9 t -90.74 133.72 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.375 179.901 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.521 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.8 mp -104.18 178.82 4.45 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.786 179.943 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -74.43 -36.86 63.42 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.132 179.731 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -75.11 -8.55 56.87 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.189 179.872 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.415 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 3.3 t0 -66.07 -57.34 7.95 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.634 179.829 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 mt -66.58 -31.34 53.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.276 -179.951 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -51.57 -40.94 60.7 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.065 -1.054 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.84 -33.19 68.24 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.687 179.924 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.553 ' CD2' HG13 ' A' ' 16' ' ' VAL . 64.9 t80 -45.47 -69.39 0.14 Allowed 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.129 -179.967 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.8 tp . . . . . 0 C--N 1.303 -1.45 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.821 -179.817 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.482 1.172 0 CA-C-O 120.828 0.347 . . . . 0.0 110.277 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 3' ' ' ALA . 18.4 mm -55.37 159.98 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.912 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.426 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -56.88 164.7 1.46 Allowed 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.491 -0.884 . . . . 0.0 110.833 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 55.6 mtt -66.79 150.62 97.54 Favored Pre-proline 0 C--N 1.303 -1.443 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.465 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -61.11 -42.68 34.38 Favored 'Trans proline' 0 C--O 1.217 -0.562 0 C-N-CA 120.769 0.98 . . . . 0.0 110.76 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.6 m -47.17 -29.97 2.63 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.647 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.9 t -87.88 -42.38 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 C-N-CA 119.442 -0.903 . . . . 0.0 111.372 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 25.1 ttm180 -61.45 -43.41 98.91 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.534 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -52.94 -39.61 63.01 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.936 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.532 ' OH ' ' NZ ' ' A' ' 14' ' ' LYS . 12.2 t80 -60.01 -50.5 73.48 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 118.7 -1.2 . . . . 0.0 109.196 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.91 -43.52 39.39 Favored 'General case' 0 C--N 1.29 -1.996 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.136 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.6 mtp180 -66.46 -45.46 79.66 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.308 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 39.1 mm-40 -46.73 -61.37 1.87 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.416 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.532 ' NZ ' ' OH ' ' A' ' 10' ' ' TYR . 11.4 ptpt -77.31 -22.99 51.11 Favored 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 118.599 -1.241 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 93.61 81.1 1.49 Allowed Glycine 0 N--CA 1.507 3.38 0 C-N-CA 119.731 -1.223 . . . . 0.0 111.477 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.557 HG13 ' CD2' ' A' ' 38' ' ' PHE . 18.7 t -148.42 129.6 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.266 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -74.03 104.52 4.89 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.651 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.535 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.5 tt -48.92 -44.2 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.928 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 19.4 ttm180 -47.88 -54.48 12.47 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.508 -0.769 . . . . 0.0 112.467 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.4 mt -57.54 -35.85 70.85 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 112.088 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 t -52.03 140.96 6.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.673 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -142.56 66.45 1.33 Allowed 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.427 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.77 -101.26 0.27 Allowed Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.067 -1.539 . . . . 0.0 109.463 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.418 ' OG1' HD13 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -82.26 -42.31 19.04 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.151 179.922 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.91 119.0 0.86 Allowed Glycine 0 N--CA 1.477 1.424 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.7 pttp -75.07 46.29 0.3 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.966 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.484 ' C ' ' H ' ' A' ' 29' ' ' ARG . 14.9 p-10 -143.19 -152.34 0.41 Allowed 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.204 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.56 -8.46 0.54 Allowed Glycine 0 C--N 1.291 -1.959 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.388 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.484 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.8 mmt180 -102.95 34.91 2.68 Favored 'General case' 0 N--CA 1.503 2.184 0 C-N-CA 119.87 -0.732 . . . . 0.0 111.821 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.429 ' C ' HD12 ' A' ' 31' ' ' LEU . 6.3 t -85.27 127.38 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.643 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.6 mp -96.31 172.36 8.0 Favored 'General case' 0 N--CA 1.505 2.314 0 C-N-CA 119.239 -0.984 . . . . 0.0 112.486 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -71.32 -33.98 70.16 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.877 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -80.21 -8.27 59.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.266 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -65.53 -53.04 47.81 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.456 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 mt -75.54 -34.4 29.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.789 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -50.53 -41.96 54.51 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.934 -1.106 . . . . 0.0 109.848 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.59 67.5 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.979 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.557 ' CD2' HG13 ' A' ' 16' ' ' VAL . 77.9 t80 -42.9 -65.87 0.43 Allowed 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.581 -0.847 . . . . 0.0 112.232 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.1 tp -72.12 -42.99 65.42 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.367 -0.933 . . . . 0.0 112.548 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -42.2 -46.56 4.47 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 119.351 -0.939 . . . . 0.0 111.454 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -47.04 -38.44 10.81 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.464 -1.351 . . . . 0.0 110.443 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.2 -92.14 1.69 Allowed Glycine 0 N--CA 1.494 2.54 0 C-N-CA 119.612 -1.28 . . . . 0.0 110.564 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.503 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.648 -179.941 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' A' ' 2' ' ' ILE . 16.5 m . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 120.904 0.383 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.449 ' O ' ' O ' ' A' ' 1' ' ' VAL . 13.6 mm 55.29 162.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.955 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.44 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -60.88 140.75 57.61 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.249 -0.981 . . . . 0.0 110.469 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 56.5 mtm -58.66 153.62 40.09 Favored Pre-proline 0 C--N 1.306 -1.308 0 C-N-CA 119.421 -0.912 . . . . 0.0 110.439 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -66.56 68.71 0.49 Allowed 'Trans proline' 0 CA--C 1.549 1.244 0 C-N-CA 120.884 1.056 . . . . 0.0 110.822 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.2 p -174.7 -39.31 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.572 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.7 t -75.02 -44.41 44.33 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.97 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.0 ttt85 -64.36 -40.69 96.36 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.177 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 17.3 mttp -53.79 -37.96 64.01 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.083 -1.047 . . . . 0.0 110.539 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -60.71 -49.99 75.3 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.766 -1.173 . . . . 0.0 108.966 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.48 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.98 -43.63 40.2 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.573 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -59.45 -45.16 92.38 Favored 'General case' 0 C--N 1.294 -1.821 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.03 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -53.67 -40.05 65.61 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.308 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 15.4 mmmt -87.99 -3.24 58.93 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.612 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.75 3.08 48.55 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.359 -1.4 . . . . 0.0 110.331 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.483 HG13 ' CD2' ' A' ' 38' ' ' PHE . 54.2 t -74.4 133.05 32.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.778 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -84.3 108.9 17.42 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.655 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.517 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.7 tt -44.14 -41.2 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.383 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.517 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.4 tpm_? -48.73 -59.93 3.14 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 114.832 -1.076 . . . . 0.0 112.552 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.6 mt -55.49 -31.44 62.01 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.528 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -53.36 140.55 9.34 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.8 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -135.46 65.4 1.55 Allowed 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 114.997 -1.002 . . . . 0.0 109.801 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.68 -118.42 0.95 Allowed Glycine 0 N--CA 1.502 3.038 0 C-N-CA 119.633 -1.27 . . . . 0.0 111.805 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.16 -72.48 0.6 Allowed 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.086 -179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.489 ' O ' ' N ' ' A' ' 27' ' ' ASN . . . -91.29 69.34 2.08 Favored Glycine 0 N--CA 1.496 2.67 0 C-N-CA 119.761 -1.209 . . . . 0.0 110.397 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -64.49 73.87 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.564 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.496 ' C ' ' H ' ' A' ' 29' ' ' ARG . 33.1 p-10 -174.37 -159.86 0.09 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.829 -0.748 . . . . 0.0 110.259 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.9 -7.62 1.1 Allowed Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.061 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.496 ' H ' ' C ' ' A' ' 27' ' ' ASN . 47.9 mmt-85 -116.5 46.26 1.64 Allowed 'General case' 0 N--CA 1.504 2.263 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.564 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.7 t -72.89 157.89 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.282 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.405 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -104.62 172.84 6.58 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.213 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -79.6 -34.34 40.83 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.582 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 51.8 mm-40 -76.04 -6.57 51.68 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 119.367 -0.933 . . . . 0.0 108.512 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -66.0 -55.47 16.53 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.408 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.48 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.5 mt -75.07 -32.59 27.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.701 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -51.24 -40.49 58.94 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.727 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.432 ' O ' ' N ' ' A' ' 41' ' ' GLY . . . -71.79 -37.24 70.45 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.533 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.483 ' CD2' HG13 ' A' ' 16' ' ' VAL . 65.7 t80 -40.78 -67.78 0.22 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.756 -0.778 . . . . 0.0 111.719 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.9 tp -73.99 -25.83 60.13 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.751 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -139.33 75.54 1.52 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.212 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 37' ' ' ALA . . . -93.76 29.66 8.3 Favored Glycine 0 N--CA 1.5 2.904 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.92 -176.84 46.55 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.533 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.345 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.857 -179.841 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 N--CA 1.48 1.047 0 CA-C-O 120.857 0.361 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.565 HG22 ' N ' ' A' ' 3' ' ' ALA . 25.0 mm -52.83 166.84 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 C-N-CA 119.532 -0.867 . . . . 0.0 110.835 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.565 ' N ' HG22 ' A' ' 2' ' ' ILE . . . 45.17 58.38 4.13 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.739 -0.784 . . . . 0.0 111.173 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.659 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 20.6 ptt? -125.45 -15.41 0.05 OUTLIER Pre-proline 0 N--CA 1.5 2.067 0 N-CA-C 114.855 1.428 . . . . 0.0 114.855 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.659 ' CD ' ' H ' ' A' ' 4' ' ' MET . 1.3 Cg_endo -66.23 -47.93 2.96 Favored 'Trans proline' 0 C--N 1.357 0.986 0 CA-C-N 120.18 1.1 . . . . 0.0 110.94 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.417 ' O ' ' OG ' ' A' ' 6' ' ' SER . 29.7 t -164.93 30.44 0.06 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.493 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 53.3 t -100.39 -76.63 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 C-N-CA 120.141 -0.624 . . . . 0.0 110.559 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -65.92 -30.82 71.46 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.007 -1.077 . . . . 0.0 110.72 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.9 mmtt -62.23 -40.03 94.8 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.014 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -57.92 -46.92 84.27 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.245 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.466 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -49.2 -45.17 43.92 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 115.111 -0.95 . . . . 0.0 111.008 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -58.5 -44.59 89.48 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.389 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 mt-10 -54.72 -51.92 64.09 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 118.986 -1.085 . . . . 0.0 110.989 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.2 mmmt -81.39 6.12 15.44 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.886 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 56.45 75.5 0.25 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.657 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.497 HG13 ' CD2' ' A' ' 38' ' ' PHE . 46.9 t -144.82 126.45 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.159 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 65.5 t0 -74.51 107.88 6.92 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.269 -0.972 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.494 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.3 tt -42.88 -40.94 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.585 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.494 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 32.7 mtm180 -54.89 -54.05 47.56 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.255 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -51.84 -36.52 48.47 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.52 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 t -56.56 142.72 11.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.843 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -142.05 62.26 1.44 Allowed 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 120.098 -0.641 . . . . 0.0 111.647 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.9 -107.23 0.83 Allowed Glycine 0 N--CA 1.5 2.916 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.82 -45.9 40.24 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.467 -0.893 . . . . 0.0 109.626 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.5 120.65 0.99 Allowed Glycine 0 N--CA 1.485 1.91 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -79.99 44.4 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.262 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.479 ' C ' ' H ' ' A' ' 29' ' ' ARG . 1.8 p30 -149.14 -152.05 0.42 Allowed 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.474 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.52 -11.44 0.48 Allowed Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.151 -1.499 . . . . 0.0 110.29 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.479 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.6 mmt180 -102.43 32.85 3.38 Favored 'General case' 0 N--CA 1.503 2.216 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.815 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.6 t -85.57 135.86 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.376 179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.436 HD12 ' N ' ' A' ' 31' ' ' LEU . 11.0 mp -103.45 173.76 6.16 Favored 'General case' 0 N--CA 1.509 2.515 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -72.75 -37.85 67.55 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.649 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -74.46 -9.19 58.34 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.997 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -66.79 -58.24 5.45 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 114.579 -1.191 . . . . 0.0 109.551 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.466 HD13 ' HB2' ' A' ' 11' ' ' ALA . 4.1 mt -72.51 -36.79 55.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.48 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 25.0 t70 -47.24 -41.12 17.9 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 119.102 -1.039 . . . . 0.0 110.245 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.402 ' O ' ' N ' ' A' ' 41' ' ' GLY . . . -72.74 -35.86 67.61 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.528 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.497 ' CD2' HG13 ' A' ' 16' ' ' VAL . 67.2 t80 -43.09 -70.73 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.377 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 30.9 tp -69.74 -60.91 2.02 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.612 -0.835 . . . . 0.0 110.79 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.48 ' HB3' ' O ' ' A' ' 36' ' ' ASP . . . -47.27 -65.58 0.54 Allowed 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.344 -0.943 . . . . 0.0 111.107 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' A' ' 37' ' ' ALA . . . -51.74 -39.5 47.0 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.445 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.31 162.55 33.09 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 119.449 -1.357 . . . . 0.0 110.531 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.371 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.762 -180.0 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.0 p . . . . . 0 N--CA 1.479 1.014 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 15.6 mm -69.2 156.14 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.069 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -91.38 -171.35 2.91 Favored 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 119.953 -0.699 . . . . 0.0 110.85 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 28.0 mtt -76.05 154.01 84.65 Favored Pre-proline 0 N--CA 1.488 1.431 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.341 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -66.14 73.38 0.36 Allowed 'Trans proline' 0 CA--C 1.546 1.103 0 C-N-CA 120.875 1.05 . . . . 0.0 111.21 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 11.5 t -178.78 -26.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 119.297 -0.961 . . . . 0.0 111.246 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.6 t -84.17 -61.49 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.513 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.402 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 68.5 ttp85 -56.61 -43.79 80.52 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.319 -0.952 . . . . 0.0 111.594 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -48.39 -46.57 37.32 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.115 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -55.34 -49.55 71.93 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 118.866 -1.134 . . . . 0.0 109.385 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.402 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -50.99 -44.47 60.89 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.688 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -59.67 -43.48 93.98 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.825 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -57.7 -43.06 84.92 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.604 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.1 mmtt -82.3 -16.79 48.12 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.618 -0.833 . . . . 0.0 111.006 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.38 3.81 90.4 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.334 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.503 HG13 ' CD2' ' A' ' 38' ' ' PHE . 37.6 t -74.28 134.65 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.56 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -81.45 107.54 14.3 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.679 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.503 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -44.84 -41.11 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 C-N-CA 119.965 -0.694 . . . . 0.0 111.142 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.503 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 1.7 tmt_? -49.64 -59.0 4.19 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.491 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.2 mt -54.39 -25.8 26.65 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.77 -0.772 . . . . 0.0 112.401 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.422 HG12 ' OD1' ' A' ' 34' ' ' ASP . 8.2 t -62.58 139.9 20.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.691 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -136.49 54.63 1.87 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.5 -110.87 0.06 OUTLIER Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.065 -1.54 . . . . 0.0 109.536 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.05 -41.31 35.91 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.429 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -159.03 116.59 0.72 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.9 ptpp? -74.75 39.01 0.13 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.235 -0.986 . . . . 0.0 111.18 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.52 ' O ' ' N ' ' A' ' 29' ' ' ARG . 2.4 p30 -142.25 -152.74 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -47.44 -11.84 0.09 OUTLIER Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.205 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.52 ' N ' ' O ' ' A' ' 27' ' ' ASN . 17.4 mmt-85 -104.33 32.84 3.79 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.178 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.4 t -82.33 128.34 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 119.391 -0.924 . . . . 0.0 108.62 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.557 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -97.83 175.68 6.07 Favored 'General case' 0 N--CA 1.507 2.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.79 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -74.06 -35.99 64.31 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 119.517 -0.873 . . . . 0.0 108.825 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -76.49 -8.01 56.3 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 119.362 -0.935 . . . . 0.0 108.627 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.422 ' OD1' HG12 ' A' ' 21' ' ' VAL . 3.8 t0 -66.4 -59.25 3.85 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 114.66 -1.154 . . . . 0.0 109.581 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mt -70.48 -30.72 43.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.556 -0.857 . . . . 0.0 110.233 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.491 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 20.5 t70 -53.77 -41.36 67.1 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.486 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.64 -32.86 70.32 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.474 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.503 ' CD2' HG13 ' A' ' 16' ' ' VAL . 67.1 t80 -45.24 -70.07 0.11 Allowed 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.32 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.416 ' O ' ' O ' ' A' ' 40' ' ' ALA . 32.2 tp -70.92 -57.36 4.66 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.713 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 36' ' ' ASP . . . -59.76 -151.3 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.298 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.913 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.55 -46.83 2.62 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.589 -1.291 . . . . 0.0 110.516 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.77 14.68 38.01 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 119.293 -1.432 . . . . 0.0 110.243 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.396 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.894 179.95 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.451 HG22 ' N ' ' A' ' 2' ' ' ILE . 6.4 p . . . . . 0 N--CA 1.48 1.051 0 CA-C-O 120.936 0.398 . . . . 0.0 110.009 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.451 ' N ' HG22 ' A' ' 1' ' ' VAL . 11.7 mm -51.85 157.46 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.875 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.426 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -88.34 61.53 6.23 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.956 -0.698 . . . . 0.0 110.669 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.63 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 23.4 ptt? -115.6 -16.01 0.1 Allowed Pre-proline 0 N--CA 1.508 2.473 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.63 ' CD ' ' N ' ' A' ' 4' ' ' MET . 5.9 Cg_endo -70.18 -70.07 0.02 OUTLIER 'Trans proline' 0 C--N 1.356 0.942 0 CA-C-N 120.177 1.099 . . . . 0.0 110.716 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.1 t -146.55 28.9 1.05 Allowed 'General case' 0 N--CA 1.49 1.537 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.832 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.5 t -97.12 -60.49 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.28 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.403 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 57.3 ttp180 -62.17 -39.75 93.71 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.984 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mttp -54.52 -40.22 68.38 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.748 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.1 t80 -58.95 -47.06 86.44 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 118.802 -1.159 . . . . 0.0 108.926 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -49.09 -44.8 42.41 Favored 'General case' 0 C--N 1.291 -1.958 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.662 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 72.1 mtt85 -59.73 -47.12 86.92 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.902 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -50.88 -41.63 58.39 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.332 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 22.7 mmtp -85.49 -19.43 31.23 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.789 -0.764 . . . . 0.0 110.797 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.38 31.58 27.47 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.467 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 40.6 t -105.37 145.3 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 C-N-CA 120.199 -0.601 . . . . 0.0 110.779 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -91.11 105.56 17.9 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 120.029 -0.669 . . . . 0.0 110.299 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.516 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.7 tt -41.08 -41.71 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 CA-C-O 121.43 0.634 . . . . 0.0 111.797 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.516 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.4 ttt85 -52.08 -57.43 9.56 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-N 115.281 -0.872 . . . . 0.0 111.975 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -52.5 -30.24 29.11 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.878 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.2 t -61.59 143.65 14.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.599 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -142.15 52.61 1.47 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.297 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.45 -106.58 0.04 OUTLIER Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.699 -1.715 . . . . 0.0 109.311 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.79 -44.03 51.67 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.464 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.51 121.97 1.08 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttm -76.79 40.14 0.24 Allowed 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.101 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.499 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.2 p-10 -142.72 -150.36 0.31 Allowed 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.797 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.4 -8.77 0.55 Allowed Glycine 0 C--N 1.284 -2.335 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.226 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.499 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.6 28.72 5.8 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.899 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 t -83.01 128.53 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.748 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.541 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -100.07 176.67 5.33 Favored 'General case' 0 N--CA 1.505 2.309 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.957 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.4 tttt -74.41 -36.01 63.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.802 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -76.37 -7.82 55.82 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.883 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -66.26 -51.97 52.26 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.187 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -74.66 -33.19 30.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.994 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -52.07 -40.89 61.85 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 118.716 -1.193 . . . . 0.0 109.566 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.81 -32.88 68.04 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.547 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -44.93 -70.54 0.1 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.433 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.533 ' O ' ' N ' ' A' ' 41' ' ' GLY . 37.4 tp -68.05 -25.21 65.25 Favored 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.478 -0.889 . . . . 0.0 111.306 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.434 ' C ' ' H ' ' A' ' 42' ' ' GLY . . . 43.47 17.86 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.191 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -67.67 4.1 4.39 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 119.346 -1.407 . . . . 0.0 110.331 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 40' ' ' ALA . . . -166.59 -6.18 0.03 OUTLIER Glycine 0 N--CA 1.484 1.871 0 C-N-CA 119.405 -1.379 . . . . 0.0 110.59 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.401 ' H ' ' H ' ' A' ' 42' ' ' GLY . . . . . . . . 0 C--N 1.303 -1.435 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.774 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 34.7 m . . . . . 0 N--CA 1.483 1.197 0 CA-C-O 120.961 0.41 . . . . 0.0 110.111 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -70.61 -175.11 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.732 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -54.0 117.21 3.03 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.437 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.649 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 0.0 OUTLIER -116.87 -13.27 0.09 OUTLIER Pre-proline 0 N--CA 1.5 2.061 0 N-CA-C 114.925 1.454 . . . . 0.0 114.925 179.919 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.649 ' CD ' ' N ' ' A' ' 4' ' ' MET . 7.6 Cg_endo -70.63 79.11 1.24 Allowed 'Trans proline' 0 C--N 1.359 1.087 0 CA-C-N 120.1 1.071 . . . . 0.0 110.832 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.2 t 54.91 12.02 0.55 Allowed 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.369 -0.932 . . . . 0.0 111.311 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.0 t -82.32 -64.63 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.628 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.416 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 64.0 ttt180 -61.42 -29.55 70.01 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.999 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 60.8 mmtt -59.5 -45.7 90.94 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.936 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -55.1 -46.67 75.52 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 119.341 -0.944 . . . . 0.0 109.04 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.555 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.93 -45.62 41.87 Favored 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.523 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 61.7 mtt-85 -64.11 -46.37 84.49 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.02 -0.991 . . . . 0.0 111.453 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 66.4 mt-10 -48.52 -48.74 38.11 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.366 -0.934 . . . . 0.0 111.344 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -83.34 -33.42 25.88 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.159 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.09 73.62 1.07 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.578 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.26 130.4 8.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 C-N-CA 120.019 -0.673 . . . . 0.0 110.193 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -76.26 103.04 6.09 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.08 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.522 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 14.1 tt -42.23 -42.61 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.707 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.522 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.7 ttp180 -45.46 -57.63 3.96 Favored 'General case' 0 C--N 1.289 -2.049 0 CA-C-N 115.264 -0.88 . . . . 0.0 112.415 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 53.1 mt -56.44 -35.97 68.47 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.647 -0.821 . . . . 0.0 112.3 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.8 t -50.18 141.44 3.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 C-N-CA 118.875 -1.13 . . . . 0.0 111.819 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -143.96 65.89 1.3 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.142 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.43 -105.55 0.6 Allowed Glycine 0 N--CA 1.499 2.84 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.07 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.94 -45.69 40.77 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.373 -0.931 . . . . 0.0 109.757 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.518 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -162.99 115.33 0.65 Allowed Glycine 0 N--CA 1.479 1.543 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -74.84 36.06 0.11 Allowed 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.091 -1.044 . . . . 0.0 110.769 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 26.3 t-20 -107.82 -179.82 4.01 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.98 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.52 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -50.01 -12.14 0.45 Allowed Glycine 0 N--CA 1.485 1.936 0 C-N-CA 119.112 -1.518 . . . . 0.0 110.016 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.49 ' N ' ' C ' ' A' ' 27' ' ' ASN . 14.7 mmt-85 -97.94 36.76 1.5 Allowed 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.624 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.4 t -71.11 153.0 8.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.001 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.407 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.7 mp -105.56 173.21 6.41 Favored 'General case' 0 N--CA 1.508 2.464 0 C-N-CA 119.332 -0.947 . . . . 0.0 111.312 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -77.18 -37.47 53.58 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.104 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -76.05 -5.58 47.1 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.396 -0.921 . . . . 0.0 109.066 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -65.12 -56.17 14.49 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.224 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.555 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 6.2 mt -69.59 -37.78 75.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.138 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -48.36 -40.46 25.58 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.985 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.21 -34.0 70.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.476 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -45.03 -71.9 0.07 Allowed 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.622 -0.831 . . . . 0.0 111.315 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.506 ' O ' ' N ' ' A' ' 41' ' ' GLY . 10.5 tp -74.95 -53.76 8.42 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.622 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 45.21 16.87 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.16 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -62.4 -68.67 1.57 Allowed Glycine 0 N--CA 1.487 2.072 0 C-N-CA 119.361 -1.4 . . . . 0.0 110.27 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.63 -112.27 0.01 OUTLIER Glycine 0 N--CA 1.488 2.16 0 C-N-CA 119.366 -1.397 . . . . 0.0 110.364 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.311 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.724 179.951 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.526 HG12 ' N ' ' A' ' 2' ' ' ILE . 96.2 t . . . . . 0 N--CA 1.483 1.204 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.526 ' N ' HG12 ' A' ' 1' ' ' VAL . 9.9 mm -49.98 166.78 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.592 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.478 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -78.98 44.72 0.57 Allowed 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.723 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.642 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 42.8 mtt -91.21 -29.92 0.33 Allowed Pre-proline 0 N--CA 1.491 1.607 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.642 ' CD ' ' N ' ' A' ' 4' ' ' MET . 6.2 Cg_exo -65.67 -153.28 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 120.367 0.711 . . . . 0.0 110.939 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.0 m -71.96 32.08 0.05 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.031 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.523 ' H ' ' C ' ' A' ' 5' ' ' PRO . 73.5 t -79.0 -62.69 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 119.505 -0.878 . . . . 0.0 110.343 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -66.22 -44.28 84.26 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.551 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -52.65 -35.4 54.86 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.745 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -62.82 -49.83 73.38 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.863 -1.135 . . . . 0.0 108.894 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.404 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -51.49 -43.69 62.27 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.973 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 44.9 mtp180 -60.78 -47.09 87.87 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.721 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.96 -53.96 28.46 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.763 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 13.7 ptmt -76.51 -24.61 53.71 Favored 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.915 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.66 70.69 1.16 Allowed Glycine 0 N--CA 1.503 3.154 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.623 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.404 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 19.2 t -148.2 145.55 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.929 -0.709 . . . . 0.0 110.287 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -90.82 106.21 18.36 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.593 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.529 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 16.6 tt -42.12 -41.72 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.512 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.529 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 84.6 mtt-85 -50.08 -60.69 2.7 Favored 'General case' 0 C--N 1.285 -2.222 0 CA-C-N 115.021 -0.991 . . . . 0.0 112.421 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 75.6 mt -51.9 -18.1 1.21 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.467 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.2 t -72.34 139.8 19.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 C-N-CA 118.671 -1.212 . . . . 0.0 111.66 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 tt0 -138.68 55.39 1.73 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.858 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.54 -109.43 0.02 OUTLIER Glycine 0 N--CA 1.492 2.378 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.698 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -70.06 -44.31 69.42 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.312 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -168.68 121.36 0.94 Allowed Glycine 0 N--CA 1.48 1.614 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.079 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.43 ' CE ' ' O ' ' A' ' 19' ' ' ARG . 0.7 OUTLIER -73.05 66.1 0.8 Allowed 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.304 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.476 ' C ' ' H ' ' A' ' 29' ' ' ARG . 12.3 p30 -152.07 -164.89 2.08 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.243 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.1 -9.52 0.9 Allowed Glycine 0 N--CA 1.483 1.783 0 C-N-CA 119.212 -1.471 . . . . 0.0 110.045 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.476 ' H ' ' C ' ' A' ' 27' ' ' ASN . 19.3 mmm-85 -100.76 30.99 3.71 Favored 'General case' 0 N--CA 1.501 2.08 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.531 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.0 t -81.42 143.67 11.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 119.596 -0.841 . . . . 0.0 108.962 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.441 ' H ' ' HB2' ' A' ' 34' ' ' ASP . 5.4 mp -112.86 174.62 5.81 Favored 'General case' 0 N--CA 1.514 2.728 0 C-N-CA 119.49 -0.884 . . . . 0.0 112.302 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -73.29 -33.65 65.33 Favored 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.168 -1.013 . . . . 0.0 108.299 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -74.55 -12.88 60.58 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.124 -0.944 . . . . 0.0 108.912 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.441 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.2 t0 -63.87 -51.3 65.23 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.228 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mt -75.79 -32.11 23.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.243 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -52.63 -40.45 62.79 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.598 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.92 -34.43 71.52 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.308 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 61.9 t80 -42.92 -70.83 0.09 Allowed 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.77 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.496 ' O ' ' N ' ' A' ' 41' ' ' GLY . 53.5 tp -69.92 -53.85 16.03 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.077 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -48.86 -11.67 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.05 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . 50.79 46.55 48.34 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.259 -1.448 . . . . 0.0 110.447 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 70.4 90.9 0.08 OUTLIER Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.424 -1.37 . . . . 0.0 110.304 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 C-N-CA 119.505 -0.878 . . . . 0.0 111.122 -179.921 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.483 1.208 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.59 HG22 ' H ' ' A' ' 3' ' ' ALA . 12.7 mm -60.79 172.38 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.448 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.59 ' H ' HG22 ' A' ' 2' ' ' ILE . . . -158.57 -154.48 0.43 Allowed 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.964 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.48 ' C ' ' H ' ' A' ' 6' ' ' SER . 67.4 mtt -75.32 150.48 85.11 Favored Pre-proline 0 N--CA 1.484 1.24 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.629 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -68.3 31.1 0.15 Allowed 'Trans proline' 0 CA--C 1.548 1.214 0 C-N-CA 121.014 1.143 . . . . 0.0 111.674 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.48 ' H ' ' C ' ' A' ' 4' ' ' MET . 31.4 t -151.68 -25.63 0.19 Allowed 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 118.94 -1.104 . . . . 0.0 111.817 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 85.7 t -76.14 -60.38 2.39 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 C-N-CA 119.258 -0.977 . . . . 0.0 111.183 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 61.3 ttt180 -63.29 -37.21 86.35 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.85 -1.14 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.8 mmtt -55.81 -40.35 72.64 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.491 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -56.62 -51.11 69.95 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.631 -1.228 . . . . 0.0 108.977 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.24 -45.38 54.01 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.246 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtp180 -62.89 -46.69 86.63 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.823 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -52.07 -55.8 18.42 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.782 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.6 mmtt -67.7 -66.03 0.61 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 133.66 64.73 0.07 OUTLIER Glycine 0 N--CA 1.499 2.867 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.427 HG13 ' CD2' ' A' ' 38' ' ' PHE . 41.9 t -142.24 138.99 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.479 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 38.2 t0 -83.96 109.23 17.45 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.639 -0.825 . . . . 0.0 110.553 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.479 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 9.2 tt -44.05 -41.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.512 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.479 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 58.6 ttp180 -50.33 -58.16 6.3 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.33 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.2 mt -54.93 -28.21 49.22 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.325 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.404 ' H ' HG23 ' A' ' 21' ' ' VAL . 6.9 t -62.43 142.28 16.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 C-N-CA 118.754 -1.179 . . . . 0.0 111.308 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -142.23 66.24 1.34 Allowed 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.52 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.1 -103.22 0.66 Allowed Glycine 0 N--CA 1.5 2.93 0 C-N-CA 119.24 -1.457 . . . . 0.0 109.552 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -79.7 -51.81 8.75 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.598 -0.841 . . . . 0.0 109.486 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.25 114.19 0.63 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 pttm -76.0 55.95 0.95 Allowed 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.045 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.488 ' C ' ' N ' ' A' ' 29' ' ' ARG . 1.5 p30 -146.2 -162.34 1.5 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.259 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.46 -10.19 0.54 Allowed Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.303 -1.427 . . . . 0.0 110.153 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.488 ' N ' ' C ' ' A' ' 27' ' ' ASN . 13.2 mmt85 -104.39 35.25 2.78 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.751 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -78.07 145.24 10.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.296 -0.962 . . . . 0.0 108.625 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.1 mp -102.86 173.04 6.49 Favored 'General case' 0 N--CA 1.511 2.596 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.708 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.6 tttm -74.18 -43.49 57.09 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.242 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -70.95 -5.18 28.96 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.45 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -68.37 -56.79 7.29 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.177 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -71.45 -31.14 42.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.405 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.421 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 17.7 m-20 -53.71 -42.33 67.92 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.602 -1.239 . . . . 0.0 109.531 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.8 -35.45 78.67 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.282 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.427 ' CD2' HG13 ' A' ' 16' ' ' VAL . 64.6 t80 -43.04 -70.47 0.11 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.266 -0.974 . . . . 0.0 111.342 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.425 ' O ' ' O ' ' A' ' 40' ' ' ALA . 55.1 tp -71.05 -65.29 0.76 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.61 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.425 ' O ' ' O ' ' A' ' 39' ' ' LEU . . . -50.4 179.53 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.271 -0.971 . . . . 0.0 110.586 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 47.74 32.58 8.43 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.295 -1.431 . . . . 0.0 110.288 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 163.21 -176.08 39.45 Favored Glycine 0 N--CA 1.485 1.916 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.076 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.322 0 C-N-CA 119.258 -0.977 . . . . 0.0 110.907 -179.97 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.5 m . . . . . 0 N--CA 1.483 1.203 0 CA-C-O 120.938 0.399 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.9 OUTLIER -103.6 -176.17 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.235 0 CA-C-O 121.376 0.608 . . . . 0.0 111.283 179.934 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.429 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 45.33 -174.9 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.279 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.5 ' C ' ' H ' ' A' ' 6' ' ' SER . 92.1 mtp -84.76 154.79 61.74 Favored Pre-proline 0 N--CA 1.487 1.384 0 C-N-CA 119.934 -0.706 . . . . 0.0 110.242 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -66.43 30.98 0.11 Allowed 'Trans proline' 0 CA--C 1.55 1.302 0 C-N-CA 120.924 1.082 . . . . 0.0 111.998 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.5 ' H ' ' C ' ' A' ' 4' ' ' MET . 21.0 t -142.52 -20.81 0.68 Allowed 'General case' 0 N--CA 1.5 2.07 0 C-N-CA 119.484 -0.886 . . . . 0.0 111.237 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 84.9 t -82.23 -52.78 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 C-N-CA 119.427 -0.909 . . . . 0.0 111.126 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 58.7 ttt-85 -58.09 -31.64 67.3 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.256 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -61.15 -39.97 92.1 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.206 -0.998 . . . . 0.0 110.511 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 6.1 t80 -59.08 -48.36 81.88 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 118.944 -1.102 . . . . 0.0 109.259 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.411 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -49.71 -42.38 45.74 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.791 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -61.96 -43.51 98.69 Favored 'General case' 0 C--N 1.292 -1.907 0 C-N-CA 119.484 -0.887 . . . . 0.0 111.082 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -55.04 -54.41 43.44 Favored 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.309 -0.956 . . . . 0.0 110.928 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.4 mmtp -79.82 -19.43 48.46 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.066 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 76.06 81.93 0.52 Allowed Glycine 0 N--CA 1.49 2.24 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.968 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.464 HG13 ' CE2' ' A' ' 38' ' ' PHE . 17.9 t -146.9 141.57 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.918 -0.713 . . . . 0.0 110.647 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -80.31 97.57 7.05 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.267 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.4 tt -40.19 -37.79 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.534 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.441 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 57.0 mtp180 -54.96 -62.72 1.48 Allowed 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.364 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.0 mt -51.17 -17.67 0.72 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.549 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.3 t -68.35 141.16 17.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 C-N-CA 118.502 -1.279 . . . . 0.0 111.447 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -139.83 67.77 1.37 Allowed 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.037 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.12 -114.01 1.34 Allowed Glycine 0 N--CA 1.498 2.814 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.025 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -74.34 -44.05 54.04 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.91 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.5 111.94 0.5 Allowed Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -75.85 53.07 0.73 Allowed 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.081 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.473 ' C ' ' N ' ' A' ' 29' ' ' ARG . 3.2 p30 -146.02 -164.09 1.88 Allowed 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 120.212 -0.595 . . . . 0.0 110.322 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -49.55 -13.57 0.5 Allowed Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.191 -1.48 . . . . 0.0 110.414 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.473 ' N ' ' C ' ' A' ' 27' ' ' ASN . 0.2 OUTLIER -101.11 33.95 2.69 Favored 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 119.917 -0.713 . . . . 0.0 112.152 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.7 t -76.66 150.18 6.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.047 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 9.6 mp -107.98 174.88 5.69 Favored 'General case' 0 N--CA 1.511 2.619 0 C-N-CA 119.482 -0.887 . . . . 0.0 111.033 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.5 tttm -77.32 -38.14 51.13 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.292 -0.963 . . . . 0.0 108.786 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -73.9 -7.49 52.52 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 119.563 -0.855 . . . . 0.0 108.876 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -64.31 -57.65 8.79 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.706 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.7 mt -72.28 -29.01 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.6 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -53.13 -43.41 66.92 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.627 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.418 ' O ' ' O ' ' A' ' 40' ' ' ALA . . . -69.56 -35.02 75.02 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.543 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.464 ' CE2' HG13 ' A' ' 16' ' ' VAL . 67.2 t80 -43.78 -68.62 0.18 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.341 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.567 ' C ' HD23 ' A' ' 39' ' ' LEU . 4.5 tt -73.78 -68.65 0.49 Allowed 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.901 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.418 ' O ' ' O ' ' A' ' 37' ' ' ALA . . . -66.62 -173.85 0.26 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.334 -0.946 . . . . 0.0 111.025 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -161.51 46.63 0.37 Allowed Glycine 0 N--CA 1.485 1.9 0 C-N-CA 119.711 -1.233 . . . . 0.0 110.208 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -71.57 75.06 0.71 Allowed Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.551 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.324 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.905 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.482 1.142 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.479 HG22 ' N ' ' A' ' 3' ' ' ALA . 18.0 mm -66.25 165.54 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.444 -0.902 . . . . 0.0 110.404 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.479 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -64.83 92.42 0.1 Allowed 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.576 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.496 ' O ' ' N ' ' A' ' 6' ' ' SER . 34.1 mtm -67.38 151.01 97.57 Favored Pre-proline 0 C--N 1.306 -1.294 0 C-N-CA 119.242 -0.983 . . . . 0.0 109.947 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -62.51 72.86 0.11 Allowed 'Trans proline' 0 CA--C 1.545 1.032 0 C-N-CA 120.683 0.922 . . . . 0.0 110.616 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.496 ' N ' ' O ' ' A' ' 4' ' ' MET . 8.8 t -175.63 -16.95 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.217 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.9 t -88.64 -48.92 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.079 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.58 HH22 HH21 ' A' ' 12' ' ' ARG . 48.7 ttt-85 -60.95 -40.18 92.32 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.528 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -56.41 -41.34 76.16 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.586 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -56.28 -46.46 79.71 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.029 -1.068 . . . . 0.0 109.149 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -51.02 -44.9 61.1 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.67 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.58 HH21 HH22 ' A' ' 8' ' ' ARG . 6.5 mmp_? -59.47 -42.83 92.92 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.179 -179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.425 ' C ' ' H ' ' A' ' 15' ' ' GLY . 48.2 mt-10 -58.14 -64.52 0.88 Allowed 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.344 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.2 mmtm -69.29 8.71 0.55 Allowed 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.295 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 13' ' ' GLU . . . 55.55 78.19 0.13 Allowed Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.787 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.512 HG13 ' CD2' ' A' ' 38' ' ' PHE . 37.1 t -147.71 137.32 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.075 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 68.6 t0 -87.43 106.4 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.7 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.534 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -43.85 -42.89 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-O 121.52 0.676 . . . . 0.0 111.862 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.534 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 46.0 mtt-85 -49.33 -59.72 3.45 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 114.999 -1.001 . . . . 0.0 113.119 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 49.3 mt -55.76 -24.68 36.85 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.961 -0.695 . . . . 0.0 112.668 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.5 t -57.86 141.1 15.29 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 C-N-CA 118.641 -1.224 . . . . 0.0 112.033 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -136.4 59.18 1.71 Allowed 'General case' 0 N--CA 1.482 1.158 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.672 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.8 -110.41 0.09 OUTLIER Glycine 0 N--CA 1.494 2.551 0 C-N-CA 118.957 -1.592 . . . . 0.0 109.751 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.84 -43.59 29.93 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.322 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.453 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -159.84 114.82 0.63 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 ptmt -74.9 38.88 0.13 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.284 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.492 ' C ' ' H ' ' A' ' 29' ' ' ARG . 18.7 p-10 -124.43 -161.96 1.04 Allowed 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.207 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.06 -6.37 0.82 Allowed Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.156 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.492 ' H ' ' C ' ' A' ' 27' ' ' ASN . 16.1 mmt180 -102.44 34.93 2.59 Favored 'General case' 0 N--CA 1.502 2.126 0 C-N-CA 119.964 -0.695 . . . . 0.0 111.805 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -80.92 150.37 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 C-N-CA 119.341 -0.944 . . . . 0.0 108.934 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.444 ' H ' ' HB2' ' A' ' 34' ' ' ASP . 5.4 mp -120.26 -179.91 4.09 Favored 'General case' 0 N--CA 1.515 2.801 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.011 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 tttp -78.86 -33.2 46.05 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.75 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.62 ' CD ' ' H ' ' A' ' 33' ' ' GLU . 2.3 pm0 -75.3 -7.67 54.57 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.444 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.2 t0 -67.6 -54.71 17.49 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 114.523 -1.217 . . . . 0.0 109.369 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mt -72.98 -35.23 48.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.316 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -48.44 -40.71 27.09 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.208 -0.997 . . . . 0.0 110.177 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.14 -32.58 64.98 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.498 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.512 ' CD2' HG13 ' A' ' 16' ' ' VAL . 72.0 t80 -44.13 -69.08 0.15 Allowed 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.601 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.3 tp -73.04 -50.23 24.21 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.12 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 45.5 54.09 7.81 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.65 -0.82 . . . . 0.0 111.125 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -158.29 16.42 0.29 Allowed Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.371 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.76 -29.81 11.37 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.301 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.327 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.865 -179.962 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 N--CA 1.481 1.097 0 CA-C-O 121.005 0.431 . . . . 0.0 109.912 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.453 ' H ' HD12 ' A' ' 2' ' ' ILE . 0.8 OUTLIER -143.7 176.02 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 C-N-CA 119.795 -0.762 . . . . 0.0 110.321 179.982 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -56.19 120.19 7.15 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.219 -0.992 . . . . 0.0 110.345 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.401 ' O ' ' N ' ' A' ' 6' ' ' SER . 61.7 mtt -64.2 150.68 92.05 Favored Pre-proline 0 C--N 1.306 -1.289 0 C-N-CA 119.08 -1.048 . . . . 0.0 110.839 -179.854 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -61.78 80.88 0.09 OUTLIER 'Trans proline' 0 CA--C 1.543 0.972 0 C-N-CA 120.874 1.049 . . . . 0.0 110.932 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.401 ' N ' ' O ' ' A' ' 4' ' ' MET . 3.9 t 175.9 -8.48 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 C-N-CA 119.569 -0.852 . . . . 0.0 110.611 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t -103.51 -66.56 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 C-N-CA 120.14 -0.624 . . . . 0.0 111.263 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 25.7 ttm-85 -60.73 -38.78 86.3 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.296 -0.961 . . . . 0.0 111.336 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -54.25 -42.31 69.79 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -57.19 -49.72 75.11 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 118.607 -1.237 . . . . 0.0 109.15 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -48.36 -42.32 31.26 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.184 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -63.55 -45.79 88.91 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 119.398 -0.921 . . . . 0.0 111.225 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -50.85 -56.17 13.5 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.951 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 55.5 mmtt -79.88 -22.55 42.73 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.114 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 83.4 80.71 1.0 Allowed Glycine 0 N--CA 1.497 2.711 0 C-N-CA 119.573 -1.299 . . . . 0.0 110.496 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.526 HG13 ' CD2' ' A' ' 38' ' ' PHE . 28.2 t -147.61 135.28 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.409 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -78.35 102.96 7.99 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.266 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.519 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -44.85 -42.99 2.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.663 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.519 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 17.5 tpp180 -52.62 -54.09 37.99 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.273 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.3 mt -55.7 -26.7 46.44 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.05 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.6 t -61.35 143.04 15.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.757 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -132.99 69.76 1.48 Allowed 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.613 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.81 -114.49 2.91 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.544 -1.313 . . . . 0.0 110.415 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.07 -46.03 31.13 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.293 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -153.4 109.82 0.42 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 11.8 pttm -77.28 61.07 2.08 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.81 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.5 OUTLIER -156.9 -161.59 1.11 Allowed 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.12 179.901 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -9.07 0.41 Allowed Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.59 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 14.9 mmt85 -111.9 40.95 2.04 Favored 'General case' 0 N--CA 1.507 2.385 0 C-N-CA 120.167 -0.613 . . . . 0.0 111.592 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.8 t -80.91 157.9 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.658 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 7.9 mp -113.42 173.39 6.43 Favored 'General case' 0 N--CA 1.509 2.522 0 C-N-CA 119.74 -0.784 . . . . 0.0 110.948 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -76.3 -43.06 43.19 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.053 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -66.79 -10.06 43.56 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 118.98 -1.088 . . . . 0.0 108.44 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -66.2 -57.52 7.41 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.568 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 mt -72.33 -33.27 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.649 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 39.5 t0 -49.71 -41.38 43.28 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.191 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.18 -35.04 68.86 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.467 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' A' ' 16' ' ' VAL . 70.5 t80 -43.72 -70.2 0.11 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.631 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' A' ' 41' ' ' GLY . 4.1 tt -69.4 -57.05 5.77 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.745 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -49.44 90.04 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.491 -0.884 . . . . 0.0 110.461 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . 137.42 -36.2 1.98 Allowed Glycine 0 N--CA 1.5 2.916 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 51.5 -105.12 0.19 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.329 -1.415 . . . . 0.0 110.505 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.363 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.661 -179.978 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.489 ' O ' ' SD ' ' A' ' 4' ' ' MET . 13.4 t . . . . . 0 N--CA 1.482 1.142 0 CA-C-O 120.938 0.399 . . . . 0.0 109.942 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.435 ' O ' ' O ' ' A' ' 3' ' ' ALA . 19.9 mm -75.38 156.28 6.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.996 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.435 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 52.42 104.6 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.637 -0.825 . . . . 0.0 111.136 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.673 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 60.9 mmm -114.34 -32.73 0.1 Allowed Pre-proline 0 N--CA 1.508 2.44 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.673 ' CD ' ' H ' ' A' ' 4' ' ' MET . 2.6 Cg_endo -72.61 -161.6 0.11 Allowed 'Trans proline' 0 C--O 1.216 -0.598 0 N-CA-C 110.325 -0.683 . . . . 0.0 110.325 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 73.0 m -77.69 53.23 1.08 Allowed 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.303 -0.959 . . . . 0.0 109.902 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 82.0 t -102.93 -83.23 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.642 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -66.71 -45.39 78.86 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.959 -1.096 . . . . 0.0 110.697 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mttm -53.83 -35.85 61.88 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.638 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -63.27 -47.14 83.61 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.405 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.06 -42.64 63.31 Favored 'General case' 0 C--N 1.291 -1.95 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.595 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 69.2 mtp180 -60.98 -46.48 90.56 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.678 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -54.59 -44.01 72.64 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.879 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.0 mmtt -86.14 -69.78 0.64 Allowed 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.692 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.75 73.35 0.06 OUTLIER Glycine 0 N--CA 1.502 3.076 0 C-N-CA 119.88 -1.153 . . . . 0.0 110.773 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 39.9 t -144.67 137.44 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.493 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.1 t0 -79.85 112.28 16.98 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.804 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 7.3 tp -43.11 -43.17 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.641 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.532 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.7 tpt180 -59.91 -56.25 24.07 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.595 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.407 HD23 ' HA ' ' A' ' 20' ' ' LEU . 74.0 mt -47.16 -21.17 0.22 Allowed 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.558 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.5 t -76.5 143.18 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.976 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -132.48 65.33 1.58 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.983 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.2 -121.99 2.62 Favored Glycine 0 N--CA 1.502 3.058 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.242 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.404 ' OG1' HD23 ' A' ' 31' ' ' LEU . 0.7 OUTLIER -73.26 -60.15 2.38 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.987 179.87 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -134.9 109.7 0.79 Allowed Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt -76.49 55.46 1.02 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.03 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.479 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.4 OUTLIER -156.89 -157.84 0.72 Allowed 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.585 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.36 -10.52 0.56 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.239 -1.458 . . . . 0.0 110.236 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.479 ' H ' ' C ' ' A' ' 27' ' ' ASN . 28.0 mmt180 -107.71 37.27 2.47 Favored 'General case' 0 N--CA 1.506 2.34 0 C-N-CA 120.074 -0.651 . . . . 0.0 111.709 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.414 ' C ' HD22 ' A' ' 31' ' ' LEU . 2.7 t -80.68 156.62 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 119.545 -0.862 . . . . 0.0 109.619 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.414 HD22 ' C ' ' A' ' 30' ' ' VAL . 3.9 mm? -105.78 172.49 6.77 Favored 'General case' 0 N--CA 1.508 2.459 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.365 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 48.4 tttm -77.1 -42.89 36.28 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 118.863 -1.135 . . . . 0.0 109.245 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -70.89 -3.38 18.87 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.47 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -67.33 -59.73 3.17 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.959 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.2 mt -72.1 -30.5 36.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.534 -0.867 . . . . 0.0 110.881 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -53.23 -41.58 65.52 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.895 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.18 -31.56 62.73 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.823 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 74.4 t80 -47.92 -69.89 0.11 Allowed 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 119.219 -0.993 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.455 ' C ' HD23 ' A' ' 39' ' ' LEU . 3.6 tt -71.63 -54.49 10.22 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.931 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 46.28 63.6 1.81 Allowed 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 119.629 -0.828 . . . . 0.0 111.039 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -62.92 -81.37 0.1 OUTLIER Glycine 0 N--CA 1.49 2.253 0 C-N-CA 119.33 -1.414 . . . . 0.0 110.366 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 57.11 -103.35 0.28 Allowed Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.285 -1.436 . . . . 0.0 110.276 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.785 179.972 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.887 HG22 ' H ' ' A' ' 3' ' ' ALA . 13.1 mt . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.695 0.283 . . . . 0.0 110.429 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.887 ' H ' HG22 ' A' ' 2' ' ' ILE . . . 55.11 162.21 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.728 -0.789 . . . . 0.0 110.935 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 36.7 mtm -61.76 152.96 73.93 Favored Pre-proline 0 C--N 1.306 -1.312 0 C-N-CA 119.007 -1.077 . . . . 0.0 110.333 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.494 ' C ' ' H ' ' A' ' 7' ' ' VAL . 3.6 Cg_endo -62.62 172.01 5.04 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 120.942 1.094 . . . . 0.0 111.452 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m 64.37 -10.06 0.15 Allowed 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.102 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.494 ' H ' ' C ' ' A' ' 5' ' ' PRO . 70.0 t -82.27 -65.08 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.714 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 34.0 ttm180 -60.62 -39.37 87.98 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.189 -1.005 . . . . 0.0 111.135 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.4 mttp -53.02 -42.84 66.06 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.9 t80 -57.61 -50.18 73.99 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.739 -1.184 . . . . 0.0 109.22 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.8 -45.01 49.5 Favored 'General case' 0 C--N 1.288 -2.101 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.811 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -60.49 -45.82 92.37 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.075 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -52.36 -51.95 56.09 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 18.2 mtpp -81.29 -8.58 59.77 Favored 'General case' 0 N--CA 1.489 1.515 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.89 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 70.52 75.4 0.61 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.358 -1.401 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.526 HG13 ' CD2' ' A' ' 38' ' ' PHE . 42.8 t -144.25 126.53 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.946 -0.701 . . . . 0.0 110.413 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -72.79 100.77 2.95 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.526 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.8 tt -41.25 -41.74 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.69 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 17.9 tpp180 -52.12 -53.06 47.31 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.327 -0.852 . . . . 0.0 112.207 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.4 mt -57.84 -28.98 64.59 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.156 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 t -59.08 140.28 17.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.559 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -140.55 63.2 1.47 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.853 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.26 -101.85 0.35 Allowed Glycine 0 N--CA 1.496 2.656 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.89 -42.7 21.02 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.631 -0.827 . . . . 0.0 110.098 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.93 114.77 0.62 Allowed Glycine 0 N--CA 1.485 1.936 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.1 pttt -75.87 57.33 1.03 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.963 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.48 ' C ' ' N ' ' A' ' 29' ' ' ARG . 41.3 p30 -149.89 -161.37 1.33 Allowed 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.633 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.09 -11.13 0.36 Allowed Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.597 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.48 ' N ' ' C ' ' A' ' 27' ' ' ASN . 18.9 mmt180 -104.58 35.52 2.72 Favored 'General case' 0 N--CA 1.504 2.258 0 C-N-CA 119.861 -0.735 . . . . 0.0 111.79 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -81.45 135.11 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.546 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.6 mp -101.52 174.01 6.17 Favored 'General case' 0 N--CA 1.511 2.616 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.795 -179.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 50.7 tttm -75.27 -34.18 61.32 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 119.137 -1.025 . . . . 0.0 108.304 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.1 tp10 -71.14 -16.21 62.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -63.22 -54.33 39.1 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 114.201 -1.363 . . . . 0.0 109.123 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.2 mt -73.34 -34.18 42.85 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.532 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -50.55 -41.31 53.92 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.502 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.46 -36.36 76.5 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.291 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' A' ' 16' ' ' VAL . 56.9 t80 -43.86 -69.96 0.12 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.374 -0.931 . . . . 0.0 111.489 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.434 ' O ' HD13 ' A' ' 39' ' ' LEU . 0.2 OUTLIER -76.08 -50.15 15.5 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.41 -179.905 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 51.02 47.88 24.08 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.715 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -81.61 3.52 78.28 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.363 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -68.72 74.84 0.31 Allowed Glycine 0 N--CA 1.491 2.319 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.383 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.387 0 C-N-CA 119.299 -0.961 . . . . 0.0 110.726 179.987 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.45 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 121.249 0.547 . . . . 0.0 110.914 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 53.75 164.35 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.078 -0.965 . . . . 0.0 111.243 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 79.1 mtp -75.48 150.66 84.84 Favored Pre-proline 0 C--N 1.305 -1.327 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.03 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -63.85 83.38 0.14 Allowed 'Trans proline' 0 CA--C 1.54 0.804 0 C-N-CA 120.665 0.91 . . . . 0.0 110.808 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 172.42 -31.21 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.469 -0.893 . . . . 0.0 110.821 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.2 t -88.25 -41.47 14.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.483 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -62.94 -40.93 99.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 118.905 -1.118 . . . . 0.0 111.224 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.445 ' H ' ' CD ' ' A' ' 9' ' ' LYS . 0.4 OUTLIER -51.64 -40.34 59.78 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.411 179.977 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -61.04 -51.43 69.21 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 118.909 -1.116 . . . . 0.0 108.904 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.11 -43.14 51.54 Favored 'General case' 0 C--N 1.291 -1.945 0 CA-C-N 115.19 -0.913 . . . . 0.0 110.25 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -63.02 -47.32 83.56 Favored 'General case' 0 C--N 1.296 -1.749 0 CA-C-N 115.057 -0.974 . . . . 0.0 110.358 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -51.85 -31.4 27.68 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.153 -1.019 . . . . 0.0 110.108 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.3 mmtp -97.78 -10.1 25.4 Favored 'General case' 0 N--CA 1.495 1.796 0 C-N-CA 119.979 -0.689 . . . . 0.0 110.692 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.08 1.5 74.2 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.358 -1.401 . . . . 0.0 109.962 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.472 HG13 ' CE2' ' A' ' 38' ' ' PHE . 41.9 t -71.31 137.32 23.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.933 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -86.38 105.8 16.97 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.278 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 19' ' ' ARG . 16.4 tt -43.04 -43.04 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.994 -179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' HG23 ' A' ' 18' ' ' ILE . 37.8 mtp180 -48.81 -57.72 5.94 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.865 -179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.2 mt -54.43 -29.63 49.93 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 119.723 -0.791 . . . . 0.0 112.56 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -55.6 140.35 13.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.623 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.8 mt-30 -132.46 62.27 1.65 Allowed 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.397 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -83.92 -121.43 0.86 Allowed Glycine 0 N--CA 1.496 2.699 0 C-N-CA 119.098 -1.525 . . . . 0.0 110.54 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.52 -66.22 0.92 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.708 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.67 -62.94 5.68 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.897 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 66.9 tttt 56.43 38.86 30.06 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.554 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.507 ' C ' ' H ' ' A' ' 29' ' ' ARG . 38.2 p-10 -163.71 -160.77 0.6 Allowed 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.182 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.29 -5.41 0.71 Allowed Glycine 0 N--CA 1.484 1.885 0 C-N-CA 119.16 -1.495 . . . . 0.0 110.249 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.507 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -122.93 45.6 2.37 Favored 'General case' 0 N--CA 1.504 2.232 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.657 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -70.4 160.4 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 C-N-CA 119.089 -1.044 . . . . 0.0 108.946 179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 9.3 mp -105.79 172.66 6.68 Favored 'General case' 0 N--CA 1.513 2.679 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.08 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -79.01 -37.51 39.01 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.393 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -72.45 -7.44 49.86 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -66.1 -59.0 4.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 114.563 -1.199 . . . . 0.0 109.621 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -72.64 -28.54 27.98 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.548 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -53.41 -40.95 65.5 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.697 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.51 -35.54 68.14 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.583 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.472 ' CE2' HG13 ' A' ' 16' ' ' VAL . 67.0 t80 -42.19 -70.12 0.12 Allowed 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.666 -0.813 . . . . 0.0 112.284 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.435 ' O ' ' O ' ' A' ' 40' ' ' ALA . 32.2 tp -67.35 -46.0 74.71 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.076 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.435 ' O ' ' O ' ' A' ' 39' ' ' LEU . . . -48.42 177.6 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.016 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 57.46 15.06 15.26 Favored Glycine 0 N--CA 1.489 2.224 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.211 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 77.99 -52.93 3.71 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.151 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.26 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.888 180.0 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 2' ' ' ILE . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.413 0 CA-C-O 121.082 0.467 . . . . 0.0 110.517 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -58.44 135.56 57.27 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.681 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 13.8 mmt -50.45 153.19 2.77 Favored Pre-proline 0 C--N 1.305 -1.352 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.261 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.419 ' O ' ' CB ' ' A' ' 6' ' ' SER . 2.5 Cg_endo -56.94 169.9 1.7 Allowed 'Trans proline' 0 C--O 1.212 -0.799 0 C-N-CA 120.634 0.89 . . . . 0.0 110.961 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.419 ' CB ' ' O ' ' A' ' 5' ' ' PRO . 1.4 p 72.45 -11.73 0.79 Allowed 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.982 -0.687 . . . . 0.0 111.894 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 60.7 t -89.08 -71.41 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.699 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.1 ttt85 -65.39 -43.97 88.99 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 118.782 -1.167 . . . . 0.0 110.254 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -56.09 -35.37 66.94 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.185 -1.006 . . . . 0.0 110.698 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -61.46 -45.5 93.99 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.837 -1.145 . . . . 0.0 109.111 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -48.32 -42.62 31.71 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.402 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -64.2 -44.82 90.8 Favored 'General case' 0 C--N 1.291 -1.935 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.061 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 78.8 mm-40 -51.29 -53.09 39.04 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.783 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -82.26 -22.62 35.71 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.646 -0.822 . . . . 0.0 111.012 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 83.36 78.85 1.06 Allowed Glycine 0 N--CA 1.497 2.702 0 C-N-CA 119.469 -1.348 . . . . 0.0 110.305 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.468 HG13 ' CD2' ' A' ' 38' ' ' PHE . 33.6 t -145.7 138.57 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 120.035 -0.666 . . . . 0.0 110.161 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.2 t0 -80.95 97.1 7.3 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.05 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.512 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 11.8 tt -41.2 -41.73 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.562 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.512 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 13.4 tpp180 -49.96 -57.92 6.52 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.713 -179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 51.2 mt -57.42 -36.62 71.58 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.547 -0.861 . . . . 0.0 112.163 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.432 ' H ' HG23 ' A' ' 21' ' ' VAL . 14.8 t -47.08 140.92 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.69 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -133.78 65.37 1.58 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.294 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.49 -114.17 0.78 Allowed Glycine 0 N--CA 1.496 2.678 0 C-N-CA 119.14 -1.505 . . . . 0.0 109.951 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.08 -61.01 2.03 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.01 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.35 102.62 0.59 Allowed Glycine 0 N--CA 1.5 2.947 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.2 pttp -74.59 61.5 0.96 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' N ' ' A' ' 29' ' ' ARG . 8.3 p30 -164.25 -154.97 0.27 Allowed 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.484 -0.887 . . . . 0.0 110.801 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.4 -9.99 0.5 Allowed Glycine 0 C--N 1.291 -1.964 0 C-N-CA 119.635 -1.269 . . . . 0.0 110.578 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.47 ' N ' ' C ' ' A' ' 27' ' ' ASN . 25.3 mmt180 -111.9 38.5 2.64 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 119.934 -0.706 . . . . 0.0 111.744 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -76.47 154.23 5.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 119.195 -1.002 . . . . 0.0 108.905 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 29.3 mt -117.52 178.87 4.23 Favored 'General case' 0 N--CA 1.513 2.69 0 C-N-CA 119.587 -0.845 . . . . 0.0 112.24 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.407 ' O ' ' OD1' ' A' ' 36' ' ' ASP . 27.3 tptp -78.39 -33.55 48.73 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -73.86 -11.58 60.41 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.4 ' OD1' HG12 ' A' ' 21' ' ' VAL . 2.1 t0 -66.98 -67.54 0.44 Allowed 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.104 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.4 mt -67.39 -35.49 73.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 C-N-CA 119.656 -0.817 . . . . 0.0 111.44 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 32' ' ' LYS . 5.7 m-20 -49.38 -42.53 42.49 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.721 -1.192 . . . . 0.0 110.081 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.62 -32.98 71.99 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.612 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.468 ' CD2' HG13 ' A' ' 16' ' ' VAL . 68.4 t80 -45.2 -69.9 0.12 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.873 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.2 tp -68.36 -27.91 66.66 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.275 -0.875 . . . . 0.0 112.112 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -46.24 -39.7 10.3 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.092 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.92 -0.88 4.56 Favored Glycine 0 N--CA 1.503 3.128 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.28 132.11 50.14 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.326 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.345 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.837 179.965 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 121.209 0.528 . . . . 0.0 110.596 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.11 157.3 23.12 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.566 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 69.1 mtm -52.07 148.0 11.9 Favored Pre-proline 0 N--CA 1.484 1.269 0 C-N-CA 119.161 -1.015 . . . . 0.0 110.727 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -64.67 156.06 63.42 Favored 'Trans proline' 0 CA--C 1.54 0.815 0 C-N-CA 120.975 1.117 . . . . 0.0 111.699 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 66.44 30.97 8.44 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.87 -0.732 . . . . 0.0 111.745 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t -130.3 -69.26 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.827 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 32.7 ttm180 -60.04 -45.62 92.23 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.31 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.9 mmmm -52.7 -41.78 64.23 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.632 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -57.85 -47.12 83.62 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 118.781 -1.167 . . . . 0.0 109.211 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.421 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -51.07 -45.47 61.42 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.793 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -56.56 -41.69 77.28 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.914 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -61.67 -33.54 74.16 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.911 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 50.6 mmtt -96.94 0.4 48.89 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.34 57.54 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.691 -1.242 . . . . 0.0 111.041 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.53 HG13 ' CD2' ' A' ' 38' ' ' PHE . 55.2 t -81.84 123.66 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.484 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -75.98 105.92 7.29 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.244 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.482 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 9.7 tt -41.62 -41.7 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.558 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.482 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.6 ttt85 -50.92 -53.87 29.06 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.987 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 74.6 mt -55.96 -28.17 55.84 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.818 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.422 HG12 ' OD1' ' A' ' 34' ' ' ASP . 10.6 t -65.31 142.6 16.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.687 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -140.52 66.28 1.39 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.051 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -78.51 -107.56 0.2 Allowed Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.095 -1.526 . . . . 0.0 110.428 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.442 ' OG1' ' CD1' ' A' ' 31' ' ' LEU . 0.7 OUTLIER -87.27 -53.02 5.06 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.473 -179.938 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 108.93 0.63 Allowed Glycine 0 N--CA 1.5 2.915 0 C-N-CA 119.857 -1.163 . . . . 0.0 110.404 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -76.58 61.41 1.78 Allowed 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.013 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.503 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.7 p-10 -152.83 -161.26 1.26 Allowed 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.434 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.76 -6.67 1.27 Allowed Glycine 0 N--CA 1.484 1.836 0 C-N-CA 119.123 -1.513 . . . . 0.0 109.909 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.503 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.8 mmt180 -108.17 31.82 5.25 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 120.187 -0.605 . . . . 0.0 111.523 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -70.08 156.11 7.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.434 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.442 ' CD1' ' OG1' ' A' ' 24' ' ' THR . 28.3 mt -108.53 173.78 6.17 Favored 'General case' 0 N--CA 1.509 2.499 0 C-N-CA 119.279 -0.969 . . . . 0.0 112.448 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 43.3 tptt -76.93 -32.23 57.22 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.063 -0.971 . . . . 0.0 108.574 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -82.58 -5.09 58.59 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.358 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.422 ' OD1' HG12 ' A' ' 21' ' ' VAL . 1.6 t0 -64.39 -53.95 40.51 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.237 -0.892 . . . . 0.0 108.933 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.421 HD13 ' HB2' ' A' ' 11' ' ' ALA . 3.3 mt -77.55 -37.89 25.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.678 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.416 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 19.8 t70 -47.17 -42.29 19.47 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.945 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.86 -37.08 73.08 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.6 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.53 ' CD2' HG13 ' A' ' 16' ' ' VAL . 66.1 t80 -42.67 -68.6 0.18 Allowed 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.463 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 11.2 tp -72.0 -66.97 0.57 Allowed 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.991 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.416 ' HB3' ' O ' ' A' ' 36' ' ' ASP . . . -54.9 118.02 3.92 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.9 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' A' ' 43' ' ' ALA . . . -56.08 -58.44 14.15 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.391 -1.385 . . . . 0.0 110.442 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 56.29 -85.6 0.01 OUTLIER Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.261 -1.447 . . . . 0.0 110.341 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 41' ' ' GLY . . . . . . . . 0 C--N 1.306 -1.294 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.919 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.44 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.413 0.625 . . . . 0.0 111.466 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 43.24 101.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.839 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.439 ' O ' ' N ' ' A' ' 6' ' ' SER . 14.2 mmt -47.99 152.8 1.31 Allowed Pre-proline 0 C--N 1.307 -1.242 0 C-N-CA 119.251 -0.98 . . . . 0.0 110.074 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -63.32 73.24 0.14 Allowed 'Trans proline' 0 CA--C 1.55 1.277 0 C-N-CA 120.844 1.03 . . . . 0.0 111.021 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.439 ' N ' ' O ' ' A' ' 4' ' ' MET . 2.1 p 175.55 3.36 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.291 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 79.9 t -113.44 -70.49 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.507 2.416 0 C-N-CA 120.091 -0.644 . . . . 0.0 111.127 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.486 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 32.2 ttm180 -57.4 -38.09 73.74 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.239 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.7 mttp -52.43 -46.48 66.41 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.634 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -54.28 -47.74 72.02 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 118.9 -1.12 . . . . 0.0 109.092 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.503 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -49.48 -44.59 46.09 Favored 'General case' 0 C--N 1.288 -2.083 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.789 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 24.1 mmm180 -57.43 -43.86 84.2 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.745 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -57.57 -33.19 67.91 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.086 -1.045 . . . . 0.0 110.496 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.6 mmtt -93.51 -10.04 36.28 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.496 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 76.38 -0.9 62.61 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.458 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 54.7 t -70.77 124.4 26.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.772 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -77.08 105.88 8.44 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.048 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.1 tt -37.82 -42.63 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.266 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.526 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 51.7 ttp85 -49.36 -55.06 14.2 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.472 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 52.7 mt -53.07 -41.83 65.25 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.556 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.5 t -48.52 144.56 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 C-N-CA 119.267 -0.973 . . . . 0.0 111.863 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -137.95 60.85 1.61 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.476 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.32 -114.82 0.24 Allowed Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.927 -1.606 . . . . 0.0 109.943 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.1 -50.03 12.8 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.879 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.404 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -150.02 109.4 0.43 Allowed Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 pttt -75.97 43.51 0.28 Allowed 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.333 -0.947 . . . . 0.0 111.177 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' H ' ' A' ' 29' ' ' ARG . 27.7 p-10 -119.05 -164.92 1.08 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.028 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.03 -4.2 2.21 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.196 -1.478 . . . . 0.0 110.332 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.47 ' H ' ' C ' ' A' ' 27' ' ' ASN . 24.1 mmt180 -110.71 41.42 1.79 Allowed 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.469 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.5 t -73.46 156.4 6.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.435 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.1 mp -105.74 173.0 6.5 Favored 'General case' 0 N--CA 1.511 2.577 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.142 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -76.94 -38.69 52.87 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 119.259 -0.977 . . . . 0.0 109.676 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -76.8 -2.91 35.61 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.222 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -67.18 -55.13 15.43 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.778 -1.101 . . . . 0.0 109.632 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.503 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.7 mt -75.17 -36.96 38.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.806 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.67 -40.54 53.89 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.421 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' A' ' 40' ' ' ALA . . . -71.35 -33.87 69.99 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.609 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -44.74 -69.65 0.13 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.067 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.419 ' C ' HD13 ' A' ' 39' ' ' LEU . 0.3 OUTLIER -66.5 -65.9 0.62 Allowed 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.441 -179.851 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' A' ' 37' ' ' ALA . . . -71.03 126.53 29.81 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.911 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 55.17 82.91 0.05 OUTLIER Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.305 -1.426 . . . . 0.0 110.324 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -154.98 98.83 0.18 Allowed Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.691 -1.242 . . . . 0.0 110.366 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.302 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.021 179.928 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.453 ' O ' ' O ' ' A' ' 3' ' ' ALA . 17.8 mm . . . . . 0 N--CA 1.485 1.304 0 CA-C-O 120.947 0.403 . . . . 0.0 111.231 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.453 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 46.24 103.03 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.669 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 15.9 mmt -46.29 149.1 1.39 Allowed Pre-proline 0 N--CA 1.485 1.317 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.23 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.444 ' C ' ' H ' ' A' ' 7' ' ' VAL . 2.3 Cg_endo -56.99 174.62 0.4 Allowed 'Trans proline' 0 C--O 1.214 -0.691 0 C-N-CA 120.707 0.938 . . . . 0.0 111.235 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 5' ' ' PRO . 1.3 t 72.3 -15.69 0.47 Allowed 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 120.046 -0.661 . . . . 0.0 111.457 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.444 ' H ' ' C ' ' A' ' 5' ' ' PRO . 47.8 t -88.99 -68.6 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.889 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 71.2 ttt180 -71.02 -39.42 72.37 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.01 -1.076 . . . . 0.0 110.504 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttp -58.92 -26.61 64.51 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 118.988 -1.085 . . . . 0.0 110.467 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.408 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 7.6 t80 -69.62 -49.73 51.08 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 118.843 -1.143 . . . . 0.0 108.579 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.83 -41.47 23.91 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.43 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.37 -46.6 86.02 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.776 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -54.9 -35.35 64.02 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.976 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.8 mmtt -92.06 -16.79 25.94 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.849 -0.741 . . . . 0.0 110.72 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 80.46 4.75 90.07 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.523 -1.322 . . . . 0.0 110.623 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.1 t -76.46 138.55 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.651 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 36.8 t0 -81.37 104.4 11.79 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.761 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.524 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.4 tt -40.87 -41.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.654 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.524 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.9 tpp180 -50.96 -59.56 4.02 Favored 'General case' 0 C--N 1.29 -2.007 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.308 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 84.8 mt -52.98 -28.44 23.84 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.013 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.413 ' H ' HG23 ' A' ' 21' ' ' VAL . 7.6 t -61.65 141.19 17.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 C-N-CA 118.915 -1.114 . . . . 0.0 112.181 -179.842 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -139.4 44.02 1.99 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.075 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.27 -104.25 0.01 OUTLIER Glycine 0 N--CA 1.492 2.37 0 C-N-CA 119.244 -1.455 . . . . 0.0 110.157 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.488 ' OG1' ' CD2' ' A' ' 31' ' ' LEU . 2.5 p -73.41 -37.84 65.8 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.08 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -179.65 121.13 0.72 Allowed Glycine 0 N--CA 1.479 1.517 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.423 ' O ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pttm -58.57 -157.31 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.507 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.517 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 25.4 t-20 59.31 176.29 0.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.013 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.517 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -46.12 -17.16 0.19 Allowed Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.733 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.482 ' N ' ' O ' ' A' ' 27' ' ' ASN . 14.5 mmt85 -80.13 35.41 0.32 Allowed 'General case' 0 N--CA 1.493 1.723 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.19 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 27' ' ' ASN . 11.7 t -101.6 156.48 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.442 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.488 ' CD2' ' OG1' ' A' ' 24' ' ' THR . 1.9 pt? -129.64 -170.71 2.35 Favored 'General case' 0 N--CA 1.512 2.634 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.633 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -71.02 -55.37 8.43 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.54 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 60.9 tt0 -61.03 -5.68 1.53 Allowed 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.9 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.85 -59.76 3.04 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.386 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.499 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.3 mp -66.55 -37.47 79.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.653 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -46.6 -42.78 16.6 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.348 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.17 -35.91 76.8 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.394 -0.923 . . . . 0.0 110.666 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -43.46 -67.54 0.27 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.467 -0.893 . . . . 0.0 112.171 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.4 tp -72.48 -25.82 61.56 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.246 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -44.9 -25.29 0.29 Allowed 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.085 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -60.18 -84.31 0.05 OUTLIER Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.405 -1.378 . . . . 0.0 110.483 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -71.11 102.85 1.13 Allowed Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.367 -1.396 . . . . 0.0 110.452 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.355 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.731 -179.959 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.589 HG22 ' H ' ' A' ' 3' ' ' ALA . 11.7 mm . . . . . 0 N--CA 1.485 1.292 0 CA-C-O 120.944 0.402 . . . . 0.0 111.128 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.589 ' H ' HG22 ' A' ' 2' ' ' ILE . . . 56.0 79.41 0.17 Allowed 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.489 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.699 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 71.0 mtp -121.84 -30.32 0.05 OUTLIER Pre-proline 0 N--CA 1.508 2.461 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.699 ' CD ' ' H ' ' A' ' 4' ' ' MET . 2.3 Cg_endo -66.36 76.3 0.36 Allowed 'Trans proline' 0 CA--C 1.543 0.974 0 CA-C-N 119.073 0.705 . . . . 0.0 111.493 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 93.9 p 40.65 52.2 3.07 Favored 'General case' 0 N--CA 1.493 1.684 0 C-N-CA 119.965 -0.694 . . . . 0.0 111.661 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 86.5 t -96.73 -77.41 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 C-N-CA 119.831 -0.748 . . . . 0.0 110.239 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 59.0 ttp85 -60.98 -51.5 68.98 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.093 -1.043 . . . . 0.0 110.749 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.1 mttt -51.26 -39.75 57.39 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.753 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -59.7 -45.95 90.56 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.206 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.451 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -53.12 -46.15 68.62 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.696 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -55.91 -40.96 73.83 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -63.08 -45.95 89.72 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.4 mmtt -78.31 -10.07 59.51 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 119.449 -0.901 . . . . 0.0 111.183 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.96 1.5 90.64 Favored Glycine 0 N--CA 1.496 2.642 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.899 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.536 HG13 ' CD2' ' A' ' 38' ' ' PHE . 57.8 t -74.5 130.54 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.507 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -83.22 110.01 17.71 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.155 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.551 HG23 ' N ' ' A' ' 19' ' ' ARG . 5.7 tp -42.26 -41.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.466 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.551 ' N ' HG23 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -48.07 -59.1 3.64 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.822 -179.83 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 46.8 mt -60.45 -18.41 51.01 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.2 t -70.64 139.73 19.56 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 118.552 -1.259 . . . . 0.0 111.649 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.401 ' O ' ' CD ' ' A' ' 22' ' ' GLN . 0.6 OUTLIER -145.7 79.44 1.56 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.706 179.901 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.18 -99.12 1.97 Allowed Glycine 0 N--CA 1.504 3.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.422 ' OG1' HD23 ' A' ' 31' ' ' LEU . 0.8 OUTLIER -79.07 -38.97 35.05 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.428 179.819 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.475 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -170.61 116.16 0.63 Allowed Glycine 0 N--CA 1.485 1.932 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 pttp -74.1 38.64 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.001 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 25.0 t-20 -117.07 -179.59 3.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.712 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.513 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -47.57 -14.95 0.24 Allowed Glycine 0 N--CA 1.492 2.432 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.197 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.513 ' N ' ' O ' ' A' ' 27' ' ' ASN . 32.2 mmm-85 -95.47 37.22 1.2 Allowed 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.119 -0.632 . . . . 0.0 111.556 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 27' ' ' ASN . 2.6 t -70.99 154.64 7.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.105 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.422 HD23 ' OG1' ' A' ' 24' ' ' THR . 2.9 mm? -106.5 173.3 6.38 Favored 'General case' 0 N--CA 1.509 2.492 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.951 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.6 tmtt? -77.13 -41.43 41.96 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.386 -0.925 . . . . 0.0 108.926 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -71.78 -3.63 23.17 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.399 -0.818 . . . . 0.0 109.35 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -68.52 -56.04 9.68 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.079 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.479 HD11 ' CD1' ' A' ' 18' ' ' ILE . 1.8 mt -73.09 -37.54 53.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.643 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -51.22 -39.37 56.42 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.341 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.5 -33.62 71.42 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.347 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.536 ' CD2' HG13 ' A' ' 16' ' ' VAL . 65.9 t80 -45.07 -68.04 0.23 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.016 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 56.1 tp -74.0 -67.19 0.63 Allowed 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.995 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 41.44 55.78 3.35 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.897 -0.721 . . . . 0.0 111.575 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 76.6 -44.33 1.98 Allowed Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.491 -1.337 . . . . 0.0 110.677 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 70.05 157.03 1.73 Allowed Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.318 -1.42 . . . . 0.0 110.158 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.394 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.944 -179.966 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.4 m . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.818 0.342 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.491 HG22 ' N ' ' A' ' 3' ' ' ALA . 18.4 mm -73.24 162.77 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 C-N-CA 119.232 -0.987 . . . . 0.0 111.006 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.491 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -55.9 148.59 16.75 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.798 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 4.2 mmt -67.91 153.96 94.41 Favored Pre-proline 0 C--N 1.304 -1.402 0 C-N-CA 119.364 -0.934 . . . . 0.0 109.93 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.414 ' O ' ' OG ' ' A' ' 6' ' ' SER . 9.2 Cg_endo -70.19 52.96 1.19 Allowed 'Trans proline' 0 CA--C 1.558 1.687 0 C-N-CA 120.79 0.993 . . . . 0.0 111.56 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.414 ' OG ' ' O ' ' A' ' 5' ' ' PRO . 27.2 m -166.24 -1.89 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.142 -1.023 . . . . 0.0 110.869 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.1 t -88.25 -66.46 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 C-N-CA 119.683 -0.807 . . . . 0.0 111.161 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.419 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 55.5 ttt180 -57.06 -36.05 70.07 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.384 -0.926 . . . . 0.0 111.199 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.1 mmtm -54.85 -47.61 73.94 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 119.136 -1.026 . . . . 0.0 110.217 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -53.73 -46.94 71.02 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.073 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.422 ' HB2' HD13 ' A' ' 35' ' ' ILE . . . -52.12 -46.32 65.29 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.651 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.2 mtp180 -59.48 -44.29 93.08 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.679 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -56.69 -42.74 79.6 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.575 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -86.8 -13.92 43.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.834 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 75.91 67.84 1.64 Allowed Glycine 0 N--CA 1.488 2.134 0 C-N-CA 119.327 -1.416 . . . . 0.0 110.089 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.492 HG13 ' CD2' ' A' ' 38' ' ' PHE . 53.1 t -137.18 130.51 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.339 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -77.3 109.53 11.26 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.07 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.534 ' CD1' HD11 ' A' ' 35' ' ' ILE . 6.9 tp -44.69 -41.96 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.503 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.53 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 63.7 ttt-85 -56.15 -52.69 63.46 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.738 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.7 mt -57.18 -31.04 65.01 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.746 -0.781 . . . . 0.0 112.725 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.41 ' H ' HG23 ' A' ' 21' ' ' VAL . 7.8 t -57.46 141.87 13.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 118.437 -1.305 . . . . 0.0 111.868 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -136.77 77.71 1.66 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.933 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.26 -108.93 3.34 Favored Glycine 0 N--CA 1.51 3.596 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -77.02 -47.91 19.36 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.513 -0.875 . . . . 0.0 110.297 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.07 109.28 0.42 Allowed Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.9 pttp -76.07 55.36 0.92 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.601 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 0.4 OUTLIER -157.16 -154.95 0.49 Allowed 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 119.746 -0.782 . . . . 0.0 110.546 179.886 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.0 -8.2 0.59 Allowed Glycine 0 C--N 1.289 -2.04 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.246 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.6 mmt85 -109.09 37.34 2.59 Favored 'General case' 0 N--CA 1.504 2.24 0 C-N-CA 120.217 -0.593 . . . . 0.0 112.076 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.525 HG11 HD11 ' A' ' 18' ' ' ILE . 3.2 t -80.92 147.4 6.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.076 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.7 mp -109.37 177.34 4.77 Favored 'General case' 0 N--CA 1.511 2.604 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.51 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 3.6 tmtt? -75.47 -48.74 21.3 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.879 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -65.47 -5.45 7.84 Favored 'General case' 0 C--N 1.309 -1.167 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.207 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -69.5 -53.62 18.2 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.605 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.534 HD11 ' CD1' ' A' ' 18' ' ' ILE . 2.5 mt -72.46 -30.05 33.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 C-N-CA 119.676 -0.81 . . . . 0.0 110.757 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 36' ' ' ASP . 5.8 m-20 -55.5 -40.69 72.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.706 -1.198 . . . . 0.0 109.279 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.68 -34.81 76.31 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.284 179.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.492 ' CD2' HG13 ' A' ' 16' ' ' VAL . 70.1 t80 -44.55 -69.27 0.14 Allowed 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.346 -0.942 . . . . 0.0 111.232 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.448 ' O ' ' O ' ' A' ' 40' ' ' ALA . 69.5 tp -66.49 -53.95 29.42 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.916 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.448 ' O ' ' O ' ' A' ' 39' ' ' LEU . . . -57.54 -113.7 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.87 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 154.63 33.6 0.03 OUTLIER Glycine 0 N--CA 1.493 2.448 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.372 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.72 -66.75 1.73 Allowed Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.551 -1.309 . . . . 0.0 110.303 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.406 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.815 179.946 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.479 HG22 ' N ' ' A' ' 3' ' ' ALA . 18.2 mm . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 121.044 0.45 . . . . 0.0 111.272 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.479 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -45.94 142.17 2.77 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.604 179.851 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.743 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 14.3 mtt -124.82 -31.97 0.04 OUTLIER Pre-proline 0 N--CA 1.509 2.483 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.743 ' CD ' ' H ' ' A' ' 4' ' ' MET . 5.7 Cg_exo -65.07 -159.47 0.04 OUTLIER 'Trans proline' 0 C--O 1.217 -0.574 0 C-N-CA 120.476 0.784 . . . . 0.0 111.439 -179.911 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.4 t -77.35 45.18 0.45 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.026 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.4 ' H ' ' C ' ' A' ' 5' ' ' PRO . 32.0 t -86.46 -71.79 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.689 179.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -61.94 -48.03 82.22 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 118.872 -1.131 . . . . 0.0 110.884 -179.906 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -53.76 -38.83 64.81 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.91 179.963 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -59.11 -44.73 92.0 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 118.883 -1.127 . . . . 0.0 109.36 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.427 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -52.05 -43.8 63.96 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.805 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -57.04 -43.49 81.98 Favored 'General case' 0 C--N 1.292 -1.893 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.886 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 59.9 mt-10 -59.06 -53.69 55.47 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.382 -0.927 . . . . 0.0 111.185 179.936 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -78.28 -14.48 59.41 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.115 -179.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 74.15 76.1 0.73 Allowed Glycine 0 N--CA 1.495 2.575 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.883 179.913 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.519 HG13 ' CD2' ' A' ' 38' ' ' PHE . 53.5 t -145.74 126.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 120.161 -0.616 . . . . 0.0 109.965 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -74.5 106.99 6.36 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.739 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.475 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 10.2 tt -44.64 -40.04 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 119.93 -0.708 . . . . 0.0 111.036 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.475 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 11.0 tpt85 -49.68 -54.3 19.44 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.411 -179.912 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 70.8 mt -63.21 -29.17 70.56 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.87 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.423 HG12 ' OD1' ' A' ' 34' ' ' ASP . 11.5 t -55.93 139.19 15.52 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 C-N-CA 118.812 -1.155 . . . . 0.0 111.987 -179.717 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.1 mm100 -137.44 44.43 2.25 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.255 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.24 -107.48 0.01 OUTLIER Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.138 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -78.75 -42.45 28.09 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.81 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -166.17 124.05 1.2 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 27' ' ' ASN . 14.9 ptmt -61.64 -156.87 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.009 -1.077 . . . . 0.0 110.678 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.553 ' ND2' ' N ' ' A' ' 28' ' ' GLY . 1.8 p-10 43.4 -154.18 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.567 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.553 ' N ' ' ND2' ' A' ' 27' ' ' ASN . . . -53.14 -20.91 10.0 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 120.074 -1.06 . . . . 0.0 111.63 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.436 ' O ' ' O ' ' A' ' 25' ' ' GLY . 22.2 mmt180 -78.25 27.03 0.2 Allowed 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 118.909 -1.116 . . . . 0.0 111.35 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.443 ' H ' ' C ' ' A' ' 28' ' ' GLY . 3.3 t -92.44 129.22 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 C-N-CA 120.028 -0.669 . . . . 0.0 110.914 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.508 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.6 mp -103.44 -177.58 3.41 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.432 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -75.8 -36.12 59.83 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.047 -1.061 . . . . 0.0 109.268 179.82 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -78.87 -2.68 40.96 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.375 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.435 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 2.3 t0 -68.78 -55.89 9.8 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.751 179.926 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -72.52 -39.21 61.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.481 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -47.8 -39.95 19.67 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 118.966 -1.093 . . . . 0.0 109.806 179.875 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.52 -34.19 67.42 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.586 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.519 ' CD2' HG13 ' A' ' 16' ' ' VAL . 76.7 t80 -40.88 -66.42 0.33 Allowed 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.086 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 10.1 tp -75.08 -61.09 2.01 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.752 -179.949 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.46 -160.04 0.02 OUTLIER 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 119.624 -0.831 . . . . 0.0 110.721 179.965 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.67 -0.69 2.25 Favored Glycine 0 N--CA 1.502 3.041 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.741 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -96.24 -152.44 29.0 Favored Glycine 0 N--CA 1.504 3.198 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.487 179.951 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.25 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.753 -179.998 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 26.7 mm . . . . . 0 N--CA 1.484 1.249 0 CA-C-O 121.126 0.489 . . . . 0.0 110.965 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.82 177.58 6.96 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.134 179.936 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.432 ' HG2' ' H ' ' A' ' 4' ' ' MET . 4.3 ptp -63.98 152.29 87.71 Favored Pre-proline 0 C--N 1.303 -1.442 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.352 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.46 ' C ' ' H ' ' A' ' 7' ' ' VAL . 1.1 Cg_endo -59.11 -179.5 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 120.956 1.104 . . . . 0.0 111.219 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.6 p 71.91 -20.69 0.24 Allowed 'General case' 0 N--CA 1.49 1.564 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.599 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.46 ' H ' ' C ' ' A' ' 5' ' ' PRO . 94.5 t -95.2 -56.64 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 C-N-CA 119.581 -0.848 . . . . 0.0 111.242 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 56.1 ttp180 -60.92 -35.85 77.78 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.46 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.7 mmtp -55.65 -42.9 75.69 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.192 -1.003 . . . . 0.0 110.395 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.5 t80 -58.26 -48.65 79.75 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.799 -1.16 . . . . 0.0 109.329 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.27 -43.25 42.88 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.018 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 79.1 mtt180 -58.27 -43.81 88.11 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.977 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -55.68 -53.15 60.11 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.826 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.3 mmmt -80.4 0.38 33.47 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.148 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 58.51 70.89 0.86 Allowed Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.25 -1.452 . . . . 0.0 110.403 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.9 t -141.64 139.2 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.113 -179.968 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.0 t0 -85.99 107.95 18.0 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.507 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.3 tt -46.49 -40.97 4.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 119.769 -0.772 . . . . 0.0 110.92 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 5.1 tpm_? -48.16 -57.59 5.67 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.71 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.1 mt -54.0 -35.47 61.9 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.704 -0.799 . . . . 0.0 111.783 -179.87 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.6 t -56.38 139.5 15.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.432 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -138.94 53.91 1.75 Allowed 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.694 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.82 -114.79 0.06 OUTLIER Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.603 -1.284 . . . . 0.0 111.378 -179.851 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.5 p -92.96 -71.06 0.67 Allowed 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.884 -179.851 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.428 ' O ' ' OD1' ' A' ' 27' ' ' ASN . . . -58.93 -50.05 71.79 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.356 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.401 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 21.6 pttp 41.6 36.56 0.59 Allowed 'General case' 0 C--N 1.294 -1.806 0 CA-C-O 121.507 0.67 . . . . 0.0 110.79 -179.894 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.47 ' C ' ' H ' ' A' ' 29' ' ' ARG . 13.6 p-10 -159.41 -160.21 0.81 Allowed 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.224 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.94 -7.79 1.18 Allowed Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.021 179.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.47 ' H ' ' C ' ' A' ' 27' ' ' ASN . 13.9 mmt85 -121.48 48.66 1.64 Allowed 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.39 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -69.69 158.18 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.344 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.8 mp -104.46 171.14 7.5 Favored 'General case' 0 N--CA 1.51 2.538 0 C-N-CA 119.408 -0.917 . . . . 0.0 111.154 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 36.0 tttp -76.77 -39.42 51.68 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.26 -0.976 . . . . 0.0 109.205 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -73.01 -6.37 45.01 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 119.337 -0.945 . . . . 0.0 108.879 179.819 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -65.32 -62.93 1.25 Allowed 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.026 -179.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mt -67.52 -31.29 52.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.801 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -51.27 -41.13 60.21 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.128 -1.029 . . . . 0.0 110.1 179.895 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -75.2 -32.71 61.28 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -43.82 -69.87 0.12 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.571 -0.852 . . . . 0.0 111.696 -179.954 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.483 ' C ' ' H ' ' A' ' 41' ' ' GLY . 24.1 tp -65.43 -49.86 67.6 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.654 -179.824 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -50.61 -10.15 0.06 Allowed 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.26 -0.976 . . . . 0.0 110.996 -179.936 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.483 ' H ' ' C ' ' A' ' 39' ' ' LEU . . . -45.19 -57.07 5.77 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.642 -1.266 . . . . 0.0 110.758 179.994 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -71.5 -87.3 0.14 Allowed Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.275 -1.441 . . . . 0.0 110.535 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.256 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.756 179.968 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 120.946 0.403 . . . . 0.0 110.146 . . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.426 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 48.74 -179.01 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.879 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.446 ' C ' ' H ' ' A' ' 6' ' ' SER . 16.1 mmt -87.91 151.13 49.21 Favored Pre-proline 0 N--CA 1.49 1.557 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.314 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -69.43 36.62 0.22 Allowed 'Trans proline' 0 CA--C 1.55 1.29 0 C-N-CA 120.82 1.013 . . . . 0.0 111.448 179.91 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.446 ' H ' ' C ' ' A' ' 4' ' ' MET . 13.8 t -154.87 33.7 0.4 Allowed 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 119.364 -0.934 . . . . 0.0 111.312 179.909 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 48.5 t -142.63 -79.03 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 119.455 -0.898 . . . . 0.0 112.32 179.973 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.417 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 47.5 ttp85 -51.91 -51.56 56.04 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.702 -0.799 . . . . 0.0 112.947 -179.751 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.458 ' CG ' ' N ' ' A' ' 10' ' ' TYR . 0.2 OUTLIER -49.07 -49.47 41.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.688 -179.846 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.458 ' N ' ' CG ' ' A' ' 9' ' ' LYS . 2.3 t80 -51.93 -44.57 63.94 Favored 'General case' 0 C--N 1.285 -2.228 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.079 179.921 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 8' ' ' ARG . . . -51.85 -43.9 63.4 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.58 -0.848 . . . . 0.0 110.928 179.997 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -59.64 -43.25 93.95 Favored 'General case' 0 C--N 1.293 -1.849 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.371 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -54.7 -60.01 3.94 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.55 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.0 mmtt -75.17 11.07 1.26 Allowed 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.374 -179.896 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 53.59 75.84 0.21 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.596 -1.288 . . . . 0.0 111.611 179.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 22.4 t -147.84 135.38 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.843 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -82.99 111.32 18.74 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.563 -0.855 . . . . 0.0 111.015 179.923 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.514 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.7 tt -46.11 -40.48 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.943 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.514 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 52.4 ttt85 -51.86 -58.81 5.39 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 114.867 -1.06 . . . . 0.0 112.301 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.0 mt -50.45 -31.42 15.12 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.524 -179.83 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -62.03 140.74 18.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 118.781 -1.167 . . . . 0.0 111.159 -179.852 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -134.9 57.15 1.82 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.644 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.4 -112.24 0.08 OUTLIER Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.132 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -73.79 -47.85 35.84 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.164 -1.014 . . . . 0.0 109.91 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.496 ' C ' ' H ' ' A' ' 27' ' ' ASN . . . -157.33 114.43 0.61 Allowed Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 12.0 ptmm? -74.83 36.9 0.11 Allowed 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.728 179.983 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.51 ' CG ' ' H ' ' A' ' 28' ' ' GLY . 25.9 t-20 -109.5 -179.02 3.71 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.51 ' H ' ' CG ' ' A' ' 27' ' ' ASN . . . -50.93 -11.07 0.5 Allowed Glycine 0 N--CA 1.488 2.124 0 C-N-CA 118.828 -1.653 . . . . 0.0 109.963 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.488 ' N ' ' C ' ' A' ' 27' ' ' ASN . 44.2 mmt-85 -101.01 43.58 1.05 Allowed 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.751 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 31' ' ' LEU . 3.0 t -76.52 163.17 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.397 179.852 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.441 ' N ' ' CG1' ' A' ' 30' ' ' VAL . 8.6 mp -112.37 174.36 5.92 Favored 'General case' 0 N--CA 1.512 2.655 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.329 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.9 tttp -78.02 -41.38 35.96 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 119.402 -0.919 . . . . 0.0 108.823 179.867 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -71.53 -5.5 33.7 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.344 -0.942 . . . . 0.0 109.213 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -67.0 -56.87 8.26 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.36 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.476 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.3 mp -72.06 -36.01 55.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.385 -0.926 . . . . 0.0 110.95 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -48.37 -42.12 30.74 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.177 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.48 -34.72 72.71 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.389 179.858 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.5 t80 -43.21 -70.63 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.602 179.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.6 tp -69.01 -60.85 2.08 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.019 -179.782 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -49.23 168.95 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.4 -0.92 . . . . 0.0 110.836 179.928 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -161.81 19.04 0.18 Allowed Glycine 0 N--CA 1.487 2.037 0 C-N-CA 119.488 -1.339 . . . . 0.0 110.55 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.89 34.79 52.05 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.394 -1.384 . . . . 0.0 110.534 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.387 -0.925 . . . . 0.0 110.77 -179.963 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.51 HG22 ' N ' ' A' ' 3' ' ' ALA . 17.0 mm . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 120.877 0.37 . . . . 0.0 110.813 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.51 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -78.56 174.52 11.27 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.668 179.979 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.465 ' O ' ' N ' ' A' ' 6' ' ' SER . 64.9 mtm -68.81 149.02 98.02 Favored Pre-proline 0 C--N 1.307 -1.26 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.615 -179.941 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -62.37 77.23 0.1 Allowed 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 120.547 0.831 . . . . 0.0 110.394 179.82 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.465 ' N ' ' O ' ' A' ' 4' ' ' MET . 7.6 p -176.76 -15.87 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 119.666 -0.813 . . . . 0.0 110.094 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.6 t -95.87 -47.85 12.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.699 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 12' ' ' ARG . 53.2 ttp180 -65.04 -42.66 94.08 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.763 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.0 mttm -53.48 -36.55 61.79 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.603 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.6 t80 -61.38 -49.6 76.27 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 118.73 -1.188 . . . . 0.0 108.857 179.773 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.464 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -50.06 -43.32 51.12 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.995 179.771 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.483 ' NH1' ' NH1' ' A' ' 8' ' ' ARG . 95.3 mtt180 -65.52 -47.05 77.25 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.025 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.1 mm-40 -48.15 -50.72 27.77 Favored 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.504 -0.879 . . . . 0.0 111.274 -179.92 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -82.88 -36.66 25.17 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 119.403 -0.919 . . . . 0.0 111.5 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.23 75.47 1.04 Allowed Glycine 0 N--CA 1.505 3.252 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.0 t -147.75 131.45 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 C-N-CA 120.012 -0.675 . . . . 0.0 110.049 179.908 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -75.13 103.02 5.13 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.925 179.975 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.477 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.4 tt -42.34 -37.88 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 CA-C-O 121.688 0.756 . . . . 0.0 110.836 179.949 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.477 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 44.3 ttt85 -50.15 -58.5 5.43 Favored 'General case' 0 C--N 1.287 -2.132 0 CA-C-N 114.413 -1.267 . . . . 0.0 112.502 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 66.7 mt -59.99 -13.84 13.28 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.774 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.6 t -75.38 140.11 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 118.582 -1.247 . . . . 0.0 111.38 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.7 mt-30 -144.08 54.83 1.29 Allowed 'General case' 0 N--CA 1.49 1.527 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.017 -179.898 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -73.87 -96.74 0.1 OUTLIER Glycine 0 N--CA 1.495 2.57 0 C-N-CA 118.827 -1.654 . . . . 0.0 109.676 179.928 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.14 -43.11 29.74 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.419 -0.912 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 29' ' ' ARG . . . -171.34 119.07 0.77 Allowed Glycine 0 N--CA 1.482 1.709 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.877 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.462 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttm -56.63 -163.23 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.868 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.484 ' OD1' ' N ' ' A' ' 28' ' ' GLY . 8.8 p30 49.99 -157.71 0.09 Allowed 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.585 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.484 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -49.16 -30.74 10.87 Favored Glycine 0 N--CA 1.498 2.791 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.172 -179.825 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.444 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.0 mmt85 -74.34 34.44 0.09 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.963 -1.095 . . . . 0.0 111.711 -179.877 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 27' ' ' ASN . 4.9 t -98.6 139.29 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.394 179.908 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.481 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -108.22 177.99 4.64 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.298 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 22.6 tttm -75.55 -35.59 60.64 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.735 179.837 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -76.89 -9.35 58.63 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.102 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.403 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 3.7 t0 -65.33 -57.92 7.18 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.704 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.464 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 5.1 mt -70.2 -29.27 38.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.878 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -53.75 -41.22 66.9 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.873 -1.131 . . . . 0.0 109.58 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.29 -33.78 67.68 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.384 -0.826 . . . . 0.0 110.561 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -43.67 -68.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.471 -0.892 . . . . 0.0 111.251 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 41' ' ' GLY . 0.2 OUTLIER -70.92 -64.32 0.93 Allowed 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.595 -179.849 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -54.57 85.47 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.385 -0.926 . . . . 0.0 111.1 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -105.45 -76.53 1.06 Allowed Glycine 0 N--CA 1.506 3.324 0 C-N-CA 120.049 -1.072 . . . . 0.0 110.459 -179.932 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.01 35.18 16.11 Favored Glycine 0 N--CA 1.494 2.549 0 C-N-CA 119.61 -1.281 . . . . 0.0 110.367 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.387 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.686 179.922 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.645 HG22 ' N ' ' A' ' 3' ' ' ALA . 21.4 mm . . . . . 0 N--CA 1.482 1.133 0 CA-C-O 120.925 0.393 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.645 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -80.26 64.0 4.93 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.952 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.67 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 62.1 mtt -116.64 -29.18 0.09 OUTLIER Pre-proline 0 N--CA 1.499 2.022 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.67 ' CD ' ' H ' ' A' ' 4' ' ' MET . 5.6 Cg_exo -62.23 80.28 0.1 OUTLIER 'Trans proline' 0 CA--C 1.541 0.874 0 CA-C-N 119.014 0.683 . . . . 0.0 111.325 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.449 ' N ' ' O ' ' A' ' 4' ' ' MET . 18.3 m 51.89 29.04 5.6 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.277 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 44.9 t -89.29 -63.66 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.802 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -66.23 -41.2 90.37 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.034 -1.066 . . . . 0.0 111.071 -179.922 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.0 mttp -53.09 -35.74 59.94 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.515 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -63.08 -51.54 66.22 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.049 179.83 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -42.15 53.17 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.186 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.9 mtp180 -62.17 -46.86 87.06 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.874 179.911 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -50.49 -50.82 51.74 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.051 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.5 ' HZ2' HD22 ' A' ' 39' ' ' LEU . 0.6 OUTLIER -78.78 -25.47 44.36 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.024 -179.963 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 96.73 68.75 0.98 Allowed Glycine 0 N--CA 1.505 3.278 0 C-N-CA 119.985 -1.102 . . . . 0.0 111.307 179.944 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.2 t -147.98 147.83 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.183 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -94.83 108.54 20.56 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.864 -0.734 . . . . 0.0 110.591 179.921 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 10.4 tt -42.68 -41.93 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 120.019 -0.673 . . . . 0.0 111.51 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.504 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 34.2 mtm-85 -52.42 -57.61 9.32 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.258 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.2 mt -52.88 -25.99 13.4 Favored 'General case' 0 N--CA 1.49 1.527 0 C-N-CA 119.611 -0.835 . . . . 0.0 111.918 -179.826 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.5 t -64.13 143.27 15.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.054 -1.058 . . . . 0.0 112.003 -179.817 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -136.63 63.0 1.59 Allowed 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.1 -113.18 0.61 Allowed Glycine 0 N--CA 1.497 2.707 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.775 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.26 -46.27 42.55 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.385 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.17 110.46 0.44 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -75.21 61.05 1.12 Allowed 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.47 -0.892 . . . . 0.0 110.797 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.457 ' C ' ' N ' ' A' ' 29' ' ' ARG . 7.4 p30 -150.35 -164.85 2.12 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.284 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -50.06 -13.3 0.61 Allowed Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.38 -1.391 . . . . 0.0 110.581 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.457 ' N ' ' C ' ' A' ' 27' ' ' ASN . 1.0 OUTLIER -102.87 34.23 2.93 Favored 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 119.863 -0.735 . . . . 0.0 112.278 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.418 ' C ' HD12 ' A' ' 31' ' ' LEU . 2.7 t -75.34 149.86 6.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 C-N-CA 119.057 -1.057 . . . . 0.0 108.818 179.804 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.418 HD12 ' C ' ' A' ' 30' ' ' VAL . 11.0 mp -107.11 173.6 6.25 Favored 'General case' 0 N--CA 1.511 2.601 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.424 -179.878 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.4 tttm -77.16 -35.06 56.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.712 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.5 mm-40 -75.71 -9.12 58.32 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 114.961 -1.018 . . . . 0.0 108.582 179.794 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -63.77 -57.01 11.25 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.005 179.958 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.533 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.8 mp -65.16 -37.03 79.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.464 -0.894 . . . . 0.0 109.694 179.792 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.435 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 12.3 t0 -45.75 -44.65 13.95 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.353 179.998 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.05 76.21 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.471 -0.891 . . . . 0.0 110.493 179.92 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -46.29 -71.04 0.08 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.347 -0.941 . . . . 0.0 111.647 -179.989 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.5 HD22 ' HZ2' ' A' ' 14' ' ' LYS . 12.6 tp -72.16 -53.73 11.82 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.416 -179.781 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 36' ' ' ASP . . . -48.09 -72.06 0.06 Allowed 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 119.324 -0.951 . . . . 0.0 111.023 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 78.22 21.07 71.19 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.296 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 62.79 126.46 0.01 OUTLIER Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.541 -1.314 . . . . 0.0 110.371 179.989 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.293 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.877 -179.995 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.765 HG22 ' H ' ' A' ' 3' ' ' ALA . 10.1 mm . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 121.021 0.439 . . . . 0.0 111.002 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.765 ' H ' HG22 ' A' ' 2' ' ' ILE . . . 44.74 53.98 6.95 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.119 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.54 ' C ' ' H ' ' A' ' 6' ' ' SER . 30.3 mmm -44.56 160.54 0.23 Allowed Pre-proline 0 N--CA 1.487 1.424 0 C-N-CA 119.857 -0.737 . . . . 0.0 110.182 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -65.58 33.63 0.11 Allowed 'Trans proline' 0 CA--C 1.551 1.358 0 C-N-CA 120.724 0.949 . . . . 0.0 111.794 179.721 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.54 ' H ' ' C ' ' A' ' 4' ' ' MET . 44.6 t -139.97 -16.43 0.98 Allowed 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.341 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t -80.21 -64.52 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.689 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 41.3 ttp180 -63.57 -34.37 77.66 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 118.737 -1.185 . . . . 0.0 110.767 -179.937 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt -60.12 -41.66 93.12 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.757 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -57.28 -46.34 83.22 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.069 -1.052 . . . . 0.0 109.062 179.909 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.445 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -51.71 -45.99 63.76 Favored 'General case' 0 C--N 1.291 -1.948 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.485 179.867 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.2 mtp85 -59.11 -46.12 89.15 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.806 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -54.58 -39.33 67.69 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.457 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -89.38 -3.75 58.32 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.67 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.27 6.99 66.55 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.568 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.537 HG13 ' CD2' ' A' ' 38' ' ' PHE . 63.6 t -78.13 125.38 37.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.978 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -78.56 110.32 13.56 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.322 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.49 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -43.23 -40.02 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.117 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.49 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 55.0 mtt-85 -52.64 -59.46 4.44 Favored 'General case' 0 C--N 1.286 -2.153 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.228 -179.896 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.1 mt -52.15 -24.84 7.67 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.215 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.6 t -63.61 139.54 21.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 118.936 -1.106 . . . . 0.0 112.18 -179.813 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -131.88 64.54 1.59 Allowed 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 114.906 -1.043 . . . . 0.0 109.876 -179.929 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.11 -114.96 0.88 Allowed Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.437 -1.363 . . . . 0.0 110.499 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.32 -44.87 15.67 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.824 -0.75 . . . . 0.0 110.136 -179.935 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -147.45 103.8 0.28 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.995 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -76.33 60.38 1.53 Allowed 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.677 -179.986 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.475 ' C ' ' H ' ' A' ' 29' ' ' ARG . 23.6 p-10 -157.05 -159.4 0.85 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.256 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.73 -9.09 0.67 Allowed Glycine 0 N--CA 1.484 1.876 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.475 ' H ' ' C ' ' A' ' 27' ' ' ASN . 10.9 mmt-85 -107.76 34.38 3.58 Favored 'General case' 0 N--CA 1.507 2.381 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.574 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -74.42 146.71 9.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.186 -1.006 . . . . 0.0 109.019 179.84 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.7 mp -105.44 177.56 4.82 Favored 'General case' 0 N--CA 1.511 2.589 0 C-N-CA 119.597 -0.841 . . . . 0.0 112.131 -179.741 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 12.9 tmtt? -76.5 -41.02 48.43 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.09 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.28 -4.21 34.75 Favored 'General case' 0 C--N 1.311 -1.07 0 C-N-CA 119.37 -0.932 . . . . 0.0 109.183 179.823 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -67.37 -61.55 1.86 Allowed 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.748 179.94 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 2.7 mt -69.63 -30.57 45.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.486 179.855 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -52.25 -40.55 61.83 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.668 179.899 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.96 -35.64 72.24 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.258 179.875 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.537 ' CD2' HG13 ' A' ' 16' ' ' VAL . 57.6 t80 -44.73 -70.05 0.12 Allowed 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.373 179.921 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.4 tp -74.92 -53.39 9.11 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.896 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 43.48 -146.92 0.07 Allowed 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.688 -0.805 . . . . 0.0 111.071 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 165.58 34.31 0.02 OUTLIER Glycine 0 N--CA 1.485 1.942 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.417 -179.974 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 178.41 -60.53 0.09 OUTLIER Glycine 0 N--CA 1.484 1.861 0 C-N-CA 119.676 -1.25 . . . . 0.0 110.237 -179.922 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.577 0 C-N-CA 119.751 -0.78 . . . . 0.0 110.633 179.934 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 120.919 0.39 . . . . 0.0 110.22 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 44.77 47.12 8.91 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.421 -0.912 . . . . 0.0 110.634 -179.987 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.647 ' N ' ' CD ' ' A' ' 5' ' ' PRO . 14.1 ptt? -110.99 -14.49 0.12 Allowed Pre-proline 0 N--CA 1.505 2.29 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.647 ' CD ' ' N ' ' A' ' 4' ' ' MET . 3.8 Cg_exo -62.14 -59.12 0.29 Allowed 'Trans proline' 0 C--N 1.353 0.792 0 CA-C-N 120.089 1.068 . . . . 0.0 110.538 -179.905 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.8 p -162.31 24.01 0.11 Allowed 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.299 179.873 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 81.1 t -86.71 -68.92 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 CA-C-N 114.817 -1.083 . . . . 0.0 111.277 -179.964 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.5 ttp180 -63.8 -43.44 96.3 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.194 -1.002 . . . . 0.0 111.364 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.2 mttm -52.98 -37.63 61.51 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.646 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -63.45 -48.84 76.04 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.035 -1.066 . . . . 0.0 109.012 179.766 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -49.38 -42.65 42.85 Favored 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.573 179.898 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 20.6 mmm180 -58.66 -45.27 89.73 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.973 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -54.0 -45.03 71.36 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 118.99 -1.084 . . . . 0.0 110.147 179.978 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -82.21 -16.64 48.92 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.54 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 81.56 1.77 90.26 Favored Glycine 0 N--CA 1.494 2.522 0 C-N-CA 119.51 -1.329 . . . . 0.0 110.582 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.1 t -70.56 127.39 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.49 -0.884 . . . . 0.0 110.678 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 48.9 t0 -75.0 107.24 6.93 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.67 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.503 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.3 tt -42.55 -41.35 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.391 -179.88 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.503 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 21.3 ttm105 -49.24 -53.08 23.27 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.185 -179.877 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.9 mt -57.42 -41.3 80.15 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.193 -179.78 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.426 HG23 ' H ' ' A' ' 21' ' ' VAL . 16.5 t -48.51 141.51 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.261 -179.827 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -141.58 55.13 1.51 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.719 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.45 -112.03 0.06 OUTLIER Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.974 -1.584 . . . . 0.0 109.96 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.1 p -78.29 -43.78 27.12 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.329 -0.948 . . . . 0.0 109.629 179.904 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -156.39 116.36 0.71 Allowed Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.934 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.6 pttm -76.58 45.83 0.42 Allowed 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.745 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.2 p-10 -142.58 -153.74 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.047 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.34 -9.07 0.9 Allowed Glycine 0 C--N 1.287 -2.171 0 C-N-CA 119.024 -1.56 . . . . 0.0 109.906 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.486 ' H ' ' C ' ' A' ' 27' ' ' ASN . 23.0 mmt180 -100.26 27.59 5.56 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 119.896 -0.722 . . . . 0.0 111.686 -179.972 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.3 t -79.95 128.31 38.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 119.475 -0.89 . . . . 0.0 108.669 179.886 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.526 HD12 ' N ' ' A' ' 31' ' ' LEU . 10.8 mp -95.11 173.13 7.72 Favored 'General case' 0 N--CA 1.502 2.127 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.691 -179.811 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -73.94 -34.12 64.2 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 119.069 -1.053 . . . . 0.0 108.649 179.897 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -78.03 -6.62 55.11 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.699 -0.8 . . . . 0.0 108.924 179.878 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.34 -58.13 5.36 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.066 179.916 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.2 mt -74.07 -35.73 42.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.082 -179.894 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -50.24 -41.61 50.39 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.857 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.32 -35.0 71.09 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.731 -0.787 . . . . 0.0 110.66 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -42.6 -69.05 0.15 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.255 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.6 tp -71.61 -23.2 61.67 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.949 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 46.83 -168.38 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.5 -0.88 . . . . 0.0 111.07 -179.95 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.435 ' O ' ' N ' ' A' ' 43' ' ' ALA . . . 74.74 90.12 0.19 Allowed Glycine 0 N--CA 1.49 2.28 0 C-N-CA 119.36 -1.4 . . . . 0.0 110.388 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.68 88.57 0.02 OUTLIER Glycine 0 N--CA 1.489 2.18 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.488 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 41' ' ' GLY . . . . . . . . 0 C--N 1.306 -1.3 0 C-N-CA 119.463 -0.895 . . . . 0.0 110.872 -179.92 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.516 HG22 ' N ' ' A' ' 3' ' ' ALA . 17.3 mm . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 120.763 0.316 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.516 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -54.16 157.35 2.66 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 119.239 -0.984 . . . . 0.0 110.132 179.925 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.516 ' O ' ' N ' ' A' ' 6' ' ' SER . 56.4 mmm -78.7 149.95 75.18 Favored Pre-proline 0 N--CA 1.487 1.378 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.449 179.99 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.1 77.79 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 120.601 0.867 . . . . 0.0 110.861 179.968 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.516 ' N ' ' O ' ' A' ' 4' ' ' MET . 13.5 t -172.88 -36.18 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.722 179.97 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.8 t -85.35 -58.44 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 119.856 -0.738 . . . . 0.0 110.754 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 39.6 ttm-85 -61.08 -38.62 86.9 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.536 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.6 mmtt -56.99 -42.88 81.07 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.558 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -55.6 -47.3 76.74 Favored 'General case' 0 C--N 1.302 -1.499 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.464 179.912 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.513 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -53.43 -48.38 68.82 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.117 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mmm-85 -60.96 -43.83 98.2 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.217 179.908 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 56.3 mm-40 -58.23 -28.66 65.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.679 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 11.5 mmmt -101.42 -11.28 19.49 Favored 'General case' 0 N--CA 1.5 2.027 0 C-N-CA 119.874 -0.73 . . . . 0.0 110.655 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.42 63.53 1.7 Allowed Glycine 0 N--CA 1.496 2.635 0 C-N-CA 119.592 -1.289 . . . . 0.0 110.675 179.948 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.513 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 62.7 t -145.21 130.36 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.127 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -87.14 121.49 29.67 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.606 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.53 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 3.8 tp -45.29 -44.1 3.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.78 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.53 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 53.9 ttp180 -49.21 -58.71 4.55 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.434 -0.803 . . . . 0.0 112.331 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 57.7 mt -52.69 -29.54 27.18 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.784 -0.766 . . . . 0.0 112.033 -179.849 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 t -69.11 139.34 20.61 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 C-N-CA 118.783 -1.167 . . . . 0.0 111.362 -179.818 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 -145.82 54.03 1.16 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.153 -179.978 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.56 -106.46 0.03 OUTLIER Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.309 -1.424 . . . . 0.0 111.174 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.81 -65.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.574 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -138.72 107.02 0.54 Allowed Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.547 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 16.6 pttp -55.9 -163.34 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.379 -0.929 . . . . 0.0 110.545 179.971 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.547 ' ND2' ' O ' ' A' ' 26' ' ' LYS . 3.0 p30 57.66 -163.06 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 CA-C-O 121.362 0.601 . . . . 0.0 112.273 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.535 ' N ' ' OD1' ' A' ' 27' ' ' ASN . . . -51.1 -21.22 5.31 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.55 -179.808 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.4 mmt85 -90.09 38.76 0.94 Allowed 'General case' 0 N--CA 1.505 2.289 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.256 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 27' ' ' ASN . 4.0 t -90.46 149.34 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.956 179.85 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 7.6 mp -106.89 175.19 5.58 Favored 'General case' 0 N--CA 1.509 2.484 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.738 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.8 tttm -76.53 -38.21 55.49 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.43 -0.908 . . . . 0.0 109.425 179.849 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 57.9 mm-40 -73.69 -6.57 47.62 Favored 'General case' 0 C--N 1.307 -1.239 0 C-N-CA 119.441 -0.903 . . . . 0.0 108.966 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -67.57 -55.79 12.03 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.443 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.497 HD13 ' HB2' ' A' ' 11' ' ' ALA . 2.5 mt -73.18 -34.18 43.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.371 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -52.22 -40.03 61.06 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.448 179.926 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.24 -34.87 68.6 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.415 ' CD2' HG13 ' A' ' 16' ' ' VAL . 72.4 t80 -45.5 -70.3 0.11 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.454 -0.898 . . . . 0.0 111.184 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.507 ' C ' HD23 ' A' ' 39' ' ' LEU . 3.0 tt -71.17 -62.99 1.19 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.606 -179.903 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 40.86 -101.39 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 120.018 -0.673 . . . . 0.0 111.558 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -177.83 28.7 0.06 OUTLIER Glycine 0 N--CA 1.485 1.908 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.6 179.962 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 75.76 161.04 9.76 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.432 179.999 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.269 0 C-N-CA 119.346 -0.942 . . . . 0.0 110.83 -179.953 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.517 HG22 ' N ' ' A' ' 3' ' ' ALA . 9.8 mm . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 121.024 0.44 . . . . 0.0 110.895 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.517 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -74.32 164.23 26.86 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.417 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 18.3 mmt -75.93 148.35 81.68 Favored Pre-proline 0 N--CA 1.485 1.29 0 C-N-CA 119.166 -1.014 . . . . 0.0 110.67 -179.955 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.427 ' O ' ' OG ' ' A' ' 6' ' ' SER . 10.2 Cg_endo -67.92 68.91 0.87 Allowed 'Trans proline' 0 CA--C 1.548 1.209 0 C-N-CA 120.821 1.014 . . . . 0.0 110.938 179.789 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 5' ' ' PRO . 2.5 m -177.31 -57.19 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.667 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 92.5 t -64.54 -41.45 92.3 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 C-N-CA 119.166 -1.014 . . . . 0.0 110.587 179.901 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.9 ttp180 -63.65 -31.19 72.28 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.67 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.9 mmtp -55.31 -44.81 76.13 Favored 'General case' 0 C--N 1.306 -1.298 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.021 179.939 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -57.98 -51.16 70.8 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.927 -1.109 . . . . 0.0 108.56 179.782 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -50.4 -45.28 55.44 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.129 179.829 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -62.32 -47.12 85.65 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.447 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -52.12 -41.0 62.13 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.239 179.8 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -81.31 -69.17 0.63 Allowed 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.53 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 138.8 33.68 0.18 Allowed Glycine 0 N--CA 1.501 2.986 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.607 179.97 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 64.5 t -109.44 138.81 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.729 -180.0 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -84.39 121.7 27.91 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.474 179.969 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.523 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 3.0 tp -48.57 -44.13 13.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 119.934 -0.707 . . . . 0.0 111.541 -179.911 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.523 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 32.9 ttm180 -54.07 -49.27 69.43 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.655 -179.908 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 82.4 mt -57.16 -34.72 68.73 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.52 -0.872 . . . . 0.0 112.102 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.8 t -66.7 139.62 20.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.394 -179.879 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -142.93 58.58 1.42 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.27 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.26 -104.36 0.23 Allowed Glycine 0 N--CA 1.496 2.666 0 C-N-CA 119.471 -1.347 . . . . 0.0 111.951 -179.838 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.34 -69.45 0.85 Allowed 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . -40.85 -52.79 3.88 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.03 -1.081 . . . . 0.0 110.559 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.521 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 5.2 mtmp? 48.36 -177.78 0.01 OUTLIER 'General case' 0 C--N 1.29 -2.012 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.925 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 25' ' ' GLY . 7.0 p30 43.13 -171.45 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.563 -179.94 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.92 -7.13 0.41 Allowed Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.178 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.487 ' H ' ' C ' ' A' ' 27' ' ' ASN . 42.2 mmt-85 -111.24 45.9 1.14 Allowed 'General case' 0 N--CA 1.503 2.201 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.794 -179.922 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -67.83 158.38 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.11 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 8.8 mt -104.27 173.14 6.43 Favored 'General case' 0 N--CA 1.51 2.564 0 C-N-CA 119.516 -0.873 . . . . 0.0 111.395 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.426 ' C ' ' H ' ' A' ' 34' ' ' ASP . 18.7 tptm -73.33 -52.77 12.67 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.381 -0.928 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -63.01 -5.5 3.02 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.224 -0.99 . . . . 0.0 109.849 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.426 ' H ' ' C ' ' A' ' 32' ' ' LYS . 4.5 t0 -66.11 -59.07 4.13 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.414 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 mt -73.24 -33.47 41.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.765 -0.774 . . . . 0.0 111.328 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -51.22 -41.53 60.36 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.917 179.916 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.96 -33.81 66.11 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.544 -0.863 . . . . 0.0 110.607 179.89 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.0 t80 -46.06 -70.93 0.08 Allowed 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.232 179.973 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt -74.59 -45.43 45.24 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.956 -179.97 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 44.43 -101.06 0.04 OUTLIER 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.671 -0.812 . . . . 0.0 111.137 -179.954 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 62.72 13.27 45.47 Favored Glycine 0 N--CA 1.49 2.288 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.467 -179.955 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 82.38 -16.56 23.36 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.604 -1.284 . . . . 0.0 110.378 179.972 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.314 0 C-N-CA 119.452 -0.899 . . . . 0.0 110.865 -179.963 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.424 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.6 OUTLIER -74.72 166.12 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.092 179.857 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.424 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 57.9 154.47 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.875 -179.955 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 60.5 mmm -79.08 147.53 69.86 Favored Pre-proline 0 N--CA 1.49 1.539 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.722 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.51 ' C ' ' H ' ' A' ' 7' ' ' VAL . 2.7 Cg_endo -62.26 173.2 3.48 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 120.766 0.977 . . . . 0.0 111.177 179.873 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 t 67.95 -21.03 0.13 Allowed 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 120.034 -0.666 . . . . 0.0 111.795 179.853 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.51 ' H ' ' C ' ' A' ' 5' ' ' PRO . 54.4 t -96.4 -55.45 6.07 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.806 -179.995 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -62.27 -29.02 70.12 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.185 -1.006 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.5 mmtm -59.59 -42.99 93.8 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.145 -179.943 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.432 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 8.3 t80 -60.02 -49.51 77.39 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 118.743 -1.183 . . . . 0.0 108.664 179.863 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.442 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -50.17 -44.1 52.64 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.858 -179.981 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 57.7 mtp85 -62.25 -46.44 88.81 Favored 'General case' 0 C--N 1.295 -1.765 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.276 -179.869 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -52.96 -32.38 45.7 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.07 -1.052 . . . . 0.0 109.896 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 48.5 mmtt -94.47 -18.34 21.59 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 78.55 13.26 83.39 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 119.207 -1.473 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 26.9 t -84.12 145.12 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.794 -179.83 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -85.62 99.23 11.14 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.297 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.525 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 17.3 tt -40.75 -42.65 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.842 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.525 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 43.9 ttt85 -50.24 -61.38 2.2 Favored 'General case' 0 C--N 1.287 -2.122 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.923 -179.938 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -52.18 -28.55 18.64 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.847 -0.741 . . . . 0.0 112.754 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.406 ' H ' HG23 ' A' ' 21' ' ' VAL . 11.1 t -55.99 141.31 12.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.72 -1.192 . . . . 0.0 112.382 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -136.69 72.55 1.43 Allowed 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.719 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.6 -105.15 1.59 Allowed Glycine 0 N--CA 1.503 3.127 0 C-N-CA 119.717 -1.23 . . . . 0.0 111.265 -179.86 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.3 p -93.7 -68.6 0.79 Allowed 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.115 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.547 ' C ' HD22 ' A' ' 27' ' ' ASN . . . -105.42 83.41 0.37 Allowed Glycine 0 N--CA 1.501 3.023 0 C-N-CA 120.022 -1.085 . . . . 0.0 110.472 -179.888 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -69.56 74.48 0.39 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.262 -0.975 . . . . 0.0 110.154 179.992 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.562 HD22 ' N ' ' A' ' 27' ' ' ASN . 0.0 OUTLIER -167.76 -161.52 0.39 Allowed 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.587 179.929 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.55 -4.08 1.25 Allowed Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.03 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.497 ' H ' ' C ' ' A' ' 27' ' ' ASN . 25.9 mmt180 -117.33 42.43 2.56 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.295 -0.562 . . . . 0.0 111.374 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.1 t -70.37 157.53 6.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 C-N-CA 119.28 -0.968 . . . . 0.0 108.74 179.841 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 60.0 mt -107.01 175.06 5.62 Favored 'General case' 0 N--CA 1.513 2.676 0 C-N-CA 119.031 -1.068 . . . . 0.0 112.037 179.973 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -77.22 -32.95 56.21 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.524 179.932 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -79.13 -8.97 59.41 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 119.39 -0.924 . . . . 0.0 108.929 -179.967 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -64.4 -54.54 31.16 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.257 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.442 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 3.4 mt -71.17 -34.22 53.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-N 114.588 -1.187 . . . . 0.0 110.867 179.874 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -49.7 -41.39 43.17 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.945 179.831 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.1 -34.83 71.48 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.646 179.79 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.3 t80 -42.43 -68.91 0.16 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.689 -0.804 . . . . 0.0 111.483 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 8.8 tp -71.38 -64.26 0.95 Allowed 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 43.13 69.93 0.35 Allowed 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.605 -0.838 . . . . 0.0 111.407 -179.965 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 155.77 64.45 0.01 OUTLIER Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.792 -1.195 . . . . 0.0 110.159 179.973 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.6 112.17 4.75 Favored Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.483 179.928 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.361 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.916 -179.993 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.433 ' O ' ' O ' ' A' ' 3' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.501 2.089 0 CA-C-O 121.216 0.531 . . . . 0.0 110.476 . . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.433 ' O ' ' O ' ' A' ' 2' ' ' ILE . . . 49.81 177.37 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.738 -179.882 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 20.1 mtt -79.19 157.13 76.03 Favored Pre-proline 0 N--CA 1.491 1.607 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.326 179.957 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -69.32 66.62 1.51 Allowed 'Trans proline' 0 CA--C 1.551 1.337 0 C-N-CA 120.857 1.038 . . . . 0.0 110.553 179.807 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.2 t -168.88 -16.61 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.641 -0.824 . . . . 0.0 110.501 -179.964 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 69.3 t -88.84 -71.28 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.223 179.939 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.626 HH21 ' HE ' ' A' ' 12' ' ' ARG . 36.0 ttt85 -59.22 -27.74 66.02 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.802 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.1 mmmt -60.99 -44.82 96.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.753 -179.926 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -56.29 -48.33 76.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.266 179.816 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.94 -45.93 67.89 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.626 ' HE ' HH21 ' A' ' 8' ' ' ARG . 13.7 mmt85 -60.42 -43.47 96.72 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.681 -179.93 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -57.37 -54.98 40.72 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.114 179.993 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -71.34 -70.17 0.33 Allowed 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.759 -179.912 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.67 69.59 0.05 OUTLIER Glycine 0 N--CA 1.499 2.849 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.996 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.0 t -144.41 129.03 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 C-N-CA 120.015 -0.674 . . . . 0.0 110.341 -179.973 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -73.55 106.61 5.4 Favored 'General case' 0 C--N 1.301 -1.508 0 C-N-CA 119.242 -0.983 . . . . 0.0 110.387 179.849 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 15.8 tt -45.11 -42.27 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 119.938 -0.705 . . . . 0.0 111.468 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.526 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 71.8 mtm180 -46.29 -58.83 3.35 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.227 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 73.6 mt -55.46 -35.78 65.85 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.725 -0.79 . . . . 0.0 112.209 -179.798 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.42 HG23 ' H ' ' A' ' 21' ' ' VAL . 12.0 t -53.88 140.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 C-N-CA 118.881 -1.128 . . . . 0.0 111.513 -179.805 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -145.2 67.18 1.23 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.896 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.403 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . -81.15 -100.63 0.35 Allowed Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.32 -1.419 . . . . 0.0 109.946 179.962 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -78.15 -47.47 18.06 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.148 179.866 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -157.68 116.23 0.7 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.979 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.4 ' HG2' ' H ' ' A' ' 26' ' ' LYS . 9.0 ptmm? -75.18 51.45 0.53 Allowed 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.991 179.953 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.507 ' O ' ' N ' ' A' ' 29' ' ' ARG . 2.9 p30 -147.6 -161.33 1.31 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.711 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.39 -10.89 0.12 Allowed Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.615 -1.279 . . . . 0.0 110.982 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.507 ' N ' ' O ' ' A' ' 27' ' ' ASN . 27.8 mmm-85 -106.0 38.73 1.94 Allowed 'General case' 0 N--CA 1.504 2.241 0 C-N-CA 120.044 -0.662 . . . . 0.0 112.259 -179.943 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -82.3 145.62 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.725 179.79 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 10.9 mp -106.78 174.49 5.86 Favored 'General case' 0 N--CA 1.51 2.572 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.185 -179.857 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -76.62 -34.31 58.34 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.368 -0.933 . . . . 0.0 108.926 179.743 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -77.0 -9.23 58.56 Favored 'General case' 0 C--N 1.312 -1.056 0 C-N-CA 119.521 -0.872 . . . . 0.0 108.912 179.84 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 23' ' ' GLY . 2.7 t0 -62.77 -49.58 74.43 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.232 179.933 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.8 mt -78.43 -33.53 17.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.259 179.889 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -52.29 -41.81 63.22 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.32 179.935 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.66 -35.88 75.56 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.704 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -43.08 -69.05 0.15 Allowed 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.335 -179.974 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 41' ' ' GLY . 37.6 tp -69.49 -38.17 77.54 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.366 -0.833 . . . . 0.0 112.643 -179.751 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -41.78 -20.81 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.897 0 C-N-CA 119.322 -0.951 . . . . 0.0 111.654 179.972 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 39' ' ' LEU . . . -157.35 -65.49 0.01 OUTLIER Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.533 179.986 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.81 98.2 0.15 Allowed Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.341 -1.409 . . . . 0.0 110.466 179.952 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.49 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.872 179.997 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.481 1.075 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 2' ' ' ILE . 0.7 OUTLIER -81.47 -176.34 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.694 -179.952 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.48 162.4 15.65 Favored 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.595 -179.93 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.455 ' O ' ' N ' ' A' ' 6' ' ' SER . 59.6 mtt -69.31 149.85 97.29 Favored Pre-proline 0 C--N 1.305 -1.349 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.671 179.928 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -63.03 77.35 0.11 Allowed 'Trans proline' 0 CA--C 1.539 0.741 0 C-N-CA 120.543 0.829 . . . . 0.0 110.54 179.993 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.455 ' N ' ' O ' ' A' ' 4' ' ' MET . 10.8 p -177.62 -27.65 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.606 -0.837 . . . . 0.0 110.551 -179.896 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t -82.91 -63.95 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 C-N-CA 119.618 -0.833 . . . . 0.0 110.796 179.914 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 28.5 ttp180 -60.83 -33.52 73.15 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.643 -179.939 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.0 mmtp -59.72 -41.13 90.19 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.334 179.895 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -58.49 -47.6 83.54 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.006 -1.078 . . . . 0.0 109.023 179.924 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.525 ' HB2' ' CD1' ' A' ' 35' ' ' ILE . . . -48.86 -46.07 41.84 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.966 179.746 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 59.2 mtp85 -57.53 -45.5 84.96 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 115.217 -0.902 . . . . 0.0 110.863 -179.875 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -53.36 -43.88 68.1 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.184 -1.007 . . . . 0.0 110.872 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 14.3 mmmt -81.43 -22.69 38.01 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.929 179.691 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.92 13.95 70.84 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.94 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.408 HG13 ' CD2' ' A' ' 38' ' ' PHE . 38.3 t -83.92 139.53 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.042 179.834 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 46.1 t0 -84.64 100.96 11.79 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.294 179.944 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.489 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 13.0 tt -39.28 -39.58 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 CA-C-O 121.437 0.636 . . . . 0.0 111.613 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.529 ' O ' ' NE ' ' A' ' 19' ' ' ARG . 0.0 OUTLIER -50.33 -62.61 1.48 Allowed 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.103 -0.953 . . . . 0.0 112.092 179.911 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -50.61 -28.38 8.65 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.944 -0.703 . . . . 0.0 112.222 -179.704 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.402 HG23 ' H ' ' A' ' 21' ' ' VAL . 9.0 t -60.4 141.34 17.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 118.888 -1.125 . . . . 0.0 112.071 -179.788 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 43.6 mt-30 -134.31 64.51 1.6 Allowed 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.602 -179.993 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.59 -115.61 0.71 Allowed Glycine 0 N--CA 1.498 2.828 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.435 -179.911 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -81.54 -68.12 0.72 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.009 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.46 100.19 0.94 Allowed Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.887 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.411 ' HG2' ' H ' ' A' ' 26' ' ' LYS . 7.4 ptmm? -76.09 50.67 0.62 Allowed 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.514 -0.874 . . . . 0.0 110.775 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.481 ' C ' ' H ' ' A' ' 29' ' ' ARG . 2.7 p30 -151.01 -155.65 0.64 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.902 -0.719 . . . . 0.0 110.583 -179.941 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.6 -7.73 0.71 Allowed Glycine 0 C--N 1.29 -1.982 0 C-N-CA 119.357 -1.401 . . . . 0.0 110.258 -179.859 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.481 ' H ' ' C ' ' A' ' 27' ' ' ASN . 11.5 mmt85 -111.56 39.25 2.38 Favored 'General case' 0 N--CA 1.506 2.353 0 C-N-CA 120.149 -0.621 . . . . 0.0 111.81 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -76.64 155.45 5.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 C-N-CA 119.364 -0.934 . . . . 0.0 108.986 179.797 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 38.0 mt -109.44 175.43 5.45 Favored 'General case' 0 N--CA 1.514 2.732 0 C-N-CA 119.276 -0.97 . . . . 0.0 111.832 -179.902 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -78.21 -33.4 49.96 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.004 179.723 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 35.1 mm-40 -79.25 -4.99 53.33 Favored 'General case' 0 C--N 1.314 -0.955 0 C-N-CA 119.468 -0.893 . . . . 0.0 109.08 179.862 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -67.31 -58.4 4.87 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 114.687 -1.142 . . . . 0.0 109.249 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.525 ' CD1' ' HB2' ' A' ' 11' ' ' ALA . 6.0 mt -70.78 -31.33 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.738 179.703 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -51.97 -41.06 61.83 Favored 'General case' 0 C--N 1.309 -1.172 0 C-N-CA 118.906 -1.118 . . . . 0.0 110.101 -179.888 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.3 -33.37 65.16 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.619 179.906 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.408 ' CD2' HG13 ' A' ' 16' ' ' VAL . 68.3 t80 -44.68 -71.23 0.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.354 -0.939 . . . . 0.0 111.801 179.937 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 32.3 tp -66.87 -58.18 5.53 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.489 -179.797 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -46.32 101.04 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.076 179.983 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -81.85 19.75 9.09 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 119.56 -1.305 . . . . 0.0 110.478 -179.924 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.44 164.92 45.93 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.289 179.982 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.443 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.86 -179.974 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.425 ' O ' HG13 ' A' ' 1' ' ' VAL . 7.1 p . . . . . 0 N--CA 1.483 1.193 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.561 HG22 ' N ' ' A' ' 3' ' ' ALA . 10.3 mm -78.0 170.87 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 119.576 -0.849 . . . . 0.0 110.752 -179.942 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.561 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -61.44 -176.82 0.08 Allowed 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.573 -0.851 . . . . 0.0 110.969 179.978 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.443 ' O ' ' N ' ' A' ' 6' ' ' SER . 45.9 mmm -69.34 149.72 97.27 Favored Pre-proline 0 C--N 1.305 -1.35 0 C-N-CA 119.504 -0.879 . . . . 0.0 110.111 -179.955 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -63.51 75.34 0.14 Allowed 'Trans proline' 0 CA--C 1.546 1.12 0 C-N-CA 120.681 0.92 . . . . 0.0 110.852 179.934 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.443 ' N ' ' O ' ' A' ' 4' ' ' MET . 5.2 t 176.94 -27.26 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.538 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.8 t -77.08 -60.12 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 119.628 -0.829 . . . . 0.0 111.166 179.987 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 24.9 ttt-85 -62.29 -48.9 77.85 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.208 -179.747 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 54.5 mttt -52.43 -38.03 58.2 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.799 179.875 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -61.48 -46.15 91.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 118.669 -1.213 . . . . 0.0 108.91 179.836 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -52.0 -43.18 63.53 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.648 179.9 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -56.29 -45.14 80.32 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.759 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -54.33 -42.64 70.42 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.077 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 63.0 mmtt -90.04 0.5 57.08 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.274 179.878 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 61.63 16.49 51.0 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.684 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.529 HG13 ' CD2' ' A' ' 38' ' ' PHE . 52.5 t -79.03 137.22 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.773 179.99 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -85.45 102.45 13.48 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.721 179.889 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.522 ' CG2' ' N ' ' A' ' 19' ' ' ARG . 12.6 tt -42.76 -42.62 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.906 -0.718 . . . . 0.0 111.712 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.522 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 56.4 ttt-85 -46.54 -60.06 2.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.689 179.901 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 50.6 mt -55.4 -37.54 67.73 Favored 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.683 -0.807 . . . . 0.0 112.255 -179.683 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.437 ' H ' HG23 ' A' ' 21' ' ' VAL . 11.0 t -49.51 141.28 2.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.19 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -140.96 62.14 1.48 Allowed 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 120.203 -0.599 . . . . 0.0 111.485 179.95 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.84 -103.74 0.31 Allowed Glycine 0 N--CA 1.499 2.85 0 C-N-CA 119.101 -1.524 . . . . 0.0 109.494 179.946 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -78.02 -36.01 49.2 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.291 -0.964 . . . . 0.0 108.718 179.791 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.07 -156.91 6.96 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 179.895 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.405 ' HZ2' ' HB3' ' A' ' 26' ' ' LYS . 14.7 ttpp -163.78 36.06 0.09 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.648 -0.821 . . . . 0.0 109.349 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.438 ' O ' HG23 ' A' ' 30' ' ' VAL . 10.8 p30 -154.08 -158.46 0.87 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.818 -179.999 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -48.28 -21.63 1.99 Allowed Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.195 -1.478 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -93.09 34.44 1.12 Allowed 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.89 179.945 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.438 HG23 ' O ' ' A' ' 27' ' ' ASN . 3.4 t -82.68 155.08 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.525 -0.87 . . . . 0.0 109.57 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.416 ' N ' ' CD2' ' A' ' 31' ' ' LEU . 3.6 mm? -104.15 173.26 6.38 Favored 'General case' 0 N--CA 1.509 2.485 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -75.31 -43.75 49.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.419 -0.912 . . . . 0.0 108.916 179.798 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -71.27 -6.79 42.49 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.48 -0.888 . . . . 0.0 109.765 -179.948 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.426 ' OD1' HG12 ' A' ' 21' ' ' VAL . 2.7 t0 -62.92 -58.2 8.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.646 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mt -69.99 -36.76 70.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.666 -0.814 . . . . 0.0 110.87 -179.92 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.465 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 23.3 t70 -48.56 -43.26 35.54 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.577 -1.249 . . . . 0.0 110.084 179.95 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.24 -35.48 78.0 Favored 'General case' 0 C--N 1.306 -1.316 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.567 -179.968 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.529 ' CD2' HG13 ' A' ' 16' ' ' VAL . 60.3 t80 -44.93 -68.04 0.23 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.385 179.984 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 17.2 tp -74.89 -69.24 0.48 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.137 -179.893 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.465 ' HB3' ' O ' ' A' ' 36' ' ' ASP . . . -50.75 143.86 9.13 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.287 179.965 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -79.68 23.35 3.62 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.566 -1.302 . . . . 0.0 110.134 -179.952 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.41 ' H ' ' C ' ' A' ' 40' ' ' ALA . . . 86.83 18.31 58.36 Favored Glycine 0 N--CA 1.497 2.752 0 C-N-CA 119.704 -1.236 . . . . 0.0 110.474 -179.938 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.371 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.755 179.933 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 34.0 t . . . . . 0 N--CA 1.481 1.111 0 CA-C-O 120.947 0.403 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.424 ' H ' HD12 ' A' ' 2' ' ' ILE . 0.8 OUTLIER -149.38 -175.78 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.8 179.928 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.06 -169.65 2.17 Favored 'General case' 0 N--CA 1.501 2.101 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.599 179.976 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.484 ' C ' ' H ' ' A' ' 6' ' ' SER . 49.2 mmm -87.44 148.05 43.46 Favored Pre-proline 0 N--CA 1.494 1.756 0 C-N-CA 119.54 -0.864 . . . . 0.0 110.727 -179.98 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -68.61 30.21 0.15 Allowed 'Trans proline' 0 CA--C 1.549 1.237 0 C-N-CA 120.96 1.107 . . . . 0.0 111.645 179.904 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.484 ' H ' ' C ' ' A' ' 4' ' ' MET . 5.6 m -143.85 -37.91 0.32 Allowed 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 119.217 -0.993 . . . . 0.0 111.749 -179.94 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.1 t -71.03 -50.22 43.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.067 -1.053 . . . . 0.0 111.114 -179.858 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.471 ' O ' ' HB3' ' A' ' 11' ' ' ALA . 56.7 ttt180 -60.1 -36.07 76.61 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.076 -1.049 . . . . 0.0 111.268 -179.936 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 51.4 mmtt -55.3 -45.63 76.27 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 119.212 -0.995 . . . . 0.0 110.336 179.87 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.411 ' CG ' ' NZ ' ' A' ' 32' ' ' LYS . 2.5 t80 -54.64 -46.64 73.98 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.101 179.906 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.529 ' HB1' ' O ' ' A' ' 16' ' ' VAL . . . -49.53 -45.62 47.6 Favored 'General case' 0 C--N 1.288 -2.095 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.933 -179.863 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 -58.65 -43.39 89.8 Favored 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.18 -179.944 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 75.5 mt-10 -57.3 -31.43 65.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.301 -0.959 . . . . 0.0 110.935 -179.943 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.9 mmtt -96.71 -6.72 35.77 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.101 179.944 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 74.62 53.72 6.4 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.529 ' O ' ' HB1' ' A' ' 11' ' ' ALA . 43.0 t -136.39 128.5 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.78 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.548 ' O ' ' N ' ' A' ' 19' ' ' ARG . 39.1 t0 -88.28 94.42 9.83 Favored 'General case' 0 N--CA 1.494 1.768 0 C-N-CA 119.556 -0.858 . . . . 0.0 111.036 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.529 HG23 ' N ' ' A' ' 19' ' ' ARG . 15.0 tt -23.25 -41.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.437 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -179.95 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.548 ' N ' ' O ' ' A' ' 17' ' ' ASP . 45.1 mtm-85 -45.59 -50.23 13.36 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -179.834 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.461 ' CD1' ' O ' ' A' ' 17' ' ' ASP . 0.3 OUTLIER -76.66 -2.25 31.85 Favored 'General case' 0 N--CA 1.5 2.061 0 C-N-CA 119.114 -1.035 . . . . 0.0 113.28 -179.665 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 85.2 t -74.75 146.25 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 C-N-CA 118.219 -1.392 . . . . 0.0 110.477 179.94 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -135.3 62.92 1.62 Allowed 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.502 179.962 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.15 -118.88 0.44 Allowed Glycine 0 N--CA 1.498 2.825 0 C-N-CA 119.215 -1.469 . . . . 0.0 110.432 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -75.62 -45.83 35.16 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.432 179.968 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.99 106.49 0.3 Allowed Glycine 0 N--CA 1.486 2.009 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -74.39 64.69 1.16 Allowed 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.79 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.474 ' C ' ' H ' ' A' ' 29' ' ' ARG . 24.8 p-10 -152.48 -164.96 2.08 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.538 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.42 -8.63 0.83 Allowed Glycine 0 N--CA 1.485 1.953 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.228 -179.936 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.474 ' H ' ' C ' ' A' ' 27' ' ' ASN . 12.3 mmt85 -108.57 37.86 2.4 Favored 'General case' 0 N--CA 1.503 2.214 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.537 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.431 ' C ' HD12 ' A' ' 31' ' ' LEU . 2.9 t -77.63 158.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 119.504 -0.879 . . . . 0.0 108.949 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.431 HD12 ' C ' ' A' ' 30' ' ' VAL . 9.9 mp -113.64 177.51 4.61 Favored 'General case' 0 N--CA 1.513 2.707 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.591 -179.954 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.411 ' NZ ' ' CG ' ' A' ' 10' ' ' TYR . 15.9 tptp -77.3 -40.3 44.91 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.871 179.692 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -74.64 -4.22 35.9 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.469 179.843 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -64.93 -54.01 37.49 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.529 179.965 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.469 HD13 ' HB2' ' A' ' 11' ' ' ALA . 4.3 mt -75.5 -36.97 36.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.698 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 55.6 t0 -48.93 -40.46 30.21 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 118.688 -1.205 . . . . 0.0 109.91 179.895 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.89 -35.73 69.83 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.357 -179.998 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -45.7 -71.48 0.07 Allowed 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.24 179.862 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.1 tp -71.29 -65.54 0.74 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.713 -179.841 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 41.45 -144.7 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.909 -0.716 . . . . 0.0 111.368 179.773 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.98 -56.69 0.01 OUTLIER Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.171 -179.878 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 68.56 82.72 0.17 Allowed Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.418 -179.911 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.317 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.728 179.989 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' A' ' 2' ' ' ILE . 5.9 m . . . . . 0 N--CA 1.479 0.992 0 CA-C-O 120.839 0.352 . . . . 0.0 110.225 . . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.438 HG22 ' N ' ' A' ' 3' ' ' ALA . 11.0 mm 54.77 165.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 119.694 -0.802 . . . . 0.0 110.758 -179.93 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.438 ' N ' HG22 ' A' ' 2' ' ' ILE . . . -76.89 138.97 40.07 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.309 -0.956 . . . . 0.0 110.582 179.975 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.695 ' H ' ' CD ' ' A' ' 5' ' ' PRO . 35.1 mtm -120.12 -31.96 0.06 OUTLIER Pre-proline 0 N--CA 1.508 2.454 0 N-CA-C 113.941 1.089 . . . . 0.0 113.941 -179.934 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.695 ' CD ' ' H ' ' A' ' 4' ' ' MET . 6.3 Cg_exo -64.91 -157.86 0.03 OUTLIER 'Trans proline' 0 C--O 1.213 -0.732 0 CA-C-N 118.826 0.617 . . . . 0.0 111.074 -179.937 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.2 m -69.32 72.5 0.31 Allowed 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.055 179.932 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.413 ' N ' ' O ' ' A' ' 5' ' ' PRO . 91.0 t -130.6 -66.84 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.721 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 27.8 ttm180 -58.36 -37.98 76.31 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 118.973 -1.091 . . . . 0.0 110.48 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -53.83 -44.81 70.58 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.152 -1.019 . . . . 0.0 110.289 -179.845 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -57.67 -48.44 79.5 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 118.991 -1.083 . . . . 0.0 109.299 179.785 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.533 ' O ' ' N ' ' A' ' 15' ' ' GLY . . . -50.82 -45.26 59.43 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.323 179.972 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -60.46 -45.83 92.28 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.433 -179.885 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -55.76 -29.42 59.56 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.796 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 67.1 mmtt -108.58 -5.31 16.55 Favored 'General case' 0 N--CA 1.502 2.158 0 C-N-CA 120.123 -0.631 . . . . 0.0 110.768 179.97 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 11' ' ' ALA . . . 62.0 81.13 0.09 OUTLIER Glycine 0 N--CA 1.491 2.305 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.588 179.923 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.553 HG13 ' CD2' ' A' ' 38' ' ' PHE . 24.5 t -147.76 129.44 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.139 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -70.7 96.92 1.28 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.577 -179.975 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 19' ' ' ARG . 16.0 tt -40.52 -41.69 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.969 179.891 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.535 ' N ' HG23 ' A' ' 18' ' ' ILE . 10.0 tpt180 -55.14 -60.42 3.41 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.278 179.996 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.0 mt -49.42 -20.39 0.69 Allowed 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.964 -179.912 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 5.9 t -68.32 139.5 20.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.997 -179.846 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -142.61 52.56 1.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.012 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.4 -95.99 0.06 OUTLIER Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.651 -1.261 . . . . 0.0 111.036 -179.95 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.46 -46.3 16.14 Favored 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.38 -0.928 . . . . 0.0 110.291 -179.863 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 26' ' ' LYS . . . -161.74 111.97 0.5 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.93 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.447 ' O ' ' OD1' ' A' ' 27' ' ' ASN . 17.5 ptmt -55.7 -163.5 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.77 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.64 ' ND2' ' N ' ' A' ' 28' ' ' GLY . 0.4 OUTLIER 50.82 -160.51 0.08 Allowed 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.416 -179.922 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.64 ' N ' ' ND2' ' A' ' 27' ' ' ASN . . . -50.2 -26.5 9.32 Favored Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.898 -1.144 . . . . 0.0 111.438 -179.823 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.435 ' O ' ' O ' ' A' ' 25' ' ' GLY . 22.0 mmt180 -75.19 29.59 0.1 Allowed 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.592 -179.883 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.475 ' H ' ' C ' ' A' ' 28' ' ' GLY . 2.9 t -90.74 133.72 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.375 179.901 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.521 HD12 ' N ' ' A' ' 31' ' ' LEU . 9.8 mp -104.18 178.82 4.45 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.786 179.943 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -74.43 -36.86 63.42 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.132 179.731 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -75.11 -8.55 56.87 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.189 179.872 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.415 ' HB2' ' H ' ' A' ' 31' ' ' LEU . 3.3 t0 -66.07 -57.34 7.95 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.634 179.829 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 mt -66.58 -31.34 53.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.276 -179.951 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -51.57 -40.94 60.7 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.065 -1.054 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.84 -33.19 68.24 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.687 179.924 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.553 ' CD2' HG13 ' A' ' 16' ' ' VAL . 64.9 t80 -45.47 -69.39 0.14 Allowed 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.129 -179.967 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.8 tp -74.31 -54.23 8.09 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.821 -179.817 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 44.0 -156.92 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.656 -0.817 . . . . 0.0 111.271 -179.902 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -77.65 15.36 7.83 Favored Glycine 0 N--CA 1.493 2.465 0 C-N-CA 119.365 -1.398 . . . . 0.0 110.443 -179.899 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.07 173.91 54.71 Favored Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.321 -1.418 . . . . 0.0 110.339 179.944 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.315 0 C-N-CA 119.426 -0.909 . . . . 0.0 110.846 179.926 . . . . . . . . 0 0 . 1 stop_ save_